



HU000035769T2



(19) **HU**

(11) Lajstromszám: **E 035 769**

(13) **T2**

MAGYARORSZÁG
Szellemi Tulajdon Nemzeti Hivatala

EURÓPAI SZABADALOM **SZÖVEGÉNEK FORDÍTÁSA**

(21) Magyar ügyszám: **E 14 184691**

(51) Int. Cl.: **A61K 31/506**

(2006.01)

(22) A bejelentés napja: **2010. 02. 12.**

G01N 33/574

(2006.01)

(96) Az európai bejelentés bejelentési száma:
EP 20100184691

C12Q 1/68

(2006.01)

(97) Az európai bejelentés közzétételi adatai:
EP 2881402 A1 **2015. 06. 10.**

A61K 31/4545

(2006.01)

(97) Az európai szabadalom megadásának meghirdetési adatai:
EP 2881402 B1 **2017. 05. 10.**

(30) Elsőbbségi adatai:

207484 P

2009. 02. 12.

US

(73) Jogosult(ak):

Cell Signaling Technology, Inc., Danvers MA 01923 (US)

(72) Feltaláló(k):

GU, Ting-lei, Woburn, MA 01801 (US)

(74) Képviselő:

TUCKER, Meghan, Ann, Salem, MA 01970 (US)

SBGK Szabadalmi Ügyvivői Iroda, Budapest

HAACK, Herbert, South Hamilton, MA 01982 (US)

CROSBY, Katherine, Eleanor, Middleton, MA 01949 (US)

RIMKUNAS, Victoria, McGuinness, Somerville, MA 02144 (US)

(54)

Mutáns ROS expresszió humán májrákban

Az európai szabadalom ellen, megadásának az Európai Szabadalmi Közlönyben való meghirdetésétől számított kilenc hónapon belül, felszólalást lehet benyújtani az Európai Szabadalmi Hivatalnál. (Európai Szabadalmi Egyezmény 99. cikk(1))

A fordítást a szabadalmas az 1995. évi XXXIII. törvény 84/H. §-a szerint nyújtotta be. A fordítás tartalmi helyességét a Szellemi Tulajdon Nemzeti Hivatala nem vizsgálta.



(19)



(11)

EP 2 881 402 B1

(12)

EUROPEAN PATENT SPECIFICATION

(45) Date of publication and mention of the grant of the patent:
10.05.2017 Bulletin 2017/19

(51) Int Cl.:
A61K 31/506 (2006.01) A61K 31/4545 (2006.01)
G01N 33/574 (2006.01) C12Q 1/68 (2006.01)

(21) Application number: 14184691.5

(22) Date of filing: 12.02.2010

(54) Mutant ROS expression in human liver cancer

Expression mutanter ROS bei menschlichem Leberkrebs

Expression de la protéine mutante ROS dans les cancers du foie chez l'être humain

(84) Designated Contracting States:
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR
HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL
PT RO SE SI SK SM TR

(30) Priority: 12.02.2009 US 207484 P

(43) Date of publication of application:
10.06.2015 Bulletin 2015/24

(62) Document number(s) of the earlier application(s) in accordance with Art. 76 EPC:
10741807.1 / 2 396 342

(73) Proprietor: Cell Signaling Technology, Inc.
Danvers MA 01923 (US)

(72) Inventors:

- Gu, Ting-lei
Woburn, MA 01801 (US)
- Tucker, Meghan, Ann
Salem, MA 01970 (US)
- Haack, Herbert
South Hamilton, MA 01982 (US)
- Crosby, Katherine, Eleanor
Middleton, MA 01949 (US)
- Rimkunas, Victoria, McGuinness
Somerville, MA 02144 (US)

(74) Representative: Hill, Justin John
Olswang LLP
90 High Holborn
London WC1V 6XX (GB)

(56) References cited:
WO-A1-2008/066498 WO-A2-2007/084631

- ACQUAVIVA J ET AL: "The multifaceted roles of the receptor tyrosine kinase ROS in development and cancer", BBA - REVIEWS ON CANCER, vol. 1795, no. 1, 1 January 2009 (2009-01-01), pages 37-52, XP025846545, ELSEVIER SCIENCE BV, AMSTERDAM, NL ISSN: 0304-419X, DOI: 10.1016/J.BBACAN.2008.07.006 [retrieved on 2008-08-03]
- ANNA V GALKIN ET AL: "Identification of NVP-TAE684, a potent, selective, and efficacious inhibitor of NPM-ALK", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, NATIONAL ACADEMY OF SCIENCES, US, vol. 104, no. 1, 2 January 2007 (2007-01-02), pages 270-275, XP002661293, ISSN: 0027-8424, DOI: 10.1073/PNAS.0609412103 [retrieved on 2006-12-21]
- TING-LEI GU ET AL: "Survey of Tyrosine Kinase Signaling Reveals ROS Kinase Fusions in Human Cholangiocarcinoma", PLOS ONE, vol. 6, no. 1, E15640, 6 January 2011 (2011-01-06), pages 1-9, XP055033496, DOI: 10.1371/journal.pone.0015640
- U. McDermott ET AL: "Genomic Alterations of Anaplastic Lymphoma Kinase May Sensitize Tumors to Anaplastic Lymphoma Kinase Inhibitors", Cancer research, vol. 68, no. 9, 1 May 2008 (2008-05-01), pages 3389-3395, XP055065902, ISSN: 0008-5472, DOI: 10.1158/0008-5472.CAN-07-6186

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

Description**FIELD OF THE INVENTION**

5 [0001] The invention relates generally to ROS kinase proteins and genes involved in cancer, and to the treatment of cancer.

BACKGROUND OF THE INVENTION

10 [0002] Many cancers are characterized by disruptions in cellular signaling pathways that lead to aberrant control of cellular processes, or to uncontrolled growth and proliferation of cells. These disruptions are often caused by changes in the activity of particular signaling proteins, such as kinases.

15 [0003] It is known that gene translocations resulting in kinase fusion proteins with aberrant signaling activity can directly lead to certain cancers. For example, it has been directly demonstrated that the BCR-ABL oncogene, a tyrosine kinase fusion protein, is the causative agent and drives human chronic myelogenous leukemia (CML). The BCR-ABL oncogene, which is found in at least 90-95% of CML cases, is generated by the translocation of gene sequences from the c-ABL protein tyrosine kinase on chromosome 9 into BCR sequences on chromosome 22, producing the so-called Philadelphia chromosome. See, e.g. Kurzrock et al., N. Engl. J. Med. 319: 990-998 (1988). The translocation is also observed in acute lymphocytic leukemia and AML cases.

20 [0004] Gene translocations leading to mutant or fusion proteins implicated in a variety of other cancers have been described. For example, Falini et al., Blood 99(2): 409-426 (2002), review translocations known to occur in hematological cancers.

25 [0005] Identifying translocations and mutations in human cancers is highly desirable because it can lead to the development of new therapeutics that target such fusion or mutant proteins, and to new diagnostics for identifying patients that have such gene translocations. For example, BCR-ABL has become a target for the development of therapeutics to treat leukemia. Most recently, Gleevec® (Imatinib mesylate, ST1-571), a small molecule inhibitor of the ABL kinase, has been approved for the treatment of CML. This drug is the first of a new class of anti-proliferative agents designed to interfere with the signaling pathways that drive the growth of tumor cells. The development of this drug represents a significant advance over the conventional therapies for CML and ALL, chemotherapy and radiation, which are plagued by well known side-effects and are often of limited effect since they fail to specifically target the underlying causes of the malignancies. Likewise, reagents and methods for specifically detecting BCR-ABL fusion protein in patients, in order to identify patients most likely to respond to targeted inhibitors like Gleevec®, have been described.

30 [0006] Accordingly, there remains a need for the identification of gene translocations or mutations resulting in fusion or mutant proteins implicated in the progression of human cancers, and the development of new reagents and methods for the study and detection of such fusion proteins. Identification of such fusion proteins will, among other things, desirably enable new methods for selecting patients for targeted therapies, as well as for the screening of new drugs that inhibit such mutant/fusion proteins.

35 [0007] WO2007/084631 discloses a novel gene translocation in human non-small cell lung carcinoma (NSCLC) that results in a fusion protein combining part of SLC34A2 with ROS kinase, and provides polynucleotides and vectors encoding the disclosed mutant ROS kinase polypeptides, probes for detecting it, isolated mutant polypeptides, recombinant polypeptides, and reagents for detecting the fusion and truncated polypeptides.

SUMMARY OF THE INVENTION

40 [0008] The invention is as claimed in claims 1-8.

45 [0009] Disclosed herein is a gene translocation involving the ROS kinase gene in human cancer, such as liver, kidney, pancreatic, and testicular cancers (including cancers in the ducts of these tissues, such as bile duct liver cancer), which results in fusion proteins combining part of the FIG protein (a Golgi apparatus protein) with the kinase domain of the ROS kinase. The FIG-ROS fusion proteins (namely, FIG-ROS(S), FIG-ROS(L), and FIG-ROS(XL)) retain ROS tyrosine kinase activity. The invention provides treatment of human cancers such as liver, kidney, pancreatic, and testicular cancers (including cancers in the ducts of these tissues, such as bile duct liver cancer), which arise not only from gene translocations involving the ROS kinase, but also from aberrant expression of the ROS kinase in these tissues. Further disclosed herein is a truncated ROS kinase whereby the kinase domain (with or without the transmembrane domain) of the ROS kinase is active but separated from the rest of the full-length ROS kinase (e.g., separate from the extracellular domain of the ROS protein). The expression of a mutant ROS kinase with active kinase activity may drive the proliferation and survival of liver, pancreatic, kidney, and testicular cancers in a subset of such cancers in which a truncated ROS kinase with active kinase activity is expressed.

50 [0010] Accordingly, disclosed herein is a purified FIG-ROS fusion polypeptide. In some embodiments, the FIG-ROS

fusion polypeptide comprises the amino acid sequence set forth in SEQ ID NO: 4. In some embodiments, the FIG-ROS fusion polypeptide comprises the amino acid sequence set forth in SEQ ID NO: 2. In some embodiments, the FIG-ROS fusion polypeptide comprises the amino acid sequence set forth in SEQ ID NO: 17. In some embodiments, the FIG-ROS fusion polypeptide is encoded by the nucleic acid sequence set forth in SEQ ID NO: 3. In some embodiments, the FIG-ROS fusion polypeptide is encoded by the nucleic acid sequence set forth in SEQ ID NO: 1. In some embodiments, the FIG-ROS fusion polypeptide is encoded by the nucleic acid sequence set forth in SEQ ID NO: 16.

[0011] Also disclosed herein is a purified FIG-ROS fusion polynucleotide. In some embodiments, the FIG-ROS fusion polynucleotide comprises the nucleotide sequence set forth in SEQ ID NO: 3. In some embodiments, the FIG-ROS fusion polynucleotide comprises the nucleotide sequence set forth in SEQ ID NO: 1. In some embodiments, the FIG-ROS fusion polynucleotide comprises the nucleotide sequence set forth in SEQ ID NO: 16.

[0012] Also disclosed herein is a binding agent that specifically binds to a FIG-ROS fusion polypeptide. In some embodiments, the binding agent specifically binds to a fusion junction between a FIG portion and a ROS portion in said FIG-ROS fusion polypeptide. In some embodiments, the fusion junction comprises an amino acid sequence selected from the group consisting of AGSTLP, LQVWHR, and LQAGVP. In some embodiments, the FIG-ROS fusion polypeptide is a FIG-ROS(S) fusion polypeptide, is a FIG-ROS (XL) fusion polypeptide, or is a FIG-ROS (L) fusion polypeptide. In some embodiments, the binding agent is an antibody and an AQUA peptide. In some embodiments, the AQUA peptide comprises an amino acid sequence selected from the group consisting of AGSTLP, LQVWHR, and LQAGVP.

[0013] Also disclosed herein is a nucleotide probe for detecting a FIG-ROS fusion polynucleotide, wherein said probe hybridizes to said FIG-ROS fusion polynucleotide under stringent conditions. In some embodiments, the FIG-ROS fusion polynucleotide comprises the nucleotide sequence set forth in SEQ ID NO: 3. In some embodiments, the FIG-ROS fusion polynucleotide encodes a polypeptide comprising the amino acid sequence set forth in SEQ ID NO: 4. In some embodiments, the FIG-ROS fusion polynucleotide comprises the nucleotide sequence set forth in SEQ ID NO: 1. In some embodiments, the FIG-ROS fusion polynucleotide encodes a polypeptide comprising the amino acid sequence set forth in SEQ ID NO: 2. In some embodiments, the FIG-ROS fusion polynucleotide comprises the nucleotide sequence set forth in SEQ ID NO: 16. In some embodiments, the FIG-ROS fusion polynucleotide encodes a polypeptide comprising the amino acid sequence set forth in SEQ ID NO: 17.

[0014] Also disclosed herein is a method for detecting a FIG-ROS gene translocation, the method comprising contacting a biological sample with a binding agent that specifically binds to a FIG-ROS fusion polypeptide (e.g., a FIG-ROS(S), FIG-ROS(XL), or a FIG-ROS(L) fusion polypeptide), where specific binding of the binding agent to the biological sample indicates the presence of a FIG-ROS gene translocation (e.g., that encodes a FIG-ROS(S), FIG-ROS(XL), or FIG-ROS(L) fusion polypeptide) in said biological sample.

[0015] Also disclosed herein is a method for detecting a FIG-ROS gene translocation by contacting a biological sample with a nucleotide probe that hybridizes to a FIG-ROS fusion polynucleotide under stringent conditions, wherein hybridization of said nucleotide probe to said biological sample indicates a FIG-ROS gene translocation (e.g., that encodes a FIG-ROS(S), FIG-ROS(XL) or FIG-ROS(L) fusion polypeptide) in said biological sample.

[0016] Also disclosed herein is a method for diagnosing a patient as having a cancer or a suspected cancer characterized by a ROS kinase. In some embodiments, the cancer or suspected cancer is not non-small cell lung carcinoma or glioblastoma. The method includes contacting a biological sample of said cancer or suspected cancer (where the biological sample comprising at least one polypeptide) with a binding agent that specifically binds to a mutant ROS polypeptide, wherein specific binding of said binding agent to at least one polypeptide in said biological sample identifies said patient as having a cancer or a suspected cancer characterized by a ROS kinase.

[0017] Also disclosed herein is a method for identifying a cancer (or a suspected cancer) that is likely to respond to a ROS inhibitor. In some embodiments, the cancer or suspected cancer is not non-small cell lung carcinoma or glioblastoma. The method includes contacting a biological sample of said cancer (or suspected cancer) comprising at least one polypeptide, with a binding agent that specifically binds to a mutant ROS polypeptide, wherein specific binding of said binding agent to at least one polypeptide in said biological sample identifies said cancer or suspected cancer as a cancer or suspected cancer that is likely to respond to a ROS inhibitor.

[0018] In various embodiments, the mutant ROS polypeptide is aberrantly expressed wild-type ROS polypeptide. For example, aberrant expression can be where wild-type ROS kinase is overexpressed in a cancer or a suspected cancer as compared to the level of expression of wild-type ROS kinase in normal tissue of the same tissue type as the cancer or suspected cancer. ROS protein expression levels can be determined by standard means (e.g., Western blotting analysis, mass spectrometry, IHC staining).

[0019] In various embodiments, the mutant ROS polypeptide is a truncated ROS polypeptide or a ROS fusion polypeptide. Non-limiting examples of ROS fusion polypeptides include a FIG-ROS(S) fusion polypeptide, a FIG-ROS(L) fusion polypeptide, a FIG-ROS(XL) fusion polypeptide, a SLC34A2-ROS(S) fusion polypeptide, a SLC34A2-ROS(L) fusion polypeptide, a SLC34A2-ROS(VS) fusion polypeptide, and a CD74-ROS fusion polypeptide. Non-limiting examples of a truncated ROS polypeptide include the kinase domain of ROS lacking the extracellular and transmembrane domains of wild-type ROS and the transmembrane and kinase domains of ROS lacking the extracellular domain of wild-type ROS.

[0020] In some embodiments, the binding agent is an antibody or an AQUA peptide. In some embodiments, the cancer is from a patient (e.g., a human patient).

[0021] Also disclosed herein is a method for diagnosing a patient as having a cancer or a suspected cancer characterized by a ROS kinase. In some embodiments, the cancer or suspected cancer is not non-small cell lung carcinoma or glioblastoma. The method includes contacting a biological sample of said cancer or a suspected cancer (where the biological sample comprising at least one nucleic acid molecule) with a probe that hybridizes under stringent conditions to a nucleic acid molecule selected from the group consisting of a FIG-ROS fusion polynucleotide, a SLC34A2-ROS fusion polypeptide, a CD74-ROS fusion polypeptide, and a truncated ROS polynucleotide, and wherein hybridization of said probe to at least one nucleic acid molecule in said biological sample identifies said patient as having a cancer or a suspected cancer characterized by a ROS kinase.

[0022] Also disclosed herein is another method for identifying a cancer (or suspected cancer) that is likely to respond to a ROS inhibitor. The method includes contacting a biological sample of said cancer comprising at least one nucleic acid molecule with a nucleotide probe that hybridizes under stringent conditions to a either a FIG-ROS fusion polynucleotide (e.g., a FIG-ROS(S) or FIG-ROS(L) fusion polynucleotide) or a mutant ROS polynucleotide, and wherein hybridization of said nucleotide probe to at least one nucleic acid molecule in said biological sample identifies said cancer as a cancer that is likely to respond to a ROS inhibitor.

[0023] In some embodiments, the FIG-ROS fusion polynucleotide encodes a FIG-ROS(S) fusion polypeptide, a FIG-ROS(L) fusion polypeptide, or a FIG-ROS(XL) fusion polypeptide. In some embodiments, the SCL34A2-ROS fusion polynucleotide encodes a SCL34A2-ROS(S) fusion polypeptide, a SCL34A2-ROS(L) fusion polypeptide, or a SCL34A2-ROS(VS) fusion polypeptide. In some embodiments, the cancer is from a patient (e.g., a cancer patient). In some embodiments, the patient is human.

[0024] In various embodiments of all aspects of the invention, the cancer may be a liver cancer, a pancreatic cancer, a kidney cancer, or a testicular cancer. In various embodiments, the cancer may be a duct cancer (e.g., a liver bile duct cancer or a pancreatic duct cancer). In further embodiments, the cancer is not a non-small cell lung cancer (NSCLC). In further embodiments, the cancer is not a glioblastoma. In further embodiments, the ROS inhibitor also inhibits the activity of an ALK kinase an LTK kinase, an insulin receptor, or an IGF1 receptor. In the present invention, the ROS inhibitor is PF-02341066 or NVP-TAE684.

[0025] In further embodiments disclosed herein, the ROS inhibitor is a binding agent that specifically binds to a FIG-ROS fusion polypeptide, a binding agent that specifically binds to a truncated ROS polypeptide, an siRNA targeting a FIG-ROS fusion polynucleotide, or an siRNA targeting a truncated ROS polynucleotide.

BRIEF DESCRIPTION OF THE DRAWINGS

[0026]

Fig. 1 shows the location of the FIG gene and ROS gene on chromosome 6. Both FIG and ROS genes are localized on chromosome 6q22.2 with about 0.2 Mega base pairs apart. The FIG gene is also known as the GOPC gene.

Fig. 2 shows the breakpoint in the FIG and the ROS proteins, forming two FIG-ROS fusion proteins. The FIG-ROS (L) fusion protein results from breaks in the Fig and the Ros genes at the black arrows, while the FIG-ROS (S) fusion protein results from breaks in the Fig and the Ros genes at the red arrows.

Fig. 3 is a depiction of an agarose gel showing the detection of the two fusion gene transcripts, FIG-ROS(S) and FIG-ROS(L) formed by the FIG and ROS translocation by RT-PCR in the liver cancer samples from two patients, namely XY3-78T and 090665LC.

Fig. 4 is a depiction of an agarose gel showing the expression of wild-type FIG, wild-type ROS, and the FIG-ROS fusion transcript by RT-PCR in the liver cancer samples from two patients, namely XY3-78T and 090665LC. The U118MG human glioblastoma cell line, which has a FIG-ROS(L) translocation, is also shown. HCC78 a human non-small cell lung cancer cell line, which contains SLC34A2-ROS translocation, was served as a negative control.

Fig. 5 is a depiction of an agarose gel showing the PCR products generated by amplifying genomic DNA from liver cancer samples from patients XY3-78T and 090665LC, and from cell line U118MG.

Fig. 6 is a depiction of a Western blotting analysis showing the expression of FIG-ROS(S) from XY3-78T, FIG-ROS(L) from 090665LC, and FIG-ROS(L) from U118MG cells.

Fig. 7 is a photograph of four tissue culture plates containing 3t3 cells cultured in soft agar, where the 3T3 cells are

stably transfected with FIG-ROS(L) (upper left), FIG-ROS(S) (upper right), src kinase (lower left) and empty vector (lower right).

5 Fig. 8 is a photograph showing nude mice injected with 3T3 cells stably transfected with empty vector (left), FIG-ROS(L) (middle), or FIG-ROS(S).

Figs. 9A and 9B are photographs of cells showing the subcellular localization of FIG-ROS(L) and FIG-ROS(S) in 3T3 cells.

10 Fig. 10 is a depiction of a Western blotting analysis showing the stable expression of FIG-ROS(S), FIG-ROS(L), and FIG-ROS(L) from U118MG in BaF3 cells grown with or without IL-3.

15 Fig. 11 is a line graph showing the ability of BaF3 cells transduced with retrovirus encoding FIG-ROS (S) (red squares) or FIG-ROS(L) (blue diamonds) to grow without the presence of IL-3. BaF3 cells transduced with empty retrovirus is also shown (light purple line).

Fig. 12 is a bar graph showing the results of an in vitro kinase assay (top) made by quantitating the bands on the gel (below) from BaF3 cells transduced with retrovirus encoding FIG-ROS(S), FIG-ROS(L) or empty virus ("neo").

20 Fig. 13 is a line graph showing the cellular growth response in the presence of 0nM, 3nM, 10 nM, 30 nM, 100 nM, 300 nM or 1000 nM TAE-684 of BaF3 expressing FIG-ROS(S) (red squares), BaF3 expressing FIG-ROS(L) (blue diamonds), BaF3 expressing FLT3ITD (green triangles), and Karpas 299 cells (purple Xs).

25 Fig. 14 is a bar graph showing that BaF3 expressing either FIG-ROS(S) or FIG-ROS(L) die by apoptosis in the presence of TAE-684.

Fig. 15 is a depiction of a Western blotting analysis showing that phosphorylation of both FIG-ROS(S) and FIG-ROS(L), as well as their downstream signaling molecules, are inhibited by TAE-684.

30 Fig. 16 is a schematic representation of the various BAC clones that hybridize to the FIG and ROS genes.

Fig.17 is an image of an IHC slide from a representative, non-limiting CCA tissue sample that stained positive for ROS expression.

35 Fig. 18 is an image of an IHC slide from a representative, non-limiting HCC tissue sample that stained moderately positive for ROS expression.

40 Figs. 19A and 9B are images of representative, non-limiting IHC slides stained with the ROS-specific antibody following the addition of peptide ROS-1 (Fig. 19A) and peptide ROS-9 (Fig. 19B).

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

45 [0027] Disclosed herein is a mutant ROS kinase which is expressed in a subset of human liver, kidney, pancreatic, and testicular cancers (e.g., bile duct liver cancer). The mutant ROS kinase may drive the proliferation and survival of liver, pancreatic, kidney, and testicular cancers in a subset of such cancers in which the mutant ROS kinase is expressed.

[0028] The further aspects, advantages, and embodiments of the invention are described in more detail below. Any conflict between an art-understood definition of a word or phrase and a definition of the word or phrase as specifically taught in this specification shall be resolved in favor of the latter. As used herein, the following terms have the meanings indicated. As used in this specification, the singular forms "a," "an" and "the" specifically also encompass the plural forms of the terms to which they refer, unless the content clearly dictates otherwise. The term "about" is used herein to mean approximately, in the region of, roughly, or around. When the term "about" is used in conjunction with a numerical range, it modifies that range by extending the boundaries above and below the numerical values set forth. In general, the term "about" is used herein to modify a numerical value above and below the stated value by a variance of 20%.

[0029] Technical and scientific terms used herein have the meaning commonly understood by one of skill in the art to which the present invention pertains, unless otherwise defined. Reference is made herein to various methodologies and materials known to those of skill in the art. Standard reference works setting forth the general principles of recombinant DNA technology include Sambrook et al., Molecular Cloning: A Laboratory Manual, 2nd Ed., Cold Spring Harbor Laboratory Press, New York (1989); Kaufman et al., Eds., Handbook of Molecular and Cellular Methods in Biology in Medicine,

CRC Press, Boca Raton (1995); McPherson, Ed., Directed Mutagenesis: A Practical Approach, IRL Press, Oxford (1991). Standard reference works setting forth the general principles of pharmacology include Goodman and Gilman's The Pharmacological Basis of Therapeutics, 11th Ed., McGraw Hill Companies Inc., New York (2006).

[0030] The invention relates to the discovery of mutant ROS (i.e., aberrantly expressed full length ROS, truncated (i.e., less than full length) ROS, or ROS fusion proteins (e.g., the FIG-ROS fusions, the SLC34A2-ROS fusions, or the CD74-ROS fusion)) in liver cancer (including bile duct cancer), pancreatic cancer, kidney cancer, and testicular cancer. The invention further relates to the discovery of new ROS gene translocations, resulting in fusions between the FIG gene and the ROS gene.

[0031] Full length (wild-type) ROS kinase is a 2347 amino acid long receptor tyrosine kinase. In humans, ROS kinase RNA has been detected in placenta, lung and skeletal muscle, with possible low levels of expression in testes (see J. Acquaviva, et al., *Biochim. Biophys. Acta* 1795(1):37-52, 2009. However, full-length ROS kinase does not appear to be expressed in normal liver, kidney, and pancreas tissue in humans (see J. Acquaviva, et al., *supra*). While Abcam Inc. (Cambridge, MA) sells a ROS-specific antibody (clone ab5512) that allegedly stains (i.e., specifically binds to) human hepatocarcinoma tissue by IHC, this ab5512 was found to stain paraffin-embedded HCC78 cells (lung carcinoma which express ROS) and HCC827 cells (lung adenocarcinoma which do not express ROS) with equal intensity (cells obtained from the ATCC, data not shown). Additionally, although ROS kinase may be present in human testicular tissue, its expression appears to be limited to the epididymis (see Acquaviva, et al., *supra*).

[0032] Accordingly, disclosed herein is a purified FIG-ROS fusion polypeptide. By "FIG-ROS fusion polypeptide" is meant the FIG-ROS fusion polypeptide (e.g., FIG-ROS(L), FIG-ROS(XL), or FIG-ROS (S)) described herein, obtained from any species, particularly mammalian, including bovine, ovine, porcine, murine, equine, and human, from any source whether natural, synthetic, semi-synthetic, or recombinant.

[0033] By "purified" (or "isolated") refers to a nucleic acid sequence (e.g., a polynucleotide) or an amino acid sequence (e.g., a polypeptide) that is removed or separated from other components present in its natural environment. For example, an isolated FIG-ROS fusion polypeptide is one that is separated from other components of a eukaryotic cell (e.g., the endoplasmic reticulum or cytoplasmic proteins and RNA). An isolated FIG-ROS polynucleotide is one that is separated from other nuclear components (e.g., histones) and/or from upstream or downstream nucleic acid sequences (e.g., an isolated FIG-ROS polynucleotide is separated from the endogenous FIG gene promoter). An isolated nucleic acid sequence of amino acid sequence disclosed herein is at least 60% free, or at least 75% free, or at least 90% free, or at least 95% free from other components present in natural environment of the indicated nucleic acid sequence or acid sequence.

[0034] A FIG-ROS fusion polypeptide disclosed herein is a non-limiting example of mutant ROS polypeptide.

[0035] As used herein, the term "mutant ROS" polypeptide or polynucleotide means either the aberrant expression of the wild-type ROS kinase polypeptide or polynucleotide in a tissue in which ROS kinase is not normally expressed (or expressed at a different level) or the kinase domain of a ROS or a polynucleotide encoding the kinase domain of a ROS kinase without the extracellular domain or without the transmembrane domains of wild-type (i.e., full length) ROS, where the kinase domain (with or without the transmembrane domain) is either alone (also referred to as truncated ROS) or is fused to all or a portion of a second protein (e.g., a FIG protein).

[0036] Wild-type ROS kinase is a 2347 amino acid long receptor tyrosine kinase, where approximately the first 36 amino acids (i.e., the N-terminal 36 amino acids) are the signal peptide. The sequence of human ROS kinase can be found at GenBank Accession No. M34353, and the protein sequence (including the signal peptide) is provided herein as SEQ ID NO: 9.

[0037] Non-limiting examples of the mutant ROS polypeptide disclosed herein include polypeptides comprising the amino acid sequences set forth in SEQ ID NO: 12 or SEQ ID NO: 13. Likewise, in certain embodiments, non-limiting examples of mutant ROS polynucleotides disclosed herein include polynucleotides encoding polypeptides comprising the amino acid sequences set forth in SEQ ID NO: 12 or SEQ ID NO: 13. In some embodiments, the mutant ROS polynucleotide comprises a portion of the nucleotide sequence set forth in SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, or SEQ ID NO: 8. In certain embodiments, the mutant ROS polypeptide disclosed herein does not include the sequences of SEQ ID NO: 10 or SEQ ID NO: 11. Likewise, in certain embodiments, non-limiting examples of mutant ROS polynucleotides disclosed herein do not include polynucleotides encoding polypeptides comprising the amino acid sequences set forth in SEQ ID NO: 10 or SEQ ID NO: 11.

[0038] Thus, a mutant ROS comprises the kinase domain, with or without the transmembrane domain, of ROS (or nucleotide sequences encoding the same) such that the kinase domain of the ROS kinase (with or without the transmembrane domain) is separated from the other domains (e.g., the extracellular domain) of wild-type (i.e., full-length) ROS kinase. The full length amino acid sequence of ROS kinase is provided in SEQ ID NO: 9. The kinase domain of the ROS kinase is provided in SEQ ID NOs: 12 and 13; however the term "mutant ROS" includes also those amino acid residues which flank the kinase domain provided that the flanking amino acid residues are not within the transmembrane domain or extracellular domain of the full-length ROS protein. In some embodiments, the mutant ROS excludes the sequence set forth in SEQ ID NO: 11. In some embodiments, the mutant ROS excludes the sequence set forth in SEQ

5 ID NO: 10. Thus, the mutant ROS described herein includes the amino acid sequence set forth in SEQ ID NO: 3 and a nucleotide sequence encoding the same. The term "mutant ROS polypeptide" also includes a chimeric protein that includes all or part of a second protein fused by a peptide bond to the kinase domain of a ROS polypeptide. As discussed above, one non-limiting example of a mutant ROS polypeptide that is a chimeric protein is the FIG-ROS(S) fusion polypeptide described herein. Likewise, the term "mutant ROS polynucleotide" also includes a polynucleotide encoding a chimeric protein that includes all or part of a second protein fused by a peptide bond to the kinase domain of a ROS polypeptide.

10 [0039] Thus, as used herein, the term mutant ROS includes, without limitation, the FIG-ROS (L) fusion polypeptide (see nucleic acid sequence in SEQ ID NO: 1 and amino acid sequence in SEQ ID NO: 2), the FIG-ROS (S) fusion polypeptide (see nucleic acid sequence in SEQ ID NO: 3 and amino acid sequence in SEQ ID NO: 4), the FIG-ROS(XL) fusion polypeptide (see nucleic acid sequence in SEQ ID NO: 16 and amino acid sequence in SEQ ID NO: 17), the SLC34A2-ROS (L) fusion polypeptide (see nucleic acid sequence in SEQ ID NO: 18 and amino acid sequence in SEQ ID NO: 19), the SLC34A2-ROS (S) fusion protein (see nucleic acid sequence in SEQ ID NO: 20 and amino acid sequence in SEQ ID NO: 21), the SLC34A2-ROS (VS) fusion protein (see nucleic acid sequence in SEQ ID NO: 22 and amino acid sequence in SEQ ID NO: 23), and the CD74-ROS fusion protein (see nucleic acid sequence in SEQ ID NO: 24 and amino acid sequence in SEQ ID NO: 25). Note that additional ROS fusion polypeptides are disclosed in PCT Publication No. WO2007084631; Rikova, K et al., Cell 131:1190-1203, 2007, and PCT Publication No. WO/2009/051846.

15 [0040] As used herein, by "polynucleotide" (or "nucleotide sequence" or "nucleic acid molecule") refers to an oligonucleotide, nucleotide, or polynucleotide, and fragments or portions thereof, and to DNA or RNA of genomic or synthetic origin, which may be single- or double-stranded, and represent the sense or anti-sense strand.

20 [0041] As used herein, by "polypeptide" (or "amino acid sequence" or protein) refers to an oligopeptide, peptide, polypeptide, or protein sequence, and fragments or portions thereof, and to naturally occurring or synthetic molecules. "Amino acid sequence" and like terms, such as "polypeptide" or "protein", are not meant to limit the indicated amino acid sequence to the complete, native amino acid sequence associated with the recited protein molecule.

25 [0042] Disclosed herein, human FIG-ROS gene translocation have been identified using global phosphopeptide profiling in liver cancer samples taken from human patients (see Examples below). These gene translocations which occurs on human chromosome (6q22) result in expression of two variant fusion proteins, namely the FIG-ROS(S) fusion polypeptide and the FIG-ROS(L) fusion polypeptide) that combine the N-terminus of FIG with the kinase domain of ROS.

30 [0043] As used herein, by "cancer" or "cancerous" is meant a cell that shows abnormal growth as compared to a normal (*i.e.*, non-cancerous) cell of the same cell type. For example, a cancerous cell may be metastatic or non-metastatic. A cancerous cell may also show lack of contact inhibition where a normal cell of that same cell type shows contact inhibition. As used herein, by "suspected cancer" or "tissue suspected of being cancerous" is meant a cell or tissue that has some aberrant characteristics (*e.g.*, hyperplastic or lack of contact inhibition) as compared to normal cells or tissues of that same cell or tissue type as the suspected cancer, but where the cell or tissue is not yet confirmed by a physician or pathologist as being cancerous.

35 [0044] As shown in Figs. 1 and 2, the FIG-ROS(L) translocation combines the nucleic acid sequence encoding the N-terminus of FIG (amino acids 1-412) with the nucleic acid sequences encoding the kinase domain of ROS (amino acids 413-878 which correspond to amino acids 1882-2347 from ROS) (see SEQ ID NO: 2), to produce a fusion, namely FIG-ROS(L) fusion polypeptide. The resulting FIG-ROS(L) fusion protein, which comprises 878 amino acids, was found to retain the kinase activity of ROS. In some embodiments, the FIG-ROS fusion polypeptide is a FIG-ROS(L) fusion polypeptide. In some embodiments, the FIG-ROS (L) fusion polypeptide comprises the amino acid sequence set forth in SEQ ID NO: 2. In some embodiments, the FIG-ROS (L) fusion polypeptide is encoded by the nucleic acid sequence set forth in SEQ ID NO: 1.

40 [0045] Also shown in Figs. 1 and 2, the FIG-ROS(S) translocation combines the nucleic acid sequence encoding the N-terminus of FIG (amino acids 1-209) with the nucleic acid sequence encoding the kinase domain of ROS (amino acids 210-630 which correspond to amino acids 1927-2347 from ROS) (see also SEQ ID NO:4), to produce a fusion, namely the FIG-ROS(S) fusion polypeptide. The resulting FIG-ROS(S) fusion protein, which comprises 630 amino acids, was found to retain the kinase activity of ROS. Thus, in some embodiments, the FIG-ROS fusion polypeptide disclosed herein is a FIG-ROS(S) fusion polypeptide. In some embodiments, the FIG-ROS(S) fusion polypeptide comprises the amino acid sequence set forth in SEQ ID NO: 4. In some embodiments, the FIG-ROS(S) fusion polypeptide is encoded by the nucleic acid sequence set forth in SEQ ID NO: 3.

45 [0046] Also disclosed herein is a third FIG-ROS fusion, namely FIG-ROS(XL), which translocation combines the nucleic acid sequence encoding the N-terminus of FIG (amino acids 1-411 or 1-412) with the nucleic acid sequences encoding the transmembrane and kinase domains of ROS kinase to result in a fusion protein of 1009 amino acids in length.

50 [0047] It should be noted that in all of the ROS fusion proteins described herein (*e.g.*, the FIG-ROS fusion proteins, the SLC34A2-ROS fusion proteins, and the CD74-ROS fusion protein), the amino acid at the fusion junction (regardless of the numbering) may appear in either wild-type protein member of the fusion (*e.g.*, the amino acid at the fusion junction in a FIG-ROS fusion polypeptide may appear in either wild-type FIG protein or wild-type ROS protein), or the amino

acid, being created by a codon with nucleotides from fused exons of both protein members, may be unique to the fusion polypeptide and not appear in either wild-type protein member of the fusion.

[0048] The invention provides that mutant ROS may be present in liver cancer (including bile duct cancer), kidney cancer, testicular cancer, and pancreatic cancer. Based on these discoveries, patients suffering from these cancers whose cancers express mutant ROS (e.g., over-express wild-type ROS or express a truncated ROS or a ROS fusion polypeptide such as one of the FIG-ROS fusion polypeptides disclosed herein) may respond favorably to administration of a ROS inhibitor (e.g., the growth of their cancer may slow or stop as compared to untreated patients suffering from the same cancer).

[0049] Disclosed herein are isolated FIG-ROS fusion polypeptides and fragments thereof. The isolated polypeptide can comprise an amino acid sequence at least 95% identical or at least 99% identical to a sequence selected from the group consisting of: (a) an amino acid sequence encoding a FIG-ROS fusion polypeptide comprising the amino acid sequence of SEQ ID NO: 1; (b) an amino acid sequence encoding a FIG-ROS fusion polypeptide comprising the amino acid sequence of SEQ ID NO: 17; (c) an amino acid sequence encoding a FIG-ROS fusion polypeptide comprising all or a portion of the FIG polypeptide with the kinase domain of ROS (e.g., SEQ ID NO: 12 or 13)); and (d) an amino acid sequence encoding a polypeptide comprising at least six contiguous amino acids encompassing the fusion junction of a FIG-ROS fusion polypeptide (e.g., AGSTLP of FIG-ROS (S), LQVWHR of FIG-ROS(L), or LQAGVP of FIG-ROS(XL)).

[0050] Also disclosed herein is an isolated FIG-ROS (S) fusion polypeptide having the amino acid sequence set forth in SEQ ID NO: 4. The isolated FIG-ROS (XL) fusion polypeptide can have the amino acid sequence set forth in SEQ ID NO: 17. In another embodiment, recombinant mutant polypeptides disclosed herein are provided, which may be produced using a recombinant vector or recombinant host cell as described above.

[0051] It will be recognized in the art that some amino acid sequences of a FIG-ROS fusion polypeptide can be varied without significant effect of the structure or function of the mutant protein. If such differences in sequence are contemplated, it should be remembered that there will be critical areas on the protein which determine activity (e.g. the kinase domain of ROS). In general, it is possible to replace residues that form the tertiary structure, provided that residues performing a similar function are used. In other instances, the type of residue may be completely unimportant if the alteration occurs at a non-critical region of the protein.

[0052] Further disclosed herein is a FIG-ROS variant of a FIG-ROS fusion polypeptide that shows substantial ROS kinase activity or that includes regions of FIG and ROS proteins. In some embodiments, a FIG-ROS variant disclosed herein contains conservative substitutions as compared to FIG-ROS(L), FIG-ROS (XL), or FIG-ROS(S). Some non-limiting conservative substitutions include the exchange, one for another, among the aliphatic amino acids Ala, Val, Leu and Ile; exchange of the hydroxyl residues Ser and Thr; exchange of the acidic residues Asp and Glu; exchange of the amide residues Asn and Gln; exchange of the basic residues Lys and Arg; and exchange of the aromatic residues Phe and Tyr. Further examples of conservative amino acid substitutions known to those skilled in the art are: Aromatic: phenylalanine tryptophan tyrosine (e.g., a tryptophan residue is replaced with a phenylalanine); Hydrophobic: leucine isoleucine valine; Polar: glutamine asparagines; Basic: arginine lysine histidine; Acidic: aspartic acid glutamic acid; Small: alanine serine threonine methionine glycine. As indicated in detail above, further guidance concerning which amino acid changes are likely to be phenotypically silent (*i.e.*, are not likely to have a significant deleterious effect on a function) can be found in Bowie et al., *Science* 247, *supra*.

[0053] In some embodiments, a variant may have "nonconservative" changes, *e.g.*, replacement of a glycine with a tryptophan. Similar variants may also include amino acid deletions or insertions, or both. Guidance in determining which amino acid residues may be substituted, inserted, or deleted without abolishing biological or immunological activity may be found using computer programs well known in the art, for example, DNASTAR software.

[0054] The FIG-ROS fusion polypeptides, fragments thereof, and variants thereof disclosed herein may be provided in an isolated or purified form. A recombinantly produced version of a FIG-ROS fusion polypeptide disclosed herein can be substantially purified by the one-step method described in Smith and Johnson, *Gene* 67: 31-40 (1988).

[0055] The polypeptides disclosed herein include the FIG-ROS fusion polypeptides having the sequences set forth in SEQ ID NOs: 2 and 4, and 17 (whether or not including a leader sequence), an amino acid sequence encoding a polypeptide comprising at least six contiguous amino acids encompassing the fusion junction of a FIG-ROS fusion polypeptide disclosed herein, as well as polypeptides that have at least 90% similarity, more preferably at least 95% similarity, and still more preferably at least 96%, 97%, 98% or 99% similarity to those described above.

[0056] By "% similarity" for two polypeptides is intended a similarity score produced by comparing the amino acid sequences of the two polypeptides using the Bestfit program (Wisconsin Sequence Analysis Package, Version 8 for Unix, Genetics Computer Group, University Research Park, 575 Science Drive, Madison, Wis. 53711) and the default settings for determining similarity. Bestfit uses the local homology algorithm of Smith and Waterman (*Advances in Applied Mathematics* 2: 482-489 (1981)) to find the best segment of similarity between two sequences.

[0057] By a polypeptide having an amino acid sequence at least, for example, 95% "identical" to a reference amino acid sequence of a mutant ROS polypeptide disclosed herein is intended that the amino acid sequence of the polypeptide is identical to the reference sequence except that the polypeptide sequence may include up to five amino acid alterations

per each 100 amino acids of the reference amino acid sequence of the FIG-ROS fusion polypeptide. In other words, to obtain a polypeptide having an amino acid sequence at least 95% identical to a reference amino acid sequence, up to 5% of the amino acid residues in the reference sequence may be deleted or substituted with another amino acid, or a number of amino acids up to 5% of the total amino acid residues in the reference sequence may be inserted into the reference sequence. These alterations of the reference sequence may occur at the amino or carboxy terminal positions of the reference amino acid sequence or anywhere between those terminal positions, interspersed either individually among residues in the reference sequence or in one or more contiguous groups within the reference sequence.

[0058] When using Bestfit or any other sequence alignment program to determine whether a particular sequence is, for instance, 95% identical to a reference sequence according to the present disclosure, the parameters are set, of course, such that the percentage of identity is calculated over the full length of the reference amino acid sequence and that gaps in homology of up to 5% of the total number of amino acid residues in the reference sequence are allowed.

[0059] A FIG-ROS fusion polypeptide disclosed herein could be used as a molecular weight marker on SDS-PAGE gels or on molecular sieve gel filtration columns, for example, using methods well known to those of skill in the art.

[0060] As further described in detail below, the polypeptides disclosed herein can also be used to generate fusion polypeptide specific reagents, such as polyclonal and monoclonal antibodies, which are useful in assays for detecting mutant ROS polypeptide expression as described below or as agonists and antagonists capable of enhancing or inhibiting mutant ROS protein function/activity. Further, such polypeptides can be used in the yeast two-hybrid system to "capture" FIG-ROS fusion polypeptide binding proteins, which are also candidate agonist and antagonist disclosed herein. The yeast two hybrid system is described in Fields and Song, *Nature* 340: 245-246 (1989).

[0061] Also disclosed herein is a peptide or polypeptide comprising an epitope-bearing portion of a polypeptide disclosed herein, such as an epitope comprising the fusion junction of a FIG-ROS fusion polypeptide variant. An "epitope" refers to either an immunogenic epitope (*i.e.*, capable of eliciting an immune response) or an antigenic epitope (*i.e.*, the region of a protein molecule to which an antibody can specifically bind. The number of immunogenic epitopes of a protein generally is less than the number of antigenic epitopes. See, for instance, Geysen et al., *Proc. Natl. Acad. Sci. USA* 81:3998-4002 (1983). The production of FIG-ROS fusion polypeptide-specific antibodies disclosed herein is described in further detail below.

[0062] The antibodies that specifically bind to an epitope-bearing peptides or polypeptides are useful to detect a mimicked protein, and antibodies to different peptides may be used for tracking the fate of various regions of a protein precursor which undergoes post-translational processing. The peptides and anti-peptide antibodies may be used in a variety of qualitative or quantitative assays for the mimicked protein, for instance in competition assays since it has been shown that even short peptides (*e.g.*, about 9 amino acids) can bind and displace the larger peptides in immunoprecipitation assays. See, for instance, Wilson et al., *Cell* 37: 767-778 (1984) at 777. The anti-peptide antibodies disclosed herein also are useful for purification of the mimicked protein, for instance, by adsorption chromatography using methods well known in the art. Immunological assay formats are described in further detail below.

[0063] Recombinant mutant ROS kinase polypeptides are also disclosed herein, and may be produced using fusion polynucleotides disclosed herein, as described above. For example, disclosed herein is a method for producing a recombinant FIG-ROS fusion polypeptide by culturing a recombinant host cell (as described above) under conditions suitable for the expression of the fusion polypeptide and recovering the polypeptide. Culture conditions suitable for the growth of host cells and the expression of recombinant polypeptides from such cells are well known to those of skill in the art.

[0064] Also disclosed herein is a purified FIG-ROS fusion polynucleotide. By "FIG-ROS fusion polynucleotide" or "FIG-ROS polynucleotide" is meant a FIG-ROS translocation gene (*i.e.*, a gene that has undergone translocation) or polynucleotide encoding a FIG-ROS fusion polypeptide (*e.g.*, the FIG-ROS(L), FIG-ROS (XL), or FIG-ROS (S)) fusion polypeptides described herein), obtained from any species, particularly mammalian, including bovine, ovine, porcine, murine, equine, and human, from any source whether natural, synthetic, semi-synthetic, or recombinant.

[0065] In some embodiments, the FIG-ROS fusion polynucleotide comprises the nucleotide sequence set forth in SEQ ID NO:1. In some embodiments, the FIG-ROS fusion polynucleotide encodes a polypeptide having the amino acid sequence set forth in SEQ ID NO: 2. In some embodiments, the FIG-ROS fusion polynucleotide comprises the nucleotide sequence set forth in SEQ ID NO:3. In some embodiments, the FIG-ROS fusion polynucleotide encodes a polypeptide having the amino acid sequence set forth in SEQ ID NO: 4. In some embodiments, the FIG-ROS fusion polynucleotide comprises the nucleotide sequence set forth in SEQ ID NO:16. In some embodiments, the FIG-ROS fusion polynucleotide encodes a polypeptide having the amino acid sequence set forth in SEQ ID NO: 17.

[0066] In some embodiments, the FIG-ROS fusion polynucleotide comprises a portion of the nucleotide sequence set forth in SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO:7, SEQ ID NO: 8, SEQ ID NO: 14, SEQ ID NO: 15, or SEQ ID NO: 26. As used herein, a "portion" or "fragment" means a sequence fragment less than the whole sequence (*e.g.*, a 50 nucleotide sequence is a portion of a 100 nucleotide long sequence). In other words, the FIG-ROS fusion polynucleotide may comprise portions of intron sequences that do not encode any amino acids in the resulting FIG-ROS fusion polypeptide.

[0067] Further disclosed herein are isolated polynucleotides that encode a FIG-ROS fusion polypeptide disclosed herein, nucleotide probes that hybridize to such polynucleotides, and methods, vectors, and host cells for utilizing such polynucleotides to produce recombinant fusion polypeptides. Unless otherwise indicated, all nucleotide sequences determined by sequencing a DNA molecule herein were determined using an automated DNA sequencer (such as the

5 Model 373 from Applied Biosystems, Inc.), and all amino acid sequences of polypeptides encoded by DNA molecules determined herein were determined using an automated peptide sequencer. As is known in the art for any DNA sequence determined by this automated approach, any nucleotide sequence determined herein may contain some errors. Nucleotide sequences determined by automation are typically at least about 90% identical, and more typically at least about 95% to about 99.9% identical to the actual nucleotide sequence of the sequenced DNA molecule. The actual sequence 10 can be more precisely determined by other approaches including manual DNA sequencing methods well known in the art. As is also known in the art, a single insertion or deletion in a determined nucleotide sequence compared to the actual sequence will cause a frame shift in translation of the nucleotide sequence such that the predicted amino acid sequence encoded by a determined nucleotide sequence will be completely different from the amino acid sequence actually 15 encoded by the sequenced DNA molecule, beginning at the point of such an insertion or deletion. Unless otherwise indicated, each nucleotide sequence set forth herein is presented as a sequence of deoxyribonucleotides (abbreviated A, G, C and T). However, by "nucleotide sequence" of a nucleic acid molecule or polynucleotide is intended, for a DNA 20 molecule or polynucleotide, a sequence of deoxyribonucleotides, and for an RNA molecule or polynucleotide, the corresponding sequence of ribonucleotides (A, G, C and U), where each thymidine deoxyribonucleotide (T) in the specified deoxyribonucleotide sequence is replaced by the ribonucleotide uridine (U). For instance, reference to an RNA molecule 25 having the sequence of SEQ ID NO: 3 or set forth using deoxyribonucleotide abbreviations is intended to indicate an RNA molecule having a sequence in which each deoxyribonucleotide A, G or C of SEQ ID NO: 3 has been replaced by the corresponding ribonucleotide A, G or C, and each deoxyribonucleotide T has been replaced by a ribonucleotide U.

[0068] Also described herein is an isolated polynucleotide comprising a nucleotide sequence at least about 95% identical to a sequence selected from the group consisting of: (a) a nucleotide sequence encoding a FIG-ROS fusion polypeptide comprising the amino acid sequence of SEQ ID NO: 4 (FIG-ROS(S)); (b) a nucleotide sequence encoding a FIG-ROS fusion polypeptide comprising the amino acid sequence of SEQ ID NO: 17 (FIG-ROS(XL)); (c) a nucleotide sequence comprising at least six contiguous nucleotides encompassing the fusion junction of a FIG-ROS(S) fusion polynucleotide (e.g., AAGTAC), a nucleotide sequence comprising at least six contiguous nucleotides encompassing the fusion junction of a FIG-ROS(XL) fusion polynucleotide (e.g., AAGctg); (d) a nucleotide sequence encoding at least 30 six contiguous amino acid residues encompassing the fusion junction of a FIG-ROS(S) fusion polypeptide (e.g., AGSTLP), (e) a nucleotide sequence encoding at least six contiguous amino acid residues encompassing the fusion junction of a FIG-ROS(XL) fusion polypeptide (e.g., LQAGVP) and (f) a nucleotide sequence complementary to any of the nucleotide sequences of (a), (b), (c), (d), or (e).

[0069] Using the information provided herein, such as the nucleotide sequences set forth in SEQ ID NOs: 1, 3, and 35 16, a nucleic acid molecule disclosed herein encoding a FIG-ROS fusion polypeptide disclosed herein may be obtained using standard cloning and screening procedures, such as those for cloning cDNAs using mRNA as starting material. The fusion gene can also be identified in cDNA libraries in other human cancers in which the FIG-ROS translocation occurs, or in which a deletion or alternative translocation results in expression of a truncated ROS kinase lacking the extracellular domain and may additionally lack the transmembrane domain of the wild type ROS kinase.

[0070] The determined nucleotide sequence of the FIG-ROS translocation genes encode the FIG-ROS(S) fusion polypeptide, the FIG-ROS(L) fusion polypeptide, and the FIG-ROS(XL) fusion polypeptide. The FIG-ROS fusion polynucleotides comprise the portion of the nucleotide sequence of wild type FIG that encodes the N-terminus of that protein with the portion of the nucleotide sequence of wild type ROS that encodes the kinase domain of that protein

[0071] The mature form of the FIG-ROS fusion proteins is also described herein. According to the signal hypothesis, 45 proteins secreted by mammalian cells have a signal or secretory leader sequence which is cleaved from the mature protein once export of the growing protein chain across the rough endoplasmic reticulum has been initiated. Most mammalian cells and even insect cells cleave secreted proteins with the same specificity. However, in some cases, cleavage of a secreted protein is not entirely uniform, which results in two or more mature species on the protein. Further, it has long been known that the cleavage specificity of a secreted protein is ultimately determined by the primary structure 50 of the complete protein, that is, it is inherent in the amino acid sequence of the polypeptide. Therefore, disclosed herein are nucleotide sequences encoding a mature FIG-ROS(S) fusion polypeptide having the nucleotide sequence set forth in SEQ ID NO: 3 with additional nucleic acid residues located 5' to the 5'-terminal residues of SEQ ID NO. 3 and includes the amino acid sequence of a FIG-ROS(S) fusion polypeptide having the amino acid sequence set forth in SEQ ID NO: 4 with additional amino acid residues located N-terminally to the N-terminal residue of SEQ ID NO. 4. Also disclosed 55 herein are nucleotide sequences encoding a mature FIG-ROS(XL) fusion polypeptide having the nucleotide sequence set forth in SEQ ID NO: 16 with additional nucleic acid residues located 5' to the 5'-terminal residues of SEQ ID NO. 16 and includes the amino acid sequence of a FIG-ROS(XL) fusion polypeptide having the amino acid sequence set forth in SEQ ID NO: 17 with additional amino acid residues located N-terminally to the N-terminal residue of SEQ ID NO. 17.

[0072] As indicated, polynucleotides disclosed herein may be in the form of RNA, such as mRNA, or in the form of DNA, including, for instance, cDNA and genomic DNA obtained by cloning or produced synthetically. The DNA may be double-stranded or single-stranded. Single-stranded DNA or RNA may be the coding strand, also known as the sense strand, or it may be the non-coding strand, also referred to as the anti-sense strand.

5 [0073] Isolated polynucleotides disclosed herein are nucleic acid molecules, DNA or RNA, which have been removed from their native environment. For example, recombinant DNA molecules contained in a vector are considered isolated for the purposes of the present disclosure. Further examples of isolated DNA molecules include recombinant DNA molecules maintained in heterologous host cells or purified (partially or substantially) DNA molecules in solution. Isolated RNA molecules include *in vivo* or *in vitro* RNA transcripts of the DNA molecules disclosed herein. Isolated nucleic acid molecules disclosed herein further include such molecules produced synthetically.

10 [0074] Isolated polynucleotides disclosed herein include the nucleic acid molecules having the sequences set forth in (SEQ ID NOs: 1, 3, and 16, nucleic acid molecules comprising the coding sequence for the FIG-ROS(S), FIG-ROS(L), and FIG-ROS(XL) fusion proteins that comprise a sequence different from those described above but which, due to the degeneracy of the genetic code, still a mutant ROS polypeptide disclosed herein. The genetic code is well known in the art, thus, it would be routine for one skilled in the art to generate such degenerate variants.

15 [0075] Also disclosed herein is an isolated polynucleotide encoding the FIG-ROS fusion polypeptide comprising the FIG-ROS translocation nucleotide sequence contained in the above-described cDNA clones. In some embodiments, such nucleic acid molecule will encode the mature FIG-ROS (S) fusion polypeptide, the mature FIG-ROS(L) fusion polypeptide, or the mature FIG-ROS(XL) fusion polypeptide. In another embodiment, an isolated nucleotide sequence 20 encoding a FIG-ROS fusion polypeptide comprising the N-terminal amino acid sequence of FIG and the kinase domain of ROS. In one embodiment, the polypeptide comprising the kinase domain of ROS comprises the amino acid sequence set forth in SEQ ID NO: 12 or SEQ ID NO: 13. In another embodiment, the N-terminal amino acid sequence of FIG and kinase domain of ROS are encoded by the nucleotide sequences set forth in SEQ ID NO: 1, SEQ ID NO: 3, or SEQ ID NO: 16.

25 [0076] Disclosed herein are isolated polynucleotides comprising nucleotide sequences having a sequence complementary to one of the mutant ROS polypeptides disclosed herein. Such isolated molecules, particularly DNA molecules, are useful as probes for gene mapping, by *in situ* hybridization with chromosomes, and for detecting expression of the FIG-ROS fusion protein or truncated ROS kinase polypeptide in human tissue, for instance, by Northern blot analysis.

30 [0077] Also disclosed herein are fragments of the isolated nucleic acid molecules described herein. By a fragment of an isolated FIG-ROS polynucleotide or truncated ROS polynucleotide disclosed herein is intended fragments at least about 15 nucleotides, or at least about 20 nucleotides, still more preferably at least about 30 nucleotides, or at least about 40 nucleotides in length, which are useful as diagnostic probes and primers as discussed herein. Of course, larger fragments of about 50-1500 nucleotides in length are also useful according to the present disclosure, as are fragments corresponding to most, if not all, of the FIG-ROS nucleotide sequence of the cDNAs having sequences set forth in SEQ 35 ID NOs: 1, 3, or 16. By "a fragment at least 20 nucleotides in length", for example, is meant fragments that include 20 or more contiguous bases from the respective nucleotide sequences from which the fragments are derived.

40 [0078] Generation of such DNA fragments is routine to the skilled artisan, and may be accomplished, by way of example, by restriction endonuclease cleavage or shearing by sonication of DNA obtainable from the cDNA clone described herein or synthesized according to the sequence disclosed herein. Alternatively, such fragments can be directly generated synthetically.

45 [0079] Further disclosed herein is an isolated polynucleotide (e.g., a nucleotide probe) that hybridizes under stringent conditions to a mutant ROS kinase polynucleotide disclosed herein, such as a FIG-ROS fusion polynucleotide). The term "stringent conditions" with respect to nucleotide sequence or nucleotide probe hybridization conditions is the "stringency" that occurs within a range from about T_m minus 5 °C (i. e., 5 °C below the melting temperature (T_m) of the probe or sequence) to about 20 °C to 25 °C below T_m . Typical stringent conditions are: overnight incubation at 42 °C in a solution comprising: 50% formamide, 5 X.SSC (750 mM NaCl, 75 mM trisodium citrate), 50 mM sodium phosphate (pH 7.6), 5X Denhardt's solution, 10% dextran sulfate, and 20 micrograms/ml denatured, sheared salmon sperm DNA, followed by washing the filters in 0.1X SSC at about 65 °C. As will be understood by those of skill in the art, the stringency of hybridization may be altered in order to identify or detect identical or related polynucleotide sequences.

50 [0080] By a polynucleotide or nucleotide probe that hybridizes to a reference polynucleotide (e.g., a FIG-ROS(S) fusion polynucleotide) is intended that the polynucleotide or nucleotide probe (e.g., DNA, RNA, or a DNA-RNA hybrid) hybridizes along the entire length of the reference polynucleotide or hybridizes to a portion of the reference polynucleotide that is at least about 15 nucleotides (nt), or to at least about 20 nt, or to at least about 30 nt, or to about 30-70 nt of the reference polynucleotide. These nucleotide probes are useful as diagnostic probes and primers (e.g. for PCR) as discussed herein.

55 [0081] Of course, polynucleotides hybridizing to a larger portion of the reference polynucleotide (e.g. the FIG-ROS(S) fusion polynucleotide having the sequence set forth in SEQ ID NO: 3, for instance, a portion 50-750 nt in length, or even to the entire length of the reference polynucleotide, are useful as probes according to the present disclosure, as are polynucleotides corresponding to most, if not all, of the nucleotide sequence of the cDNAs described herein or the

nucleotide sequences set forth in SEQ ID NOS: 1 or 3.

[0082] As used herein, by "a portion of a polynucleotide of 'at least 15 nucleotides' in length", for example, is intended 15 or more contiguous nucleotides from the nucleotide sequence of the reference polynucleotide. As indicated, such portions are useful as nucleotide probes for use diagnostically according to conventional DNA hybridization techniques or for use as primers for amplification of a target sequence by the polymerase chain reaction (PCR), as described, for instance, in MOLECULAR CLONING, A LABORATORY MANUAL, 2nd. edition, Sambrook, J., Fritsch, E. F. and Maniatis, T., eds., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. (1989). Of course, a polynucleotide which hybridizes only to a poly A sequence (such as the 3' terminal poly(A) tract of the FIG-ROS sequences (e.g., SEQ ID NOS: 1 or 3) or to a complementary stretch of T (or U) resides, would not be included in a polynucleotide disclosed herein used to hybridize to a portion of a nucleic acid disclosed herein, since such a polynucleotide would hybridize to any nucleic acid molecule containing a poly (A) stretch or the complement thereof (e.g., practically any double-stranded cDNA clone).

[0083] As indicated, nucleic acid molecules disclosed herein, which encode a mutant ROS kinase polypeptide disclosed herein, may include but are not limited to those encoding the amino acid sequence of the mature polypeptide, by itself; the coding sequence for the mature polypeptide and additional sequences, such as those encoding the leader or secretory sequence, such as a pre-, or pro- or pre-pro-protein sequence; the coding sequence of the mature polypeptide, with or without the aforementioned additional coding sequences, together with additional, non-coding sequences, including for example, but not limited to introns and non-coding 5' and 3' sequences, such as the transcribed, non-translated sequences that play a role in transcription, mRNA processing, including splicing and polyadenylation signals, for example ribosome binding and stability of mRNA; an additional coding sequence which codes for additional amino acids, such as those which provide additional functionalities.

[0084] Thus, the sequence encoding the polypeptide may be fused to a marker sequence, such as a sequence encoding a peptide that facilitates purification of the fused polypeptide. In certain embodiments of this aspect disclosed herein, the marker amino acid sequence is a hexa-histidine peptide, such as the tag provided in a pQE vector (Qiagen, Inc.), among others, many of which are commercially available. As described in Gentz et al., Proc. Natl. Acad. Sci. USA 86: 821-824 (1989), for instance, hexa-histidine provides for convenient purification of the fusion protein. The "HA" tag is another peptide useful for purification which corresponds to an epitope derived from the influenza hemagglutinin protein, which has been described by Wilson et al., Cell 37: 767 (1984). As discussed below, other such fusion proteins include the FIG-ROS fusion polypeptide itself fused to Fc at the N- or C-terminus.

[0085] Also disclosed herein are variants of the nucleic acid molecules disclosed herein, which encode portions, analogs or derivatives of a FIG-ROS fusion polypeptide or truncated ROS kinase polypeptide disclosed herein. Variants may occur naturally, such as a natural allelic variant. By an "allelic variant" is intended one of several alternate forms of a gene occupying a given locus on a chromosome of an organism. See, e.g. GENES II, Lewin, B., ed., John Wiley & Sons, New York (1985). Non-naturally occurring variants may be produced using art-known mutagenesis techniques.

[0086] Such variants include those produced by nucleotide substitutions, deletions or additions. The substitutions, deletions or additions may involve one or more nucleotides. The variants may be altered in coding regions, non-coding regions, or both. Alterations in the coding regions may produce conservative or non-conservative amino acid substitutions, deletions or additions. Some alterations included are silent substitutions, additions and deletions, which do not alter the properties and activities (e.g. kinase activity) of the FIG-ROS fusion polypeptides disclosed herein.

[0087] Further embodiments include isolated polynucleotides comprising a nucleotide sequence at least 90% identical. In some embodiments the nucleotide is at least 95%, 96%, 97%, 98% or 99% identical, to a mutant ROS polynucleotide disclosed herein (for example, a nucleotide sequence encoding the FIG-ROS(S) fusion polypeptide having the complete amino acid sequence set forth in SEQ ID NOS: 4, or a nucleotide sequence encoding the N-terminal of FIG and the kinase domain of ROS; or a nucleotide complementary to such exemplary sequences.

[0088] By a polynucleotide having a nucleotide sequence at least, for example, 95% "identical" to a reference nucleotide sequence encoding a mutant ROS polypeptide is intended that the nucleotide sequence of the polynucleotide is identical to the reference sequence except that the polynucleotide sequence may include up to five point mutations per each 100 nucleotides of the reference nucleotide sequence encoding the mutant ROS polypeptide. In other words, to obtain a polynucleotide having a nucleotide sequence at least 95% identical to a reference nucleotide sequence, up to 5% of the nucleotides in the reference sequence may be deleted or substituted with another nucleotide, or a number of nucleotides up to 5% of the total nucleotides in the reference sequence may be inserted into the reference sequence. These mutations of the reference sequence may occur at the 5' terminal positions of the reference nucleotide sequence or anywhere between those terminal positions, interspersed either individually among nucleotides in the reference sequence or in one or more contiguous groups within the reference sequence.

[0089] As a practical matter, whether any particular nucleic acid molecule is at least 90%, 95%, 96%, 97%, 98% or 99% identical to, for instance, the nucleotide sequences set forth in SEQ ID NOS: 1 and 3 or to the nucleotide sequence of the cDNA clones described herein can be determined conventionally using known computer programs such as the Bestfit program (Wisconsin Sequence Analysis Package, Version 8 for Unix, Genetics Computer Group, University

Research Park, 575 Science Drive, Madison, Wis. 53711. Bestfit uses the local homology algorithm of Smith and Waterman, *Advances in Applied Mathematics* 2: 482-489 (1981), to find the best segment of homology between two sequences. When using Bestfit or any other sequence alignment program to determine whether a particular sequence is, for instance, 95% identical to a reference FIG-ROS fusion polynucleotide sequence disclosed herein, the parameters are set, of course, such that the percentage of identity is calculated over the full length of the reference nucleotide sequence and that gaps in homology of up to 5% of the total number of nucleotides in the reference sequence are allowed.

5 **[0090]** Also disclosed herein are nucleic acid molecules at least 90%, 95%, 96%, 97%, 98% or 99% identical to the nucleic acid sequences set forth in SEQ ID NOs: 1 or 3, or nucleotides encoding the amino acid sequences set forth in SEQ ID NOs 2, 4, D, or E, irrespective of whether they encode a polypeptide having ROS kinase activity. This is because even where a particular nucleic acid molecule does not encode a fusion polypeptide having ROS kinase activity, one of skill in the art would still know how to use the nucleic acid molecule, for instance, as a hybridization probe or a polymerase chain reaction (PCR) primer. Uses of the nucleic acid molecules disclosed herein that do not encode a polypeptide having kinase include, *inter alia*, (1) isolating the FIG-ROS translocation gene or allelic variants thereof in a cDNA library; (2) *in situ* hybridization (e.g., "FISH") to metaphase chromosomal spreads to provide precise chromosomal location of the FIG-ROS translocation gene, as described in Verma et al., *HUMAN CHROMOSOMES: A MANUAL OF BASIC TECHNIQUES*, Pergamon Press, New York (1988); and Northern Blot analysis for detecting FIG-ROS fusion protein mRNA expression in specific tissues.

10 **[0091]** Further disclosed herein are nucleic acid molecules having sequences at least 95% identical to a nucleic acid sequence that encodes a FIG-ROS fusion polypeptide (e.g., FIG-ROS(S)) or truncated ROS lacking an extracellular domain of wild-type ROS kinase or lacking both the extracellular domain and transmembrane domain of wild-type ROS kinase. In some embodiments, the encoded Fig-ROS fusion polypeptide and/or truncated ROS has kinase activity. Such activity may be similar, but not necessarily identical, to the activity of the FIG-ROS fusion protein disclosed herein (either the full-length protein, the mature protein, or a protein fragment that retains kinase activity), as measured in a particular biological assay. For example, the kinase activity of ROS can be examined by determining its ability to phosphorylate 15 one or more tyrosine containing peptide substrates, for example, "Src-related peptide" (RRLIEDAEYAARG), which is a substrate for many receptor and nonreceptor tyrosine kinases.

20 **[0092]** Due to the degeneracy of the genetic code, one of ordinary skill in the art will immediately recognize that a large number of the nucleic acid molecules having a sequence at least 90%, 95%, 96%, 97%, 98%, or 99% identical to the nucleic acid sequence of the cDNAs described herein, to the nucleic acid sequences set forth in SEQ ID NOs 1, 3, or 16 or to nucleic acid sequences encoding the amino acid sequences set forth in SEQ ID NOs: 2, 4, or 17 will encode 25 a fusion polypeptide having ROS kinase activity. In fact, since degenerate variants of these nucleotide sequences all encode the same polypeptide, this will be clear to the skilled artisan even without performing the above described comparison assay. It will be further recognized in the art that, for such nucleic acid molecules that are not degenerate variants, a reasonable number will also encode a polypeptide that retains ROS kinase activity. This is because the skilled 30 artisan is fully aware of amino acid substitutions that are either less likely or not likely to significantly effect protein function (e.g., replacing one aliphatic amino acid with a second aliphatic amino acid). For example, guidance concerning how to make phenotypically silent amino acid substitutions is provided in Bowie et al., "Deciphering the Message in Protein Sequences: Tolerance to Amino Acid Substitutions," *Science* 247: 1306-1310 (1990), which describes two main approaches for studying the tolerance of an amino acid sequence to change. Skilled artisans familiar with such techniques 35 also appreciate which amino acid changes are likely to be permissive at a certain position of the protein. For example, most buried amino acid residues require nonpolar side chains, whereas few features of surface side chains are generally conserved. Other such phenotypically silent substitutions are described in Bowie et al., *supra.*, and the references cited 40 therein.

45 **[0093]** Methods for DNA sequencing that are well known and generally available in the art may be used to practice any polynucleotide embodiments disclosed herein. The methods may employ such enzymes as the Klenow fragment of DNA polymerase I, SEQUENASE® (US Biochemical Corp, Cleveland, Ohio), Taq polymerase (Invitrogen), thermostable T7 polymerase (Amersham, Chicago, Ill.), or combinations of recombinant polymerases and proofreading exonucleases such as the ELONGASE Amplification System marketed by Gibco BRL (Gaithersburg, Md.). The process may be automated with machines such as the Hamilton Micro Lab 2200 (Hamilton, Reno, Nev.), Peltier Thermal Cycler (PTC200; MJ Research, Watertown, Mass.) and the ABI 377 DNA sequencers (Applied Biosystems).

50 **[0094]** Polynucleotide sequences encoding a mutant ROS polypeptide disclosed herein may be extended utilizing a partial nucleotide sequence and employing various methods known in the art to detect upstream sequences such as promoters and regulatory elements. For example, one method that may be employed, "restriction-site" PCR, uses universal primers to retrieve unknown sequence adjacent to a known locus (Sarkar, G., *PCR Methods Applic.* 2: 318-322 (1993)). In particular, genomic DNA is first amplified in the presence of primer to linker sequence and a primer specific to the known region. Exemplary primers are those described in Example 4 herein. The amplified sequences are then subjected to a second round of PCR with the same linker primer and another specific primer internal to the first one. Products of each round of PCR are transcribed with an appropriate RNA polymerase and sequenced using reverse

transcriptase.

[0095] Inverse PCR may also be used to amplify or extend sequences using divergent primers based on a known region (Triglia et al., *Nucleic Acids Res.* 16: 8186 (1988)). The primers may be designed using OLIGO 4.06 Primer Analysis software (National Biosciences Inc., Plymouth, Minn.), or another appropriate program, to be 22-30 nucleotides in length, to have a GC content of 50% or more, and to anneal to the target sequence at temperatures about 68-72 °C. The method uses several restriction enzymes to generate a suitable fragment in the known region of a gene. The fragment is then circularized by intramolecular ligation and used as a PCR template.

[0096] Another method which may be used is capture PCR which involves PCR amplification of DNA fragments adjacent to a known sequence in human and yeast artificial chromosome DNA (Lagerstrom et al., *PCR Methods Applic.* 1: 111-119 (1991)). In this method, multiple restriction enzyme digestions and ligations may also be used to place an engineered double-stranded sequence into an unknown portion of the DNA molecule before performing PCR. Another method which may be used to retrieve unknown sequences is that described in Parker et al., *Nucleic Acids Res.* 19: 3055-3060 (1991)). Additionally, one may use PCR, nested primers, and PROMOTERFINDER® libraries to walk in genomic DNA (Clontech, Palo Alto, Calif.). This process avoids the need to screen libraries and is useful in finding 15 intron/exon junctions.

[0097] When screening for full-length cDNAs, libraries that have been size-selected to include larger cDNAs may be used or random-primed libraries, which contain more sequences that contain the 5' regions of genes. A randomly primed library is useful for situations in which an oligo d(T) library does not yield a full-length cDNA. Genomic libraries may be useful for extension of sequence into the 5' and 3' non-transcribed regulatory regions.

[0098] Capillary electrophoresis systems, which are commercially available, may be used to analyze the size or confirm the nucleotide sequence of sequencing or PCR products. In particular, capillary sequencing may employ flowable polymers for electrophoretic separation, four different fluorescent dyes (one for each nucleotide) that are laser activated, and detection of the emitted wavelengths by a charge coupled device camera. Output/light intensity may be converted to electrical signal using appropriate software (e.g., GENOTYPER™ and SEQUENCE NAVIGATOR™, Applied Biosystems) and the entire process from loading of samples to computer analysis and electronic data display may be computer controlled. Capillary electrophoresis is useful for the sequencing of small pieces of DNA that might be present in limited amounts in a particular sample.

[0099] Disclosed herein are recombinant vectors that comprise an isolated polynucleotide disclosed herein, host cells which are genetically engineered with the recombinant vectors, and the production of recombinant FIG-ROS polypeptides or fragments thereof by recombinant techniques.

[0100] Recombinant constructs may be introduced into host cells using well-known techniques such infection, transduction, transfection, transvection, electroporation and transformation. The vector may be, for example, a phage, plasmid, viral or retroviral vector. Retroviral vectors may be replication competent or replication defective. In the latter case, viral propagation generally will occur only in complementing host cells.

[0101] The polynucleotides may be joined to a vector containing a selectable marker for propagation in a host. Generally, a plasmid vector is introduced in a precipitate, such as a calcium phosphate precipitate, or in a complex with a charged lipid. If the vector is a virus, it may be packaged in vitro using an appropriate packaging cell line and then transduced into host cells. Vectors comprising cis-acting control regions to the polynucleotide of interest are disclosed herein. Appropriate trans-acting factors may be supplied by the host, supplied by a complementing vector or supplied by the vector itself upon introduction into the host. In certain embodiments in this regard, the vectors provide for specific expression, which may be inducible and/or cell type-specific (e.g., those inducible by environmental factors that are easy to manipulate, such as temperature and nutrient additives).

[0102] The DNA insert comprising a FIG-ROS polynucleotide or truncated ROS polynucleotide disclosed herein should be operatively linked to an appropriate promoter, such as the phage lambda PL promoter, the *E. coli* lac, trp and tac promoters, the SV40 early and late promoters and promoters of retroviral LTRs, to name a few. Other suitable promoters are known to the skilled artisan. The expression constructs will further contain sites for transcription initiation, termination and, in the transcribed region, a ribosome binding site for translation. The coding portion of the mature transcripts expressed by the constructs may include a translation initiating at the beginning and a termination codon (UAA, UGA or UAG) appropriately positioned at the end of the polypeptide to be translated.

[0103] As indicated, the expression vectors may include at least one selectable marker. Such markers include dihydrofolate reductase or neomycin resistance for eukaryotic cell culture and tetracycline or ampicillin resistance genes for culturing in *E. coli* and other bacteria. Representative examples of appropriate hosts include, but are not limited to, bacterial cells, such as *E. coli*, *Streptomyces* and *Salmonella typhimurium* cells; fungal cells, such as yeast cells; insect cells such as *Drosophila S2* and *Spodoptera Sf9* cells; animal cells such as CHO, COS and Bowes melanoma cells; and plant cells. Appropriate culture mediums and conditions for the above-described host cells are known in the art.

[0104] Non-limiting vectors for use in bacteria include pQE70, pQE60 and pQE-9, available from Qiagen; pBS vectors, Phagescript vectors, Bluescript vectors, pNH8A, pNH16a, pNH18A, pNH46A, available from Stratagene; and pTRC99a, pKK223-3, pKK233-3, pDR540, pRIT5 available from Pharmacia. Non-limiting eukaryotic vectors include pWLNEO,

pSV2CAT, pOG44, pXT1 and pSG available from Stratagene; and pSVK3, pBPV, pMSG and pSVL available from Pharmacia. Other suitable vectors will be readily apparent to the skilled artisan.

[0105] Non-limiting bacterial promoters suitable for use in the present disclosure include the *E. coli* lacI and lacZ promoters, the T3 and T7 promoters, the gpt promoter, the lambda PR and PL promoters and the trp promoter. Suitable eukaryotic promoters include the CMV immediate early promoter, the HSV thymidine kinase promoter, the early and late SV40 promoters, the promoters of retroviral LTRs, such as those of the Rous sarcoma virus (RSV), and metallothionein promoters, such as the mouse metallothionein-I promoter.

[0106] In the yeast, *Saccharomyces cerevisiae*, a number of vectors containing constitutive or inducible promoters such as alpha factor, alcohol oxidase, and PGH may be used. For reviews, see Ausubel et al. (1989) CURRENT PROTOCOLS IN MOLECULAR BIOLOGY, John Wiley & Sons, New York, N.Y, and Grant et al., Methods Enzymol. 153: 516-544 (1997).

[0107] Introduction of the construct into the host cell can be effected by calcium phosphate transfection, DEAE-dextran mediated transfection, cationic lipid-mediated transfection, electroporation, transduction, infection or other methods. Such methods are described in many standard laboratory manuals, such as Davis et al., BASIC METHODS IN MOLECULAR BIOLOGY (1986).

[0108] Transcription of DNA encoding a FIG-ROS fusion polypeptide disclosed herein by higher eukaryotes may be increased by inserting an enhancer sequence into the vector. Enhancers are cis-acting elements of DNA, usually about from 10 to 300 bp that act to increase transcriptional activity of a promoter in a given host cell-type. Examples of enhancers include the SV40 enhancer, which is located on the late side of the replication origin at basepairs 100 to 270, the cytomegalovirus early promoter enhancer, the polyoma enhancer on the late side of the replication origin, and adenovirus enhancers.

[0109] For secretion of the translated protein into the lumen of the endoplasmic reticulum, into the periplasmic space or into the extracellular environment, appropriate secretion signals may be incorporated into the expressed polypeptide. The signals may be endogenous to the polypeptide or they may be heterologous signals.

[0110] The polypeptide may be expressed in a modified form, such as a fusion protein (e.g., a GST-fusion), and may include not only secretion signals, but also additional heterologous functional regions. For instance, a region of additional amino acids, particularly charged amino acids, may be added to the N-terminus of the polypeptide to improve stability and persistence in the host cell, during purification, or during subsequent handling and storage. Also, peptide moieties may be added to the polypeptide to facilitate purification. Such regions may be removed prior to final preparation of the polypeptide. The addition of peptide moieties to polypeptides to engender secretion or excretion, to improve stability and to facilitate purification, among others, are familiar and routine techniques in the art.

[0111] In one non-limiting example, a FIG-ROS fusion polypeptide disclosed herein may comprise a heterologous region from an immunoglobulin that is useful to solubilize proteins. For example, EP-A-O 464 533 (Canadian counterpart 2045869) discloses fusion proteins comprising various portions of constant region of immunoglobulin molecules together with another human protein or part thereof. In many cases, the Fc part in a fusion protein is thoroughly advantageous for use in therapy and diagnosis and thus results, for example, in improved pharmacokinetic properties (EP-A 0232 262). On the other hand, for some uses it would be desirable to be able to delete the Fc part after the fusion protein has been expressed, detected and purified in the advantageous manner described. This is the case when Fc portion proves to be a hindrance to use in therapy and diagnosis, for example when the fusion protein is to be used as antigen for immunizations. In drug discovery, for example, human proteins, such as, hIL-5- has been fused with Fc portions for the purpose of high-throughput screening assays to identify antagonists of hIL-5. See Bennett et al., Journal of Molecular Recognition 8: 52-58 (1995) and Johanson et al., The Journal of Biological Chemistry 270(16): 9459-9471 (1995).

[0112] FIG-ROS polypeptides can be recovered and purified from recombinant cell cultures by well-known methods including ammonium sulfate or ethanol precipitation, acid extraction, anion or cation exchange chromatography, phosphocellulose chromatography, hydrophobic interaction chromatography, affinity chromatography, hydroxylapatite chromatography and lectin chromatography. In some embodiments, high performance liquid chromatography ("HPLC") is employed for purification. Polypeptides disclosed herein include naturally purified products, products of chemical synthetic procedures, and products produced by recombinant techniques from a prokaryotic or eukaryotic host, including, for example, bacterial, yeast, higher plant, insect and mammalian cells. Depending upon the host employed in a recombinant production procedure, the polypeptides disclosed herein may be glycosylated or may be non-glycosylated. In addition, polypeptides disclosed herein may also include an initial modified methionine residue, in some cases as a result of host-mediated processes.

[0113] Accordingly, also disclosed herein is a method for producing a recombinant FIG-ROS fusion polypeptide by culturing a recombinant host cell (as described above) under conditions suitable for the expression of the fusion polypeptide and recovering the polypeptide. Culture conditions suitable for the growth of host cells and the expression of recombinant polypeptides from such cells are well known to those of skill in the art. See, e.g., CURRENT PROTOCOLS IN MOLECULAR BIOLOGY, Ausubel FM et al., eds., Volume 2, Chapter 16, Wiley Interscience.

[0114] Further disclosed herein is a binding agent that specifically binds to a FIG-ROS fusion polypeptide. In some

embodiments, the binding agent specifically binds to a fusion junction between a FIG portion and a ROS portion in said FIG-ROS fusion polypeptide. In some embodiments, the FIG-ROS fusion polypeptide is a FIG-ROS(S) fusion polypeptide, a FIG-ROS(L) fusion polypeptide, or a FIG-ROS (XL) fusion polypeptide.

[0115] In some embodiments, the binding agent is attached to a detectable label. By "detectable label" with respect to a polypeptide, polynucleotide, or binding agent disclosed herein means a chemical, biological, or other modification of or to the polypeptide, polynucleotide, or binding agent, including but not limited to fluorescence, mass, residue, dye, radioisotope, label, or tag modifications, etc., by which the presence of the molecule of interest may be detected. The detectable label may be attached to the polypeptide, polynucleotide, or binding agent by a covalent or non-covalent chemical bond.

[0116] Also disclosed herein are binding agents, such as antibodies or AQUA peptides, or binding fractions thereof, that specifically bind to the FIG-ROS fusion polypeptides (e.g., FIG-ROS(S), FIG-ROS(L), or FIG-ROS(XL) disclosed herein). By "specifically binding" or "specifically binds" means that a binding agent disclosed herein (e.g., an antibody or AQUA peptide) interacts with its target molecule (e.g., a FIG-ROS fusion polypeptide), where the interaction is interaction is dependent upon the presence of a particular structure (*i.e.*, the antigenic determinant or epitope) on the protein; in other words, the reagent is recognizing and binding to a specific protein structure rather than to all proteins in general. By "binding fragment thereof" means a fragment or portion of a binding reagent that specifically binds the target molecule (e.g., an Fab fragment of an antibody). A binding agent that specifically binds to the target molecule may be referred to as a target specific binding agent. For example, an antibody that specifically binds to a FIG-ROS(L) polypeptide may be referred to as a FIG-ROS(L) specific antibody. In some embodiments, a binding agent has a binding affinity (K_D) for its target molecule (e.g., a FIG-ROS fusion polypeptide) of 1×10^{-6} M or less. In some embodiments, a binding agent binds to its target molecule with a K_D of 1×10^{-7} M or less, or a K_D of 1×10^{-8} M or less, or a K_D of 1×10^{-9} M or less, or a K_D of 1×10^{-10} M or less, or a K_D of 1×10^{-11} M or less, or a K_D of 1×10^{-12} M or less. In certain embodiments, the K_D of a binding agent for its target molecule is 1 pM to 500 pM, or between 500 pM to 1 μ M, or between 1 μ M to 100 nM, or between 100 mM to 10 nM. Non-limiting examples of a target molecule to which a binding agent specifically binds to include the FIG-ROS(L) fusion polypeptide, the FIG-ROS(S) fusion polypeptide, and fragments thereof, particularly those fragments that include the junction between the FIG portion and the ROS portion of a FIG-ROS fusion polypeptide.

[0117] The binding agent disclosed herein, including those useful in the practice of the disclosed methods, include, among others, FIG-ROS fusion polypeptide specific antibodies and AQUA peptides (heavy-isotope labeled peptides) corresponding to, and suitable for detection and quantification of, FIG-ROS fusion polypeptide expression in a biological sample. Thus, a "FIG-ROS fusion polypeptide-specific binding agent" is any reagent, biological or chemical, capable of specifically binding to, detecting and/or quantifying the presence/level of expressed FIG-ROS fusion polypeptide in a biological sample. The term includes, but is not limited to, the antibodies and AQUA peptide reagents discussed below, and equivalent binding agents.

[0118] In some embodiments, the binding agent that specifically binds to a FIG-ROS fusion polypeptide is an antibody (*i.e.*, a FIG-ROS fusion polypeptide-specific antibody). In some embodiments, a FIG-ROS fusion polypeptide-specific antibody disclosed herein is an isolated antibody or antibodies that specifically bind(s) a FIG-ROS fusion polypeptide disclosed herein (e.g., FIG-ROS(L), FIG-ROS (XL) or FIG-ROS(S)) but does not substantially bind either wild-type FIG or wild-type ROS. Also useful in practicing the methods disclosed herein are other reagents such as epitope-specific antibodies that specifically bind to an epitope in the extracellular or kinase domains of wild-type ROS protein sequence (which domains are not present in the truncated ROS kinase disclosed herein), and are therefore capable of detecting the presence (or absence) of wild type ROS in a sample.

[0119] Human FIG-ROS fusion polypeptide-specific antibodies may also bind to highly homologous and equivalent epitopic peptide sequences in other mammalian species, for example murine or rabbit, and vice versa. Antibodies useful in practicing the methods disclosed herein include (a) monoclonal antibodies, (b) purified polyclonal antibodies that specifically bind to the target polypeptide (e.g., the fusion junction of FIG-ROS fusion polypeptide, (c) antibodies as described in (a)-(b) above that bind equivalent and highly homologous epitopes or phosphorylation sites in other non-human species (e.g., mouse, rat), and (d) fragments of (a)-(c) above that bind to the antigen (or more preferably the epitope) bound by the exemplary antibodies disclosed herein.

[0120] The term "antibody" or "antibodies" refers to all types of immunoglobulins, including IgG, IgM, IgA, IgD, and IgE, including binding fragments thereof (*i.e.*, fragments of an antibody that are capable of specifically binding to the antibody's target molecule, such as F_{ab} , and $F(ab')_2$ fragments), as well as recombinant, humanized, polyclonal, and monoclonal antibodies and/or binding fragments thereof. Antibodies disclosed herein can be derived from any species of animal, such as from a mammal. Non-limiting exemplary natural antibodies include antibodies derived from human, chicken, goats, and rodents (e.g., rats, mice, hamsters and rabbits), including transgenic rodents genetically engineered to produce human antibodies (see, e.g., Lonberg et al., WO93/12227; U.S. Pat. No. 5,545,806; and Kucherlapati, et al., WO91/10741; U.S. Pat. No. 6,150,584. Antibodies disclosed herein may be also be chimeric antibodies. See, e.g., M. Walker et al., Molec. Immunol. 26: 403-11 (1989); Morrison et al., Proc. Nat'l. Acad. Sci. 81: 6851 (1984); Neuberger et al., Nature 312: 604 (1984)). The antibodies may be recombinant monoclonal antibodies produced according to the

methods disclosed in U.S. Pat. No. 4,474,893 (Reading) or U.S. Pat. No. 4,816,567 (Cabilly et al.) The antibodies may also be chemically constructed specific antibodies made according to the method disclosed in U.S. Pat. No. 4,676,980 (Segel et al.).

[0121] Natural antibodies are the antibodies produced by a host animal, however also contemplated are genetically altered antibodies wherein the amino acid sequence has been varied from that of a native antibody. Because of the relevance of recombinant DNA techniques to this application, one need not be confined to the sequences of amino acids found in natural antibodies; antibodies can be redesigned to obtain desired characteristics. The possible variations are many and range from the changing of just one or a few amino acids to the complete redesign of, for example, the variable or constant region. Changes in the constant region will, in general, be made in order to improve or alter characteristics, such as complement fixation, interaction with membranes and other effector functions. Changes in the variable region will be made in order to improve the antigen binding characteristics. The term "humanized antibody", as used herein, refers to antibody molecules in which amino acids have been replaced in the non-antigen binding regions in order to more closely resemble a human antibody, while still retaining the original binding ability. Other antibodies specifically contemplated are oligoclonal antibodies. As used herein, the phrase "oligoclonal antibodies" refers to a predetermined mixture of distinct monoclonal antibodies. See, e.g., PCT publication WO 95/20401; U.S. Patent Nos. 5,789,208 and 6,335,163. In one embodiment, oligoclonal antibodies consisting of a predetermined mixture of antibodies against one or more epitopes are generated in a single cell. In other embodiments, oligoclonal antibodies comprise a plurality of heavy chains capable of pairing with a common light chain to generate antibodies with multiple specificities (e.g., PCT publication WO 04/009618). Oligoclonal antibodies are particularly useful when it is desired to target multiple epitopes on a single target molecule. In view of the assays and epitopes disclosed herein, those skilled in the art can generate or select antibodies or mixtures of antibodies that are applicable for an intended purpose and desired need.

[0122] Recombinant antibodies are also included in the present disclosure. These recombinant antibodies have the same amino acid sequence as the natural antibodies or have altered amino acid sequences of the natural antibodies. They can be made in any expression systems including both prokaryotic and eukaryotic expression systems or using phage display methods (see, e.g., Dower et al., WO91/17271 and McCafferty et al., WO92/01047; U.S. Pat. No. 5,969,108). Antibodies can be engineered in numerous ways. They can be made as single-chain antibodies (including small modular immunopharmaceuticals or SMIPs™), Fab and F(ab')₂ fragments, etc. Antibodies can be humanized, chimerized, deimmunized, or fully human. Numerous publications set forth the many types of antibodies and the methods of engineering such antibodies. For example, see U.S. Patent Nos. 6,355,245; 6,180,370; 5,693,762; 6,407,213; 6,548,640; 5,565,332; 5,225,539; 6,103,889; and 5,260,203. The genetically altered antibodies disclosed herein may be functionally equivalent to the above-mentioned natural antibodies. In certain embodiments, modified antibodies disclosed herein provide improved stability or/and therapeutic efficacy. Non-limiting examples of modified antibodies include those with conservative substitutions of amino acid residues, and one or more deletions or additions of amino acids that do not significantly deleteriously alter the antigen binding utility. Substitutions can range from changing or modifying one or more amino acid residues to complete redesign of a region as long as the therapeutic utility is maintained. Antibodies disclosed herein can be modified post-translationally (e.g., acetylation, and/or phosphorylation) or can be modified synthetically (e.g., the attachment of a labeling group). Antibodies with engineered or variant constant or Fc regions can be useful in modulating effector functions, such as, for example, antigen-dependent cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). Such antibodies with engineered or variant constant or Fc regions may be useful in instances where a parent singling protein (Table 1) is expressed in normal tissue; variant antibodies without effector function in these instances may elicit the desired therapeutic response while not damaging normal tissue. Accordingly, certain aspects and methods of the present disclosure relate to antibodies with altered effector functions that comprise one or more amino acid substitutions, insertions, and/or deletions. The term "biologically active" refers to a protein having structural, regulatory, or biochemical functions of a naturally occurring molecule. Likewise, "immunologically active" refers to the capability of the natural, recombinant, or synthetic FIG-ROS fusion polypeptide or truncated ROS polypeptide, or any oligopeptide thereof, to induce a specific immune response in appropriate animals or cells and to bind with specific antibodies.

[0123] Also disclosed herein are antibody molecules with fewer than 4 chains, including single chain antibodies, Camelid antibodies and the like and components of an antibody, including a heavy chain or a light chain. In some embodiments an immunoglobulin chain may comprise in order from 5' to 3', a variable region and a constant region. The variable region may comprise three complementarity determining regions (CDRs), with interspersed framework (FR) regions for a structure FR1, CDR1, FR2, CDR2, FR3, CDR3 and FR4. Also disclosed herein are heavy or light chain variable regions, framework regions and CDRs. An antibody disclosed herein may comprise a heavy chain constant region that comprises some or all of a CH1 region, hinge, CH2 and CH3 region.

[0124] One non-limiting epitopic site of a FIG-ROS fusion polypeptide specific antibody disclosed herein is a peptide fragment consisting essentially of about 11 to 17 amino acids of a human FIG-ROS fusion polypeptide sequence, which fragment encompasses the fusion junction between the FIG portion of the molecule and the ROS portion of the molecule. It will be appreciated that antibodies that specifically bind shorter or longer peptides/epitopes encompassing the

fusion junction of a FIG-ROS fusion polypeptide are envisaged.

[0125] The disclosure is not limited to use of antibodies, but includes equivalent molecules, such as protein binding domains or nucleic acid aptamers, which bind, in a fusion-protein or truncated-protein specific manner, to essentially the same epitope to which a FIG-ROS fusion polypeptide-specific antibody or ROS truncation point epitope-specific antibody useful in the methods disclosed herein binds. See, e.g., Neuberger et al., *Nature* 312: 604 (1984). Such equivalent non-antibody reagents may be suitably employed in the methods disclosed herein further described below.

[0126] Polyclonal antibodies useful in practicing the methods disclosed herein may be produced according to standard techniques by immunizing a suitable animal (e.g., rabbit, goat, etc.) with an antigen encompassing a desired fusion-protein specific epitope (e.g. the fusion junction between FIG and ROS in the FIG-ROS fusion polypeptide), collecting immune serum from the animal, and separating the polyclonal antibodies from the immune serum, and purifying polyclonal antibodies having the desired specificity, in accordance with known procedures. The antigen may be a synthetic peptide antigen comprising the desired epitopic sequence, selected and constructed in accordance with well-known techniques. See, e.g., *ANTIBODIES: A LABORATORY MANUAL*, Chapter 5, p. 75-76, Harlow & Lane Eds., Cold Spring Harbor Laboratory (1988); Czernik, *Methods In Enzymology*, 201: 264-283 (1991); Merrifield, *J. Am. Chem. Soc.* 85: 21-49 (1962)). Polyclonal antibodies produced as described herein may be screened and isolated as further described below.

[0127] Monoclonal antibodies may also be beneficially employed in the methods disclosed herein, and may be produced in hybridoma cell lines according to the well-known technique of Kohler and Milstein. *Nature* 265: 495-97 (1975); Kohler and Milstein, *Eur. J. Immunol.* 6: 511 (1976); see also, *CURRENT PROTOCOLS IN MOLECULAR BIOLOGY*, Ausubel et al. Eds. (1989). Monoclonal antibodies so produced are highly specific, and improve the selectivity and specificity of assay methods disclosed herein. For example, a solution containing the appropriate antigen (e.g. a synthetic peptide comprising the fusion junction of FIG-ROS fusion polypeptide) may be injected into a mouse and, after a sufficient time (in keeping with conventional techniques), the mouse sacrificed and spleen cells obtained. The spleen cells are then immortalized by fusing them with myeloma cells, typically in the presence of polyethylene glycol, to produce hybridoma cells. Rabbit fusion hybridomas, for example, may be produced as described in U.S Patent No. 5,675,063. The hybridoma cells are then grown in a suitable selection media, such as hypoxanthine-aminopterin-thymidine (HAT), and the supernatant screened for monoclonal antibodies having the desired specificity, as described below. The secreted antibody may be recovered from tissue culture supernatant by conventional methods such as precipitation, ion exchange or affinity chromatography, or the like.

[0128] Monoclonal Fab fragments may also be produced in *Escherichia coli* by recombinant techniques known to those skilled in the art. See, e.g., W. Huse, *Science* 246: 1275-81 (1989); Mullinax et al., *Proc. Nat'l Acad. Sci.* 87: 8095 (1990). If monoclonal antibodies of one isotype are desired for a particular application, particular isotypes can be prepared directly, by selecting from the initial fusion, or prepared secondarily, from a parental hybridoma secreting a monoclonal antibody of different isotype by using the sib selection technique to isolate class-switch variants (Steplewski, et al., *Proc. Nat'l. Acad. Sci.*, 82: 8653 (1985); Spira et al., *J. Immunol. Methods*, 74: 307 (1984)). The antigen combining site of the monoclonal antibody can be cloned by PCR and single-chain antibodies produced as phage-displayed recombinant antibodies or soluble antibodies in *E. coli* (see, e.g., *ANTIBODY ENGINEERING PROTOCOLS*, 1995, Humana Press, Sudhir Paul editor.)

[0129] Further still, U.S. Pat. No. 5,194,392, Geysen (1990) describes a general method of detecting or determining the sequence of monomers (amino acids or other compounds) which is a topological equivalent of the epitope (*i. e.*, a "mimotope") which is complementary to a particular paratope (antigen binding site) of an antibody of interest. More generally, this method involves detecting or determining a sequence of monomers which is a topographical equivalent of a ligand which is complementary to the ligand binding site of a particular receptor of interest. Similarly, U.S. Pat. No. 5,480,971, Houghten et al. (1996) discloses linear C₁-C-alkyl peralkylated oligopeptides and sets and libraries of such peptides, as well as methods for using such oligopeptide sets and libraries for determining the sequence of a peralkylated oligopeptide that preferentially binds to an acceptor molecule of interest. Thus, non-peptide analogs of the epitope-bearing peptides disclosed herein also can be made routinely by these methods.

[0130] Antibodies useful in the methods disclosed herein, whether polyclonal or monoclonal, may be screened for epitope and fusion protein specificity according to standard techniques. See, e.g., Czernik et al., *Methods in Enzymology*, 201: 264-283 (1991). For example, the antibodies may be screened against a peptide library by ELISA to ensure specificity for both the desired antigen and, if desired, for reactivity only with a FIG-ROS fusion polypeptide disclosed herein and not with wild type FIG or wild type ROS. The antibodies may also be tested by Western blotting against cell preparations containing target protein to confirm reactivity with the only the desired target and to ensure no appreciable binding to other fusion proteins involving ROS. The production, screening, and use of fusion protein-specific antibodies is known to those of skill in the art, and has been described. See, e.g., U.S. Patent Publication No. 20050214301.

[0131] FIG-ROS fusion polypeptide-specific antibodies useful in the methods disclosed herein may exhibit some limited cross-reactivity with similar fusion epitopes in other fusion proteins or with the epitopes in wild type FIG and wild type ROS that form the fusion junction. This is not unexpected as most antibodies exhibit some degree of cross-reactivity, and anti-peptide antibodies will often cross-react with epitopes having high homology or identity to the immunizing

peptide. See, e.g., Czernik, *supra*. Cross-reactivity with other fusion proteins is readily characterized by Western blotting alongside markers of known molecular weight. Amino acid sequences of cross-reacting proteins may be examined to identify sites highly homologous or identical to the FIG-ROS fusion polypeptide sequence to which the antibody binds. Undesirable cross-reactivity can be removed by negative selection using antibody purification on peptide columns (e.g. 5 selecting out antibodies that bind either wild type FIG and/or wild type ROS).

[0132] FIG-ROS fusion polypeptide-specific antibodies disclosed herein that are useful in practicing the methods disclosed herein are ideally specific for human fusion polypeptide, but are not limited only to binding the human species, *per se*. The disclosure includes the production and use of antibodies that also bind conserved and highly homologous or identical epitopes in other mammalian species (e.g., mouse, rat, monkey). Highly homologous or identical sequences 10 in other species can readily be identified by standard sequence comparisons, such as using BLAST, with the human FIG-ROS fusion polypeptide sequences disclosed herein (SEQ ID NOs: 1).

[0133] Antibodies employed in the methods disclosed herein may be further characterized by, and validated for, use 15 in a particular assay format, for example FC, IHC, and/or ICC. The use of FIG-ROS fusion polypeptide-specific antibodies in such methods is further described herein. The antibodies described herein, used alone or in the below-described assays, may also be advantageously conjugated to fluorescent dyes (e.g. Alexa488, phycoerythrin), or labels such as 20 quantum dots, for use in multi-parametric analyses along with other signal transduction (phospho-AKT, phospho-Erk 1/2) and/or cell marker (cytokeratin) antibodies, as further described below.

[0134] In practicing the methods disclosed herein, the expression and/or activity of wild type FIG and/or wild type ROS 25 in a given biological sample may also be advantageously examined using antibodies (either phospho-specific or total) for these wild type proteins. For example, CSF receptor phosphorylation-site specific antibodies are commercially available (see CELL SIGNALING TECHNOLOGY, INC., Danvers, MA, 2005/06 Catalogue, #'s 3151, 3155, and 3154; and Upstate Biotechnology, 2006 Catalogue, #06-457). Such antibodies may also be produced according to standard methods, as described above. The amino acid sequences of both human FIG and ROS are published, as are the sequences 30 of these proteins from other species.

[0135] Detection of wild type FIG and wild type ROS expression and/or activation, along with FIG-ROS fusion polypeptide expression, in a biological sample (e.g. a tumor sample) can provide information on whether the fusion protein alone 35 is driving the tumor, or whether wild type ROS is also activated and driving the tumor. Such information is clinically useful in assessing whether targeting the fusion protein or the wild type protein(s), or both, or is likely to be most beneficial in inhibiting progression of the tumor, and in selecting an appropriate therapeutic or combination thereof. Antibodies specific for the wild type ROS kinase extracellular domain, which is not present in the truncated ROS kinase disclosed herein, 40 may be particularly useful for determining the presence/absence of the mutant ROS kinase.

[0136] It will be understood that more than one antibody may be used in the practice of the above-described methods. For example, one or more FIG-ROS fusion polypeptide-specific antibodies together with one or more antibodies specific 45 for another kinase, receptor, or kinase substrate that is suspected of being, or potentially is, activated in a cancer in which FIG-ROS fusion polypeptide is expressed may be simultaneously employed to detect the activity of such other signaling molecules in a biological sample comprising cells from such cancer.

[0137] Those of skill in the art will appreciate that FIG-ROS fusion polypeptides disclosed herein and the epitope-bearing fragments thereof described above can be combined with parts of other molecules to create chimeric polypeptides. For example, an epitope-bearing fragment of a FIG-ROS fusion polypeptide may be combined with the constant 50 domain of immunoglobulins (IgG) to facilitate purification of the chimeric polypeptide and increase the *in vivo* half-life of the chimeric polypeptide (see, e.g., examples of CD4-Ig chimeric proteins in EPA 394,827; Traunecker et al., *Nature* 331: 84-86 (1988)). Fusion proteins that have a disulfide-linked dimeric structure (e.g., from an IgG portion may also be more efficient in binding and neutralizing other molecules than the monomeric FIG-ROS fusion polypeptide alone (see Fountoulakis et al., *J Biochem* 270: 3958-3964(1995)).

[0138] In some embodiments, a binding agent that specifically binds to a FIG-ROS fusion polypeptide is a heavy-isotope labeled peptide (*i. e.*, an AQUA peptide). Such an AQUA peptide may be suitable for the absolute quantification 55 of an expressed FIG-ROS fusion polypeptide in a biological sample. As used herein, the term "heavy-isotope labeled peptide" is used interchangeably with "AQUA peptide". The production and use of AQUA peptides for the absolute quantification or detection of proteins (AQUA) in complex mixtures has been described. See WO/03016861, "Absolute Quantification of Proteins and Modified Forms Thereof by Multistage Mass Spectrometry," Gygi et al. and also Gerber et al., *Proc. Natl. Acad. Sci. U.S.A.* 100: 6940-5 (2003) (the teachings of which are hereby incorporated herein by reference, in their entirety). The term "specifically detects" with respect to such an AQUA peptide means the peptide will only detect and quantify polypeptides and proteins that contain the AQUA peptide sequence and will not substantially detect polypeptides and proteins that do not contain the AQUA peptide sequence.

[0139] The AQUA methodology employs the introduction of a known quantity of at least one heavy-isotope labeled peptide standard (which has a unique signature detectable by LC-SRM chromatography) into a digested biological sample in order to determine, by comparison to the peptide standard, the absolute quantity of a peptide with the same sequence and protein modification in the biological sample. Briefly, the AQUA methodology has two stages: peptide

internal standard selection and validation and method development; and implementation using validated peptide internal standards to detect and quantify a target protein in sample. The method is a powerful technique for detecting and quantifying a given peptide/protein within a complex biological mixture, such as a cell lysate, and may be employed, e.g., to quantify change in protein phosphorylation as a result of drug treatment, or to quantify differences in the level of a protein in different biological states.

[0140] Generally, to develop a suitable internal standard, a particular peptide (or modified peptide) within a target protein sequence is chosen based on its amino acid sequence and the particular protease to be used to digest. The peptide is then generated by solid-phase peptide synthesis such that one residue is replaced with that same residue containing stable isotopes (^{13}C , ^{15}N). The result is a peptide that is chemically identical to its native counterpart formed by proteolysis, but is easily distinguishable by MS via a 7-Da mass shift. The newly synthesized AQUA internal standard peptide is then evaluated by LC-MS/MS. This process provides qualitative information about peptide retention by reverse-phase chromatography, ionization efficiency, and fragmentation via collision-induced dissociation. Informative and abundant fragment ions for sets of native and internal standard peptides are chosen and then specifically monitored in rapid succession as a function of chromatographic retention to form a selected reaction monitoring (LC-SRM) method based on the unique profile of the peptide standard.

[0141] The second stage of the AQUA strategy is its implementation to measure the amount of a protein or modified protein from complex mixtures. Whole cell lysates are typically fractionated by SDS-PAGE gel electrophoresis, and regions of the gel consistent with protein migration are excised. This process is followed by in-gel proteolysis in the presence of the AQUA peptides and LC-SRM analysis. (See Gerber *et al.*, *supra*.) AQUA peptides are spiked in to the complex peptide mixture obtained by digestion of the whole cell lysate with a proteolytic enzyme and subjected to immunoaffinity purification as described above. The retention time and fragmentation pattern of the native peptide formed by digestion (e.g., trypsinization) is identical to that of the AQUA internal standard peptide determined previously; thus, LC-MS/MS analysis using an SRM experiment results in the highly specific and sensitive measurement of both internal standard and analyte directly from extremely complex peptide mixtures.

[0142] Since an absolute amount of the AQUA peptide is added (e.g., 250 fmol), the ratio of the areas under the curve can be used to determine the precise expression levels of a protein or phosphorylated form of a protein in the original cell lysate. In addition, the internal standard is present during in-gel digestion as native peptides are formed, such that peptide extraction efficiency from gel pieces, absolute losses during sample handling (including vacuum centrifugation), and variability during introduction into the LC-MS system do not affect the determined ratio of native and AQUA peptide abundances.

[0143] An AQUA peptide standard is developed for a known sequence previously identified by the IAP-LC-MS/MS method within in a target protein. If the site is modified, one AQUA peptide incorporating the modified form of the particular residue within the site may be developed, and a second AQUA peptide incorporating the unmodified form of the residue developed. In this way, the two standards may be used to detect and quantify both the modified and unmodified forms of the site in a biological sample.

[0144] Peptide internal standards may also be generated by examining the primary amino acid sequence of a protein and determining the boundaries of peptides produced by protease cleavage. Alternatively, a protein may actually be digested with a protease and a particular peptide fragment produced can then be sequenced. Suitable proteases include, but are not limited to, serine proteases (e.g. trypsin, hepsin), metallo proteases (e.g., PUMP1), chymotrypsin, cathepsin, pepsin, thermolysin, carboxypeptidases, etc.

[0145] A peptide sequence within a target protein is selected according to one or more criteria to optimize the use of the peptide as an internal standard. Preferably, the size of the peptide is selected to minimize the chances that the peptide sequence will be repeated elsewhere in other non-target proteins. Thus, a peptide is preferably at least about 6 amino acids. The size of the peptide is also optimized to maximize ionization frequency. Thus, in some embodiments, the peptide is not longer than about 20 amino acids. In some embodiments, the peptide is between about 7 to 15 amino acids in length. A peptide sequence is also selected that is not likely to be chemically reactive during mass spectrometry, thus sequences comprising cysteine, tryptophan, or methionine are avoided.

[0146] A peptide sequence that does not include a modified region of the target region may be selected so that the peptide internal standard can be used to determine the quantity of all forms of the protein. Alternatively, a peptide internal standard encompassing a modified amino acid may be desirable to detect and quantify only the modified form of the target protein. Peptide standards for both modified and unmodified regions can be used together, to determine the extent of a modification in a particular sample (*i.e.* to determine what fraction of the total amount of protein is represented by the modified form). For example, peptide standards for both the phosphorylated and unphosphorylated form of a protein known to be phosphorylated at a particular site can be used to quantify the amount of phosphorylated form in a sample.

[0147] The peptide is labeled using one or more labeled amino acids (*i.e.*, the label is an actual part of the peptide) or less preferably, labels may be attached after synthesis according to standard methods. Preferably, the label is a mass-altering label selected based on the following considerations: The mass should be unique to shift fragments masses produced by MS analysis to regions of the spectrum with low background; the ion mass signature component is the

portion of the labeling moiety that preferably exhibits a unique ion mass signature in MS analysis; the sum of the masses of the constituent atoms of the label is preferably uniquely different than the fragments of all the possible amino acids. As a result, the labeled amino acids and peptides are readily distinguished from unlabeled ones by the ion/mass pattern in the resulting mass spectrum. Preferably, the ion mass signature component imparts a mass to a protein fragment that does not match the residue mass for any of the 20 natural amino acids.

[0148] The label should be robust under the fragmentation conditions of MS and not undergo unfavorable fragmentation. Labeling chemistry should be efficient under a range of conditions, particularly denaturing conditions, and the labeled tag preferably remains soluble in the MS buffer system of choice. The label preferably does not suppress the ionization efficiency of the protein and is not chemically reactive. The label may contain a mixture of two or more isotopically distinct species to generate a unique mass spectrometric pattern at each labeled fragment position. Stable isotopes, such as ^2H , ^{13}C , ^{15}N , ^{17}O , ^{18}O , or ^{34}S , are some non-limiting labels. Pairs of peptide internal standards that incorporate a different isotope label may also be prepared. Non-limiting amino acid residues into which a heavy isotope label may be incorporated include leucine, proline, valine, and phenylalanine.

[0149] Peptide internal standards are characterized according to their mass-to-charge (m/z) ratio, and preferably, also according to their retention time on a chromatographic column (e.g., an HPLC column). Internal standards that co-elute with unlabeled peptides of identical sequence are selected as optimal internal standards. The internal standard is then analyzed by fragmenting the peptide by any suitable means, for example by collision-induced dissociation (CID) using, e.g., argon or helium as a collision gas. The fragments are then analyzed, for example by multistage mass spectrometry (MSⁿ) to obtain a fragment ion spectrum, to obtain a peptide fragmentation signature. Preferably, peptide fragments have significant differences in m/z ratios to enable peaks corresponding to each fragment to be well separated, and a signature that is unique for the target peptide is obtained. If a suitable fragment signature is not obtained at the first stage, additional stages of MS are performed until a unique signature is obtained.

[0150] Fragment ions in the MS/MS and MS³ spectra are typically highly specific for the peptide of interest, and, in conjunction with LC methods, allow a highly selective means of detecting and quantifying a target peptide/protein in a complex protein mixture, such as a cell lysate, containing many thousands or tens of thousands of proteins. Any biological sample potentially containing a target protein/peptide of interest may be assayed. Crude or partially purified cell extracts are preferably employed. Generally, the sample has at least 0.01 mg of protein, typically a concentration of 0.1-10 mg/mL, and may be adjusted to a desired buffer concentration and pH.

[0151] A known amount of a labeled peptide internal standard, preferably about 10 femtmoles, corresponding to a target protein to be detected/quantified is then added to a biological sample, such as a cell lysate. The spiked sample is then digested with one or more protease(s) for a suitable time period to allow digestion. A separation is then performed (e.g. by HPLC, reverse-phase HPLC, capillary electrophoresis, ion exchange chromatography, etc.) to isolate the labeled internal standard and its corresponding target peptide from other peptides in the sample. Microcapillary LC is a one non-limiting method.

[0152] Each isolated peptide is then examined by monitoring of a selected reaction in the MS. This involves using the prior knowledge gained by the characterization of the peptide internal standard and then requiring the MS to continuously monitor a specific ion in the MS/MS or MSⁿ spectrum for both the peptide of interest and the internal standard. After elution, the area under the curve (AUC) for both peptide standard and target peptide peaks are calculated. The ratio of the two areas provides the absolute quantification that can be normalized for the number of cells used in the analysis and the protein's molecular weight, to provide the precise number of copies of the protein per cell. Further details of the AQUA methodology are described in Gygi *et al.*, and Gerber *et al. supra*.

[0153] AQUA internal peptide standards (heavy-isotope labeled peptides) may desirably be produced, as described above, to detect any quantify any unique site (e.g., the fusion junction within a FIG-ROS fusion polypeptide) within a mutant ROS polypeptide disclosed herein. For example, an AQUA phosphopeptide may be prepared that corresponds to the fusion junction sequence of FIG-ROS fusion polypeptide. Peptide standards may be produced for the FIG-ROS fusion junction and such standards employed in the AQUA methodology to detect and quantify the fusion junction (i.e. the presence of FIG-ROS fusion polypeptide) in a biological sample.

[0154] For example, an exemplary AQUA peptide disclosed herein comprises the amino acid sequence AGSTLP, which corresponds to the three amino acids immediately flanking each side of the fusion junction in the second (short) variant of FIG-ROS fusion polypeptide (i. e., FIG-ROS(S) fusion polypeptide). It will be appreciated that larger AQUA peptides comprising the fusion junction sequence (and additional residues downstream or upstream of it) may also be constructed. Similarly, a smaller AQUA peptide comprising less than all of the residues of such sequence (but still comprising the point of fusion junction itself) may alternatively be constructed. Such larger or shorter AQUA peptides are envisaged, and the selection and production of AQUA peptides may be carried out as described above (see Gygi *et al.*, Gerber *et al. supra*).

[0155] Also disclosed herein is a method for detecting a FIG-ROS gene translocation, the method comprising contacting a biological sample with a binding agent that specifically binds to a FIG-ROS fusion polypeptide (e.g., a FIG-ROS(S), FIG-ROS(XL) or a FIG-ROS(L) fusion polypeptide), where specific binding of the binding agent to the biological sample

indicates the presence of a FIG-ROS gene translocation (e.g., that encodes a FIG-ROS(S), FIG-ROS(XL) or FIG-ROS(L) fusion polypeptide) in said biological sample.

[0156] Also disclosed herein is a method for detecting a FIG-ROS gene translocation by contacting a biological sample with a nucleotide probe that hybridizes to a FIG-ROS fusion polynucleotide under stringent conditions, wherein hybridization of said nucleotide probe to said biological sample indicates a FIG-ROS gene translocation (e.g., that encodes a FIG-ROS(S), FIG-ROS(XL), or FIG-ROS(L) fusion polypeptide) in said biological sample.

[0157] Also disclosed herein is a method for identifying a cancer that is likely to respond to a ROS inhibitor. The method includes contacting a biological sample of said cancer comprising at least one polypeptide with a binding agent that specifically binds to either a FIG-ROS fusion polypeptide (e.g., a FIG-ROS(S), FIG-ROS(XL), or FIG-ROS(L) fusion polypeptide) or a mutant ROS polypeptide, wherein specific binding of said binding agent to at least one polypeptide in said biological sample identifies said cancer as a cancer that is likely to respond to a ROS inhibitor. In some embodiments, the binding agent is an antibody or an AQUA peptide. In some embodiments, the cancer is from a patient (e.g., a cancer patient). In further embodiments, the cancer may be a liver cancer, a pancreatic cancer, a kidney cancer, a testicular cancer, or may be a duct cancer (e.g., a bile duct cancer or a pancreatic duct cancer).

[0158] As used herein, by "likely to respond" is meant that a cancer is more likely to show growth retardation or abrogation in response to (e.g., upon contact with or treatment by) a ROS inhibitor. In some embodiments, a cancer that is likely to respond to a ROS inhibitor is one that dies (e.g., the cancer cells apoptose) in response to the ROS inhibitor.

[0159] As described herein, certain normal cells (e.g., liver cells) do not express any ROS kinase (or show any ROS kinase activity) while cancerous cells of that cell type do. This may be, for example, because the cancerous cell expresses a truncated ROS polypeptide or a ROS fusion protein (e.g., a FIG-ROS fusion polypeptide). The cancerous cell may also simply overexpress wild-type, full-length ROS kinase (where "overexpress" simply means that the cancerous cell expresses more ROS kinase than a non-cancerous cell of that same cell type). As mentioned above, such overexpression of ROS is included in the term "mutant ROS". For example, as described below, normal liver cells do not express ROS kinase (and do not show any ROS kinase activity) while cancerous liver cells do. Thus, in some embodiments disclosed herein, the identification of the presence of the ROS kinase (or the identification of the presence of ROS kinase activity) in a cell type that does not normally express ROS (or show any ROS kinase activity) may be an indicator that the cell thus identified is a cancer that is likely to respond to a ROS inhibitor. This identification of the presence of ROS kinase (or ROS kinase activity) may be followed by further analysis of the ROS kinase within that cell (e.g., binding of a protein in the cell with a binding agent that specifically binds to a mutant ROS polypeptide or hybridization of a nucleic acid molecule from the cell with a probe that hybridizes to a mutant ROS polynucleotide).

[0160] Also disclosed herein is another method for identifying a cancer that is likely to respond to a ROS inhibitor. The method includes contacting a biological sample of said cancer comprising at least one nucleic acid molecule with a nucleotide probe that hybridizes under stringent conditions to either a FIG-ROS fusion polynucleotide (e.g., a FIG-ROS(S), FIG-ROS(XL), or FIG-ROS(L) fusion polynucleotide) or a mutant ROS polynucleotide, and wherein hybridization of said nucleotide probe to at least one nucleic acid molecule in said biological sample identifies said cancer as a cancer that is likely to respond to a ROS inhibitor. In some embodiments, the FIG-ROS fusion polynucleotide encodes a FIG-ROS(S) fusion polypeptide. In some embodiments, the FIG-ROS fusion polynucleotide encodes a FIG-ROS(L) fusion polypeptide. In some embodiments, the FIG-ROS fusion polynucleotide encodes a FIG-ROS(XL) fusion polypeptide. In some embodiments, the cancer is from a patient (e.g., a cancer patient). In further embodiments, the cancer may be a liver cancer, a pancreatic cancer, a kidney cancer, a testicular cancer, or may be a duct cancer (e.g., a bile duct cancer or a pancreatic duct cancer).

[0161] The methods disclosed herein may be carried out in a variety of different assay formats known to those of skill in the art. Some non-limiting examples of methods include immunoassays and peptide and nucleotide assays.

45 Immunoassays.

[0162] Immunoassays useful in the practice of the methods disclosed herein may be homogenous immunoassays or heterogeneous immunoassays. In a homogeneous assay the immunological reaction usually involves a mutant ROS polypeptide-specific reagent (e.g. a FIG-ROS fusion polypeptide-specific antibody), a labeled analyte, and the biological sample of interest. The signal arising from the label is modified, directly or indirectly, upon the binding of the antibody to the labeled analyte. Both the immunological reaction and detection of the extent thereof are carried out in a homogeneous solution. Immunochemical labels that may be employed include free radicals, radio-isotopes, fluorescent dyes, enzymes, bacteriophages, coenzymes, and so forth. Semi-conductor nanocrystal labels, or "quantum dots", may also be advantageously employed, and their preparation and use has been well described. See generally, K. Barovsky, Nanotech. Law & Bus. 1(2): Article 14 (2004) and patents cited therein.

[0163] In a heterogeneous assay approach, the reagents are usually the biological sample, a mutant ROS kinase polypeptide-specific reagent (e.g., an antibody), and suitable means for producing a detectable signal. Biological samples as further described below may be used. The antibody is generally immobilized on a support, such as a bead, plate or

slide, and contacted with the sample suspected of containing the antigen in a liquid phase. The support is then separated from the liquid phase and either the support phase or the liquid phase is examined for a detectable signal employing means for producing such signal. The signal is related to the presence of the analyte in the biological sample. Means for producing a detectable signal include the use of radioactive labels, fluorescent labels, enzyme labels, quantum dots, and so forth. For example, if the antigen to be detected contains a second binding site, an antibody which binds to that site can be conjugated to a detectable group and added to the liquid phase reaction solution before the separation step. The presence of the detectable group on the solid support indicates the presence of the antigen in the test sample. Examples of suitable immunoassays are the radioimmunoassay, immunofluorescence methods, enzyme-linked immunoassays, and the like.

[0164] Immunoassay formats and variations thereof, which may be useful for carrying out the methods disclosed herein, are well known in the art. See generally E. Maggio, Enzyme-Immunoassay, (1980) (CRC Press, Inc., Boca Raton, Fla.); see also, e.g., U.S. Pat. No. 4,727,022 (Skold *et al.*, "Methods for Modulating Ligand-Receptor Interactions and their Application"); U.S. Pat. No. 4,659,678 (Forrest *et al.*, "Immunoassay of Antigens"); U.S. Pat. No. 4,376,110 (David *et al.*, "Immunometric Assays Using Monoclonal Antibodies"). Conditions suitable for the formation of reagent-antibody complexes are well known to those of skill in the art. See *id.* FIG-ROS fusion polypeptide-specific monoclonal antibodies may be used in a "two-site" or "sandwich" assay, with a single hybridoma cell line serving as a source for both the labeled monoclonal antibody and the bound monoclonal antibody. Such assays are described in U.S. Pat. No. 4,376,110. The concentration of detectable reagent should be sufficient such that the binding of FIG-ROS fusion polypeptide is detectable compared to background.

[0165] Antibodies useful in the practice of the methods disclosed herein may be conjugated to a solid support suitable for a diagnostic assay (e.g., beads, plates, slides or wells formed from materials such as latex or polystyrene) in accordance with known techniques, such as precipitation. Antibodies or other FIG-ROS fusion polypeptide-binding reagents may likewise be conjugated to detectable groups such as radiolabels (e.g., ^{35}S , ^{125}I , ^{131}I), enzyme labels (e.g., horseradish peroxidase, alkaline phosphatase), and fluorescent labels (e.g., fluorescein) in accordance with known techniques.

[0166] Cell-based assays, such flow cytometry (FC), immuno-histochemistry (IHC), or immunofluorescence (IF) are particularly desirable in practicing the methods disclosed herein, since such assay formats are clinically-suitable, allow the detection of mutant ROS polypeptide expression *in vivo*, and avoid the risk of artifact changes in activity resulting from manipulating cells obtained from, e.g. a tumor sample in order to obtain extracts. Accordingly, in some embodiments, the methods disclosed herein are implemented in a flow-cytometry (FC), immuno-histochemistry (IHC), or immunofluorescence (IF) assay format.

[0167] Flow cytometry (FC) may be employed to determine the expression of mutant ROS polypeptide in a mammalian tumor before, during, and after treatment with a drug targeted at inhibiting ROS kinase activity. For example, tumor cells from a fine needle aspirate may be analyzed by flow cytometry for FIG-ROS fusion polypeptide expression and/or activation, as well as for markers identifying cancer cell types, etc., if so desired. Flow cytometry may be carried out according to standard methods. See, e.g. Chow *et al.*, Cytometry (Communications in Clinical Cytometry) 46: 72-78 (2001). Briefly and by way of example, the following protocol for cytometric analysis may be employed: fixation of the cells with 2% paraformaldehyde for 10 minutes at 37 C followed by permeabilization in 90% methanol for 10 minutes on ice. Cells may then be stained with the primary FIG-ROS fusion polypeptide-specific antibody, washed and labeled with a fluorescent-labeled secondary antibody. The cells would then be analyzed on a flow cytometer (e.g. a Beckman Coulter FC500) according to the specific protocols of the instrument used. Such an analysis would identify the level of expressed FIG-ROS fusion polypeptide in the tumor. Similar analysis after treatment of the tumor with a ROS-inhibiting therapeutic would reveal the responsiveness of a FIG-ROS fusion polypeptide-expressing tumor to the targeted inhibitor of ROS kinase.

[0168] Immunohistochemical (IHC) staining may be also employed to determine the expression and/or activation status of mutant ROS kinase polypeptide in a mammalian cancer (e.g., a liver or pancreatic cancer) before, during, and after treatment with a drug targeted at inhibiting ROS kinase activity. IHC may be carried out according to well-known techniques. See, e.g., ANTIBODIES: A LABORATORY MANUAL, Chapter 10, Harlow & Lane Eds., Cold Spring Harbor Laboratory (1988). Briefly, and by way of example, paraffin-embedded tissue (e.g. tumor tissue from a biopsy) is prepared for immunohistochemical staining by deparaffinizing tissue sections with xylene followed by ethanol; hydrating in water then PBS; unmasking antigen by heating slide in sodium citrate buffer; incubating sections in hydrogen peroxide; blocking in blocking solution; incubating slide in primary anti-FIG-ROS fusion polypeptide antibody and secondary antibody; and finally detecting using ABC avidin/biotin method according to manufacturer's instructions.

[0169] Immunofluorescence (IF) assays may be also employed to determine the expression and/or activation status of FIG-ROS fusion polypeptide in a mammalian cancer before, during, and after treatment with a drug targeted at inhibiting ROS kinase activity. IF may be carried out according to well-known techniques. See, e.g., J.M. polak and S. Van Noorden (1997) INTRODUCTION TO IMMUNOCYTOCHEMISTRY, 2nd Ed.; ROYAL MICROSCOPY SOCIETY MICROSCOPY HANDBOOK 37, BioScientific/Springer-Verlag. Briefly, and by way of example, patient samples may be fixed in paraformaldehyde followed by methanol, blocked with a blocking solution such as horse serum, incubated with the primary

antibody against FIG-ROS fusion polypeptide followed by a secondary antibody labeled with a fluorescent dye such as Alexa 488 and analyzed with an epifluorescent microscope.

[0170] A variety of other protocols, including enzyme-linked immunosorbent assay (ELISA), radio-immunoassay (RIA), and fluorescent-activated cell sorting (FACS), for measuring mutant ROS kinase polypeptides are known in the art and provide a basis for diagnosing altered or abnormal levels of FIG-ROS fusion polypeptide expression. Normal or standard values for FIG-ROS fusion polypeptide expression are established by combining body fluids or cell extracts taken from normal mammalian subjects, preferably human, with antibody to FIG-ROS fusion polypeptide under conditions suitable for complex formation. The amount of standard complex formation may be quantified by various methods, but preferably by photometric means. Quantities of FIG-ROS fusion polypeptide expressed in subject, control, and disease samples from biopsied tissues are compared with the standard values. Deviation between standard and subject values establishes the parameters for diagnosing disease.

Peptide & Nucleotide Assays.

[0171] Similarly, AQUA peptides for the detection/quantification of expressed mutant ROS polypeptide in a biological sample comprising cells from a tumor may be prepared and used in standard AQUA assays, as described in detail above. Accordingly, in some embodiments of the methods disclosed herein, the FIG-ROS fusion polypeptide-specific reagent comprises a heavy isotope labeled phosphopeptide (AQUA peptide) corresponding to a peptide sequence comprising the fusion junction of FIG-ROS fusion polypeptide, as described above.

[0172] FIG-ROS fusion polypeptide-specific reagents useful in practicing the methods disclosed herein may also be mRNA, oligonucleotide or DNA probes that can directly hybridize to, and detect, fusion or truncated polypeptide expression transcripts in a biological sample. Such probes are discussed in detail herein. Briefly, and by way of example, formalin-fixed, paraffin-embedded patient samples may be probed with a fluorescein-labeled RNA probe followed by washes with formamide, SSC and PBS and analysis with a fluorescent microscope.

[0173] Polynucleotides encoding mutant ROS kinase polypeptide may also be used for diagnostic purposes. The polynucleotides that may be used include oligonucleotide sequences, antisense RNA and DNA molecules, and PNAs. The polynucleotides may be used to detect and quantitate gene expression in biopsied tissues in which expression of FIG-ROS fusion polypeptide or truncated ROS polypeptide may be correlated with disease. The diagnostic assay may be used to distinguish between absence, presence, and excess expression of FIG -ROS fusion polypeptide, and to monitor regulation of FIG -ROS fusion polypeptide levels during therapeutic intervention.

[0174] In one embodiment, hybridization with PCR probes which are capable of detecting polynucleotide sequences, including genomic sequences, encoding FIG-ROS fusion polypeptide or truncated ROS kinase polypeptide or closely related molecules, may be used to identify nucleic acid sequences that encode mutant ROS polypeptide. The construction and use of such probes is described herein. The specificity of the probe, whether it is made from a highly specific region, e.g., 10 unique nucleotides in the fusion junction, or a less specific region, e.g., the 3' coding region, and the stringency of the hybridization or amplification (maximal, high, intermediate, or low) will determine whether the probe identifies only naturally occurring sequences encoding mutant ROS kinase polypeptide, alleles, or related sequences.

[0175] Probes may also be used for the detection of related sequences, and should preferably contain at least 50% of the nucleotides from any of the mutant ROS polypeptide encoding sequences. The hybridization probes disclosed herein may be DNA or RNA and derived from the nucleotide sequences of SEQ ID NOs: 2 or SEQ ID NO: 16, most preferably encompassing the fusion junction, or from genomic sequence including promoter, enhancer elements, and introns of the naturally occurring FIG and ROS polypeptides, as further described above.

[0176] A FIG-ROS fusion polynucleotide or truncated ROS polynucleotide disclosed herein may be used in Southern or northern analysis, dot blot, or other membrane-based technologies; in PCR technologies; or in dip stick, pin, ELISA or chip assays utilizing fluids or tissues from patient biopsies to detect altered mutant ROS kinase polypeptide expression. Such qualitative or quantitative methods are well known in the art. In a particular aspect, the nucleotide sequences encoding mutant ROS polypeptide may be useful in assays that detect activation or induction of various cancers, including cancers of the liver, pancreas, kidneys, and testes (as well as cancers that arise in the ducts, such as the bile duct, of these tissues). Mutant ROS polynucleotides may be labeled by standard methods, and added to a fluid or tissue sample from a patient under conditions suitable for the formation of hybridization complexes. After a suitable incubation period, the sample is washed and the signal is quantitated and compared with a standard value. If the amount of signal in the biopsied or extracted sample is significantly altered from that of a comparable control sample, the nucleotide sequences have hybridized with nucleotide sequences in the sample, and the presence of altered levels of nucleotide sequences encoding FIG -ROS fusion polypeptide or truncated ROS kinase polypeptide in the sample indicates the presence of the associated disease. Such assays may also be used to evaluate the efficacy of a particular therapeutic treatment regimen in animal studies, in clinical trials, or in monitoring the treatment of an individual patient.

[0177] Also disclosed herein is a method for diagnosing a patient as having a cancer or a suspected cancer driven by a ROS kinase. The method includes contacting a biological sample of said cancer or a suspected cancer (where the

5 biological sample comprising at least one nucleic acid molecule) with a probe that hybridizes under stringent conditions to a nucleic acid molecule selected from the group consisting of a FIG-ROS fusion polynucleotide, a SLC34A2-ROS fusion polypeptide, a CD74-ROS fusion polypeptide, and a truncated ROS polynucleotide, and wherein hybridization of said probe to at least one nucleic acid molecule in said biological sample identifies said patient as having a cancer or a suspected cancer driven by a ROS kinase.

10 [0178] Further disclosed herein is a method for diagnosing a patient as having a cancer or a suspected cancer driven by a ROS kinase. The method includes contacting a biological sample of said cancer or suspected cancer (where said biological sample comprises at least one polypeptide) with a binding agent that specifically binds to a mutant ROS polypeptide, wherein specific binding of said binding agent to at least one polypeptide in said biological sample identifies said patient as having a cancer or a suspected cancer driven by a ROS kinase.

15 [0179] In order to provide a basis for the diagnosis of disease (e.g., a cancer) characterized by expression of mutant ROS polypeptide (e.g., a FIG-ROS(S) fusion polypeptide), a normal or standard profile for expression is established. This may be accomplished by combining body fluids or cell extracts taken from normal subjects, either animal or human, with a sequence, or a fragment thereof, which encodes FIG-ROS fusion polypeptide or truncated ROS kinase polypeptide, under conditions suitable for hybridization or amplification. Standard hybridization may be quantified by comparing the values obtained from normal subjects with those from an experiment where a known amount of a substantially purified polynucleotide is used. Standard values obtained from normal samples may be compared with values obtained from samples from patients who are symptomatic for disease. Deviation between standard and subject values is used to establish the presence of disease.

20 [0180] Once disease is established and a treatment protocol is initiated, hybridization assays may be repeated on a regular basis to evaluate whether the level of expression in the patient begins to approximate that which is observed in the normal patient. The results obtained from successive assays may be used to show the efficacy of treatment over a period ranging from several days to months.

25 [0181] Additional diagnostic uses for FIG-ROS fusion polynucleotides and truncated ROS polynucleotides (i.e., either lacking the sequences encoding the extracellular domain of wild-type ROS or lacking the sequences encoding both the extracellular and transmembrane domains of wild-type ROS) disclosed herein may involve the use of polymerase chain reaction (PCR), another assay format that is standard to those of skill in the art. See, e.g., MOLECULAR CLONING, A LABORATORY MANUAL, 2nd. edition, Sambrook, J., Fritsch, E. F. and Maniatis, T., eds., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. (1989). PCR oligomers may be chemically synthesized, generated enzymatically, or produced from a recombinant source. Oligomers will preferably consist of two nucleotide sequences, one with sense orientation (5' to 3') and another with antisense (3' to 5'), employed under optimized conditions for identification of a specific gene or condition. The same two oligomers, nested sets of oligomers, or even a degenerate pool of oligomers may be employed under less stringent conditions for detection and/or quantitation of closely related DNA or RNA sequences.

30 [0182] Methods which may also be used to quantitate the expression of FIG-ROS fusion polypeptide or truncated ROS kinase polypeptide include radiolabeling or biotinylation nucleotides, coamplification of a control nucleic acid, and standard curves onto which the experimental results are interpolated (Melby et al., J. Immunol. Methods, 159: 235-244 (1993); Duplaa et al. Anal. Biochem. 229-236 (1993)). The speed of quantitation of multiple samples may be accelerated by running the assay in an ELISA format where the oligomer of interest is presented in various dilutions and a spectrophotometric or colorimetric response gives rapid quantitation.

35 [0183] In another embodiment disclosed herein, the mutant ROS polynucleotides disclosed herein may be used to generate hybridization probes which are useful for mapping the naturally occurring genomic sequence. The sequences may be mapped to a particular chromosome or to a specific region of the chromosome using well known techniques. Such techniques include fluorescence in-situ hybridization (FISH), FACS, or artificial chromosome constructions, such as yeast artificial chromosomes, bacterial artificial chromosomes, bacterial P1 constructions or single chromosome cDNA libraries, as reviewed in Price, C. M., Blood Rev. 7: 127-134 (1993), and Trask, B. J., Trends Genet. 7: 149-154 (1991).

40 [0184] In one embodiment, fluorescence in-situ hybridization (FISH) is employed (as described in Verma et al. HUMAN CHROMOSOMES: A MANUAL OF BASIC TECHNIQUES, Pergamon Press, New York, N.Y. (1988)) and may be correlated with other physical chromosome mapping techniques and genetic map data. The FISH technique is well known (see, e.g., US Patent Nos. 5,756,696; 5,447,841; 5,776,688; and 5,663,319). Examples of genetic map data can be found in the 1994 Genome Issue of Science (265: 1981f). Correlation between the location of the gene encoding FIG-ROS fusion polypeptide or truncated ROS polypeptide on a physical chromosomal map and a specific disease, or predisposition to a specific disease, may help delimit the region of DNA associated with that genetic disease. The nucleotide sequences disclosed herein may be used to detect differences in gene sequences between normal, carrier, or affected individuals.

45 [0185] *In situ* hybridization of chromosomal preparations and physical mapping techniques such as linkage analysis using established chromosomal markers may be used for extending genetic maps. Often the placement of a gene on

the chromosome of another mammalian species, such as mouse, may reveal associated markers even if the number or arm of a particular human chromosome is not known. New sequences can be assigned to chromosomal arms, or parts thereof, by physical mapping. This provides valuable information to investigators searching for disease genes using positional cloning or other gene discovery techniques. Once the disease or syndrome has been crudely localized by genetic linkage to a particular genomic region, for example, AT to 11q22-23 (Gatti et al., *Nature* 336: 577-580 (1988)), any sequences mapping to that area may represent associated or regulatory genes for further investigation. The nucleotide sequence disclosed herein may also be used to detect differences in the chromosomal location due to translocation, inversion, etc., among normal, carrier, or affected individuals.

[0186] It shall be understood that all of the methods (e.g., PCR and FISH) that detect mutant ROS polynucleotides (e.g., aberrantly expressed wild-type ROS, FIG-ROS fusion polynucleotides, SLC34A2-ROS fusion polynucleotides, and the CD74-ROS fusion polynucleotide disclosed herein) may be combined with other methods that detect either mutant ROS polynucleotides or mutant ROS polypeptides. For example, detection of a FIG-ROS polynucleotide in the genetic material of a biological sample (e.g., FIG-ROS (S) in a circulating tumor cell) may be followed by Western blotting analysis or immuno-histochemistry (IHC) analysis of the proteins of the sample to determine if the FIG-ROS (S) polynucleotide was actually expressed as a FIG-ROS (S) fusion polypeptide in the biological sample. Such Western blotting or IHC analyses may be performed using an antibody that specifically binds to the polypeptide encoded by the detected FIG-ROS (S) polynucleotide, or the analyses may be performed using antibodies that specifically bind either to full length FIG (e.g., bind to the N-terminus of the protein) or to full length ROS (e.g., bind an epitope in the kinase domain of ROS). Such assays are known in the art (see, e.g., US Patent 7,468,252).

[0187] In another example, the CISH technology of Dako allows chromatogenic in-situ hybridization with immuno-histochemistry on the same tissue section. See Elliot et al., *Br J Biomed Sci* 2008; 65(4): 167-171, 2008 for a comparison of CISH and FISH.

[0188] As used throughout the specification, the term "biological sample" is used in its broadest sense, and means any biological sample suspected of containing a FIG-ROS fusion polypeptide, a FIG-ROS fusion polynucleotide, a truncated ROS polynucleotide, a truncated ROS polypeptide (*i.e.*, either lacking the sequences encoding the extracellular domain of wild-type ROS or lacking the sequences encoding both the extracellular and transmembrane domains of wild-type, full-length ROS), a truncated ROS polynucleotide, or a fragment thereof, and may comprise a cell, chromosomes isolated from a cell (e.g., a spread of metaphase chromosomes), genomic DNA (in solution or bound to a solid support such as for Southern analysis), RNA (in solution or bound to a solid support such as for northern analysis), cDNA (in solution or bound to a solid support), an extract from cells, blood, urine, marrow, or a tissue, and the like.

[0189] Biological samples useful in the practice of the methods disclosed herein may be obtained from any mammal in which a cancer characterized by the presence of a FIG-ROS fusion polypeptide is or might be present or developing. As used herein, the phrase "characterized by" with respect to a cancer and indicated molecule (e.g., a ROS fusion or a mutant ROS) is meant a cancer in which a gene translocation or mutation (e.g., causing overexpression of wild-type ROS) and/or an expressed polypeptide (e.g., a FIG-ROS fusion polypeptide) is present, as compared to a cancer or a normal tissue in which such translocation, overexpression of wild-type ROS, and/or fusion polypeptide are not present. The presence of such translocation, overexpression of wild-type ROS, and/or fusion polypeptide may drive (*i.e.*, stimulate or be the causative agent of), in whole or in part, the growth and survival of such cancer or suspected cancer.

[0190] In one embodiment, the mammal is a human, and the human may be a candidate for a ROS-inhibiting therapeutic, for the treatment of a cancer, e.g., a liver, pancreatic, kidney, or testicular cancer. The human candidate may be a patient currently being treated with, or considered for treatment with, a ROS kinase inhibitor. In another embodiment, the mammal is large animal, such as a horse or cow, while in other embodiments, the mammal is a small animal, such as a dog or cat, all of which are known to develop cancers, including liver, kidney, testicular, and pancreatic cancers.

[0191] Any biological sample comprising cells (or extracts of cells) from a mammalian cancer is suitable for use in the methods disclosed herein. In one embodiment, the biological sample comprises cells obtained from a tumor biopsy. The biopsy may be obtained, according to standard clinical techniques, from primary tumors occurring in an organ of a mammal, or by secondary tumors that have metastasized in other tissues. In another embodiment, the biological sample comprises cells obtained from a fine needle aspirate taken from a tumor, and techniques for obtaining such aspirates are well known in the art (see Cristallini et al., *Acta Cytol.* 36(3): 416-22 (1992)).

[0192] In some embodiments, the biological sample comprises circulating tumor cells. Circulating tumor cells ("CTCs") may be purified, for example, using the kits and reagents sold under the trademarks Vita-Assays™, Vita-Cap™, and CellSearch® (commercially available from Vitatex, LLC (a Johnson and Johnson corporation). Other methods for isolating CTCs are described (see, for example, PCT Publication No. WO/2002/020825, Cristofanilli et al., *New Engl. J. of Med.* 351 (8): 781-791 (2004), and Adams et al., *J. Amer. Chem. Soc.* 130(27): 8633-8641 (July 2008)). In a particular embodiment, a circulating tumor cell ("CTC") may be isolated and identified as having originated from the lung.

[0193] Also disclosed herein is a method for isolating a CTC, and then screening the CTC one or more assay formats to identify the presence of a mutant ROS polypeptide or polynucleotide disclosed herein (e.g., a FIG-ROS fusion polypeptide or polynucleotide) in the CTC. Some non-limiting assay formats include Western blotting analysis, flow-cytometry

(FC), immuno-histochemistry (IHC), immuno-fluorescence (IF), fluorescence in situ hybridization (FISH) and polymerase chain reaction (PCR). A CTC from a patient that is identified as comprising a mutant ROS polypeptide or polynucleotide disclosed herein (e.g., a FIG-ROS fusion polypeptide or polynucleotide) may indicate that the patient's originating cancer (e.g., a lung cancer such as a non-small cell lung cancer) is likely to respond to a composition comprising at least one ROS kinase-inhibiting therapeutic.

[0194] A biological sample may comprise cells (or cell extracts) from a cancer in which FIG-ROS fusion polypeptide or mutant ROS polypeptide (e.g., lacking the extracellular and transmembrane domains) is expressed and/or activated but wild type ROS kinase is not. Alternatively, the sample may comprise cells from a cancer in which both a mutant ROS fusion polypeptide and a wild type ROS kinase are expressed and/or activated, or in which wild type ROS kinase is expressed and/or active, but ROS fusion polypeptide is not.

[0195] Cellular extracts of the foregoing biological samples may be prepared, either crude or partially (or entirely) purified, in accordance with standard techniques, and used in the methods disclosed herein. Alternatively, biological samples comprising whole cells may be utilized in assay formats such as immunohistochemistry (IHC), flow cytometry (FC), and immunofluorescence (IF), as further described above. Such whole-cell assays are advantageous in that they minimize manipulation of the tumor cell sample and thus reduce the risks of altering the *in vivo* signaling/activation state of the cells and/or introducing artifact signals. Whole cell assays are also advantageous because they characterize expression and signaling only in tumor cells, rather than a mixture of tumor and normal cells.

[0196] In practicing the disclosed method for determining whether a compound inhibits progression of a tumor characterized by a FIG-ROS translocation and/or fusion polypeptide, biological samples comprising cells from mammalian xenografts (or bone marrow transplants) may also be advantageously employed. Non-limiting xenografts (or transplant recipients) are small mammals, such as mice, harboring human tumors (or leukemias) that express a FIG-ROS fusion polypeptide (or a mutant ROS kinase containing the kinase domain but lacking the transmembrane and extracellular domains). Xenografts harboring human tumors are well known in the art (see Kal, *Cancer Treat Res.* 72: 155-69 (1995)) and the production of mammalian xenografts harboring human tumors is well described (see Winograd et al., *In Vivo*. 1(1): 1-13 (1987)). Similarly the generation and use of bone marrow transplant models is well described (see, e.g., Schwaller, et al., *EMBO J.* 17: 5321-33 (1998); Kelly et al., *Blood* 99: 310-318 (2002)).

[0197] In assessing mutant ROS polynucleotide presence or mutant ROS polypeptide expression in a biological sample comprising cells from a mammalian cancer tumor, a control sample representing a cell in which such translocation and/or fusion protein do not occur may desirably be employed for comparative purposes. Ideally, the control sample comprises cells from a subset of the particular cancer (e.g., bile duct liver cancer) that is representative of the subset in which the mutation (e.g., FIG -ROS translocation) does not occur and/or the fusion polypeptide is *not* expressed. Comparing the level in the control sample versus the test biological sample thus identifies whether the mutant polynucleotide and/or polypeptide is/are present. Alternatively, since FIG -ROS fusion polynucleotide and/or polypeptide may not be present in the majority of cancers, any tissue that similarly does not express mutant ROS polypeptide (or harbor the mutant polynucleotide) may be employed as a control.

[0198] The methods described below will have valuable diagnostic utility for cancers characterized by mutant ROS polynucleotide and/or polypeptide, and treatment decisions pertaining to the same. For example, biological samples may be obtained from a subject that has not been previously diagnosed as having a cancer characterized by since a FIG -ROS translocation and/or fusion polypeptide, nor has yet undergone treatment for such cancer, and the method is employed to diagnostically identify a tumor in such subject as belonging to a subset of tumors (e.g., a bile duct tumor) in which mutant ROS polynucleotide and/or polypeptide is present/expressed.

[0199] Alternatively, a biological sample may be obtained from a subject that has been diagnosed as having a cancer characterized by the presence of one type of kinase, such as EGFR, and has been receiving therapy, such as EGFR inhibitor therapy (e.g., Tarceva™, Iressa™) for treatment of such cancer, and the method disclosed herein is employed to identify whether the subject's tumor is also characterized by a FIG -ROS translocation and/or fusion polypeptide, and is therefore likely to fully respond to the existing therapy and/or whether alternative or additional ROS-inhibiting therapy is desirable or warranted. The methods disclosed herein may also be employed to monitor the progression or inhibition of a mutant ROS polypeptide-expressing cancer following treatment of a subject with a composition comprising a ROS-inhibiting therapeutic or combination of therapeutics.

[0200] Such diagnostic assay may be carried out subsequent to or prior to preliminary evaluation or surgical surveillance procedures. The identification method disclosed herein may be advantageously employed as a diagnostic to identify patients having cancer, such as bile duct liver cancer, characterized by the presence of the FIG-ROS fusion protein, which patients would be most likely to respond to therapeutics targeted at inhibiting ROS kinase activity. The ability to select such patients would also be useful in the clinical evaluation of efficacy of future ROS-targeted therapeutics as well as in the future prescription of such drugs to patients.

[0201] The ability to selectively identify cancers in which a FIG -ROS translocation and/or fusion polypeptide is/are present enables important new methods for accurately identifying such tumors for diagnostic purposes, as well as obtaining information useful in determining whether such a tumor is likely to respond to a ROS-inhibiting therapeutic

composition, or likely to be partially or wholly non-responsive to an inhibitor targeting a different kinase when administered as a single agent for the treatment of the cancer.

[0202] Accordingly, disclosed herein is a method for detecting the presence of a mutant ROS polynucleotide and/or polypeptide in a cancer, the method comprising the steps of: (a) obtaining a biological sample from a patient having cancer; and (b) utilizing at least one reagent that detects a mutant ROS polynucleotide or polypeptide disclosed herein to determine whether a FIG-ROS fusion polynucleotide and/or polypeptide is/are present in the biological sample.

[0203] In some embodiments, the cancer is a liver cancer, such as bile duct liver cancer. In some embodiments, the cancer is a pancreatic cancer, a kidney cancer, or a testicular cancer. In other embodiments, the presence of a FIG-ROS fusion polypeptide identifies a cancer that is likely to respond to a composition or therapeutic comprising at least one ROS-inhibiting compound.

[0204] In some embodiments, the diagnostic methods disclosed herein are implemented in a flow-cytometry (FC), immuno-histochemistry (IHC), or immuno-fluorescence (IF) assay format. In another embodiment, the activity of the FIG-ROS fusion polypeptide is detected. In other embodiments, the diagnostic methods disclosed herein are implemented in a fluorescence *in situ* hybridization (FISH) or polymerase chain reaction (PCR) assay format.

[0205] Disclosed herein is a method for determining whether a compound inhibits the progression of a cancer characterized by a FIG-ROS fusion polynucleotide or polypeptide, said method comprising the step of determining whether said compound inhibits the expression and/or activity of said FIG-ROS fusion in said cancer. In one embodiment, inhibition of expression and/or activity of the FIG-ROS fusion polypeptide is determined using at least one reagent that detects an FIG-ROS fusion polynucleotide or polypeptide disclosed herein. Compounds suitable for inhibition of ROS kinase activity are discussed in more detail herein.

[0206] Mutant ROS polynucleotide probes and polypeptide-specific reagents useful in the practice of the methods disclosed herein are described in further detail above. In one embodiment, the FIG-ROS fusion polypeptide-specific reagent comprises a fusion polypeptide-specific antibody. In another embodiment, the fusion polypeptide-specific reagent comprises a heavy-isotope labeled phosphopeptide (AQUA peptide) corresponding to the fusion junction of FIG-ROS fusion polypeptide

[0207] The methods disclosed herein described above may also optionally comprise the step of determining the level of expression or activation of other kinases, such as wild type ROS and EGFR, or other downstream signaling molecules in said biological sample. Profiling both FIG-ROS fusion polypeptide expression/activation and expression/activation of other kinases and pathways in a given biological sample can provide valuable information on which kinase(s) and pathway(s) is/are driving the disease, and which therapeutic regime is therefore likely to be of most benefit.

[0208] The discovery of the mutant ROS polypeptides (e.g., the FIG-ROS fusion polypeptides) in human cancer also enables the development of new compounds that inhibit the activity of these mutant ROS proteins, particularly their ROS kinase activity. Accordingly, disclosed herein is a method for determining whether a compound inhibits the progression of a cancer characterized by a FIG-ROS fusion polynucleotide and/or polypeptide, said method comprising the step of determining whether said compound inhibits the expression and/or activity of said FIG-ROS fusion polypeptide in said cancer. In one embodiment, inhibition of expression and/or activity of the FIG-ROS fusion polypeptide is determined using at least one reagent that detects a FIG-ROS fusion polynucleotide and/or FIG-ROS fusion polypeptide disclosed herein. Non-limiting examples of such reagents disclosed herein have been described above. Compounds suitable for the inhibition of ROS kinase activity are described in more detail below.

[0209] As used herein, a "ROS inhibitor" or a "ROS-inhibiting compound" means any composition comprising one or more compounds, chemical or biological, which inhibits, either directly or indirectly, the expression and/or activity of either wild type (full length) ROS or the kinase domain of ROS, either alone and/or as part of the FIG-ROS fusion polypeptides disclosed herein. Such inhibition may be *in vitro* or *in vivo*. "ROS inhibitor therapeutic" or "ROS-inhibiting therapeutic" means a ROS -inhibiting compound used as a therapeutic to treat a patient harboring a cancer (e.g., a liver, testicular, kidney, or pancreatic cancer) characterized by the presence of a FIG-ROS fusion polypeptide disclosed herein.

[0210] In some embodiments disclosed herein, the ROS inhibitor is a binding agent that specifically binds to a FIG-ROS fusion polypeptide, a binding agent that specifically binds to a mutant ROS polypeptide, an siRNA targeting a FIG-ROS fusion polynucleotide (e.g., a FIG-ROS(S) fusion polynucleotide), or an siRNA targeting a mutant ROS polynucleotide.

[0211] The ROS-inhibiting compound may be, for example, a kinase inhibitor, such as a small molecule or antibody inhibitor. It may be a pan-kinase inhibitor with activity against several different kinases, or a kinase-specific inhibitor. Since ROS, ALK, LTK, InsR, and IGF1R belong to the same family of tyrosine kinases, they may share similar structure in the kinase domain. Thus, in some embodiments, a ROS inhibitor of the invention also inhibits the activity of an ALK kinase an LTK kinase, an insulin receptor, or an IGF1 receptor. ROS-inhibiting compounds are discussed in further detail below. Patient biological samples may be taken before and after treatment with the inhibitor and then analyzed, using methods described above, for the biological effect of the inhibitor on ROS kinase activity, including the phosphorylation of downstream substrate protein. Such a pharmacodynamic assay may be useful in determining the biologically active dose of the drug that may be preferable to a maximal tolerable dose. Such information would also be useful in submissions


for drug approval by demonstrating the mechanism of drug action.

[0212] As disclosed herein, the FIG -ROS fusion polypeptide may occur in at least one subgroup of human liver, pancreatic, kidney, or testicular cancer. Accordingly, the progression of a mammalian cancer (e.g., liver, pancreatic, kidney, or testicular cancer) in which FIG -ROS fusion protein is expressed may be inhibited, *in vivo*, by inhibiting the activity of ROS kinase in such cancer. ROS activity in cancers characterized by expression of a FIG-ROS fusion polypeptide (or a mutant ROS polypeptide comprising only the kinase domain) may be inhibited by contacting the cancer (e.g., a tumor) with a ROS-inhibiting therapeutic. Accordingly, the invention provides, in part, a compound for use in inhibiting the progression of a FIG -ROS fusion polypeptide-expressing cancer by inhibiting the expression and/or activity of ROS kinase in the cancer.

[0213] A ROS-inhibiting therapeutic may be any composition comprising at least one ROS inhibitor. Such compositions also include compositions comprising only a single ROS-inhibiting compound, as well as compositions comprising multiple therapeutics (including those against other RTKs), which may also include a non-specific therapeutic agent like a chemotherapeutic agent or general transcription inhibitor.

[0214] The ROS-inhibiting therapeutic for use according to the invention is a targeted, small molecule inhibitor. Small molecule targeted inhibitors are a class of molecules that typically inhibit the activity of their target enzyme by specifically, and often irreversibly, binding to the catalytic site of the enzyme, and/or binding to an ATP-binding cleft or other binding site within the enzyme that prevents the enzyme from adopting a conformation necessary for its activity. An exemplary small-molecule targeted kinase inhibitor is Gleevec® (Imatinib, STI-571), which inhibits CSF1R and BCR-ABL, and its properties have been well described. See Dewar et al., Blood 105(8): 3127-32 (2005). Additional small molecule kinase inhibitors that may target ROS include TAE-684 (see examples below) and PF-02341066 (Pfizer, Inc).

[0215] PF-02341066 has the structure:



[0216] Additional small molecule inhibitors and other inhibitors (e.g., indirect inhibitors) of ROS kinase activity may be rationally designed using X-ray crystallographic or computer modeling of ROS three dimensional structure, or may be found by high throughput screening of compound libraries for inhibition of key upstream regulatory enzymes and/or necessary binding molecules, which results in inhibition of ROS kinase activity. Such approaches are well known in the art, and have been described. ROS inhibition by such therapeutics may be confirmed, for example, by examining the ability of the compound to inhibit ROS activity, but not other kinase activity, in a panel of kinases, and/or by examining the inhibition of ROS activity in a biological sample comprising cancer cells (e.g., liver, pancreatic, kidney, or testicular al cancer). Methods for identifying compounds that inhibit a cancer characterized by the expression/presence of a FIG -ROS translocation and/or fusion polypeptide, and/or mutant ROS polynucleotide and/or polypeptide, are further described below.

[0217] ROS-inhibiting therapeutics useful in the methods disclosed herein may also be targeted antibodies that specifically bind to critical catalytic or binding sites or domains required for ROS activity, and inhibit the kinase by blocking access of ligands, substrates or secondary molecules to a and/or preventing the enzyme from adopting a conformation necessary for its activity. The production, screening, and therapeutic use of humanized target-specific antibodies has been well-described. See Merluzzi et al., Adv Clin Path. 4(2): 77-85 (2000). Commercial technologies and systems, such as Morphosys, Inc.'s Human Combinatorial Antibody Library (HuCAL®), for the high-throughput generation and screening of humanized target-specific inhibiting antibodies are available.

[0218] The production of various anti-receptor kinase targeted antibodies and their use to inhibit activity of the targeted

receptor has been described. See, e.g. U.S. Patent Publication No. 20040202655, U.S. Patent Publication No. 20040086503, U.S. Patent Publication No. 20040033543, Standardized methods for producing, and using, receptor tyrosine kinase activity-inhibiting antibodies are known in the art. See, e.g., European Patent No. EP1423428,

[0219] Phage display approaches may also be employed to generate ROS-specific antibody inhibitors, and protocols for bacteriophage library construction and selection of recombinant antibodies are provided in the well-known reference text CURRENT PROTOCOLS IN IMMUNOLOGY, Colligan et al. (Eds.), John Wiley & Sons, Inc. (1992-2000), Chapter 17, Section 17.1. See also U.S. Patent No. 6,319,690, U.S. Patent No. 6,300,064, U.S. Patent No. 5,840,479, and U.S. Patent Publication No. 20030219839.

[0220] A library of antibody fragments displayed on the surface of bacteriophages may be produced (see, e.g. U. S. Patent 6,300,064) and screened for binding to a FIG-ROS fusion protein disclosed herein. An antibody fragment that binds to a FIG-ROS fusion polypeptide is identified as a candidate molecule for blocking constitutive activation of the FIG-ROS fusion polypeptide in a cell. See European Patent No. EP1423428.

[0221] ROS-binding targeted antibodies identified in screening of antibody libraries as described above may then be further screened for their ability to block the activity of ROS, both *in vitro* kinase assay and *in vivo* in cell lines and/or tumors. ROS inhibition may be confirmed, for example, by examining the ability of such antibody therapeutic to inhibit ROS kinase activity in a panel of kinases, and/or by examining the inhibition of ROS activity in a biological sample comprising cancer cells, as described above. In some embodiments, a ROS-inhibiting compound for use according to the invention reduces ROS kinase activity, but reduces the kinase activity of other kinases to a lesser extent (or not at all). Methods for screening such compounds for ROS kinase inhibition are further described above.

[0222] ROS-inhibiting compounds that useful in the practice of the disclosed methods may also be compounds that indirectly inhibit ROS activity by inhibiting the activity of proteins or molecules other than ROS kinase itself. Such inhibiting therapeutics may be targeted inhibitors that modulate the activity of key regulatory kinases that phosphorylate or dephosphorylate (and hence activate or deactivate) ROS itself, or interfere with binding of ligands. As with other receptor tyrosine kinases, ROS regulates downstream signaling through a network of adaptor proteins and downstream kinases. As a result, induction of cell growth and survival by ROS activity may be inhibited by targeting these interacting or downstream proteins.

[0223] ROS kinase activity may also be indirectly inhibited by using a compound that inhibits the binding of an activating molecule necessary for ROS to adopt its active conformation. For example, the production and use of anti-PDGF antibodies has been described. See U.S. Patent Publication No. 20030219839, "Anti-PDGF Antibodies and Methods for Producing Engineered Antibodies," Bowdish *et al.* Inhibition of ligand (PDGF) binding to the receptor directly down-regulates the receptor activity.

[0224] ROS inhibiting compounds or therapeutics may also comprise anti-sense and/or transcription inhibiting compounds that inhibit ROS kinase activity by blocking transcription of the gene encoding ROS and/or the FIG-ROS fusion gene. The inhibition of various receptor kinases, including VEGFR, EGFR, and IGFR, and FGFR, by antisense therapeutics for the treatment of cancer has been described. See, e.g., U.S. Patent Nos. 6,734,017; 6, 710,174, 6,617,162; 6,340,674; 5,783,683; 5,610,288.

[0225] Antisense oligonucleotides may be designed, constructed, and employed as therapeutic agents against target genes in accordance with known techniques. See, e.g. Cohen, J., Trends in Pharmacol. Sci. 10(11): 435-437 (1989); Marcus-Sekura, Anal. Biochem. 172: 289-295 (1988); Weintraub, H., Sci. AM. pp. 40-46 (1990); Van Der Krol *et al.*, BioTechniques 6(10): 958-976 (1988); Skorski *et al.*, Proc. Natl. Acad. Sci. USA (1994) 91: 4504-4508. Inhibition of human carcinoma growth *in vivo* using an antisense RNA inhibitor of EGFR has recently been described. See U.S. Patent Publication No. 20040047847. Similarly, a ROS-inhibiting therapeutic comprising at least one antisense oligonucleotide against a mammalian ROS gene or FIG-ROS fusion polynucleotide or mutant ROS polynucleotide may be prepared according to methods described above. Pharmaceutical compositions comprising ROS-inhibiting antisense compounds may be prepared and administered as further described below.

[0226] Small interfering RNA molecule (siRNA) compositions, which inhibit translation, and hence activity, of ROS through the process of RNA interference, may also be desirably employed in the methods disclosed herein. RNA interference, and the selective silencing of target protein expression by introduction of exogenous small double-stranded RNA molecules comprising sequence complimentary to mRNA encoding the target protein, has been well described. See, e.g. U.S. Patent Publication No. 20040038921, U.S. Patent Publication No. 20020086356, and U.S. Patent Publication 20040229266.

[0227] Double-stranded RNA molecules (dsRNA) have been shown to block gene expression in a highly conserved regulatory mechanism known as RNA interference (RNAi). Briefly, the RNase III Dicer processes dsRNA into small interfering RNAs (siRNA) of approximately 22 nucleotides, which serve as guide sequences to induce target-specific mRNA cleavage by an RNA-induced silencing complex RISC (see Hammond *et al.*, Nature (2000) 404: 293-296). RNAi involves a catalytic-type reaction whereby new siRNAs are generated through successive cleavage of longer dsRNA. Thus, unlike antisense, RNAi degrades target RNA in a non-stoichiometric manner. When administered to a cell or organism, exogenous dsRNA has been shown to direct the sequence-specific degradation of endogenous messenger

RNA (mRNA) through RNAi.

[0228] A wide variety of target-specific siRNA products, including vectors and systems for their expression and use in mammalian cells, are now commercially available. See, e.g., Promega, Inc. (www.promega.com); Dharmacon, Inc. (www.dharmacon.com). Detailed technical manuals on the design, construction, and use of dsRNA for RNAi are available.

5 See, e.g., Dharmacon's "RNAi Technical Reference & Application Guide"; Promega's "RNAi: A Guide to Gene Silencing." ROS-inhibiting siRNA products are also commercially available, and may be suitably employed in the method disclosed herein. See, e.g., Dharmacon, Inc., Lafayette, CO (Cat Nos. M-003162-03, MU-003162-03, D-003162-07 thru -10 (siG-ENOME™ SMARTselection and SMARTpool® siRNAs).

[0229] It has recently been established that small dsRNA less than 49 nucleotides in length, and preferably 19-25 10 nucleotides, comprising at least one sequence that is substantially identical to part of a target mRNA sequence, and which dsRNA optimally has at least one overhang of 1-4 nucleotides at an end, are most effective in mediating RNAi in mammals. See U.S. Patent Publication Nos. 20040038921 and 20040229266. The construction of such dsRNA, and their use in pharmaceutical preparations to silence expression of a target protein, *in vivo*, are described in detail in such 15 publications.

[0230] 20 If the sequence of the gene to be targeted in a mammal is known, 21-23 nt RNAs, for example, can be produced and tested for their ability to mediate RNAi in a mammalian cell, such as a human or other primate cell. Those 21-23 nt RNA molecules shown to mediate RNAi can be tested, if desired, in an appropriate animal model to further assess their *in vivo* effectiveness. Target sites that are known, for example target sites determined to be effective target sites based on studies with other nucleic acid molecules, for example ribozymes or antisense, or those targets known to be associated 25 with a disease or condition such as those sites containing mutations or deletions, can be used to design siRNA molecules targeting those sites as well.

[0231] 30 Alternatively, the sequences of effective dsRNA can be rationally designed/predicted screening the target mRNA of interest for target sites, for example by using a computer folding algorithm. The target sequence can be parsed *in silico* into a list of all fragments or subsequences of a particular length, for example 23 nucleotide fragments, using a custom Perl script or commercial sequence analysis programs such as Oligo, MacVector, or the GCG Wisconsin Package.

[0232] 35 Various parameters can be used to determine which sites are the most suitable target sites within the target RNA sequence. These parameters include but are not limited to secondary or tertiary RNA structure, the nucleotide base composition of the target sequence, the degree of homology between various regions of the target sequence, or the relative position of the target sequence within the RNA transcript. Based on these determinations, any number of 40 target sites within the RNA transcript can be chosen to screen siRNA molecules for efficacy, for example by using *in vitro* RNA cleavage assays, cell culture, or animal models. See, e.g., U.S. Patent Publication No. 20030170891. An algorithm for identifying and selecting RNAi target sites has also recently been described. See U.S. Patent Publication No. 20040236517.

[0233] 45 Commonly used gene transfer techniques include calcium phosphate, DEAE-dextran, electroporation and microinjection and viral methods (Graham et al. (1973) Virol. 52: 456; McCutchan et al., (1968), J. Natl. Cancer Inst. 41: 351; Chu et al. (1987), Nucl. Acids Res. 15: 1311; Fraley et al. (1980), J. Biol. Chem. 255: 10431; Capecchi (1980), Cell 22: 479). DNA may also be introduced into cells using cationic liposomes (Feigner et al. (1987), Proc. Natl. Acad. Sci. USA 84: 7413). Commercially available cationic lipid formulations include Tfx 50 (Promega) or Lipofectamin 200 (Life Technologies). Alternatively, viral vectors may be employed to deliver dsRNA to a cell and mediate RNAi. See U.S. Patent Publication No. 20040023390.

[0234] 50 Transfection and vector/expression systems for RNAi in mammalian cells are commercially available and have been well described. See, e.g., Dharmacon, Inc., DharmaFECT™ system; Promega, Inc., siSTRIKE™ U6 Hairpin system; see also Gou et al. (2003) FEBS. 548, 113-118; Sui, G. et al. A DNA vector-based RNAi technology to suppress gene expression in mammalian cells (2002) Proc. Natl. Acad. Sci. 99, 5515-5520; Yu et al. (2002) Proc. Natl. Acad. Sci. 99, 6047-6052; Paul, C. et al. (2002) Nature Biotechnology 19, 505-508; McManus et al. (2002) RNA 8, 842-850.

[0235] 55 siRNA interference in a mammal using prepared dsRNA molecules may then be effected by administering a pharmaceutical preparation comprising the dsRNA to the mammal. The pharmaceutical composition is administered in a dosage sufficient to inhibit expression of the target gene. dsRNA can typically be administered at a dosage of less than 5 mg dsRNA per kilogram body weight per day, and is sufficient to inhibit or completely suppress expression of the target gene. In general a suitable dose of dsRNA will be in the range of 0.01 to 2.5 milligrams per kilogram body weight of the recipient per day, preferably in the range of 0.1 to 200 micrograms per kilogram body weight per day, more preferably in the range of 0.1 to 100 micrograms per kilogram body weight per day, even more preferably in the range of 1.0 to 50 micrograms per kilogram body weight per day, and most preferably in the range of 1.0 to 25 micrograms per kilogram body weight per day. A pharmaceutical composition comprising the dsRNA is administered once daily, or in multiple sub-doses, for example, using sustained release formulations well known in the art. The preparation and administration of such pharmaceutical compositions may be carried out accordingly to standard techniques, as further described below.

[0236] 60 Such dsRNA may then be used to inhibit ROS expression and activity in a cancer, by preparing a pharmaceutical

preparation comprising a therapeutically-effective amount of such dsRNA, as described above, and administering the preparation to a human subject having a cancer (e.g., a liver, pancreatic, kidney, or testicular cancer) expressing FIG-ROS fusion protein or mutant ROS polypeptide, for example, via direct injection to the tumor. The similar inhibition of other receptor tyrosine kinases, such as VEGFR and EGFR using siRNA inhibitors has recently been described. See 5 U.S. Patent Publication No. 20040209832, U.S. Patent Publication No. 20030170891, and U.S. Patent Publication No. 20040175703.

[0237] ROS-inhibiting therapeutic compositions for use according to the invention may be administered to a mammal by any means known in the art including, but not limited to oral or peritoneal routes, including intravenous, intramuscular, 10 intraperitoneal, subcutaneous, transdermal, airway (aerosol), rectal, vaginal and topical (including buccal and sublingual) administration.

[0238] For oral administration, a ROS-inhibiting therapeutic will generally be provided in the form of tablets or capsules, 15 as a powder or granules, or as an aqueous solution or suspension. Tablets for oral use may include the active ingredients mixed with pharmaceutically acceptable excipients such as inert diluents, disintegrating agents, binding agents, lubricating agents, sweetening agents, flavoring agents, coloring agents and preservatives. Suitable inert diluents include sodium and calcium carbonate, sodium and calcium phosphate, and lactose, while corn starch and alginic acid are suitable disintegrating agents. Binding agents may include starch and gelatin, while the lubricating agent, if present, will generally be magnesium stearate, stearic acid or talc. If desired, the tablets may be coated with a material such as glyceryl monostearate or glyceryl distearate, to delay absorption in the gastrointestinal tract.

[0239] Capsules for oral use include hard gelatin capsules in which the active ingredient is mixed with a solid diluent, 20 and soft gelatin capsules wherein the active ingredients is mixed with water or an oil such as peanut oil, liquid paraffin or olive oil. For intramuscular, intraperitoneal, subcutaneous and intravenous use, the pharmaceutical compositions for use according to the invention will generally be provided in sterile aqueous solutions or suspensions, buffered to an appropriate pH and isotonicity. Suitable aqueous vehicles include Ringer's solution and isotonic sodium chloride. The carrier may consist exclusively of an aqueous buffer ("exclusively" means no auxiliary agents or encapsulating substances 25 are present which might affect or mediate uptake of the ROS-inhibiting therapeutic). Such substances include, for example, micellar structures, such as liposomes or capsids, as described below. Aqueous suspensions may include suspending agents such as cellulose derivatives, sodium alginate, polyvinyl-pyrrolidone and gum tragacanth, and a wetting agent such as lecithin. Suitable preservatives for aqueous suspensions include ethyl and n-propyl p-hydroxybenzoate.

[0240] ROS-inhibiting therapeutic compositions may also include encapsulated formulations to protect the therapeutic (e.g., a dsRNA compound or an antibody that specifically binds a FIG-ROS fusion polypeptide) against rapid elimination from the body, such as a controlled release formulation, including implants and microencapsulated delivery systems. Biodegradable, biocompatible polymers can be used, such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, 30 collagen, polyorthoesters, and polylactic acid. Methods for preparation of such formulations will be apparent to those skilled in the art. The materials can also be obtained commercially from Alza Corporation and Nova Pharmaceuticals, Inc. Liposomal suspensions (including liposomes targeted to infected cells with monoclonal antibodies to viral antigens) can also be used as pharmaceutically acceptable carriers. These can be prepared according to methods known to those skilled in the art, for example, as described in U.S. Pat. No. 4,522,811; PCT publication WO 91/06309; and European 35 patent publication EP-A-43075. An encapsulated formulation may comprise a viral coat protein. The viral coat protein may be derived from or associated with a virus, such as a polyoma virus, or it may be partially or entirely artificial. For example, the coat protein may be a Virus Protein 1 and/or Virus Protein 2 of the polyoma virus, or a derivative thereof.

[0241] ROS-inhibiting compounds can also comprise a delivery vehicle, including liposomes, for administration to a subject, carriers and diluents and their salts, and/or can be present in pharmaceutically acceptable formulations. For example, methods for the delivery of nucleic acid molecules are described in Akhtar et al., 1992, Trends Cell Bio., 2, 40 139; DELIVERY STRATEGIES FOR ANTISENSE OLIGONUCLEOTIDE THERAPEUTICS, ed. Akhtar, 1995, Maurer et al., 1999, Mol. Membr. Biol., 16, 129-140; Hofland and Huang, 1999, Handb. Exp. Pharmacol., 137, 165-192; and Lee et al., 2000, ACS Symp. Ser., 752, 184-192. U.S. Pat. No. 6,395,713 and PCT Publication No. WO 94/02595 further describe the general methods for delivery of nucleic acid molecules. These protocols can be utilized for the delivery of virtually any nucleic acid molecule.

[0242] ROS-inhibiting therapeutics (i.e., a ROS-inhibiting compound being administered as a therapeutic) can be administered to a mammalian tumor by a variety of methods known to those of skill in the art, including, but not restricted to, encapsulation in liposomes, by iontophoresis, or by incorporation into other vehicles, such as hydrogels, cyclodextrins, biodegradable nanocapsules, and biodegradable microspheres, or by proteinaceous vectors (see PCT Publication No. WO 00/53722). Alternatively, the therapeutic/vehicle combination is locally delivered by direct injection or by use of an infusion pump. Direct injection of the composition, whether subcutaneous, intramuscular, or intradermal, can take place using standard needle and syringe methodologies, or by needle-free technologies such as those described in Conry et al., 1999, Clin. Cancer Res., 5, 2330-2337 and PCT Publication No. WO 99/3 1262.

[0243] Pharmaceutically acceptable formulations of ROS-inhibitor therapeutics include salts of the above described

compounds, e.g., acid addition salts, for example, salts of hydrochloric, hydrobromic, acetic acid, and benzene sulfonic acid. A pharmacological composition or formulation refers to a composition or formulation in a form suitable for administration, e.g., systemic administration, into a cell or patient, including for example a human. Suitable forms, in part, depend upon the use or the route of entry, for example oral, transdermal, or by injection. Such forms should not prevent the composition or formulation from reaching a target cell. For example, pharmacological compositions injected into the blood stream should be soluble. Other factors are known in the art, and include considerations such as toxicity and forms that prevent the composition or formulation from exerting its effect.

[0244] Administration routes that lead to systemic absorption (e.g., systemic absorption or accumulation of drugs in the blood stream followed by distribution throughout the entire body), are desirable and include, without limitation: intravenous, subcutaneous, intraperitoneal, inhalation, oral, intrapulmonary and intramuscular. Each of these administration routes exposes the ROS-inhibiting therapeutic to an accessible diseased tissue or tumor. The rate of entry of a drug into the circulation has been shown to be a function of molecular weight or size. The use of a liposome or other drug carrier comprising the compounds for use according to the instant invention can potentially localize the drug, for example, in certain tissue types, such as the tissues of the reticular endothelial system (RES). A liposome formulation that can facilitate the association of drug with the surface of cells, such as, lymphocytes and macrophages is also useful. This approach can provide enhanced delivery of the drug to target cells by taking advantage of the specificity of macrophage and lymphocyte immune recognition of abnormal cells, such as cancer cells.

[0245] By "pharmaceutically acceptable formulation" is meant, a composition or formulation that allows for the effective distribution of the nucleic acid molecules for use according to the instant invention in the physical location most suitable for their desired activity. Nonlimiting examples of agents suitable for formulation with the nucleic acid molecules for use according to the instant invention include: P-glycoprotein inhibitors (such as Pluronic P85), which can enhance entry of drugs into the CNS (Jolliet-Riant and Tillement, 1999, *Fundam. Clin. Pharmacol.*, 13, 16-26); biodegradable polymers, such as poly (DL-lactide-coglycolide) microspheres for sustained release delivery after intracerebral implantation (Emerich et al, 1999, *Cell Transplant*, 8, 47-58) (Alkermes, Inc. Cambridge, Mass.); and loaded nanoparticles, such as those made of polybutylcyanoacrylate, which can deliver drugs across the blood brain barrier and can alter neuronal uptake mechanisms (*Prog Neuro-psychopharmacol Biol Psychiatry*, 23, 941-949, 1999). Other non-limiting examples of delivery strategies for the ROS-inhibiting compounds for use according to the invention include material described in Boado et al., 1998, *J. Pharm. Sci.*, 87, 1308-1315; Tyler et al., 1999, *FEBS Lett.*, 421, 280-284; Pardridge et al., 1995, *PNAS USA.*, 92, 5592-5596; Boado, 1995, *Adv. Drug Delivery Rev.*, 15, 73-107; Aldrian-Herrada et al., 1998, *Nucleic Acids Res.*, 26, 4910-4916; and Tyler et al., 1999, *PNAS USA.*, 96, 7053-7058.

[0246] Therapeutic compositions comprising surface-modified liposomes containing poly (ethylene glycol) lipids (PEG-modified, or long-circulating liposomes or stealth liposomes) may also be suitably employed for use according to the invention. These formulations offer a method for increasing the accumulation of drugs in target tissues. This class of drug carriers resists opsonization and elimination by the mononuclear phagocytic system (MPS or RES), thereby enabling longer blood circulation times and enhanced tissue exposure for the encapsulated drug (Lasic et al. *Chem. Rev.* 1995, 95, 2601-2627; Ishiwata et al., *Chem. Pharm. Bull.* 1995, 43, 1005-1011). Such liposomes have been shown to accumulate selectively in tumors, presumably by extravasation and capture in the neovascularized target tissues (Lasic et al., *Science* 1995, 267, 1275-1276; Oku et al., 1995, *Biochim. Biophys. Acta*, 1238, 86-90). The long-circulating liposomes enhance the pharmacokinetics and pharmacodynamics of DNA and RNA, particularly compared to conventional cationic liposomes which are known to accumulate in tissues of the MPS (Liu et al., *J. Biol. Chem.* 1995, 42, 24864-24870; PCT Publication No. WO 96/10391; PCT Publication No. WO 96/10390; and PCT Publication No. WO 96/10392). Long-circulating liposomes are also likely to protect drugs from nuclease degradation to a greater extent compared to cationic liposomes, based on their ability to avoid accumulation in metabolically aggressive MPS tissues such as the liver and spleen.

[0247] Therapeutic compositions may include a pharmaceutically effective amount of the desired compounds in a pharmaceutically acceptable carrier or diluent. Acceptable carriers or diluents for therapeutic use are well known in the pharmaceutical art, and are described, for example, in REMINGTON'S PHARMACEUTICAL SCIENCES, Mack Publishing Co. (A. R. Gennaro edit. 1985). For example, preservatives, stabilizers, dyes and flavoring agents can be provided. These include sodium benzoate, sorbic acid and esters of p-hydroxybenzoic acid. In addition, antioxidants and suspending agents can be used.

[0248] A pharmaceutically effective dose is that dose required to prevent, inhibit the occurrence, or treat (alleviate a symptom to some extent, preferably all of the symptoms) of a disease state. The pharmaceutically effective dose depends on the type of disease, the composition used, the route of administration, the type of mammal being treated, the physical characteristics of the specific mammal under consideration, concurrent medication, and other factors that those skilled in the medical arts will recognize. Generally, an amount between 0.1 mg/kg and 100 mg/kg body weight/day of active ingredients is administered dependent upon potency of the negatively charged polymer.

[0249] Dosage levels of the order of from about 0.1 mg to about 140 mg per kilogram of body weight per day are useful in the treatment of the above-indicated conditions (about 0.5 mg to about 7 g per patient per day). The amount of active

ingredient that can be combined with the carrier materials to produce a single dosage form varies depending upon the host treated and the particular mode of administration. Dosage unit forms generally contain between about 1 mg to about 500 mg of an active ingredient. It is understood that the specific dose level for any particular patient depends upon a variety of factors including the activity of the specific compound employed, the age, body weight, general health, sex, diet, time of administration, route of administration, and rate of excretion, drug combination and the severity of the particular disease undergoing therapy.

[0250] For administration to non-human animals, the composition can also be added to the animal feed or drinking water. It can be convenient to formulate the animal feed and drinking water compositions so that the animal takes in a therapeutically appropriate quantity of the composition along with its diet. It can also be convenient to present the composition as a premix for addition to the feed or drinking water.

[0251] A ROS-inhibiting therapeutic useful in the practice of the disclosure may comprise a single compound as described above, or a combination of multiple compounds, whether in the same class of inhibitor (e.g., antibody inhibitor), or in different classes (e.g., antibody inhibitors and small-molecule inhibitors). Such combination of compounds may increase the overall therapeutic effect in inhibiting the progression of a fusion protein-expressing cancer. For example, the therapeutic composition may a small molecule inhibitor, such as ST1-571 (Gleevec®) alone, or in combination with other Gleevec® analogues targeting ROS activity and/or small molecule inhibitors of EGFR, such as Tarceva™ or Iressa™. The therapeutic composition may also comprise one or more non-specific chemotherapeutic agent in addition to one or more targeted inhibitors. Such combinations have recently been shown to provide a synergistic tumor killing effect in many cancers. The effectiveness of such combinations in inhibiting ROS activity and tumor growth *in vivo* can be assessed as described below.

[0252] Disclosed herein is a method for determining whether a compound inhibits the progression of a cancer (e.g., a liver, pancreatic, kidney, or testicular cancer) characterized by a FIG-ROS translocation and/or fusion polypeptide or characterized by a mutant ROS polynucleotide or polypeptide, by determining whether the compound inhibits the ROS kinase activity of the mutant ROS polypeptide in the cancer. In some embodiments, inhibition of activity of ROS is determined by examining a biological sample comprising cells from bone marrow, blood, or a tumor. In another embodiment, inhibition of activity of ROS is determined using at least one mutant ROS polynucleotide or polypeptide-specific reagent disclosed herein.

[0253] The tested compound may be any type of therapeutic or composition as described above. Methods for assessing the efficacy of a compound, both *in vitro* and *in vivo*, are well established and known in the art. For example, a composition may be tested for ability to inhibit ROS *in vitro* using a cell or cell extract in which ROS kinase is activated. A panel of compounds may be employed to test the specificity of the compound for ROS (as opposed to other targets, such as EGFR or PDGFR).

[0254] Another technique for drug screening which may be used provides for high throughput screening of compounds having suitable binding affinity to a protein of interest, as described in PCT Publication No. WO 84/03564. In this method, as applied to FIG-ROS fusion polypeptides disclosed herein, large numbers of different small test compounds are synthesized on a solid substrate, such as plastic pins or some other surface. The test compounds are reacted with the FIG-ROS fusion polypeptide, or fragments thereof, and washed. Bound polypeptide (e.g. FIG-ROS(L), FIG-ROS(XL), or FIG-ROS(S) fusion polypeptide) is then detected by methods well known in the art. A purified FIG-ROS fusion polypeptide can also be coated directly onto plates for use in the aforementioned drug screening techniques. Alternatively, non-neutralizing antibodies can be used to capture the peptide and immobilize it on a solid support.

[0255] A compound found to be an effective inhibitor of ROS activity *in vitro* may then be examined for its ability to inhibit the progression of a cancer expressing FIG-ROS fusion polypeptide (such as a liver cancer, testicular cancer, kidney cancer, or a pancreatic cancer), *in vivo*, using, for example, mammalian xenografts harboring human liver, pancreatic, kidney, or testicular tumors (e.g., bile duct cancers) that are express a FIG-ROS fusion polypeptide. In this procedure, cancer cell lines known to express a FIG-ROS fusion protein (e.g., a FIG-ROS(S), FIG-ROS(XL), or a FIG-ROS(L)) may be placed subcutaneously in an animal (e.g., into a nude or SCID mouse, or other immune-compromised animal). The cells then grow into a tumor mass that may be visually monitored. The animal may then be treated with the drug. The effect of the drug treatment on tumor size may be externally observed. The animal is then sacrificed and the tumor removed for analysis by IHC and Western blot. Similarly, mammalian bone marrow transplants may be prepared, by standard methods, to examine drug response in hematological tumors expressing a mutant ROS kinase. In this way, the effects of the drug may be observed in a biological setting most closely resembling a patient. The drug's ability to alter signaling in the tumor cells or surrounding stromal cells may be determined by analysis with phosphorylation-specific antibodies. The drug's effectiveness in inducing cell death or inhibition of cell proliferation may also be observed by analysis with apoptosis specific markers such as cleaved caspase 3 and cleaved PARP.

[0256] Toxicity and therapeutic efficacy of such compounds can be determined by standard pharmaceutical procedures in cell cultures or experimental animals, e.g., for determining the LD₅₀ (the dose lethal to 50% of the population) and the ED₅₀ (the dose therapeutically effective in 50% of the population). The dose ratio between toxic and therapeutic effects is the therapeutic index and it can be expressed as the ratio LD₅₀/ED₅₀. In some embodiments, the compounds

exhibit high therapeutic indices.

[0257] The following Examples are provided only to further illustrate the invention and disclosures, and are not intended to limit its scope, except as provided in the claims appended hereto. The present invention encompasses modifications and variations of the methods taught herein which would be obvious to one of ordinary skill in the art. Materials, reagents and the like to which reference is made are obtainable from commercial sources, unless otherwise noted.

EXAMPLE 1

Identification of ROS Kinase Activity in Liver Cancer Patients by Global Phosphopeptide Profiling

[0258] The global phosphorylation profile of kinase activation in several human liver cancer patients, including patients XY3-78T and 090665LC, were examined using a recently described and powerful technique for the isolation and mass spectrometric characterization of modified peptides from complex mixtures (the "IAP" technique, see U.S. Patent Publication No. 20030044848, Rush *et al.*, "Immunoaffinity Isolation of Modified Peptides from Complex Mixtures"). The IAP technique was performed using a phosphotyrosine-specific antibody (CELL SIGNALING TECHNOLOGY, INC., Danvers, MA, 2003/04 Cat. #9411) to isolate, and subsequently characterize, phosphotyrosine-containing peptides from extracts of liver cancer cells taken from 23 human patients and para-tumor tissues.

Liver cancer cell samples

[0259] Liver tumors (n=23) were collected from surgical resections from patients when sufficient material for PhosphoScan analysis, RNA, and DNA extractions were available. According to the Edmonson grading system, all tumor samples have differentiation grades II-III. The collected tumors were frozen in liquid nitrogen according to standard methods.

Phosphopeptide Immunoprecipitation.

[0260] A total of 0.2g to 0.5 g tumor tissue was homogenized and lysed in urea lysis buffer (20mM HEPES pH 8.0, 9M urea, 1 mM sodium vanadate, 2.5 mM sodium pyrophosphate, 1mM beta-glycerophosphate) at 1.25×10^8 cells/ml and sonicated. Sonicated lysates were cleared by centrifugation at 20,000 x g, and proteins were reduced and alkylated as described previously (see Rush *et al.*, Nat. Biotechnol. 23(1): 94-101 (2005)). Samples were diluted with 20 mM HEPES pH 8.0 to a final urea concentration of 2M. Trypsin (1mg/ml in 0.001 M HCl) was added to the clarified lysate at 1:100 v/v. Samples were digested overnight at room temperature.

[0261] Following digestion, lysates were acidified to a final concentration of 1% TFA. Phosphopeptides were prepared using the PhosphoScan kit commercially available from Cell Signaling Technology, Inc. (Danvers, MA). Briefly, peptide purification was carried out using Sep-Pak C₁₈ columns as described previously (see Rush *et al.*, *supra*). Following purification, all elutions (10%, 15%, 20%, 25%, 30%, 35% and 40% acetonitrile in 0.1% TFA) were combined and lyophilized. Dried peptides were resuspended in 1.4 ml MOPS buffer (50 mM MOPS/NaOH pH 7.2, 10 mM Na₂HPO₄, 50 mM NaCl) and insoluble material removed by centrifugation at 12,000 x g for 10 minutes.

[0262] The phosphotyrosine monoclonal antibody P-Tyr-100 (Cell Signaling Technology, Inc., Danvers, MA) from ascites fluid was coupled non-covalently to protein G agarose beads (Roche) at 4 mg/ml beads overnight at 4°C. After coupling, antibody-resin was washed twice with PBS and three times with MOPS buffer. Immobilized antibody (40 µl, 160 µg) was added as a 1:1 slurry in MOPS IP buffer to the solubilized peptide fraction, and the mixture was incubated overnight at 4°C. The immobilized antibody beads were washed three times with MOPS buffer and twice with ddH₂O. Peptides were eluted twice from beads by incubation with 40 µl of 0.1 % TFA for 20 minutes each, and the fractions were combined.

Analysis by LC-MS/MS Mass Spectrometry.

[0263] Peptides in the IP eluate (40 µl) were concentrated and separated from eluted antibody using Stop and Go extraction tips (StageTips) (see Rappaport *et al.*, Anal. Chem., 75(3): 663-70 (2003)). Peptides were eluted from the microcolumns with 1 µl of 60% MeCN, 0.1% TFA into 7.6 µl of 0.4% acetic acid/0.005% heptafluorobutyric acid (HFBA). The sample was loaded onto a 10 cm x 75 µm PicoFrit capillary column (New Objective) packed with Magic C18 AQ reversed-phase resin (Michrom Bioresources) using a Famos autosampler with an inert sample injection valve (Dionex). The column was developed with a 45-min linear gradient of acetonitrile in 0.4% acetic acid, 0.005% HFBA delivered at 280 nL/min (Ultimate, Dionex).

[0264] Tandem mass spectra were collected as previously described (Rikova *et al.*, Cell 131: 1190-1203-, 2007). Briefly, pTyr-containing peptides were concentrated on reverse-phase micro tips. LC-MS/MS analysis was performed

with an LTQ Orbitrap Mass Spectrometer and peptide mass accuracy of 10 ppm was one of the filters used for peptide identification (Thermo Fisher Scientific). Samples were collected with an LTQ-Orbitrap hybrid mass spectrometer, using a top-ten method, a dynamic exclusion repeat count of 1, and a repeat duration of 30 sec. MS spectra were collected in the Orbitrap component of the mass spectrometer and MS/MS spectra was collected in the LTQ.

5

Database Analysis & Assignments.

[0265] MS/MS spectra were evaluated using TurboSequest (ThermoFinnigan) (in the Sequest Browser package (v. 27, rev. 12) supplied as part of BioWorks 3.0). Individual MS/MS spectra were extracted from the raw data file using the Sequest Browser program CreateDta, with the following settings: bottom MW, 700; top MW, 4,500; minimum number of ions, 20; minimum TIC, 4×10^5 ; and precursor charge state, unspecified. Spectra were extracted from the beginning of the raw data file before sample injection to the end of the eluting gradient. The IonQuest and VuDta programs were not used to further select MS/MS spectra for Sequest analysis. MS/MS spectra were evaluated with the following TurboSequest parameters: peptide mass tolerance, 2.5; fragment ion tolerance, 0.0; maximum number of differential amino acids per modification, 4; mass type parent, average; mass type fragment, average; maximum number of internal cleavage sites, 10; neutral losses of water and ammonia from b and y ions were considered in the correlation analysis. Proteolytic enzyme was specified except for spectra collected from elastase digests.

[0266] Searches were done against the NCBI human database released on 03/04/2008 containing 37742 proteins allowing oxidized methionine (M+16) and phosphorylation (Y+80) as dynamic modifications.

20

[0267] In proteomics research, it is desirable to validate protein identifications based solely on the observation of a single peptide in one experimental result, in order to indicate that the protein is, in fact, present in a sample. This has led to the development of statistical methods for validating peptide assignments, which are not yet universally accepted, and guidelines for the publication of protein and peptide identification results (see Carr et al., Mol. Cell Proteomics 3: 531-533 (2004)), which were followed in this Example. However, because the immunoaffinity strategy separates phosphorylated peptides from unphosphorylated peptides, observing just one phosphopeptide from a protein is a common result, since many phosphorylated proteins have only one tyrosine-phosphorylated site.

25

[0268] For this reason, it is appropriate to use additional criteria to validate phosphopeptide assignments. Assignments are likely to be correct if any of these additional criteria are met: (i) the same sequence is assigned to co-eluting ions with different charge states, since the MS/MS spectrum changes markedly with charge state; (ii) the site is found in more than one peptide sequence context due to sequence overlaps from incomplete proteolysis or use of proteases other than trypsin; (iii) the site is found in more than one peptide sequence context due to homologous but not identical protein isoforms; (iv) the site is found in more than one peptide sequence context due to homologous but not identical proteins among species; and (v) sites validated by MS/MS analysis of synthetic phosphopeptides corresponding to assigned sequences, since the ion trap mass spectrometer produces highly reproducible MS/MS spectra. The last criterion is routinely employed to confirm novel site assignments of particular interest.

30

[0269] All spectra and all sequence assignments made by Sequest were imported into a relational database. Assigned sequences were accepted by filtering for XCorr values of at least 1.5 and Mass Error Range within 10 ppm.

35

[0270] The foregoing IAP analysis identified many tyrosine phosphorylated proteins, the majority of which are novel (data not shown). Among the 23 patients with liver cancer, three had bile duct liver cancer. Two patients with bile duct liver cancer, namely patients XY3-78T and 090665LC, had liver cancer samples that were found to contain tyrosine phosphorylated ROS kinase, which was not detected by MS analysis in tissue adjacent to tumor nor in any of the remaining 21 patient samples.

EXAMPLE 2

45

Isolation & Sequencing of FIG-ROS Fusion Gene

50

[0271] Given the presence of the activated form of ROS kinase detected in two liver cancer patient samples, 5' rapid amplification of cDNA ends on the sequence encoding the kinase domain of ROS was conducted in order to determine whether a chimeric ROS transcript was present.

Rapid Amplification of Complementary DNA Ends

55

[0272] RNeasy Mini Kit (Qiagen) was used to extract RNA from human tumor samples. DNA was extracted with the use of DNeasy Tissue Kit (Qiagen). Rapid amplification of cDNA ends was performed with the use of 5' RACE system (Invitrogen) with primers ROS-GSP1 for cDNA synthesis and ROS-GSP2 and ROS-GSP3.1 for a nested PCR reaction, followed by cloning and sequencing PCR products.

For the 5'RACE system, the following primers were used:

ROS-GSP1: 5'ACCCTCTCGGTTCTCGTTCCA

For the nested PCR reaction, the following primers were used.

5 ROS-GSP2: 5'TCTGGCGAGTCCAAAGTCTCCAAT

ROS-GSP3.1: 5'CAGCAAGAGACGCAGAGTCAGTT

10 [0273] Sequencing of the PCR products revealed that the ROS kinases in the patient samples of XY3-78T and 090665LC, were indeed products of a chimeric ROS transcript, namely a fusion of part of a ROS transcript with part of a transcript of a FIG gene. Sequence analysis revealed that both patients XY3-78T and 090665LC had liver cancer cells that contained fusion protein resulting from the fusion of the c-terminus of ROS to the N-terminus of FIG (see Fig. 2, panel B and C). The FIG-ROS fusions in both samples were in-frame. In patient XY3-78T, a shorter fusion protein, namely FIG-ROS(S) resulted from the fusion of the first 209 amino acids of FIG to the last 421 amino acids of ROS. In 15 patient 090665LC, a longer fusion protein, namely FIG-ROS(L) resulted from the fusion of the first 412 amino acids of FIG to the last 466 amino acids of ROS.

20 [0274] In addition, a third FIG-ROS fusion is discovered (FIG-ROS (XL)), where the fusion occurs after exon 7 of the FIG gene and before exon 32 of the ROS gene. The nucleic acid sequence for the coding region of fusion gene is provided in SEQ ID NO: 16 and the amino acid sequence for the fusion polypeptide encoded by the fusion gene is provided in SEQ NO: 17.

EXAMPLE 3

Detection of Mutant ROS Kinase Expression in a Human Cancer Sample Using PCR Assay

25 [0275] The presence of mutant ROS kinase and/or a FIG-ROS fusion protein of the invention (e.g., FIG-ROS(S) or FIG-ROS(L)) in a human cancer sample was detected using cDNA or genomic reverse transcriptase (RT) and/or polymerase chain reaction (PCR). These methods have been previously described. See, e.g., Cools et al., N. Engl. J. Med. 348: 1201-1214 (2003).

PCR Assay

30 [0276] To confirm that the FIG-ROS fusion had occurred, RT-PCR was performed on RNA extracted from the liver cancer cell samples of patients XY3-78T and 090665LC. For RT-PCR, first-strand cDNA was synthesized from 2.5 ug of total RNA with the use of SuperScript™ III first-strand synthesis system (Invitrogen) with oligo (dT)₂₀. Then, the FIG-ROS fusion gene was amplified with the use of primer pairs FIG-F2 and ROS-GSP3.1. Their sequences are:

FIG-F2: 5'ACTGGTCAAAGTGCTGACTCTGGT

40 ROS-GSP3.1: 5'CAGCAAGAGACGCAGAGTCAGTT

45 [0277] As shown on Fig. 3, patient XY3-78T's liver cancer cell samples contained mRNA predicted to encode the FIG-ROS(S) fusion polypeptide. The liver cancer cell samples from patient 090665LC contained mRNA predicted to encode the FIG-ROS(L) fusion polypeptide. As a control, RT-PCR was conducted on RNA isolated from the U118MG cell line, a human glioblastoma known to contain the FIG-ROS(S) translocation. U118 MG cells were purchased from American Type Culture Collection (Manassas, VA) and grown in DMEM with 10% FBS.

50 [0278] To determine whether the liver cell samples from patient 090665LC, liver cell samples from patient XY3-78T's, or the U118MG human glioblastoma cell line expressed full length FIG or full length ROS, RT-PCR was performed using the FIG-F2 and ROS-GSP3.1 primers to amplify the FIG-ROS translocation, as well as the following primers pairs to amplify wild-type FIG (i.e., full-length FIG), wild-type ROS, and, as a control, wild-type GAPDH.

[0279] Wild type FIG gene was amplified with the use of primer pairs FIG-F3 and FIG-R8.

FIG-F3: 5'TTGGATAAGGAACCTGGCAGGAAGG

FIG-R8: 5'ACCGTCATCTAGCGGAGTTCACT

55 [0280] Wild-type ROS gene was amplified using primer pairs ROS-Ex31F and ROS-GSP2.

ROS-EX31F: 5'AGCCAAGGTCTGCTTATGTCTGT

ROS-GSP2: 5'TCTGGCGAGTCCAAAGTCTCCAAT

[0281] Wild-type GAPDH was amplified using primer pairs GAPDH-F and GAPDH-R

5 GAPDH-F: 5'TGGAAATCCCATCACCATCT
GAPDH-R: 5'GTCTTCTGGTGGCAGTGAT

10 [0282] As shown in Fig. 4, liver cancer cells from patients XY3-78T and 090665LC express wild-type FIG, but neither expresses wild-type ROS. The U118MG cell line expresses neither wild-type FIG nor wild-type ROS. HCC78 a human non-small cell lung cancer cell line, which contains an SLC34A2-ROS translocation, served as a negative control. HCC78 cells were purchased from the ATCC (Manassas, VA), and were maintained in DMEM with 10% FBS.

15 [0283] For genomic PCR, DNA was extracted from the cell samples with the use of DNeasy Tissue Kit (Qiagen). PCR amplification of the fusion gene was performed with the use of LongRange PCR kit (Qiagen) with primer pairs FIG-F3 and ROS-GSP3.1 for XY3-78T.

FIG-F3: 5' TTGGATAAGGAAGTGGCAGGAAGG
ROS-GSP3.1: 5' CAGCAAGAGACGCAGAGTCAGTTT

20 [0284] PCR amplification of the fusion gene was performed with the use of LongRange PCR kit (Qiagen) with primer pairs FIG-F7 and ROS-GSP4.1 for 090665LC and U118MG.

FIG-F7: 5' TGTGGCTCCTGAAGTGGATTCTGA
ROS-GSP4.1: 5'GCAGCTCAGCCAACCTTTGTCTT

25 [0285] As shown in Fig. 5, the FIG-ROS translocation occurred in the genome of the liver cancer cells of patients XY3-78T and 090665LC. Although the U118MG cell line expresses the same FIG-ROS(L) fusion polypeptide as the cells of patient 090665LC, the exact genomic breakpoints in FIG and ROS gene between these two samples are different. The breakpoints were found to be:

30 XY3-78T

[0286]

35 1-822 bp of FIG-Intron3
659-619 bp of ROS-Intron35
660-1228 bp of ROS Intron35

090665LC

40 [0287]

1-2402 bp of FIG-Intron7
2317-2937 bp of ros-Intron34

45 U118MG

[0288]

50 1-2304 bp of FIG-Intron7
583-2937 bp ros-Intron34

55 [0289] The nucleotide sequence of intron 3 of the human FIG gene is provided herewith as SEQ ID NO:5. The nucleotide sequence of intron 7 of the human FIG gene is provided herewith as SEQ ID NO: 6. The nucleotide sequence of intron 34 of the human ROS gene is provided herewith as SEQ ID NO: 7. The nucleotide sequence of intron 35 of the human ROS gene is provided herewith as SEQ ID NO: 8.

[0290] This assay may be used to detect the presence of a mutant ROS kinase and/or a FIG-ROS fusion protein of the invention (e.g., FIG-ROS(S) or FIG-ROS(S) in a human cancer sample in other biological tissue samples (e.g., tumor tissue samples may be obtained from a patient having liver, pancreatic, kidney, or testicular cancer). Such an analysis

will identify a patient having a cancer characterized by expression of the truncated ROS kinase (and/or FIG-ROS fusion protein), which patient is likely to respond to treatment with a ROS inhibitor.

Example 4

5

Generation of Recombinant Retrovirus Encoding Fig-Ros Fusion Polypeptides

[0291] The open reading frame of the FIG-ROS (L) and FIG-ROS (S) fusion gene was amplified by PCR from cDNA isolated from patients 090665LC and XY3-78T, respectively, using the following pair of primers (FIG-Fc: 5'ATGTCG-GCGGGCGGTCCATG; ROS-Rc: 5'TTAACAGACCCATCTCCAT). These PCR products were cloned into the retroviral vector MSCV-Neo with a C-terminal Myc tag (EQKLISEEDL) (MSCV-neo vector and MSCV-puro vector are commercially available from Clontech.). Additional recombinant retroviral constructs (e.g., empty MSCV-neo vector, MSCV-puro-src, etc.) were also generated. The FIG-ROS(S) containing MSCV-Neo vector was deposited with the American Type Culture Collection ("ATCC", Manassas, Virginia) under the terms of the Budapest Treaty on January 21, 2009 and assigned ATCC Patent Deposit Designation No. PTA-9721 .

[0292] The resulting recombinant retroviral constructs (*i.e.*, containing FIG-ROS(S) or FIG-ROS(L)) were transfected into 293T cells to be packaged into recombinant retrovirus capable of infecting (and thereby transducing) cells. To do this, 293T cells (e.g., commercially available from ATCC) were maintained in 10% DMEM containing 10% fetal bovine serum in 10cm tissue culture plates. 24-48 hours prior to transfection, the 293T cells were plated at about 50-80% confluence. Transfection was performed using the FuGENE reagent (commercially available from Roche Diagnostics), according to the manufacturer's instructions. Typically, for each recombinant construct, a 3:1 ratio of the FuGENE reagent (in μ l) to DNA (ug) was used (e.g., 3 μ l FuGENE to 1 ug Myc-tagged FIG-ROS(S) in MSCV-Neo). 48 hours following transfection, the media was removed, and any cells within the media (now containing recombinant virus) was removed by filtering the media through a 0.45 μ m syringe filter. The media (also referred to as viral soup) was stored at -80°C.

25

EXAMPLE 5

Expression of FIG-ROS Fusion Proteins in 3T3 cells

[0293] 3T3 cells were purchased from American Type Culture Collection (Manassas, VA). 3T3 cells were grown at 37°C in DMEM media with 10% FBS.

[0294] 1 ml of recombinant retrovirus encoding the Fig-Ros fusion polypeptides generated as described in Example 4 were used to transducer 3T3 cells from 10 cm plate with 50% confluence. In addition, an empty retrovirus (*i.e.*, generated from an empty MSCV-Neo vector with a C-terminal Myc tag was transduced into 3T3 cells as a control.

[0295] 3T3 cells were infected with (*i.e.*, transduced with) recombinant retrovirus expressing FIG-ROS(S) from XY3-78T, FIG-ROS(L) from 090665LC. Empty retrovirus was also used to infect 3T3 cells as a control. Two days after transduction, 0.5 mg/ml G418 was added to the cell culture media. Two weeks after being transduced (*i.e.*, 12 days after selection in G418), 1 million cells were lysed and Western blotting analysis performed, staining the electrophoretically resolved cell lysates with an antibody that specifically bound to the kinase domain of ROS, as well as a phospho-antibody against ROS. The cell lysates were also probed with antibodies against several downstream signaling substrates of ROS kinase including p-STAT3 (*i.e.*, phosphorylated STAT3), STAT3, p-AKT (*i.e.*, phosphorylated AKT), and AKT. b-actin was also stained to ensure that equivalent amounts of lysates were present in all lanes. All antibodies are from Cell Signaling Technology, Inc.

[0296] As shown in Fig. 6, the 3T3 cells transduced with recombinant retrovirus stably expressed FIG-ROS(S) and FIG-ROS(L). As expected, the NC (empty vector) cells did not express any ROS. Expression of FIG-ROS(S) and FIG-ROS(L) activate downstream signaling molecules, STAT3 and AKT.

EXAMPLE 6

Effect of FIG-ROS Fusion Proteins on 3T3 Cells' Growth In Vitro and In Vivo

[0297] 3T3 cells have contact inhibition, meaning that they do not form colonies in soft agar. To determine if the presence of active ROS kinase in these cells removed their contact inhibition, retrovirally transduced 3T3 cells were selected for G418 (0.5 mg/ml) for 7 days, and the cells were then cultured in soft agar in triplicate for 17 days. A retrovirus encoding the short version of SLC34A2-ROS was also used to transduce 3T3 cells. As a control, a retrovirus encoding the src kinase was also used to transducer 3T3 cells. The protocol for soft agar assay is attached.

[0298] As shown in Fig. 7, 3T3 cells transduced with either src kinase- or FIG-ROS(S)-encoding retrovirus lost their contact inhibition dramatically. This provides evidence that the presence of FIG-ROS(S) is able to drive a cell into a

cancerous state of growth. The presence of FIG-ROS(L) also enabled 3T3 cells to lose their contact inhibition (see Fig. 7, top left panel), as did SLC34A2-ROS(S) (data not shown), although the effect was not as significant as that seen with FIG-ROS(S).

[0299] In addition, the ability of transduced 3T3 cells to form tumors *in vivo* was analyzed. Immunocompromised nude mice (which lack a thymus, available from the Jackson Laboratory, Bar Harbor, Maine) were injected with 1×10^6 3T3 cells transduced with retrovirus containing empty vector, FIG-ROS(L) or FIG-ROS(S). Mice were monitored daily for tumor formation and size, and were sacrificed when tumors reached approximately 1 cm x 1 cm.

[0300] As shown in Fig. 8, two weeks after being injected with 3T3 cells transduced with either FIG-ROS(S) or FIG-ROS(L), tumor formation was apparent in the injected nude mice.

EXAMPLE 7

Subcellular Localization of FIG-ROS(L) and FIG-ROS(S) in 3T3 Cells

[0301] Recombinant vectors were generated to express Myc-tagged versions of FIG-ROS(L) and FIG-ROS(S), where the myc tag was incorporated onto the C-terminus of the FIG-ROS fusion polypeptide. 3T3 cells were stably transfected with the recombinant expression vectors or with an empty "neo" only vector (control).

[0302] Immunofluorescence was performed with a standard protocol (publicly available from Cell Signaling Technology, Inc.). Briefly, The 9E1H1D9 ROS antibody, Myc-Tag antibody (CST# 2278) and the Golgin-97 antibody were from Cell Signaling Technology, Inc. (Danvers, MA).

[0303] As shown in Figs. 9A and 9B, the two different FIG-ROS fusion polypeptides of the invention localized to different areas of the cell. FIG-ROS(L) localized to Golgi apparatus, and co-localizes with the Golgi marker (golgin-97) (see images under "Myc-FR(L)" in both Figs. 9A and 9B). To our surprise, the staining pattern of FIG-ROS(S) was cytoplasmic (see images under "Myc-FR(S)" in both Figs. 9A and 9B), even though it contains the second coiled-coil domain of FIG, suggesting that the coiled-coil domain of FIG is necessary, but not sufficient to target FIG-ROS(S) to the Golgi apparatus. This may be because the PDZ domain of FIG is present in FIG-ROS(L), but not in FIG-ROS(S). Interestingly, SLC34A2-ROS(S) was localized to para-nuclei compartment (see images under "Myc-SR(S)" in both Figs. 9A and 9B). The fact that the SLC34A2-ROS (S) fusion, which contains transmembrane domain of ROS, is localized in perinuclear compartment suggests that transmembrane domain of ROS also contributes to its localization.

[0304] Thus, different ROS fusions have distinct subcellular localization, suggesting that they may activate different substrates *in vivo*.

EXAMPLE 8

FIG-ROS(L) and FIG-ROS(S) Activity in Transduced BaF3 Cells

[0305] Murine BaF3 cells normally need interleukin-3 (IL-3) to survive. BaF3 cells were obtained from DSMZ (Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH, Germany) and were maintained at 37°C in RPMI-1640 medium (Invitrogen) with 10% fetal bovine serum (FBS) (Sigma) and 1.0 ng/ml murine IL-3 (R&D Systems).

[0306] To determine if expression of a FIG-ROS fusion polypeptide of the invention could enable BaF3 cells to survive without IL-3, we transduced BaF3 cells with the retroviruses described in Example 4 encoding FIG-ROS(L) and FIG-ROS(S). In addition, retrovirus encoding the FIG-ROS(L) from U118MG were also generated and used to transduce BaF3 cells.

[0307] As shown in Fig. 10, FIG-ROS(S), FIG-ROS(L), and FIG-ROS(L) from U118MG were stably expressed in BaF3 cells grown with or without IL-3. Indeed, as shown in Fig. 11, we found that the presence of FIG-ROS(L) or FIG-ROS(S) enabled BaF3 cells to grow in the absence of IL-3. Interestingly, FIG-ROS(S) expressing BaF3 cells grew at a faster pace than the BaF3 expressing FIG-ROS(L).

[0308] Next, an *in vitro* kinase assay was performed to determine if the ROS kinase portion of the FIG-ROS fusion polypeptides was active. Cell lysates from FIG-ROS transduced BaF3 cells were subjected to immunoprecipitation with anti-Myc-Tag antibody (which pulls down the Myc-tagged FIG-ROS fusion polypeptides). The pulled-down ROS immune complex were washed 3 times with cell lysis buffer, followed by kinase buffer (Cell Signaling Technology). Kinase reactions were initiated by re-suspending the ROS immune complex into 25 μ l kinase buffer that contains 50uM ATP, 0.2 uCi/ μ l [gamma32p] ATP, with 1 mg/ml of either Poly (EY, 4:1). Reactions were stopped by spotting reaction cocktail onto p81 filter papers. Samples were then washed and assayed for kinase activity by detection with a scintillation counter. As shown in Fig. 12, while both FIG-ROS (L) and FIG-ROS (S) can phosphorylate its substrate, FIG-ROS(S) is more potent than FIG-ROS(L). In other words, FIG-ROS(S) has a much higher kinase activity than FIG-ROS(L). Equal loading of the lanes is shown in the Western blotting analysis of the ROS immune complexes using a ROS-specific antibody (see Fig. 12, lower panel).

[0309] The higher potency of FIG-ROS(S) as compared to FIG-ROS(L) is consistent with data from soft agar assay (see Fig. 7) and IL-3 independent growth assay (see Fig. 11).

EXAMPLE 9

5

Sensitivity of FIG-ROS(L) and FIG-ROS(S) to TAE-684

[0310] The small molecule, TAE-684, a 5-chloro-2,4-diaminophenylpyrimidine, which has the structure:

10

15

20

25

30


35

40

45

50

55



and has been shown to inhibit the ALK kinase. Galkin, et al., Proc. National Acad. Sci 104(1) 270-275, 2007.

[0311] In this example, we determined whether or not TAE-684 also inhibited FIG-ROS fusion polypeptide. To do this, BaF3 and Karpas 299 cells were obtained from DSMZ (Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH, Germany). BaF3 cells were maintained as described above and Karpas 299 cells (a lymphoma cell line) were grown in RPMI-1640 with 10% FBS.

[0312] BaF3 cells were transduced with retrovirus encoding FIG-ROS(S), FIG-ROS(L), or FLT-3ITD (the Internal tandem duplication mutation in FLT3 causes AML leukemia), and selected for IL3 independent growth. Karpas 299 cells, which express NPM-ALK, was used as a positive control.

[0313] A MTS assay was performed using the CellTiter 96 Aqueous One Solution Reagent, (Promega, Catalog No. G3582). Briefly, 1×10^5 cells/well in 24 well plate were grown in 1 ml medium that included 0nM, 3nM, 10 nM, 30 nM, 100 nM, 300 nM or 1000 nM TAE-684. After 72 hours, 20 μ l of the CellTiter 96 Aqueous One Solution Reagent was added into each well of a 96 well assay plate (flat bottom), and then 100 μ l of cells grown with or without treatment. Media-only wells were used as controls. The 96 well plate was incubated for 1-4 hours at 37°C, and then viable cells were counted by reading the absorbance at 490 nm using a 96 well plate reader.

[0314] As shown in Fig. 13, the BaF3 cells transduced with retrovirus expressing one of the FIG-ROS polypeptides stopped growing in the presence of TAE-684. Interestingly, FIG-ROS(S) is less susceptible to TAE-684 than FIG-ROS(L). Karpas 299 cells also responded (*i.e.*, stopped growing) in the presence of TAE-684, which was expected since they express ALK and TAE-684 inhibits the ALK kinase. The BaF3 cells transduced with FLT3/ITD were not susceptible to TAE-684.

[0315] The mechanism of death of the BaF3 and Karpas 299 cells was next reviewed by measuring the percentage of cleaved-caspase 3 positive cells by flow cytometry assay using cleaved caspase-3 as a marker for apoptosis. These results were obtained using the protocol publically available from Cell Signaling Technology, Inc. (Danvers, MA)

5 [0316] As shown in Fig. 14, the presence of TAE-684 caused the BaF3 cells expressing FIG-ROS(S) or FIG-ROS(L) to die by apoptosis. Interestingly, Karpas 299 cells, which stop growing in the presence of TAE-684, did not die by apoptosis-they simply underwent cell cycle arrest. Thus, the mechanism by which TAE-684 inhibits FIG-ROS fusion polypeptides is likely different from the mechanism by which TAE-684 inhibits the ALK kinase.

10 [0317] To further identify the mechanism of action of TAE-684 on the FIG-ROS fusion polypeptides of the invention, all four cell lines (*i.e.*, Karpas 299 cells and BaF3 cells transduced with retrovirus encoding FIG-ROS(S), FIG-ROS(L), and FLT-3ITD) were subjected to Western blotting analysis following treatment with 0, 10, 50, or 100 nM TAE-684 for three hours. All antibodies were from Cell Signaling Technology, Inc.

15 [0318] As shown in Fig. 15, phosphorylation of both FIG-ROS(S) and FIG-ROS(L) in FIG-ROS(S) and FIG-ROS(L) expressing BaF3 cells was inhibited by TAE-684. In addition, phosphorylation of STAT3, AKT, and ERK, and Shp2 were inhibited in FIG-ROS(S) and FIG-ROS(L) expressing BaF3 cells. The phosphorylation of STAT3, AKT, and ERK, and Shp2 was not affected in the BaF3 cells transduced with the FLT-3ITD retrovirus. TAE-684 also inhibited ALK and ERK phosphorylation in Karpas 299 cells. Since ROS, ALK, LTK, InsR, and IGF1R belong to the same family of tyrosine kinases, they may share similar structure in the kinase domain. Kinase inhibitors or antibodies designed against ALK, LTK, InsR, and IGF1R may have therapeutic effects against ROS kinase.

20 **EXAMPLE 10**

Detection of Mutant ROS Expression in a Human Cancer Sample Using FISH Assay

[0319] The presence of a ROS fusion polynucleotide (*e.g.*, a FIG-ROS(L), FIG-ROS(S), FIG-ROS(XL), SLC34A2-ROS(S), SLC34A2-ROS(VS), SLC34A2-ROS(L), or CD74-ROS) in liver cancer (*e.g.*, in a cholangiocarcinoma), pancreatic cancer, kidney cancer, or testicular cancer is detected using a fluorescence *in situ* hybridization (FISH) assay. Such FISH assays are well known in the art (*see, e.g.*, Verma et al. *Human Chromosomes: A Manual of Basic Techniques*, Pergamon Press, New York, N.Y. (1988)).

30 [0320] To do this, paraffin-embedded human tumor samples are examined. Some tissues that are examined include liver, pancreas, testicular, and kidney cancers, particularly cancers affecting the ducts of all of these tissues.

[0321] For analyzing rearrangements involving the ROS gene, a dual color break-apart probe can be designed. As shown in Figure 16, several BAC probes surround the FIG and ROS genes on chromosome 6. While these probes are ideal for identifying translocations between the FIG gene (*also known as the GOPC gene*-*see* Fig. 16) and the ROS gene, these probes can also be used to identify other ROS gene translocation.

35 [0322] For these studies, a proximal probe (BAC clone RP1-179P9) and two distal probes (BAC clone RP11-323O17, RP1-94G16) (*all of which are commercially available, for example, from Invitrogen Inc., Carlsbad, CA, as Catalog Nos. RPCI1.C and RPCI11.C*) are designed. The proximal probe may be labeled with Spectrum Orange dUTP and the distal probe may be labeled with Spectrum Green dUTP. Labeling of the probes by nick translation and interphase FISH using FFPE tissue sections may be done according to the manufacturer's instructions (Vysis Inc., Downers Grove, IL) with the following modifications. In brief, paraffin embedded tissue sections are re-hydrated and are subjected to pretreatment first in 0.2N HCl for 20 minutes followed by 1 M sodium thiocyanate at 80C for 30 min.

40 [0323] Following a brief wash, sections are digested with protease (8mg Pepsin, 2000-3000U/mg) for 45-60 minutes at 37C then fixed in 10% NBF and dehydrated. The probe set is then loaded onto the sections and incubated at 94C for 3 min in order to denature the probe and target chromosome. Following denaturation the slides are incubated at 37C for a minimum of 18 hours. After washing, 4',6-diamidino-2-phenylindole (DAPI; mg/ml) in Vectashield mounting medium (Vector Laboratories, Burlingame, CA) will be applied for nuclear counterstaining.

45 [0324] The FIG-ROS rearrangement probe will contain three differently labeled probes. Two of these probes (RP11-323O17, RP1-94G16) target the deletion area between the break points of the FIG gene and the ROS gene and the other probe (RP1-179P9) targets the remaining portion of the ROS gene (*see* Figure 16). The sequences of the 50 introns containing the break points of the FIG and ROS genes are provided in SEQ ID NO: 5 (intron 3 of FIG), SEQ ID NO: 6 (intron 7 of FIG), SEQ ID NO: 7 (intron 33 of ROS), SEQ ID NO: 8 (intron 34 of ROS), and SEQ ID NO:26 (intron 31 of ROS). The probes are designed based on the breakpoints identified in Example 2. When hybridized, the native (*i.e.*, wild-type) ROS region will appear as an orange/ green fusion signal (which may appear yellow under a microscope), while rearrangement at this locus (as occurs in the FIG-ROS fusion protein) will result in only orange signals since the 55 target areas for the green probes have been deleted.

[0325] For rearrangements of the ROS gene with either CD74 (on chromosome 5) or SLC34A2 (on chromosome 4), because these genes lie on chromosomes other than chromosome 6, the native (*i.e.*, wild-type or non-rearranged) ROS region will appear as an orange/green fusion signal(which may appear yellow under a microscope), while rearrangement

at this locus (as occurs in the SLC34A2-ROS fusion proteins and the CD74-ROS fusion proteins) will result in a separate orange signal (on chromosome 6) and separate green signal (on chromosome 5 for CD74 and chromosome 4 for SLC34A2).

[0326] The FISH analysis will likely reveal a low incidence of ROS gene translocations in the sample population having liver cancer (e.g., in a cholangiocarcinoma), pancreatic cancer, kidney cancer, or testicular cancer. However, it is predicted that a subset of the studied cancers will contain a ROS translocation. These cancers containing the FIG-ROS translocation are identified as those cancers likely to respond to a ROS inhibitor. In other words, cells of the cancer, upon treatment (or contact) with a ROS inhibitor are predicted to show growth retardation, growth abrogation (*i.e.*, stop growing) or actually die (e.g., by apoptosis) as compared to untreated cancer cells (*i.e.*, cells not contacted with the ROS inhibitor).

EXAMPLE 11

Identification of Mutant ROS Expression in Human Liver Cancers

[0327] Next, studies were performed to determine if ROS expression could be observed in samples from human liver cancers. The two most common types of liver cancer are hepatocellular carcinoma (HCC), accounting for 80% of all cases, and cholangiocarcinoma (CCA, or bile duct cancer), representing 10-15% of hepatobiliary neoplasms (Blehacz et al., Hepatology 48:308-321, 2008 and de Groen, P.C., N Engl J Med 341:1368-1378, 1999). For these studies, an ROS-specific antibody (clone no. D4D6) that specifically bound to the c-terminus of ROS was used. Such antibodies are commercially available (see, e.g., the Ros (C-20) antibody, Catalog No. sc-6347 from Santa Cruz Biotechnology, Inc., Santa Cruz, CA).

[0328] For the studies on cholangiocarcinoma, nineteen human cholangiocarcinoma paraffin-embedded tissue blocks and slides were obtained from BioChain Institute, Inc., Hayward, CA, Folio Biosciences, Columbus, OH and Analytical Biological Services, Inc., Wilmington, DE. 4-6 μ m tissue sections were deparaffinized through three changes of xylene for 5 minutes each, then rehydrated through two changes of 100% ethanol and 2 changes of 95% ethanol, each for 5 minutes.

[0329] The deparaffinized slides were then rinsed for 5 minutes each in three changes of diH₂O, then were subjected to antigen retrieval in a Decloaking Chamber (Biocare Medical, Concord, CA). Slides were immersed in 250ml 1.0 mM EDTA, pH 8.0 in a 24 slide holder from Tissue Tek. The Decloaking Chamber was filled with 500 ml diH₂O, the slide holder was placed in the chamber touching the heat shield, and retrieval was performed with the following settings as set by the manufacturer: SP1 125°C for 30 seconds and SP2 90°C for 10 seconds. Slides were cooled on the bench for 10 minutes, rinsed in diH₂O, submerged in 3% H₂O₂ for 10 minutes, then washed twice in diH₂O.

[0330] After blocking for 1 hour at room temperature in Tris buffered saline + 0.5% Tween-20 (TBST)/5% goat serum in a humidified chamber, slides were incubated overnight at 4°C with Ros (D4D6) XP™ Rabbit mAb at 0.19 μ g/ml diluted in SignalStain® Antibody Diluent (catalog #8112 Cell Signaling Technology, Danvers, MA). After washing three times in TBST, detection was performed with SignalStain® Boost IHC Detection Reagent (HRP, Rabbit) (catalog #8114 Cell Signaling Technology, Danvers, MA) with a 30 minute incubation at room temperature in a humidified chamber.

[0331] After washing three times in TBST to remove the SignalStain® Boost IHC Detection Reagent, the slides were next exposed to NovaRed (Vector Laboratories, Burlingame, CA) prepared per the manufacturer's instructions. Slides were developed for 1 minute and then rinsed in diH₂O. Slides were counterstained by incubating in hematoxylin (Ready to use Invitrogen (Carlsbad, CA) Catalog #00-8011) for 1 minute, rinsed for 30 seconds in diH₂O, incubated for 20 seconds in bluing reagent (Richard Allan Scientific, Kalamazoo, MI (a Thermo Scientific company), Catalog #7301), and then finally washed for 30 seconds in diH₂O. Slides were dehydrated in 2 changes of 95% ethanol for 20 seconds each and 2 changes of 100% ethanol for 2 minutes each. Slides were cleared in 2 changes of xylene for 20 seconds each, then air dried. Coverslips were mounted using VectaMount (Vector Laboratories, Burlingame, CA). Slides were air dried, then evaluated under the microscope.

[0332] Of the nineteen samples assayed, six samples stained positive for binding of the ROS-specific antibody. Figure 17 shows a representative image of slide from a CCA tissue sample that stained positive for ROS expression. This finding is notable because ROS is not expressed in normal bile duct tissue and is also not expressed in normal liver tissue.

[0333] Sequencing analysis of the samples showing strong staining with the ROS-specific antibody is expected to reveal the presence of either mutant ROS expression (e.g., overexpression of wild-type ROS in the bile duct cancer tissue where in normal bile duct tissue there is none) or the presence of a truncated ROS polypeptide or a ROS fusion protein (e.g., a FIG-ROS fusion polypeptide).

[0334] For studies on hepatocellular carcinoma, 23 paraffin-embedded human HCC tissue array sectioned at 4 μ m were deparaffinized through three changes of xylene for 5 minutes each, then rehydrated through two changes of 100% ethanol and 2 changes of 95% ethanol, each for 5 minutes. Slides were rinsed for 5 minutes each in three changes of diH₂O, then were subjected to antigen retrieval in a Decloaking Chamber (Biocare Medical, Concord, CA) as follows. Slides were immersed in 250ml 1.0 mM EDTA, pH 8.0 in a 24 slide holder from Tissue Tek. The Decloaking Chamber

was filled with 500 ml diH₂O, the slide holder was placed in the chamber touching the heat shield, and retrieval was performed with the following settings as set by the manufacturer: SP1 125°C for 30 seconds and SP2 90°C for 10 seconds. Slides were cooled on the bench for 10 minutes, rinsed in diH₂O, submerged in 3% H₂O₂ for 10 minutes, then washed twice in diH₂O.

5 [0335] After blocking for 1 hour at room temperature in Tris buffered saline + 0.5% Tween-20 (TBST)/5% goat serum in a humidified chamber, slides were incubated overnight at 4°C with Ros (D4D6) XP™ Rabbit mAb at 0.19 µg/ml diluted in SignalStain® Antibody Diluent (#8112 Cell Signaling Technology, Danvers, MA). After washing three times in TBST, detection was performed with SignalStain® Boost IHC Detection Reagent (HRP, Rabbit) (#8114 Cell Signaling Technology, Danvers, MA) with a 30 minute incubation at room temperature in a humidified chamber.

10 [0336] After washing three times in TBST slides were exposed to NovaRed (Vector Laboratories, Burlingame, CA) prepared per the manufacturer's instructions. Slides were developed for 1 minute then rinsed in diH₂O. Slides were counterstained by incubating in hematoxylin (Ready to use Invitrogen #00-8011) for 1 minute, rinsed for 30 seconds in diH₂O, incubated for 20 seconds in bluing reagent (Richard Allan Scientific #7301), then finally washed for 30 seconds in diH₂O. Slides were dehydrated in 2 changes of 95% ethanol for 20 seconds each and 2 changes of 100% ethanol for 15 2 minutes each. Slides were cleared in 2 changes of xylene for 20 seconds each, then air dried. Coverslips were mounted using VectaMount (Vector Laboratories, Burlingame, CA). Slides were air dried, then evaluated under the microscope.

[0337] Of the twenty-three samples assayed, one sample was strongly positive for staining (i.e., binding) by the ROS-specific antibody and nine cases showed weak to moderate staining. Figure 18 shows a representative image of slide from a HCC tissue sample that stained moderately positive for ROS expression. This finding is notable because ROS 20 is not expressed in normal bile duct tissue and is also not expressed in normal liver tissue.

[0338] Sequencing analysis of the samples showing strong staining with the ROS-specific antibody is expected to reveal the presence of either mutant ROS expression (e.g., overexpression of wild-type ROS in the hepatocellular carcinoma tissue where there is none in normal liver tissue) or the presence of a truncated ROS polypeptide or a ROS fusion protein (e.g., a FIG-ROS fusion polypeptide).

25 [0339] To determine whether or not the ROS antibody used was able to bind mutant ROS in these liver tissues, an IHC assay was performed on HCC78 cells (a non-small cell lung cancer known to express an SLC34A2-ROS fusion polypeptide) in the presence or absence of a competing ROS peptide.

[0340] IHC was performed as described above for the HCC and CCA tissue samples. Briefly, paraffin embedded HCC78 cell pellets were deparaffinized and rehydrated through three changes of xylene and graded ethanol, then rinsed 30 in diH₂O. Slides were subjected to antigen retrieval in 1.0mM EDTA, pH 8.0 in the microwave. After blocking for 1 hour in TBST/5% goat serum, slides were incubated overnight at 4°C with Ros (D4D6) XP™ Rabbit mAb at 0.19 µg/ml in the absence of peptide or in the presence of one of 13 different ROS peptides at 1.9 µg/ml. The ROS peptides were as follows:

Peptide number: M09-6291
 35 Peptide name: ROS-1
 Peptide sequence: (biotin)AGAGCGQGEEKSEG
 Peptide carboxyl-terminus: CONH2
 Synthesis scale (µmol): 5
 Peptide number: M09-6300
 40 Peptide name: ROS-10
 Peptide sequence: (biotin)AGAGSGKPEGLNAYA
 Peptide carboxyl-terminus: CONH2
 Synthesis scale (µmol): 5
 Peptide number: M09-6301
 45 Peptide name: ROS-11
 Peptide sequence: (biotin)AGAGGLNYACLTHS
 Peptide carboxyl-terminus: CONH2
 Synthesis scale (µmol): 5
 Peptide number: M09-6302
 50 Peptide name: ROS-12
 Peptide sequence: (biotin)AGAGCLTHSGYGDG
 Peptide carboxyl-terminus: CONH2
 Synthesis scale (µmol): 5
 Peptide number: M09-6303
 55 Peptide name: ROS-13
 Peptide sequence: (biotin)AGAGTHSGYGDGSD
 Peptide carboxyl-terminus: CONH2
 Synthesis scale (µmol): 5

Peptide number: M09-6292
 Peptide name: ROS-2
 Peptide sequence: (biotin)AGAGEKSEGPLGSQ
 Peptide carboxyl-terminus: CONH2
 5 Synthesis scale (μmol): 5
 Peptide number: M09-6293
 Peptide name: ROS-3
 Peptide sequence: (biotin)AGAGPLGSQESESC
 Peptide carboxyl-terminus: CONH2
 10 Synthesis scale (μmol): 5
 Peptide number: M09-6294
 Peptide name: ROS-4
 Peptide sequence: (biotin)AGAGESESCGLRKE
 Peptide carboxyl-terminus: CONH2
 15 Synthesis scale (μmol): 5
 Peptide number: M09-6295
 Peptide name: ROS-5
 Peptide sequence: (biotin)AGAGGLRKEEKEPH
 Peptide carboxyl-terminus: CONH2
 20 Synthesis scale (μmol): 5
 Peptide number: M09-6296
 Peptide name: ROS-6
 Peptide sequence: (biotin)AGAGEKEPHADKDF
 Peptide carboxyl-terminus: CONH2
 25 Synthesis scale (μmol): 5
 Peptide number: M09-6297
 Peptide name: ROS-7
 Peptide sequence: (biotin)AGAGADKDFCQEKQ
 Peptide carboxyl-terminus: CONH2
 30 Synthesis scale (μmol): 5
 Peptide number: M09-6298
 Peptide name: ROS-8
 Peptide sequence: (biotin)AGAGCQEKKVAYCP
 Peptide carboxyl-terminus: CONH2
 35 Synthesis scale (μmol): 5
 Peptide number: M09-6299
 Peptide name: ROS-9
 Peptide sequence: (biotin)AGAGVAYCPSGKPE
 Peptide carboxyl-terminus: CONH2
 40 Synthesis scale (μmol): 5

[0341] After washing, detection was performed with SignalStain® Boost IHC Detection Reagent (HRP, Rabbit) #8114 and NovaRed (Vector Laboratories, Burlingame, CA).

[0342] The results show that only peptide 9 was able to compete the binding of the antibody off of the IHC slide. Figure 45 19A shows an IHC slide with the addition of peptide ROS-1 and Figure 19B shows an IHC slide with the addition of peptide ROS-9. Thus, the sequence of ROS-9, namely AGAGVAYCPSGKPE, is within the ROS kinase fragment specifically bound to by the antibody used in these studies. Since this sequence appears within the kinase domain of the ROS kinase, these studies strongly suggest that the CCA and HCC tissues that stained positive for binding with the ROS-specific antibody were expressing the kinase domain of ROS.

50

The disclosure can be further described by the following clauses:

[0343]

55 1. A purified FIG-ROS(S) fusion polypeptide, wherein said polypeptide comprises the amino acid sequence set forth in SEQ ID NO: 4 or SEQ ID NO: 17.

2. A purified FIG-ROS(S) fusion polynucleotide, wherein said polynucleotide comprises the nucleic acid sequence

set forth in SEQ ID NO: 3 or SEQ ID NO: 16.

3. A binding agent that specifically binds to a FIG-ROS fusion polypeptide.

5 4. The binding agent of clause 3, wherein the binding agent specifically binds to a fusion junction between a FIG portion and a ROS portion in said FIG-ROS fusion polypeptide.

10 5. The binding agent of clause 4, wherein the fusion junction comprises an amino acid sequence selected from the group consisting of AGSTLP, LQVWHR, and LQAGVP.

15 6. The binding agent of clause 3, wherein the FIG-ROS fusion polypeptide is selected from the group consisting of a FIG-ROS(S) fusion polypeptide, a FIG-ROS(L) fusion polypeptide, and a FIG-ROS(XL) fusion polypeptide.

20 7. The binding agent of clause 3, wherein the binding agent is selected from the group consisting of an antibody and an AQUA peptide.

25 8. A nucleotide probe for detecting a FIG-ROS(S)fusion polynucleotide or a FIG-ROS(XL) fusion polynucleotide, wherein said probe hybridizes to said FIG-ROS(S) fusion polynucleotide or to a FIG-ROS(XL) fusion polynucleotide under stringent conditions.

30 9. A method for detecting a FIG-ROS gene translocation in a biological sample, said method comprising contacting a biological sample with a binding agent that specifically binds to a FIG-ROS fusion polypeptide, wherein specific binding of said binding agent to said biological sample indicates a FIG-ROS gene translocation in said biological sample.

35 10. A method for detecting a FIG-ROS gene translocation in a biological sample, said method comprising contacting a biological sample with a nucleotide probe that hybridizes to a FIG-ROS fusion polynucleotide under stringent conditions, wherein hybridization of said nucleotide probe to said biological sample indicates a FIG-ROS gene translocation in said biological sample.

40 11. A method for diagnosing a patient as having a cancer or a suspected cancer characterized by a ROS kinase, wherein said cancer or suspected cancer is not a cancer or suspected cancer selected from the group consisting of non-small cell lung carcinoma and glioblastoma, said method comprising contacting a biological sample of said cancer or suspected cancer, said biological sample comprising at least one polypeptide, with a binding agent that specifically binds to a mutant ROS polypeptide, wherein specific binding of said binding agent to at least one polypeptide in said biological sample identifies said patient as having a cancer or a suspected cancer characterized by a ROS kinase.

45 12. A method for identifying a cancer or a suspected cancer that is likely to respond to a ROS inhibitor, wherein said cancer or suspected cancer is not a cancer or suspected cancer selected from the group consisting of non-small cell lung carcinoma and glioblastoma, said method comprising contacting a biological sample of said cancer or suspected cancer, said biological sample comprising at least one polypeptide with a binding agent that specifically binds to a mutant ROS polypeptide, wherein specific binding of said binding agent to at least one polypeptide in said biological sample identifies said cancer or suspected cancer as a cancer or suspected cancer that is likely to respond to a ROS inhibitor.

50 13. The method of clause 11 or 12, wherein said mutant ROS polypeptide is aberrantly expressed wild-type ROS polypeptide.

55 14. The method of clause 11or 12, wherein said mutant ROS polypeptide is selected from the group consisting of a truncated ROS polypeptide and a ROS fusion polypeptide.

15. The method of clause 14, wherein the ROS fusion polypeptide is selected from the group consisting of a FIG-ROS(S) fusion polypeptide, a FIG-ROS(L) fusion polypeptide, a FIG-ROS(XL) fusion polypeptide, a SLC34A2-ROS(S) fusion polypeptide, a SLC34A2-ROS(L) fusion polypeptide, a SLC34A2-ROS(VS) fusion polypeptide, and a CD74-ROS fusion polypeptide.

16. The method of clause 11or 12, wherein the binding agent is selected the group consisting of an antibody or an

AQUA peptide.

17. A method for diagnosing a patient as having a cancer or a suspected cancer characterized by a ROS kinase, wherein said cancer or suspected cancer is not a cancer or suspected cancer selected from the group consisting of non-small cell lung carcinoma and glioblastoma, said method comprising contacting a biological sample of said cancer or a suspected cancer, said biological sample comprising at least one nucleic acid molecule, with a probe that hybridizes under stringent conditions to a nucleic acid molecule selected from the group consisting of a FIG-

5 ROS fusion polynucleotide, a SLC34A2-ROS fusion polypeptide, a CD74-ROS fusion polypeptide, and a truncated ROS polynucleotide, and wherein hybridization of said probe to at least one nucleic acid molecule in said biological sample identifies said patient as having a cancer or a suspected cancer characterized by a ROS kinase.

18. A method for identifying a cancer or a suspected cancer that is likely to respond to a ROS inhibitor, wherein said cancer or suspected cancer is not a cancer or suspected cancer selected from the group consisting of non-small cell lung carcinoma and glioblastoma, said method comprising contacting a biological sample of said cancer or

15 suspected cancer, said biological sample comprising at least one nucleic acid molecule, with a probe that hybridizes under stringent conditions to a nucleic acid molecule selected from the group consisting of a FIG-ROS fusion polynucleotide, a SLC34A2-ROS fusion polypeptide, a CD74-ROS fusion polypeptide, and a truncated ROS polynucleotide, wherein hybridization of said probe to at least one nucleic acid molecule in said biological sample identifies said cancer or suspected cancer as a cancer or suspected cancer that is likely to respond to a ROS inhibitor.

20 19. The method of clause 17 or 18, wherein the FIG-ROS fusion polynucleotide encodes a fusion polypeptide selected from the group consisting of FIG-ROS(S) fusion polypeptide, a FIG-ROS(L) fusion polypeptide, and a FIG-ROS(XL) fusion polypeptide.

25 20. The method of clause 17 or 18, wherein the SCL34A2-ROS fusion polynucleotide encodes a fusion polypeptide selected from the group consisting of SCL34A2-ROS(S) fusion polypeptide, a SCL34A2-ROS(L) fusion polypeptide, and a SCL34A2-ROS(VS) fusion polypeptide.

30 21. The method of clause 11, 12, 17, or 18, wherein said cancer or suspected cancer is selected from the group consisting of a kidney cancer, a liver cancer, a pancreatic cancer, and a testicular cancer,

35 22. The method of clause 11, 12, 17, or 18, wherein the cancer is from a human.

23. The method of clause 12 or 18, wherein the ROS inhibitor is selected from the group consisting of a binding agent that specifically binds to a FIG-ROS fusion polypeptide, a binding agent that specifically binds to a truncated ROS polypeptide, an siRNA targeting a FIG-ROS fusion polynucleotide, and an siRNA targeting a truncated ROS polynucleotide.

40 24. The method of clause 12 or 18, wherein the ROS inhibitor is an inhibitor of a kinase selected from the group consisting of an ALK kinase, a LTK kinase, an Insulin Receptor, and an IGF1 Receptor.

SEQUENCE LISTING

[0344]

45 <110> Cell Signaling Technology, Inc.

<120> Mutant ROS Expression In Human Cancer

50 <130> 28126 (CST-281)

<140> PCT/US2010/024109

<141> 2010-03-25

55 <150> 61/207,484

<151> 2009-02-12

<160> 61

<170> PatentIn version 3.5

5 <210> 1

<211> 2637

<212> DNA

<213> Artificial Sequence

10 <220>

<223> Synthetic Nucleotide

<400> 1

15	atgtcggcgg gcggtccatg cccagcagca gccggagggg gcccaggggg cgcctcctgc	60
20	tccgtggggg cccctggcgg ggtatccatg ttccggtgtgc tggaggtgct ggagaaggag	120
25	ttcgacaaag ctttgtgga tgtggatctg ctcctggag agatcgatcc agaccaagcg	180
30	gacatcactt atgaggggcg acagaagatg accagcctga gctcctgctt tgcacagctt	240
35	tgccacaaag cccagtctgt gtctcaaattc aaccacaagc tggaggcaca gttggtgttat	300
40	ctgaaatctg aactgacaga aacccaagca gagaaagttg tttggagaa agaagtacat	360
45	gatcagcttt tacagctgca ctctattcag ctgcagcttc atgctaaaac tggtaaagt	420
50	gctgactctg gtaccattaa ggcaaaattt gaaagagagc ttgaggcaaa caaaaaagaa	480
55	aaaatgaaag aaggcacaact tgaagctgaa gtgaaattgt tgagaaaaga gaatgaagcc	540
60	cttcgttagac atatacgctgt tctccaggct gaagtatatg gggcgagact agctgccaag	600
65	tacttggata aggaactggc aggaagggtc caacagatac aattgctagg acgagatatg	660
70	aagggacctg ctcatgataa gctttggAAC caattagaag ctgaaataca tttgcattgt	720
75	cacaaaaactg tgatccgagc ctgcagagga cgtaatgact tgaaacgacc aatgcaagca	780
80	ccaccaggcc atgatcaaga ttccctaaag aaaagccaag gtgttgtcc aattagaaaa	840
85	gttctcctcc ttaaggaaga tcatgaaggc cttggcattt caattacagg tggaaagaa	900
90	catggtgttc caatcctcat ctctgagatc catccggggc aacctgctga tagatgcgga	960
95	gggctgcacg ttggggatgc tattttggca gtcaacggag ttaacctaag ggacacaaag	1020
100	cataaagaag ctgtaactat tctttctcag cagagaggag agattgaatt tgaagtatgtt	1080

	tatgtggctc ctgaagtggaa ttctgatgtat gaaaacgttag agtatgaaga tgagagtgga	1140
	catcggttacc gtttgtaccc ttagttagttt gaaggaggtt gtaaccctgg tgcttagttgc	1200
5	aaagacacaa gtggggaaat caaagtattt caagtctggc atagaagatt aaagaatcaa	1260
	aaaagtgcctt aggaaggggt gacagtgcctt ataaacgaag acaaagagtt ggctgagctg	1320
10	cgaggcttgg cagccggagt aggccctggctt aatgcctgtt atgcataataca tactcttcca	1380
	accgaagagg agattgaaaaa tcttcctgccc ttccctcgaa aaaaactgac tctgcgttcc	1440
	ttgctggaa gtggagcctt tggagaagtgtatgaaggaa cagcagtggaa catcttagga	1500
15	gttgaaagtggaaatcaa agtagcagtggaa aagactttga agaagggttc cacagaccag	1560
	gagaagatttgaatttgcggaa ggaggcacat ctgtatggca aatttataatca tcccaacatt	1620
	ctgaagcagc ttggagtttgcgtt tctgcgttgcgtt gaaccccaat acattatcgtt ggaactgtat	1680
20	gagggaggag accttcttac ttatttgcgtt aaagcccgaa tggcaacgtt ttatggcctt	1740
	ttactcacct tgggttgcacct tggtagacctg tggtagata tttcaaaagg ctgtgttcc	1800
	ttggaaacggaa tgcatttcat tcacagggtt ctggcagctt gaaattgcct tggatggcgtt	1860
25	aaagactata ccagtcacg gatagtgaag attggagact ttggactcgc cagagacatc	1920
	tataaaaatg attactatag aaagagaggg gaaggcctgc tcccaagttcg tggatggcgtt	1980
30	ccagaaaatgtt gatggatggaaatcttact actcaatcttgcgtt atgtatggcgtt ttttggaaatt	2040
	ctgatttggaaatcttact tcttgcgttcat cagccttatac cagcttatttca caacccatgtt	2100
	gtgtttaactt atgtgcacaaatc aggagggaga ctggagccac caagaaatttgcgtt tcttgcgtt	2160
35	ctgtggaaattttaatgcacca gtgtggcgtt caagaaccccg accaaagacc tacttttcat	2220
	agaatttcagg accaacttca gttattcaga aattttttct taaatagcat ttataagtcc	2280
	agagatgaag caaacaacag tggagtcata aatgaaagct ttgaaggtga agatggcgat	2340
40	gtgatttggaaatcttact tcttgcgttcat cagccttatac cagcttatttca caacccatgtt	2400
	gaagggtttaacttacttgcgttcat gatgtggcc aaggtgaaga aaagtctgag	2460
	ggtcctcttag gctcccagga atctgaatct tggatggcgtt taatggaaac gaagaaccga	2520
45	catgcagaca aagatttcttgcgttcat ccaagaaaaa caagtggcgtt actgccttc tggcaagcgtt	2580
	gaaggccttgcgttcat tcttgcgttcat agtggatatgtt gatgtggcgtt tgattaa	2637
50	<210> 2	
	<211> 878	
	<212> PRT	
	<213> Artificial Sequence	
55	<220>	
	<223> Synthetic Peptide	
	<400> 2	

Met Ser Ala Gly Gly Pro Cys Pro Ala Ala Ala Gly Gly Gly Pro Gly
 1 5 10 15

5 Gly Ala Ser Cys Ser Val Gly Ala Pro Gly Gly Val Ser Met Phe Arg
 20 25 30

10 Trp Leu Glu Val Leu Glu Lys Glu Phe Asp Lys Ala Phe Val Asp Val
 35 40 45

Asp Leu Leu Leu Gly Glu Ile Asp Pro Asp Gln Ala Asp Ile Thr Tyr
 50 55 60

15 Glu Gly Arg Gln Lys Met Thr Ser Leu Ser Ser Cys Phe Ala Gln Leu
 65 70 75 80

20 Cys His Lys Ala Gln Ser Val Ser Gln Ile Asn His Lys Leu Glu Ala
 85 90 95

25 Gln Leu Val Asp Leu Lys Ser Glu Leu Thr Glu Thr Gln Ala Glu Lys
 100 105 110

Val Val Leu Glu Lys Glu Val His Asp Gln Leu Leu Gln Leu His Ser
 115 120 125

30 Ile Gln Leu Gln Leu His Ala Lys Thr Gly Gln Ser Ala Asp Ser Gly
 130 135 140

35 Thr Ile Lys Ala Lys Leu Glu Arg Glu Leu Glu Ala Asn Lys Lys Glu
 145 150 155 160

Lys Met Lys Glu Ala Gln Leu Glu Ala Glu Val Lys Leu Leu Arg Lys
 165 170 175

40 Glu Asn Glu Ala Leu Arg Arg His Ile Ala Val Leu Gln Ala Glu Val
 180 185 190

45 Tyr Gly Ala Arg Leu Ala Ala Lys Tyr Leu Asp Lys Glu Leu Ala Gly
 195 200 205

50 Arg Val Gln Gln Ile Gln Leu Leu Gly Arg Asp Met Lys Gly Pro Ala
 210 215 220

His Asp Lys Leu Trp Asn Gln Leu Glu Ala Glu Ile His Leu His Arg
 225 230 235 240

55 His Lys Thr Val Ile Arg Ala Cys Arg Gly Arg Asn Asp Leu Lys Arg
 245 250 255

EP 2 881 402 B1

Pro Met Gln Ala Pro Pro Gly His Asp Gln Asp Ser Leu Lys Lys Ser
260 265 270

5 Gln Gly Val Gly Pro Ile Arg Lys Val Leu Leu Leu Lys Glu Asp His
275 280 285

10 Glu Gly Leu Gly Ile Ser Ile Thr Gly Gly Lys Glu His Gly Val Pro
290 295 300

Ile Leu Ile Ser Glu Ile His Pro Gly Gln Pro Ala Asp Arg Cys Gly
305 310 315 320

15 Gly Leu His Val Gly Asp Ala Ile Leu Ala Val Asn Gly Val Asn Leu
325 330 335

20 Arg Asp Thr Lys His Lys Glu Ala Val Thr Ile Leu Ser Gln Gln Arg
340 345 350

Gly Glu Ile Glu Phe Glu Val Val Tyr Val Ala Pro Glu Val Asp Ser
355 360 365

25 Asp Asp Glu Asn Val Glu Tyr Glu Asp Glu Ser Gly His Arg Tyr Arg
370 375 380

30 Leu Tyr Leu Asp Glu Leu Glu Gly Gly Asn Pro Gly Ala Ser Cys
385 390 395 400

35 Lys Asp Thr Ser Gly Glu Ile Lys Val Leu Gln Val Trp His Arg Arg
405 410 415

Leu Lys Asn Gln Lys Ser Ala Lys Glu Gly Val Thr Val Leu Ile Asn
420 425 430

40 Glu Asp Lys Glu Leu Ala Glu Leu Arg Gly Leu Ala Ala Gly Val Gly
435 440 445

45 Leu Ala Asn Ala Cys Tyr Ala Ile His Thr Leu Pro Thr Gln Glu Glu
450 455 460

Ile Glu Asn Leu Pro Ala Phe Pro Arg Glu Lys Leu Thr Leu Arg Leu
465 470 475 480

50 Leu Leu Gly Ser Gly Ala Phe Gly Glu Val Tyr Glu Gly Thr Ala Val
485 490 495

55 Asp Ile Leu Gly Val Gly Ser Gly Glu Ile Lys Val Ala Val Lys Thr
500 505 510

EP 2 881 402 B1

Leu Lys Lys Gly Ser Thr Asp Gln Glu Lys Ile Glu Phe Leu Lys Glu
 515 520 525

5 Ala His Leu Met Ser Lys Phe Asn His Pro Asn Ile Leu Lys Gln Leu
 530 535 540

10 Gly Val Cys Leu Leu Asn Glu Pro Gln Tyr Ile Ile Leu Glu Leu Met
 545 550 555 560

15 Glu Gly Gly Asp Leu Leu Thr Tyr Leu Arg Lys Ala Arg Met Ala Thr
 565 570 575

20 Phe Tyr Gly Pro Leu Leu Thr Leu Val Asp Leu Val Asp Leu Cys Val
 580 585 590

25 Asp Ile Ser Lys Gly Cys Val Tyr Leu Glu Arg Met His Phe Ile His
 595 600 605

30 Arg Asp Leu Ala Ala Arg Asn Cys Leu Val Ser Val Lys Asp Tyr Thr
 610 615 620

35 Ser Pro Arg Ile Val Lys Ile Gly Asp Phe Gly Leu Ala Arg Asp Ile
 625 630 635 640

40 Tyr Lys Asn Asp Tyr Tyr Arg Lys Arg Gly Glu Gly Leu Leu Pro Val
 645 650 655

45 Arg Trp Met Ala Pro Glu Ser Leu Met Asp Gly Ile Phe Thr Thr Gln
 660 665 670

50 Ser Asp Val Trp Ser Phe Gly Ile Leu Ile Trp Glu Ile Leu Thr Leu
 675 680 685

55 Gly His Gln Pro Tyr Pro Ala His Ser Asn Leu Asp Val Leu Asn Tyr
 690 695 700

Val Gln Thr Gly Gly Arg Leu Glu Pro Pro Arg Asn Cys Pro Asp Asp
 705 710 715 720

Leu Trp Asn Leu Met Thr Gln Cys Trp Ala Gln Glu Pro Asp Gln Arg
 725 730 735

Pro Thr Phe His Arg Ile Gln Asp Gln Leu Gln Leu Phe Arg Asn Phe
 740 745 750

Phe Leu Asn Ser Ile Tyr Lys Ser Arg Asp Glu Ala Asn Asn Ser Gly

5 Val Ile Asn Glu Ser Phe Glu Gly Glu Asp Gly Asp Val Ile Cys Leu
770 775 780

Asn	Ser	Asp	Asp	Ile	Met	Pro	Val	Ala	Leu	Met	Glu	Thr	Lys	Asn	Arg
785					790					795					800

10

Glu Gly Leu Asn Tyr Met Val Leu Ala Thr Glu Cys Gly Gln Gly Glu
 805 810 815

15

Glu Lys Ser Glu Gly Pro Leu Gly Ser Gln Glu Ser Glu Ser Cys Gly
820 825 830

20

Leu Arg Lys Glu Glu Lys Glu Pro His Ala Asp Lys Asp Phe Cys Gln
835 840 845

25

Glu Lys Gln Val Ala Tyr Cys Pro Ser Gly Lys Pro Glu Gly Leu Asn
850 855 860

25

Tyr Ala Cys Leu Thr His Ser Gly Tyr Gly Asp Gly Ser Asp
 865 870 875

30

<210> 3

<211> 1893

<211> 1555

<212> DNA

35

<220>

<223> Synthetic Nucleotide

<400> 3

40

45

50

55

EP 2 881 402 B1

atgtcggcgg	gcggtccatg	cccagcagca	gccggagggg	gcccaggggg	cgccctcctgc	60	
tccgtggggg	cccctggcgg	ggtatccatg	ttccggtgtgc	tggaggtgct	ggagaaggag	120	
5	ttcgacaaag	cttttgtgga	tgtggatctg	ctcctggag	agatcgatcc	agaccaagcg	180
gacatcactt	atgaggggcg	acagaagatg	accagcctga	gctcctgctt	tgcacagctt	240	
10	tgccacaaag	cccagtctgt	gtctcaaatac	aaccacaagc	tggaggcaca	gttggtgat	300
ctgaaatctg	aactgacaga	aacccaagca	gagaaagttg	ttttggagaa	agaagtacat	360	
15	gatcagctt	tacagctgca	ctctattcag	ctgcagcttc	atgctaaaac	tggtcaaagt	420
gctgactctg	gtaccattaa	ggcaaaattg	gaaagagagc	ttgaggcaaa	caaaaaagaa	480	
aaaatgaaaag	aagcacaact	tgaagctgaa	gtgaaattgt	tgagaaaaga	gaatgaagcc	540	
20	cttcgtagac	atatacgctgt	tctccaggct	gaagtatatg	gggcgagact	agctgccaag	600
tacttggata	aggaactggc	aggaagtact	cttccaaccc	aagaggagat	tgaaaatctt	660	
cctgccttcc	ctcgggaaaa	actgactctg	cgtctttgc	tggaaagtgg	agcctttgga	720	

25

30

35

40

45

50

55

gaagtgtatg aaggaacagc agtggacatc ttaggagttg gaagtggaga aatcaaagta	780
gcagtgaaga ctttgaagaa gggttccaca gaccaggaga agattgaatt cctgaaggag	840
5 gcacatctga tgagcaaatt taatcatccc aacattctga agcagcttgg agtttgcctg	900
ctgaatgaac cccaaatacat tattcctggaa ctgatggagg gaggagacct tcttacttat	960
ttgcgtaaag cccggatggc aacgttttat ggtccttac tcaccttggt tgaccttgta	1020
10 gacctgtgtg tagatatttc aaaaggctgt gtctacttgg aacggatgca tttcattcac	1080
agggatctgg cagctagaaa ttgccttgg tccgtgaaag actataccag tccacggata	1140
15 gtgaagattg gagactttgg actcgccaga gacatctata aaaatgatta ctatagaaag	1200
agagggaaag gcctgctccc agttcggtgg atggctccag aaagtttgcatggaaatc	1260
ttcactactc aatctgtatgt atggctttt ggaattctga tttggagat tttaactctt	1320
20 ggtcatcagc ctatccagc tcattccaac cttgatgtgt taaactatgt gcaaacagga	1380
gggagactgg agccaccaag aaattgtcct gatgatctgt ggaatttaat gacccagtc	1440
25 tgggctcaag aacccgacca aagacctact tttcatagaa ttcaggacca acttcagtt	1500
ttcagaaatt ttttcttaaa tagcattat aagtccagag atgaagcaaa caacagtgg	1560
gtcataaaatg aaagctttga aggtgaagat ggcgatgtga tttgttgcatttgcagatgac	1620
30 attatgccag ttgcttaat ggaaacgaag aaccgagaag gttaaacta tatggactt	1680
gctacagaat gtggccaagg tgaagaaaag tctgagggtc ctctaggctc ccaggaatct	1740
gaatcttgcgtgt gtctgaggaa agaagagaag gaaccacatg cagacaaaga tttctgcca	1800
35 gaaaaacaag tggcttactg cccttctggc aagcctgaag gcctgaacta tgcctgtctc	1860
actcacagtg gatatggaga tgggtctgat taa	1893

40 <210> 4

<211> 630

<212> PRT

<213> Artificial Sequence

45 <220>

<223> Synthetic Peptide

<400> 4

50 Met Ser Ala Gly Gly Pro Cys Pro Ala Ala Ala Gly Gly Gly Pro Gly	
1 5 10 15	

55 Gly Ala Ser Cys Ser Val Gly Ala Pro Gly Gly Val Ser Met Phe Arg	
20 25 30	

Trp Leu Glu Val Leu Glu Lys Glu Phe Asp Lys Ala Phe Val Asp Val	
35 40 45	

Asp	Leu	Leu	Leu	Gly	Glu	Ile	Asp	Pro	Asp	Gln	Ala	Asp	Ile	Thr	Tyr	
50							55						60			
5																
	Glu	Gly	Arg	Gln	Lys	Met	Thr	Ser	Leu	Ser	Ser	Cys	Phe	Ala	Gln	Leu
	65						70					75				80
10																
	Cys	His	Lys	Ala	Gln	Ser	Val	Ser	Gln	Ile	Asn	His	Lys	Leu	Glu	Ala
							85			90						95
15																
	Gln	Leu	Val	Asp	Leu	Lys	Ser	Glu	Leu	Thr	Glu	Thr	Gln	Ala	Glu	Lys
							100			105						110
20																
	Val	Val	Leu	Glu	Lys	Glu	Val	His	Asp	Gln	Leu	Leu	Gln	Leu	His	Ser
							115			120			125			
25																
	Ile	Gln	Leu	Gln	Leu	His	Ala	Lys	Thr	Gly	Gln	Ser	Ala	Asp	Ser	Gly
							130			135			140			
30																
	Thr	Ile	Lys	Ala	Lys	Leu	Glu	Arg	Glu	Leu	Glu	Ala	Asn	Lys	Glu	
							145			150			155			160
35																
	Lys	Met	Lys	Glu	Ala	Gln	Leu	Glu	Ala	Glu	Val	Lys	Leu	Leu	Arg	Lys
							165			170			175			
40																
	Glu	Asn	Glu	Ala	Leu	Arg	Arg	His	Ile	Ala	Val	Leu	Gln	Ala	Glu	Val
							180			185			190			
45																
	Tyr	Gly	Ala	Arg	Leu	Ala	Ala	Lys	Tyr	Leu	Asp	Lys	Glu	Leu	Ala	Gly
							195			200			205			
50																
	Ser	Thr	Leu	Pro	Thr	Gln	Glu	Glu	Ile	Glu	Asn	Leu	Pro	Ala	Phe	Pro
							210			215			220			
55																
	Arg	Glu	Lys	Leu	Thr	Leu	Arg	Leu	Leu	Gly	Ser	Gly	Ala	Phe	Gly	
							225			230			235			240
60																
	Glu	Val	Tyr	Glu	Gly	Thr	Ala	Val	Asp	Ile	Leu	Gly	Val	Gly	Ser	Gly
							245			250			255			
65																
	Glu	Ile	Lys	Val	Ala	Val	Lys	Thr	Leu	Lys	Lys	Gly	Ser	Thr	Asp	Gln
							260			265			270			
70																
	Glu	Lys	Ile	Glu	Phe	Leu	Lys	Glu	Ala	His	Leu	Met	Ser	Lys	Phe	Asn
							275			280			285			
75																
	His	Pro	Asn	Ile	Leu	Lys	Gln	Leu	Gly	Val	Cys	Leu	Leu	Asn	Glu	Pro
							290			295			300			

EP 2 881 402 B1

Gln Tyr Ile Ile Leu Glu Leu Met Glu Gly Gly Asp Leu Leu Thr Tyr
 305 310 315 320

5 Leu Arg Lys Ala Arg Met Ala Thr Phe Tyr Gly Pro Leu Leu Thr Leu
 325 330 335

10 Val Asp Leu Val Asp Leu Cys Val Asp Ile Ser Lys Gly Cys Val Tyr
 340 345 350

15 Leu Glu Arg Met His Phe Ile His Arg Asp Leu Ala Ala Arg Asn Cys
 355 360 365

20 Leu Val Ser Val Lys Asp Tyr Thr Ser Pro Arg Ile Val Lys Ile Gly
 370 375 380

25 Asp Phe Gly Leu Ala Arg Asp Ile Tyr Lys Asn Asp Tyr Tyr Arg Lys
 385 390 395 400

30 Arg Gly Glu Gly Leu Leu Pro Val Arg Trp Met Ala Pro Glu Ser Leu
 405 410 415

35 Met Asp Gly Ile Phe Thr Thr Gln Ser Asp Val Trp Ser Phe Gly Ile
 420 425 430

40 Leu Ile Trp Glu Ile Leu Thr Leu Gly His Gln Pro Tyr Pro Ala His
 435 440 445

45 Ser Asn Leu Asp Val Leu Asn Tyr Val Gln Thr Gly Gly Arg Leu Glu
 450 455 460

50 Pro Pro Arg Asn Cys Pro Asp Asp Leu Trp Asn Leu Met Thr Gln Cys
 465 470 475 480

55 Trp Ala Gln Glu Pro Asp Gln Arg Pro Thr Phe His Arg Ile Gln Asp
 485 490 495

60 Gln Leu Gln Leu Phe Arg Asn Phe Phe Leu Asn Ser Ile Tyr Lys Ser
 500 505 510

65 Arg Asp Glu Ala Asn Asn Ser Gly Val Ile Asn Glu Ser Phe Glu Gly
 515 520 525

70 Glu Asp Gly Asp Val Ile Cys Leu Asn Ser Asp Asp Ile Met Pro Val
 530 535 540

75 Ala Leu Met Glu Thr Lys Asn Arg Glu Gly Leu Asn Tyr Met Val Leu

545 550 555 560

5 Ala Thr Glu Cys Gly Gln Gly Glu Glu Lys Ser Glu Gly Pro Leu Gly
565 570 57510 Ser Gln Glu Ser Glu Ser Cys Gly Leu Arg Lys Glu Glu Lys Glu Pro
580 585 590His Ala Asp Lys Asp Phe Cys Gln Glu Lys Gln Val Ala Tyr Cys Pro
595 600 60515 Ser Gly Lys Pro Glu Gly Leu Asn Tyr Ala Cys Leu Thr His Ser Gly
610 615 62020 Tyr Gly Asp Gly Ser Asp
625 630

<210> 5

<211> 1544

<212> DNA

25 <213> Artificial Sequence

<220>

<223> Synthetic Nucleotide

30 <400> 5

35

40

45

50

55

	gtgtgtaaaa aatgggtatt attgtactct taagtaccaa attggatatt taatgaggtt	60
5	gactcttact tctttctttt tttatTTTTT atTTTTTGA gatggagtct tgctctgttgc	120
	cccaggctgg agtgcagtgg catgatctct gctcaactgca acctctgcct cctgggttca	180
10	agcgattctc ctacctcagc ctccctgagta gctgggatta caggtgcctg ccaccacggc	240
	cagctaaatt ttgtatTTTTT agtagagatg gggTTTcacc atgttggcca ggctggtctc	300
15	aaactcctga ccttgtgatc catccacctt ggccTCCCAA agtgcggaa ttacagggtgt	360
	gagccaccgc acctggccta ctcttttc ttatggtaaa tgaagcatta atcttttcc	420
20	tcagaattat ttacagttt gtttaactt actgttgtta aattaatact gacagcatta	480
	tgtatcgcag atctagttat ccatactaaa tatgttttagt ttacacacac aaacactgat	540
25	agtatcttac tggaaatgc taacaactct gtagagcagc actttcaac tattttgtgc	600
	cttgagacca gtacagccga tattcacatg catagcagaa cttccataag gaattcttt	660
30	tatgatcaact gaaacccagt ctttcttgcc cttcaaaaaaa acgtgttggt atttagttaa	720
	tgacaatgat ttatcataa tcatacacag aattctgctg tatttattaa gtaaattatt	780
35	aacaaacttt ggtgacttat tagtactaaa tcattttgtg catattctt taatgtcaca	840
	ttaaaaacat ggaacaaaga aaaaataatt tatatcatct tgaagtacaa attttcttagt	900
40	aactttttt tttttttaaa ttttggaga tggggtctca ctctgtcgct caggatggag	960
	tgcagtggtg caacggtggc tcactgcagc gtccacctt caggctcaag tgatcctccc	1020
45	acctcagcct tccaaagtgc tgagaccaca ggcattgcac catgcctggt taattgtttaa	1080
	ggTTTgcct tggccctg gctggttcta gtaactttta accacattta aagtaatcat	1140
50	tttggaaaa gaaactctaa tttagaaaaa tattttgtc catttatctc atctaaaagc	1200
	taacatttaa tagtatctga gttcagtgcac tttgcattgca agacatagat tgacattaat	1260
55	ctcataaatt tttttttaga ttatTTGAA ttaagtatat gactaaagga gttcacattta	1320
	atcccttaa aaatTTTTT tactggTTT tcccttgagg atacctgttc ttttcagagt	1380
	tttcatatTTT ttttatATC tgagagacat caagaagttc gtgagtatta gttttatcac	1440
	taatttgaga ttcatgcaaa agctacttat gttcaactaat tttcctgaat tctcactgtat	1500
	gtgaatataa tgaaaaatca atgtactctt ttcccaatataa gaag	1544
	<210> 6	
	<211> 3469	
	<212> DNA	
	<213> Artificial Sequence	
	<220>	
	<223> Synthetic Nucleotide	

<400> 6

5	gtaaaaatca ctctaaaaat tattattaac atattcatta ttatcaaatg tttaaaatgt	60
	gaaggcctca gaatttcttc agtaaaaactg ttttgtgagg aaatcaaagg aatgaagagc	120
	tttcccttgt ttattgtttt attgtatact atgctaacag tttatattacc atatatgttc	180
10	ttctatattc atcttggact gttaagacaa gtacattacc agttactcta ctgcaagtga	240
	tccttgaaaa ataaaataaaa tttttctag actctgaaac aaagaccaat atactatTTT	300
	gagtagatct atcttgtaga ctacattgtc tgtctgtctt gatgcaaatt catctctcac	360
15	aatgaatttt aagctaatta tgaataagta tgaagtatac tgtcacctta tgattgctat	420
	tagaatcaac ttatattatc ttggggatgt ttggTTTtagt tccttgcta tcatttagac	480
	atattttaag gaaaaactct agcacttcct tttacataga gcagtggtcc tcaaattgtg	540
20	atctgtggat ctctgagggt ctctgagata ttttagcaga gttcatgagg tcaaagcttt	600
	tcataataat actaagacat catttgcattt ttttgctat gttgatattt gcactgatgg	660
	tatctggttg atgcaaaagc aattgggta aaactgctgg tgccttagca ctaatcaagg	720
25	cagtgttgct aatactagta actgtactag taatcattgt tttttccctt gccatccatt	780
	catagtaaaa gaagaagata ccaattttgc taaaaatat ctttgcataa atggcagtaa	840
30	cagttaattt ttaaatatttgc acctttgagt acctgtctt ttaatattct ttgtgatgag	900
	atgggaagta tgcataaaagc acttactctg cacactgaac aaagatgctg gtttcaaggg	960

35

40

45

50

55

	aaagtacata agtgactgaa ctagccattt ttcttcattgg aagacaattt ttacttgaat	1020
5	gaatgactaa caaagtatgg atttcggac tatttggaaag ccattttctt aaaaatgaac	1080
	aaagtccatc acttcaggaa agacaactga taatatttta tgccagtgtat aaaatgtgag	1140
	ctctcaagtg aaagtttagaa ctttgtaaaa catacggtga tcaccatgag cttgacagct	1200
10	tcctaacact taagctttc tgatgagatt gatgatgata ttaatgaatg tgatttttg	1260
	atacagtaaa gtgaaatgtg tcaacttttgaattgctac ataacttcat ggtccaaat	1320
	tttcaaatc accagtaaat gaagttataa aattttgcattt gggaaaagat ccattcaaaa	1380
15	tgcaagatag gcaaattggat ttaatataa cagagtgtga aaagttcact gataaggtt	1440
	caaattccac attgtcaaat tttgtataa tatcagagaa caatactgac agttatctga	1500
	aaaggctgtt aaaatactct tccatttgc aactacatctt ctgtgtgagg ctgaactttc	1560
20	ttcatataact tgtaatagat tgaatggaag cagatataatg aaaatacagc tatcatctac	1620
	aaagccattt aagagatttg taaaattgtaa aataatgtt actcttctaa ctagaatttt	1680
	tttggggaa acatagagtt atttgcattt agacaaatgt tatttattt aaccttctgg	1740
25	atttattgtc atttttaaca aagaaatgaa ttttttttta gattttcaaa ttttacctac	1800
	taatatggaa aacatcgat gctataatcc acataaacag aagcttcttgc gagtccctcaa	1860
	tgcttagtat aaaggcctcc tgagacaaa atgttgaact cctggcatgg agttttatgg	1920
30	tgaactgata aactgttgca ctttgataa acttgtgtgt tgtaaactgt ctgcacaaag	1980
	atagcagtag cagttactgt tttcaactgtg catcttgc aaaaactattt tggcagtagt	2040
	tcaaaacctt aattgttggg ctgctctcca tatggtttca ttgtatttca cacttgctgt	2100
35	tttctgtcgg gattagaaag cctgtctctt cctttttttt gtaactgagg ctagaagtct	2160
	tctctgtcac atatgcaaat tgcagacact taaaatgtga ctcaactaaa aatttgcgt	2220
	tatataatctt ttaactgact cactaaaaaa aatgtatcta ttgggttattt tttcacacgt	2280
40	ctatacttta tagatataata tatcacctaa ataggtgata tagtcaacac ttatattt	2340
	ataaggctat tatttatttt atagatgatc agaattcggt ttaagtttta gctagacatc	2400
	atcttgccaa caaattacat tttaagcaat taacttagtat atgcctcagt taactgaagt	2460
45	taatgtataa tgaaagcaac aatgaaaaat aaaaatataa ttcacagttc agtagatatt	2520
	tatataagta gaattgactg aattttacaa ttatatgtat tacttctaag tcttacagac	2580
	agcttgcgttgg tggctcatgc ctgttaattca agcactttgg gaggccaaagg caggaggatc	2640
50	gcttggggcc aggagttacc aacctgggca acatagtgaa ccctgtctct tcaaaaaaaat	2700
	ttttaaaata tagctggaca tggggcaca tgcttgcgtc tccagctact caggaggctg	2760
	aggtggaaagg attgcttgag cctaggaggt caaggcagca gtgagccgtatcatgccac	2820
55	tgcaatccag cctggcaat agagtgagac cctgtctcag aaaaaaaaaaaa gaaaaaaaaaa	2880

aaaggaaaagg	aaaacttgat	aggaaaactta	atacaatttt	tacataagcc	caatata	tagta	2940
tttttaaaatc	tgtacaat	at	ttgatacctg	ccataagagg	gaagaattcc	cctgttagga	3000
5	attactgatt	tgattaat	aaggcattat	tttgcctca	gattactaat	gttaattact	3060
ttggcattcc	tttgttttc	actcaataaa	cttatacaac	taacttttt	tttttttta		3120
10	attttttaa	tcgagacaga	gtttcactct	gtcacccagg	ctagagtgcg	gtggtacgat	3180
ctcagctcac	tgcaacctcc	acttcctggc	ttcaagtgtat	tctccttcct	cagtctccca		3240
15	aatagctggg	attacaggca	tgtgccacca	tgcccggcga	atttttgtat	tttaataga	3300
gacggggttt	caccacattg	tccaggctgg	tctcgaaccc	ctaaccctcag	gttatccacc		3360
20	caccttggcc	tctcaaagtg	ctgggattac	aggtatgagc	cactgcacct	gaccaaaacc	3420
aacttttaa	accagaaagt	gtctgctttt	ttttctcct	ttctttcag			3469

20 <210> 7

<211> 3616

<212> DNA

<213> Artificial Sequence

25 <220>

<223> Synthetic Nucleotide

<400> 7

30

35

40

45

50

55

gtatgttacc atgtctgtct acacactagc ttattaccta aaggttcagt aataaaatatc	60
5 agtacattct taacattagc aatagataat ggtgactata tatatatata tatatatata	120
tatatatata taatcttatt atccaaacta ttaaactatt ccattcatgt gatgtgatct	180
10 ttctaaaaca tcattatcat catgtcattt ttctcccaa taataatcag ccacccctt	240
aattcctacc acatcaattc catgctccta attaggcttc caaggctgtt cacaatctgt	300
tctatccagc catataattc tattcacatt ataccagcct tatgaccact cctacattat	360
15 acataacagg cctaagacct ttgtttcttc cccaatatct acctcttcca ctgtgtattt	420
tatTTtagtt tatgatatat tgtctttcta atcacatagg cagggaaatct cagtgcata	480
tgtgattttt ccctctactc agtaatcagg tcctgttcat tttaccatct tgattttct	540
20 ctgatgagtt ctcatcttcc tctttccacc ttggctttcc taatTTaagg tatcatttct	600
tgcctgtgcc cttgacttac gcatactgct gacagttaaa tttagttgaa gcacaggctg	660
gattacttaa tccctctctg aaataccac aatggctctc cattactgc tttcagaatc	720
25 agctacaaac ttctttgtgg catgtgaggt cttctgtat ttatccttcca attgtggttt	780
atcttttcca atatTTatgt ctgtgctgta gccatatcag accagttaaa agttttatg	840
tcacttagtc tttggccctg tgTTTgcctc agcctagaat acaggtcccc actacctacc	900
30 ctgtgcccct tagctgtgat ttccattat ttatTTctg ccaattgaaa ttcttctcat	960

35

40

45

50

55

	ccttcaagac ttaaatgaac tcatacataat gcttacctga tgctccttag tcaaataaat	1020
	tattgcattt tatacactca catgctataat aaaacttaca tgattcttgt ttatattata	1080
5	gttagttatc tagttagttg tgtacagaag tttgctaccc agctcagcaa acttttctg	1140
	aaaagaacca aatagtaaat atgttagact ttgcaggcta catgtgatct ctgtagcatg	1200
	ttctctttt cttcttttc tgttctctt ttccctctcc ttcttttaa aaataacact	1260
10	ttacaaaggt aaaacttatt catagctaata agggggtaca aaatcaggct atagccagat	1320
	ttggtcctca tgccatagtt tgccagactc tggcctacgt gtttggcc tctacacaac	1380
	tgaaactacc taagagaaat taccatgttt attcctcagt ttaatatcca tgaaattaaa	1440
15	tatgtatgaa gatattatac aaaataataa tgccaactat ttagtatcca aagactgaga	1500
	tttcttggc ctaaatttat taaaaagata tatatgttc ctaagtcatt taaaagtaga	1560
	agattgagtg gatattattcc agtgggtgt tgctctctgc aaaaaaaagc aaaaacacct	1620
20	tgctttgtat ttcacatggc ataaacactg tctgtatgga tgcttcaag ctaccaacgg	1680
	tctaacaact ggcttgcaaa aatccagtag tagctagctc tgctatatta ctctgtgtgc	1740
	ttaggttagag ctggggcaac ttagctttta tctatgaatt aatttctttt tctgattttat	1800
25	attattaggt atgttaccat gtctgtctac acactagctt attacctaaa ggttcagtaa	1860
	taaatatcag tacattctta acattagcaa tagataatgg tgactatata tatatatata	1920
30	tatatatata tatatatata atcttattat ccaaactatt aaactattcc attcatgtga	1980
	tgtgatctt ctaaaacatc attatcatca tgtcattttt ctccccata ataatcagcc	2040
	accccttaa ttcctaccac atcaattcca tgctcctaata taggcttcca aggctgtca	2100
35	caatctgttc tatccagcca tataattcta ttcacattat accagcctta tgaccactcc	2160
	tacattatac ataacaggcc taagacctt gtttcttccc caatatctac ctcttccact	2220
	gtgtatTTTA tttagTTTA tgatataattg tctttctaat cacataggca ggaaatctca	2280
40	gtgccatatg tgatTTTCC ctctactcag taatcaggc ctgttgattt taccatcttgc	2340
	atTTTCTCT gatgagttct catcttcctc ttccacctt ggcttcccta atttaaggta	2400
	tcatttcttgc cctgtgcct tgacttacgc atactgctga cagttaaatt tagttaaagc	2460
45	acaggctgga ttacttaatc cctctctgaa atacccacaa tggctctcca ttactgctt	2520
	tcagaatcag ctacaaactt cttagtggca tgtgaggct tctgtatTTT atcctccaat	2580
	tgtggTTTat ctTTTccaat atttatgtct gtgctgtac catatcagac cagtaaaaag	2640
50	tttttatgtc acttagtctt tggccctgtg tttgcctcag cctagaatac aggtccccac	2700
	tacctaccct gtgcccctta gctgtgattt cctattattt atTTTCTGCC aattgaaatt	2760
	cttctcatcc ttcaagactt aaatgaactc atcataatgc ttacctgatg ctcccttagtc	2820
55	aaatgaatta ttgcattttta tacactcaca tgctatataa aacttacatg attcttggtt	2880

5	atattatagt tagttatcta gtttagttgtg tacagaagtt tgctacccag ctcagcaaac	2940
	tttttctgaa aagaaccaa tagtaaatat gtttagacttt gcaggctaca tgtgatctct	3000
10	gtagcatgtt cttctttct tcttttctg ttctctttt ccttctcctt ctttttaaaa	3060
	ataacacttt acaaaggtaa aacttattca tagctaata tagggtacaaa atcaggctat	3120
	agccagattt ggtcctcatg ccatagttt ccagactctg gcctacgtgt ttgtttcctc	3180
15	tacacaactg aaactaccta agagaaatta ccatgtttat tcctcagttt aatatccatg	3240
	aaattaaata tgtatgaaga tattatacaa aataataatg ccaactatgg agtaccaaa	3300
	gactgagatt tcttggcct aaatttatta aaaagatata tatgtttcct aagtcattt	3360
	aaagtagaag attgagtgga tatattccag tggttgtt ctctctgcaa aaaaaagcaa	3420
20	aaacaccttg ctttgattt cacatggcat aaacactgtc tgtatggatg ctttcaagct	3480
	accaacggtc taacaactgg cttgaaaaa tccagtagta gctagctctg ctatattact	3540
	ctgtgtgctt aggtagagct ggggcaactt agctttatc tatgaattaa tttcttttc	3600
25	tgatttatat tattag	3616

<210> 8
 <211> 2937
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Synthetic Nucleotide

<400> 8

35

40

45

50

55

5	gtaagtataa tagaattttt aaaataggca acaaactgtt tacttaatca tacctgattg	60
	atttatctct tagtgatct aatctccac atgaaatatt gcctgattaa gttataaaaa	120
	tttacattgt taccttggc tatacatttta taaccactaa cttctgtgaa ttgtttctg	180
	atctaggcat aactattttt tggaaaatat acatgtacat ttcatgttat actttagata	240
10	aaactacttg caagggcacc aacttttagg tttctttaaa acagtattta tttctgattg	300
	gctgcataca aatgtttgt ggcttatggt taaaataaaa taaaagaaaa ataaccctgg	360
	gtacagaaaa aagtatagaa ttaatggag gccagtgaca atcttgatt gggatagttt	420
15	tggtttctaa gcagacagggc tggtttggaa tgagttaggc ctctttgca gaagatccat	480
	ttctggcttg tgggatcgac tcttgcttc agacatctga tctgcttatt tcaaatccct	540
	gctcatttat aaatgaccag gaaggcagaa aaatttagtt aggtagatag aaagctattt	600
20	tttttcttaag aagatttact ttaatgataa taaaatgcag taaaacaccc aaaggaaatg	660
	gtcaagtact gattggactt ttagagttat cacagtgatc atacattctt gtttatttct	720
	gtttcagcac aaataataat agcactttct ttcattcccc aaactgtccg agtttgctta	780
25		
30		
35		
40		
45		
50		
55		

	taagatatat ggaccctat ctattgctaa tattgagagt ccccaacaca ctgaatcatt	840
	aaaagaaggg catgattctt accagaaaag aacactcaa cacatattaa gaaagttgtg	900
5	gcttgaaaa ttcacaagta gggtaagtt acaaggaaa gttgatggaa aagtcacaaa	960
	cataaagttg aactctcagg ataaagacag ccaacactt actgtgtct aagtctttat	1020
	tcttctgca aagtgattgg agtcacaatc tttatgagag cacttgaag ctcgatttga	1080
10	gattttttc aaagattcca cccagacaat atgtgaaact cttcagcaa acttggaaag	1140
	ctaaaaattt cagctgaccc tgccaggatt ttaacctgtg gttccagaga gtctaagtat	1200
	tgcacagctg atgtttgcactaagcca gcccctccag acttacgcatt atgactgcag	1260
15	tatatttggc agttggcata taggcttgac tgcttgcact ctttctact gggaggaga	1320
	attacatgaa gaatccttca gctgacctt gcttgcttc ttgtacatca ccattgttta	1380
	aaccataac tctagtggat gaacatgaga taatttcaga caacctattt gcttccaag	1440
20	acatcctatg gatatctgac tttctcagga cttaaaggc tttattctgt ttgaaattca	1500
	cgaattttt ggtctagcta agctaattcg gttcttgct tttagcagca gtgcattgtgg	1560
	ttttactagt aagagcgtgt gtgtcatga gaaaagattt agtaattaaa ataacaaaac	1620
25	agtccacatt attttaaaat ttgtattgtg ctgagggcac tcattcatttta taaacataaa	1680
	attagacaat tttaaaatg agtggacaca gccttgctt ctgagcagtc atatctaattt	1740
	cataacatta gccttctgct gggagtaggg gaaaatgtaa acctgtaaaa tacaactgt	1800
30	gacccatcagga gcttgcatt taatgagggta gttttagacat gcctgtgtgg gaagacaaat	1860
	agcaagatattt gtgttaataataacaaaatg acaaaaatag atgaaataag taagacagt	1920
	cataggataa gcactcacag agaggcgcaat ttagtcttc aagttcagat atgaaagatt	1980
35	agtagaggtt gctgaggattt cagaaggcat cattgaggat gtgggcttac attgggcatt	2040
	taaaagtggaa gcgagggtgg gagaacattt caagttggaa aaattaattt agcaaaaggt	2100
40	acttggatc ttctactgtg tagcccttca aatttgaattt catgtgataa aaactctaaac	2160
	ttcttgaaca tagaagctac tgtgaaattt agttcaattt ttaatgtca tctctcaaag	2220
	catgcttgcact tctgagccaa tagtccagta cagatgacaa tcctattgac	2280
45	ataattgtat tttaatattt aaaaaattttt attattataa aactaataact gcttattata	2340
	taaggaagac agtacaaattt actcatgattt ctacaacttag ggcagaccac tgcttacatt	2400
	tggtaagctt cggttccataa cttttctac atattcgagt atgtgtatataa gaaacaacaat	2460
50	gataaaacactt cttgtactct gcaaaaaaaa aaaaaaaaaa aattggcattt atactgaaag	2520
	cattttcttt tctactgagg aatataacctt ggatgtgactt gaaactcaaaa atgaaatttgt	2580
	tttcaactaata attatgtttt gtttgggtta ttttgcactcg tttatgggtg attttgacaa	2640
55	ataagtttta atattaagat actttaattt gtttataaca acagtaagaa atacattaaa	2700

ttttaagaag	tgagattaaa	aatgggttag	tatgatttgc	gtacttatat	atggctttt	2760	
acctggattt	aatttagttt	ttataagata	ttttaaaatc	aaattatgaa	aacttctata	2820	
5	actattctac	tgatagtgtt	cttgcataaa	aacacttcaa	atgcactgtt	aacatttcct	2880
	aaagaaaaaa	agaagcaata	ttttattttg	taaattatgt	catttttcc	tttata	2937

10 <210> 9

<211> 2347

<212> PRT

<213> Artificial Sequence

15 <220>

<223> Synthetic Peptide

<400> 9

20	Met	Lys	Asn	Ile	Tyr	Cys	Leu	Ile	Pro	Lys	Leu	Val	Asn	Phe	Ala	Thr
	1						5			10				15		

25	Leu	Gly	Cys	Leu	Trp	Ile	Ser	Val	Val	Gln	Cys	Thr	Val	Leu	Asn	Ser
							20			25				30		

30	Cys	Leu	Lys	Ser	Cys	Val	Thr	Asn	Leu	Gly	Gln	Gln	Leu	Asp	Leu	Gly
							35			40			45			

35	Thr	Pro	His	Asn	Leu	Ser	Glu	Pro	Cys	Ile	Gln	Gly	Cys	His	Phe	Trp
							50			55			60			

40	Asn	Ser	Val	Asp	Gln	Lys	Asn	Cys	Ala	Leu	Lys	Cys	Arg	Glu	Ser	Cys
						65			70			75		80		

45	Glu	Val	Gly	Cys	Ser	Ser	Ala	Glu	Gly	Ala	Tyr	Glu	Glu	Val	Leu
							85			90			95		

50	Glu	Asn	Ala	Asp	Leu	Pro	Thr	Ala	Pro	Phe	Ala	Ser	Ser	Ile	Gly	Ser
							100			105			110			

55	His	Asn	Met	Thr	Leu	Arg	Trp	Lys	Ser	Ala	Asn	Phe	Ser	Gly	Val	Lys
							115			120			125			

60	Tyr	Ile	Ile	Gln	Trp	Lys	Tyr	Ala	Gln	Leu	Leu	Gly	Ser	Trp	Thr	Tyr
							130			135			140			

65	Thr	Lys	Thr	Val	Ser	Arg	Pro	Ser	Tyr	Val	Val	Lys	Pro	Leu	His	Pro
							145			150			155		160	

70	Phe	Thr	Glu	Tyr	Ile	Phe	Arg	Val	Val	Trp	Ile	Phe	Thr	Ala	Gln	Leu
							165			170			175			

EP 2 881 402 B1

Gln Leu Tyr Ser Pro Pro Ser Pro Ser Tyr Arg Thr His Pro His Gly
 180 185 190

5 Val Pro Glu Thr Ala Pro Leu Ile Arg Asn Ile Glu Ser Ser Ser Pro
 195 200 205

10 Asp Thr Val Glu Val Ser Trp Asp Pro Pro Gln Phe Pro Gly Gly Pro
 210 215 220

Ile Leu Gly Tyr Asn Leu Arg Leu Ile Ser Lys Asn Gln Lys Leu Asp
 225 230 235 240

15 Ala Gly Thr Gln Arg Thr Ser Phe Gln Phe Tyr Ser Thr Leu Pro Asn
 245 250 255

20 Thr Ile Tyr Arg Phe Ser Ile Ala Ala Val Asn Glu Val Gly Glu Gly
 260 265 270

25 Pro Glu Ala Glu Ser Ser Ile Thr Thr Ser Ser Ser Ala Val Gln Gln
 275 280 285

Glu Glu Gln Trp Leu Phe Leu Ser Arg Lys Thr Ser Leu Arg Lys Arg
 290 295 300

30 Ser Leu Lys His Leu Val Asp Glu Ala His Cys Leu Arg Leu Asp Ala
 305 310 315 320

35 Ile Tyr His Asn Ile Thr Gly Ile Ser Val Asp Val His Gln Gln Ile
 325 330 335

Val Tyr Phe Ser Glu Gly Thr Leu Ile Trp Ala Lys Lys Ala Ala Asn
 340 345 350

40 Met Ser Asp Val Ser Asp Leu Arg Ile Phe Tyr Arg Gly Ser Gly Leu
 355 360 365

45 Ile Ser Ser Ile Ser Ile Asp Trp Leu Tyr Gln Arg Met Tyr Phe Ile
 370 375 380

50 Met Asp Glu Leu Val Cys Val Cys Asp Leu Glu Asn Cys Ser Asn Ile
 385 390 395 400

Glu Glu Ile Thr Pro Pro Ser Ile Ser Ala Pro Gln Lys Ile Val Ala
 405 410 415

55 Asp Ser Tyr Asn Gly Tyr Val Phe Tyr Leu Leu Arg Asp Gly Ile Tyr
 420 425 430

EP 2 881 402 B1

Arg Ala Asp Leu Pro Val Pro Ser Gly Arg Cys Ala Glu Ala Val Arg
 435 440 445

5 Ile Val Glu Ser Cys Thr Leu Lys Asp Phe Ala Ile Lys Pro Gln Ala
 450 455 460

10 Lys Arg Ile Ile Tyr Phe Asn Asp Thr Ala Gln Val Phe Met Ser Thr
 465 470 475 480

15 Phe Leu Asp Gly Ser Ala Ser His Leu Ile Leu Pro Arg Ile Pro Phe
 485 490 495

20 Ala Asp Val Lys Ser Phe Ala Cys Glu Asn Asn Asp Phe Leu Val Thr
 500 505 510

25 Asp Gly Lys Val Ile Phe Gln Gln Asp Ala Leu Ser Phe Asn Glu Phe
 515 520 525

30 Ile Val Gly Cys Asp Leu Ser His Ile Glu Glu Phe Gly Phe Gly Asn
 530 535 540

35 Leu Val Ile Phe Gly Ser Ser Ser Gln Leu His Pro Leu Pro Gly Arg
 545 550 555 560

40 Pro Gln Glu Leu Ser Val Leu Phe Gly Ser His Gln Ala Leu Val Gln
 565 570 575

45 Trp Lys Pro Pro Ala Leu Ala Ile Gly Ala Asn Val Ile Leu Ile Ser
 580 585 590

50 Asp Ile Ile Glu Leu Phe Glu Leu Gly Pro Ser Ala Trp Gln Asn Trp
 595 600 605

55 Thr Tyr Glu Val Lys Val Ser Thr Gln Asp Pro Pro Glu Val Thr His
 610 615 620

60 Ile Phe Leu Asn Ile Ser Gly Thr Met Leu Asn Val Pro Glu Leu Gln
 625 630 635 640

65 Ser Ala Met Lys Tyr Lys Val Ser Val Arg Ala Ser Ser Pro Lys Arg
 645 650 655

70 Pro Gly Pro Trp Ser Glu Pro Ser Val Gly Thr Thr Leu Val Pro Ala
 660 665 670

75 Ser Glu Pro Pro Phe Ile Met Ala Val Lys Glu Asp Gly Leu Trp Ser

EP 2 881 402 B1

675

680

685

5 Lys Pro Leu Asn Ser Phe Gly Pro Gly Glu Phe Leu Ser Ser Asp Ile
690 695 700

10 Gly Asn Val Ser Asp Met Asp Trp Tyr Asn Asn Ser Leu Tyr Tyr Ser
705 710 715 720

15 Asp Thr Lys Gly Asp Val Phe Val Trp Leu Leu Asn Gly Thr Asp Ile
725 730 735

20 Ser Glu Asn Tyr His Leu Pro Ser Ile Ala Gly Ala Gly Ala Leu Ala
740 745 750

25 Phe Glu Trp Leu Gly His Phe Leu Tyr Trp Ala Gly Lys Thr Tyr Val
755 760 765

30 Ile Gln Arg Gln Ser Val Leu Thr Gly His Thr Asp Ile Val Thr His
770 775 780

35 Val Lys Leu Leu Val Asn Asp Met Val Val Asp Ser Val Gly Gly Tyr
785 790 795 800

40 Leu Tyr Trp Thr Thr Leu Tyr Ser Val Glu Ser Thr Arg Leu Asn Gly
805 810 815

45 Glu Ser Ser Leu Val Leu Gln Thr Gln Pro Trp Phe Ser Gly Lys Lys
820 825 830

50 Val Ile Ala Leu Thr Leu Asp Leu Ser Asp Gly Leu Leu Tyr Trp Leu
835 840 845

55 Val Gln Asp Ser Gln Cys Ile His Leu Tyr Thr Ala Val Leu Arg Gly
850 855 860

60 Gln Ser Thr Gly Asp Thr Thr Ile Thr Glu Phe Ala Ala Trp Ser Thr
865 870 875 880

65 Ser Glu Ile Ser Gln Asn Ala Leu Met Tyr Tyr Ser Gly Arg Leu Phe
885 890 895

70 Trp Ile Asn Gly Phe Arg Ile Ile Thr Thr Gln Glu Ile Gly Gln Lys
900 905 910

75 Thr Ser Val Ser Val Leu Glu Pro Ala Arg Phe Asn Gln Phe Thr Ile
915 920 925

EP 2 881 402 B1

Ile Gln Thr Ser Leu Lys Pro Leu Pro Gly Asn Phe Ser Phe Thr Pro
 930 935 940

5 Lys Val Ile Pro Asp Ser Val Gln Glu Ser Ser Phe Arg Ile Glu Gly
 945 950 955 960

10 Asn Ala Ser Ser Phe Gln Ile Leu Trp Asn Gly Pro Pro Ala Val Asp
 965 970 975

Trp Gly Val Val Phe Tyr Ser Val Glu Phe Ser Ala His Ser Lys Phe
 980 985 990

15 Leu Ala Ser Glu Gln His Ser Leu Pro Val Phe Thr Val Glu Gly Leu
 995 1000 1005

20 Glu Pro Tyr Ala Leu Phe Asn Leu Ser Val Thr Pro Tyr Thr Tyr
 1010 1015 1020

25 Trp Gly Lys Gly Pro Lys Thr Ser Leu Ser Leu Arg Ala Pro Glu
 1025 1030 1035

Thr Val Pro Ser Ala Pro Glu Asn Pro Arg Ile Phe Ile Leu Pro
 1040 1045 1050

30 Ser Gly Lys Cys Cys Asn Lys Asn Glu Val Val Val Glu Phe Arg
 1055 1060 1065

35 Trp Asn Lys Pro Lys His Glu Asn Gly Val Leu Thr Lys Phe Glu
 1070 1075 1080

40 Ile Phe Tyr Asn Ile Ser Asn Gln Ser Ile Thr Asn Lys Thr Cys
 1085 1090 1095

45 Glu Asp Trp Ile Ala Val Asn Val Thr Pro Ser Val Met Ser Phe
 1100 1105 1110

Gln Leu Glu Gly Met Ser Pro Arg Cys Phe Ile Ala Phe Gln Val
 1115 1120 1125

50 Arg Ala Phe Thr Ser Lys Gly Pro Gly Pro Tyr Ala Asp Val Val
 1130 1135 1140

Lys Ser Thr Thr Ser Glu Ile Asn Pro Phe Pro His Leu Ile Thr
 1145 1150 1155

55 Leu Leu Gly Asn Lys Ile Val Phe Leu Asp Met Asp Gln Asn Gln
 1160 1165 1170

EP 2 881 402 B1

Val Val Trp Thr Phe Ser Ala Glu Arg Val Ile Ser Ala Val Cys
 1175 1180 1185

5 Tyr Thr Ala Asp Asn Glu Met Gly Tyr Tyr Ala Glu Gly Asp Ser
 1190 1195 1200

10 Leu Phe Leu Leu His Leu His Asn Arg Ser Ser Ser Glu Leu Phe
 1205 1210 1215

15 Gln Asp Ser Leu Val Phe Asp Ile Thr Val Ile Thr Ile Asp Trp
 1220 1225 1230

20 Ile Ser Arg His Leu Tyr Phe Ala Leu Lys Glu Ser Gln Asn Gly
 1235 1240 1245

25 Met Gln Val Phe Asp Val Asp Leu Glu His Lys Val Lys Tyr Pro
 1250 1255 1260

30 Arg Glu Val Lys Ile His Asn Arg Asn Ser Thr Ile Ile Ser Phe
 1265 1270 1275

35 Ser Val Tyr Pro Leu Leu Ser Arg Leu Tyr Trp Thr Glu Val Ser
 1280 1285 1290

40 Asn Phe Gly Tyr Gln Met Phe Tyr Tyr Ser Ile Ile Ser His Thr
 1295 1300 1305

45 Leu His Arg Ile Leu Gln Pro Thr Ala Thr Asn Gln Gln Asn Lys
 1310 1315 1320

50 Arg Asn Gln Cys Ser Cys Asn Val Thr Glu Phe Glu Leu Ser Gly
 1325 1330 1335

Ala Met Ala Ile Asp Thr Ser Asn Leu Glu Lys Pro Leu Ile Tyr
 1340 1345 1350

Phe Ala Lys Ala Gln Glu Ile Trp Ala Met Asp Leu Glu Gly Cys
 1355 1360 1365

Gln Cys Trp Arg Val Ile Thr Val Pro Ala Met Leu Ala Gly Lys
 1370 1375 1380

55 Thr Leu Val Ser Leu Thr Val Asp Gly Asp Leu Ile Tyr Trp Ile
 1385 1390 1395

Ile Thr Ala Lys Asp Ser Thr Gln Ile Tyr Gln Ala Lys Lys Gly
 1400 1405 1410

Asn Gly Ala Ile Val Ser Gln Val Lys Ala Leu Arg Ser Arg His 1415 1420 1425	
Ile Leu Ala Tyr Ser Ser Val Met Gln Pro Phe Pro Asp Lys Ala 1430 1435 1440	
Phe Leu Ser Leu Ala Ser Asp Thr Val Glu Pro Thr Ile Leu Asn 1445 1450 1455	
Ala Thr Asn Thr Ser Leu Thr Ile Arg Leu Pro Leu Ala Lys Thr 1460 1465 1470	
Asn Leu Thr Trp Tyr Gly Ile Thr Ser Pro Thr Pro Thr Tyr Leu 1475 1480 1485	
Val Tyr Tyr Ala Glu Val Asn Asp Arg Lys Asn Ser Ser Asp Leu 1490 1495 1500	
Lys Tyr Arg Ile Leu Glu Phe Gln Asp Ser Ile Ala Leu Ile Glu 1505 1510 1515	
Asp Leu Gln Pro Phe Ser Thr Tyr Met Ile Gln Ile Ala Val Lys 1520 1525 1530	
Asn Tyr Tyr Ser Asp Pro Leu Glu His Leu Pro Pro Gly Lys Glu 1535 1540 1545	
Ile Trp Gly Lys Thr Lys Asn Gly Val Pro Glu Ala Val Gln Leu 1550 1555 1560	
Ile Asn Thr Thr Val Arg Ser Asp Thr Ser Leu Ile Ile Ser Trp 1565 1570 1575	
Arg Glu Ser His Lys Pro Asn Gly Pro Lys Glu Ser Val Arg Tyr 1580 1585 1590	
Gln Leu Ala Ile Ser His Leu Ala Leu Ile Pro Glu Thr Pro Leu 1595 1600 1605	
Arg Gln Ser Glu Phe Pro Asn Gly Arg Leu Thr Leu Leu Val Thr 1610 1615 1620	
Arg Leu Ser Gly Gly Asn Ile Tyr Val Leu Lys Val Leu Ala Cys 1625 1630 1635	
His Ser Glu Glu Met Trp Cys Thr Glu Ser His Pro Val Thr Val	

EP 2 881 402 B1

1640

1645

1650

5 1655 1660 1665

Ash Thr Ser Leu Gin Phe Ash Trp Lys Ala Pro Leu Ash Val Ash
1670 1675 1680

10

Leu Ile Arg Phe Trp Val Glu Leu Gln Lys Trp Lys Tyr Asn Glu
 1685 1690 1695

15 Phe Tyr His Val Lys Thr Ser Cys Ser Gln Gly Pro Ala Tyr Val
1700 1705 1710

20 Cys Asn Ile Thr Asn Leu Gln Pro Tyr Thr Ser Tyr Asn Val Arg
1715 1720 1725

Val Val Val Val Tyr Lys Thr Gly Glu Asn Ser Thr Ser Leu Pro
1730 1735 1740

25

Glu Ser Phe Lys Thr Lys Ala Gly Val Pro Asn Lys Pro Gly Ile
1745 1750 1755

30 Pro Lys Leu Leu Glu Gly Ser Lys Asn Ser Ile Gln Trp Glu Lys
1760 1765 1770

Ala Glu Asp Asn Gly Cys Arg Ile Thr Tyr Tyr Ile Leu Glu Ile
1775 1780 1785

35

Arg Lys Ser Thr Ser Asn Asn Leu Gln Asn Gln Asn Leu Arg Trp
 1790 1795 1800

40

Lys Met Thr Phe Asn Gly Ser Cys Ser Ser Val Cys Thr Trp Lys

45 Ser Lys Asn Leu Lys Gly Ile Phe Gln Phe Arg Val Val Ala Ala

Asn Asn Leu Gly Phe Gly Glu Tyr Ser Gly Ile Ser Glu Asn Ile

50

Ile Leu Val Gly Asp Asp Phe Trp Ile Pro Glu Thr Ser Phe Ile
1850 1855 1860

55 Leu Thr Ile Ile Val Gly Ile Phe Leu Val Val Thr Ile Pro Leu
 1865 1870 1875

Thr Phe Val Trp His Arg Arg Leu Lys Asn Gln Lys Ser Ala Lys
 1880 1885 1890

5 Glu Gly Val Thr Val Leu Ile Asn Glu Asp Lys Glu Leu Ala Glu
 1895 1900 1905

10 Leu Arg Gly Leu Ala Ala Gly Val Gly Leu Ala Asn Ala Cys Tyr
 1910 1915 1920

Ala Ile His Thr Leu Pro Thr Gln Glu Glu Ile Glu Asn Leu Pro
 1925 1930 1935

15 Ala Phe Pro Arg Glu Lys Leu Thr Leu Arg Leu Leu Leu Gly Ser
 1940 1945 1950

20 Gly Ala Phe Gly Glu Val Tyr Glu Gly Thr Ala Val Asp Ile Leu
 1955 1960 1965

Gly Val Gly Ser Gly Glu Ile Lys Val Ala Val Lys Thr Leu Lys
 1970 1975 1980

25 Lys Gly Ser Thr Asp Gln Glu Lys Ile Glu Phe Leu Lys Glu Ala
 1985 1990 1995

30 His Leu Met Ser Lys Phe Asn His Pro Asn Ile Leu Lys Gln Leu
 2000 2005 2010

35 Gly Val Cys Leu Leu Asn Glu Pro Gln Tyr Ile Ile Leu Glu Leu
 2015 2020 2025

Met Glu Gly Gly Asp Leu Leu Thr Tyr Leu Arg Lys Ala Arg Met
 2030 2035 2040

40 Ala Thr Phe Tyr Gly Pro Leu Leu Thr Leu Val Asp Leu Val Asp
 2045 2050 2055

45 Leu Cys Val Asp Ile Ser Lys Gly Cys Val Tyr Leu Glu Arg Met
 2060 2065 2070

50 His Phe Ile His Arg Asp Leu Ala Ala Arg Asn Cys Leu Val Ser
 2075 2080 2085

Val Lys Asp Tyr Thr Ser Pro Arg Ile Val Lys Ile Gly Asp Phe
 2090 2095 2100

55 Gly Leu Ala Arg Asp Ile Tyr Lys Asn Asp Tyr Tyr Arg Lys Arg
 2105 2110 2115

EP 2 881 402 B1

Gly Glu Gly Leu Leu Pro Val Arg Trp Met Ala Pro Glu Ser Leu
 2120 2125 2130

5 Met Asp Gly Ile Phe Thr Thr Gln Ser Asp Val Trp Ser Phe Gly
 2135 2140 2145

10 Ile Leu Ile Trp Glu Ile Leu Thr Leu Gly His Gln Pro Tyr Pro
 2150 2155 2160

Ala His Ser Asn Leu Asp Val Leu Asn Tyr Val Gln Thr Gly Gly
 2165 2170 2175

15 Arg Leu Glu Pro Pro Arg Asn Cys Pro Asp Asp Leu Trp Asn Leu
 2180 2185 2190

20 Met Thr Gln Cys Trp Ala Gln Glu Pro Asp Gln Arg Pro Thr Phe
 2195 2200 2205

25 His Arg Ile Gln Asp Gln Leu Gln Leu Phe Arg Asn Phe Phe Leu
 2210 2215 2220

Asn Ser Ile Tyr Lys Ser Arg Asp Glu Ala Asn Asn Ser Gly Val
 2225 2230 2235

30 Ile Asn Glu Ser Phe Glu Gly Glu Asp Gly Asp Val Ile Cys Leu
 2240 2245 2250

35 Asn Ser Asp Asp Ile Met Pro Val Ala Leu Met Glu Thr Lys Asn
 2255 2260 2265

Arg Glu Gly Leu Asn Tyr Met Val Leu Ala Thr Glu Cys Gly Gln
 2270 2275 2280

40 Gly Glu Glu Lys Ser Glu Gly Pro Leu Gly Ser Gln Glu Ser Glu
 2285 2290 2295

45 Ser Cys Gly Leu Arg Lys Glu Glu Lys Glu Pro His Ala Asp Lys
 2300 2305 2310

50 Asp Phe Cys Gln Glu Lys Gln Val Ala Tyr Cys Pro Ser Gly Lys
 2315 2320 2325

Pro Glu Gly Leu Asn Tyr Ala Cys Leu Thr His Ser Gly Tyr Gly
 2330 2335 2340

55 Asp Gly Ser Asp
 2345

<210> 10
 <211> 1881
 <212> PRT
 <213> Artificial Sequence

5

<220>
 <223> Synthetic Peptide

10 <400> 10

10

Met Lys Asn Ile Tyr Cys Leu Ile Pro Lys Leu Val Asn Phe Ala Thr
 1 5 10 15

15 Leu Gly Cys Leu Trp Ile Ser Val Val Gln Cys Thr Val Leu Asn Ser
 20 25 30

20 Cys Leu Lys Ser Cys Val Thr Asn Leu Gly Gln Gln Leu Asp Leu Gly
 35 40 45

Thr Pro His Asn Leu Ser Glu Pro Cys Ile Gln Gly Cys His Phe Trp
 50 55 60

25

Asn Ser Val Asp Gln Lys Asn Cys Ala Leu Lys Cys Arg Glu Ser Cys
 65 70 75 80

30 Glu Val Gly Cys Ser Ser Ala Glu Gly Ala Tyr Glu Glu Val Leu
 85 90 95

35 Glu Asn Ala Asp Leu Pro Thr Ala Pro Phe Ala Ser Ser Ile Gly Ser
 100 105 110

40 His Asn Met Thr Leu Arg Trp Lys Ser Ala Asn Phe Ser Gly Val Lys
 115 120 125

45 Tyr Ile Ile Gln Trp Lys Tyr Ala Gln Leu Leu Gly Ser Trp Thr Tyr
 130 135 140

50 Phe Thr Glu Tyr Ile Phe Arg Val Val Trp Ile Phe Thr Ala Gln Leu
 165 170 175

Gln Leu Tyr Ser Pro Pro Ser Pro Ser Tyr Arg Thr His Pro His Gly
 180 185 190

55 Val Pro Glu Thr Ala Pro Leu Ile Arg Asn Ile Glu Ser Ser Ser Pro
 195 200 205

Asp Thr Val Glu Val Ser Trp Asp Pro Pro Gln Phe Pro Gly Gly Pro
 210 215 220

5 Ile Leu Gly Tyr Asn Leu Arg Leu Ile Ser Lys Asn Gln Lys Leu Asp
 225 230 235 240

10 Ala Gly Thr Gln Arg Thr Ser Phe Gln Phe Tyr Ser Thr Leu Pro Asn
 245 250 255

15 Thr Ile Tyr Arg Phe Ser Ile Ala Ala Val Asn Glu Val Gly Glu Gly
 260 265 270

20 Pro Glu Ala Glu Ser Ser Ile Thr Thr Ser Ser Ala Val Gln Gln
 275 280 285

25 Glu Glu Gln Trp Leu Phe Leu Ser Arg Lys Thr Ser Leu Arg Lys Arg
 290 295 300

30 Ser Leu Lys His Leu Val Asp Glu Ala His Cys Leu Arg Leu Asp Ala
 305 310 315 320

35 Ile Tyr His Asn Ile Thr Gly Ile Ser Val Asp Val His Gln Gln Ile
 325 330 335

40 Val Tyr Phe Ser Glu Gly Thr Leu Ile Trp Ala Lys Lys Ala Ala Asn
 340 345 350

45 Met Ser Asp Val Ser Asp Leu Arg Ile Phe Tyr Arg Gly Ser Gly Leu
 355 360 365

50 Ile Ser Ser Ile Ser Ile Asp Trp Leu Tyr Gln Arg Met Tyr Phe Ile
 370 375 380

55 Met Asp Glu Leu Val Cys Val Cys Asp Leu Glu Asn Cys Ser Asn Ile
 385 390 395 400

60 Glu Glu Ile Thr Pro Pro Ser Ile Ser Ala Pro Gln Lys Ile Val Ala
 405 410 415

65 Asp Ser Tyr Asn Gly Tyr Val Phe Tyr Leu Leu Arg Asp Gly Ile Tyr
 420 425 430

70 Arg Ala Asp Leu Pro Val Pro Ser Gly Arg Cys Ala Glu Ala Val Arg
 435 440 445

75 Ile Val Glu Ser Cys Thr Leu Lys Asp Phe Ala Ile Lys Pro Gln Ala
 450 455 460

EP 2 881 402 B1

Lys Arg Ile Ile Tyr Phe Asn Asp Thr Ala Gln Val Phe Met Ser Thr
 465 470 475 480

5 Phe Leu Asp Gly Ser Ala Ser His Leu Ile Leu Pro Arg Ile Pro Phe
 485 490 495

10 Ala Asp Val Lys Ser Phe Ala Cys Glu Asn Asn Asp Phe Leu Val Thr
 500 505 510

15 Asp Gly Lys Val Ile Phe Gln Gln Asp Ala Leu Ser Phe Asn Glu Phe
 515 520 525

20 Ile Val Gly Cys Asp Leu Ser His Ile Glu Glu Phe Gly Phe Gly Asn
 530 535 540

25 Leu Val Ile Phe Gly Ser Ser Ser Gln Leu His Pro Leu Pro Gly Arg
 545 550 555 560

30 Pro Gln Glu Leu Ser Val Leu Phe Gly Ser His Gln Ala Leu Val Gln
 565 570 575

35 Trp Lys Pro Pro Ala Leu Ala Ile Gly Ala Asn Val Ile Leu Ile Ser
 580 585 590

40 Asp Ile Ile Glu Leu Phe Glu Leu Gly Pro Ser Ala Trp Gln Asn Trp
 595 600 605

45 Thr Tyr Glu Val Lys Val Ser Thr Gln Asp Pro Pro Glu Val Thr His
 610 615 620

50 Ile Phe Leu Asn Ile Ser Gly Thr Met Leu Asn Val Pro Glu Leu Gln
 625 630 635 640

55 Ser Ala Met Lys Tyr Lys Val Ser Val Arg Ala Ser Ser Pro Lys Arg
 645 650 655

60 Pro Gly Pro Trp Ser Glu Pro Ser Val Gly Thr Thr Leu Val Pro Ala
 660 665 670

65 Ser Glu Pro Pro Phe Ile Met Ala Val Lys Glu Asp Gly Leu Trp Ser
 675 680 685

70 Lys Pro Leu Asn Ser Phe Gly Pro Gly Glu Phe Leu Ser Ser Asp Ile
 690 695 700

75 Gly Asn Val Ser Asp Met Asp Trp Tyr Asn Asn Ser Leu Tyr Tyr Ser

EP 2 881 402 B1

705	710	715	720
Asp Thr Lys Gly Asp Val Phe Val Trp Leu Leu Asn Gly Thr Asp Ile			
725 730 735			
Ser Glu Asn Tyr His Leu Pro Ser Ile Ala Gly Ala Gly Ala Leu Ala			
740 745 750			
Phe Glu Trp Leu Gly His Phe Leu Tyr Trp Ala Gly Lys Thr Tyr Val			
755 760 765			
Ile Gln Arg Gln Ser Val Leu Thr Gly His Thr Asp Ile Val Thr His			
770 775 780			
Val Lys Leu Leu Val Asn Asp Met Val Val Asp Ser Val Gly Gly Tyr			
785 790 795 800			
Leu Tyr Trp Thr Thr Leu Tyr Ser Val Glu Ser Thr Arg Leu Asn Gly			
805 810 815			
Glu Ser Ser Leu Val Leu Gln Thr Gln Pro Trp Phe Ser Gly Lys Lys			
820 825 830			
Val Ile Ala Leu Thr Leu Asp Leu Ser Asp Gly Leu Leu Tyr Trp Leu			
835 840 845			
Val Gln Asp Ser Gln Cys Ile His Leu Tyr Thr Ala Val Leu Arg Gly			
850 855 860			
Gln Ser Thr Gly Asp Thr Thr Ile Thr Glu Phe Ala Ala Trp Ser Thr			
865 870 875 880			
Ser Glu Ile Ser Gln Asn Ala Leu Met Tyr Tyr Ser Gly Arg Leu Phe			
885 890 895			
Trp Ile Asn Gly Phe Arg Ile Ile Thr Thr Gln Glu Ile Gly Gln Lys			
900 905 910			
Thr Ser Val Ser Val Leu Glu Pro Ala Arg Phe Asn Gln Phe Thr Ile			
915 920 925			
Ile Gln Thr Ser Leu Lys Pro Leu Pro Gly Asn Phe Ser Phe Thr Pro			
930 935 940			
Lys Val Ile Pro Asp Ser Val Gln Glu Ser Ser Phe Arg Ile Glu Gly			
945 950 955 960			

EP 2 881 402 B1

Asn Ala Ser Ser Phe Gln Ile Leu Trp Asn Gly Pro Pro Ala Val Asp
 965 970 975

5 Trp Gly Val Val Phe Tyr Ser Val Glu Phe Ser Ala His Ser Lys Phe
 980 985 990

10 Leu Ala Ser Glu Gln His Ser Leu Pro Val Phe Thr Val Glu Gly Leu
 995 1000 1005

15 Glu Pro Tyr Ala Leu Phe Asn Leu Ser Val Thr Pro Tyr Thr Tyr
 1010 1015 1020

20 Trp Gly Lys Gly Pro Lys Thr Ser Leu Ser Leu Arg Ala Pro Glu
 1025 1030 1035

25 Thr Val Pro Ser Ala Pro Glu Asn Pro Arg Ile Phe Ile Leu Pro
 1040 1045 1050

30 Ser Gly Lys Cys Cys Asn Lys Asn Glu Val Val Val Glu Phe Arg
 1055 1060 1065

35 Trp Asn Lys Pro Lys His Glu Asn Gly Val Leu Thr Lys Phe Glu
 1070 1075 1080

40 Ile Phe Tyr Asn Ile Ser Asn Gln Ser Ile Thr Asn Lys Thr Cys
 1085 1090 1095

45 Glu Asp Trp Ile Ala Val Asn Val Thr Pro Ser Val Met Ser Phe
 1100 1105 1110

50 Gln Leu Glu Gly Met Ser Pro Arg Cys Phe Ile Ala Phe Gln Val
 1115 1120 1125

55 Arg Ala Phe Thr Ser Lys Gly Pro Gly Pro Tyr Ala Asp Val Val
 1130 1135 1140

60 Lys Ser Thr Thr Ser Glu Ile Asn Pro Phe Pro His Leu Ile Thr
 1145 1150 1155

65 Leu Leu Gly Asn Lys Ile Val Phe Leu Asp Met Asp Gln Asn Gln
 1160 1165 1170

70 Val Val Trp Thr Phe Ser Ala Glu Arg Val Ile Ser Ala Val Cys
 1175 1180 1185

75 Tyr Thr Ala Asp Asn Glu Met Gly Tyr Tyr Ala Glu Gly Asp Ser
 1190 1195 1200

EP 2 881 402 B1

Leu Phe Leu Leu His Leu His Asn Arg Ser Ser Ser Glu Leu Phe
 1205 1210 1215

5 Gln Asp Ser Leu Val Phe Asp Ile Thr Val Ile Thr Ile Asp Trp
 1220 1225 1230

10 Ile Ser Arg His Leu Tyr Phe Ala Leu Lys Glu Ser Gln Asn Gly
 1235 1240 1245

15 Met Gln Val Phe Asp Val Asp Leu Glu His Lys Val Lys Tyr Pro
 1250 1255 1260

20 Arg Glu Val Lys Ile His Asn Arg Asn Ser Thr Ile Ile Ser Phe
 1265 1270 1275

25 Ser Val Tyr Pro Leu Leu Ser Arg Leu Tyr Trp Thr Glu Val Ser
 1280 1285 1290

30 Asn Phe Gly Tyr Gln Met Phe Tyr Tyr Ser Ile Ile Ser His Thr
 1295 1300 1305

35 Leu His Arg Ile Leu Gln Pro Thr Ala Thr Asn Gln Gln Asn Lys
 1310 1315 1320

40 Arg Asn Gln Cys Ser Cys Asn Val Thr Glu Phe Glu Leu Ser Gly
 1325 1330 1335

45 Ala Met Ala Ile Asp Thr Ser Asn Leu Glu Lys Pro Leu Ile Tyr
 1340 1345 1350

50 Phe Ala Lys Ala Gln Glu Ile Trp Ala Met Asp Leu Glu Gly Cys
 1355 1360 1365

55 Gln Cys Trp Arg Val Ile Thr Val Pro Ala Met Leu Ala Gly Lys
 1370 1375 1380

Thr Leu Val Ser Leu Thr Val Asp Gly Asp Leu Ile Tyr Trp Ile
 1385 1390 1395

Ile Thr Ala Lys Asp Ser Thr Gln Ile Tyr Gln Ala Lys Lys Gly
 1400 1405 1410

Asn Gly Ala Ile Val Ser Gln Val Lys Ala Leu Arg Ser Arg His
 1415 1420 1425

Ile Leu Ala Tyr Ser Ser Val Met Gln Pro Phe Pro Asp Lys Ala
 1430 1435 1440

EP 2 881 402 B1

Phe Leu Ser Leu Ala Ser Asp	Thr Val Glu Pro Thr	Ile Leu Asn
1445	1450	1455
Ala Thr Asn Thr Ser Leu Thr	Ile Arg Leu Pro Leu	Ala Lys Thr
5 1460	1465	1470
Asn Leu Thr Trp Tyr Gly	Ile Thr Ser Pro Thr Pro	Thr Tyr Leu
10 1475	1480	1485
Val Tyr Tyr Ala Glu Val Asn	Asp Arg Lys Asn Ser	Ser Asp Leu
1490	1495	1500
Lys Tyr Arg Ile Leu Glu Phe	Gln Asp Ser Ile Ala	Leu Ile Glu
15 1505	1510	1515
Asp Leu Gln Pro Phe Ser	Thr Tyr Met Ile Gln Ile	Ala Val Lys
20 1520	1525	1530
Asn Tyr Tyr Ser Asp Pro Leu	Glu His Leu Pro Pro	Gly Lys Glu
25 1535	1540	1545
Ile Trp Gly Lys Thr Lys Asn	Gly Val Pro Glu Ala	Val Gln Leu
1550	1555	1560
Ile Asn Thr Thr Val Arg Ser	Asp Thr Ser Leu Ile	Ile Ser Trp
30 1565	1570	1575
Arg Glu Ser His Lys Pro Asn	Gly Pro Lys Glu Ser	Val Arg Tyr
35 1580	1585	1590
Gln Leu Ala Ile Ser His Leu	Ala Leu Ile Pro Glu	Thr Pro Leu
40 1595	1600	1605
Arg Gln Ser Glu Phe Pro Asn	Gly Arg Leu Thr Leu	Leu Val Thr
1610	1615	1620
Arg Leu Ser Gly Gly Asn Ile	Tyr Val Leu Lys Val	Leu Ala Cys
45 1625	1630	1635
His Ser Glu Glu Met Trp Cys	Thr Glu Ser His Pro	Val Thr Val
50 1640	1645	1650
Glu Met Phe Asn Thr Pro Glu	Lys Pro Tyr Ser Leu	Val Pro Glu
55 1655	1660	1665
Asn Thr Ser Leu Gln Phe Asn	Trp Lys Ala Pro Leu	Asn Val Asn

	1670	1675	1680
5	Leu Ile Arg Phe Trp Val Glu	Leu Gln Lys Trp Lys	Tyr Asn Glu
	1685	1690	1695
10	Phe Tyr His Val Lys Thr Ser	Cys Ser Gln Gly Pro	Ala Tyr Val
	1700	1705	1710
15	Cys Asn Ile Thr Asn Leu Gln	Pro Tyr Thr Ser Tyr	Asn Val Arg
	1715	1720	1725
20	Val Val Val Val Tyr Lys Thr	Gly Glu Asn Ser Thr	Ser Leu Pro
	1730	1735	1740
25	Glu Ser Phe Lys Thr Lys Ala	Gly Val Pro Asn Lys	Pro Gly Ile
	1745	1750	1755
30	Pro Lys Leu Leu Glu Gly Ser	Lys Asn Ser Ile Gln	Trp Glu Lys
	1760	1765	1770
35	Ala Glu Asp Asn Gly Cys Arg	Ile Thr Tyr Tyr Ile	Leu Glu Ile
	1775	1780	1785
40	Arg Lys Ser Thr Ser Asn Asn	Leu Gln Asn Gln Asn	Leu Arg Trp
	1790	1795	1800
45	Lys Met Thr Phe Asn Gly Ser	Cys Ser Ser Val Cys	Thr Trp Lys
	1805	1810	1815
50	Ser Lys Asn Leu Lys Gly Ile	Phe Gln Phe Arg Val	Val Ala Ala
	1820	1825	1830
55	Asn Asn Leu Gly Phe Gly Glu	Tyr Ser Gly Ile Ser	Glu Asn Ile
	1835	1840	1845
	Ile Leu Val Gly Asp Asp Phe	Trp Ile Pro Glu Thr	Ser Phe Ile
	1850	1855	1860
	Leu Thr Ile Ile Val Gly Ile	Phe Leu Val Val Thr	Ile Pro Leu
	1865	1870	1875
	Thr Phe Val		
	1880		
	<210> 11		
	<211> 28		
	<212> PRT		

<213> Artificial Sequence

<220>

<223> Synthetic Peptide

5

<400> 11

10

Asp Phe Trp Ile Pro Glu Thr Ser Phe Ile Leu Thr Ile Ile Val Gly
1 5 10 15

Ile Phe Leu Val Val Thr Ile Pro Leu Thr Phe Val
20 25

15

<210> 12

<211> 466

<212> PRT

<213> Artificial Sequence

20

<220>

<223> Synthetic Peptide

<400> 12

25

30

35

40

45

50

55

Trp His Arg Arg Leu Lys Asn Gln Lys Ser Ala Lys Glu Gly Val Thr
 1 5 10 15

5 Val Leu Ile Asn Glu Asp Lys Glu Leu Ala Glu Leu Arg Gly Leu Ala
 20 25 30

10 Ala Gly Val Gly Leu Ala Asn Ala Cys Tyr Ala Ile His Thr Leu Pro
 35 40 45

15 Thr Gln Glu Glu Ile Glu Asn Leu Pro Ala Phe Pro Arg Glu Lys Leu
 50 55 60

Thr Leu Arg Leu Leu Gly Ser Gly Ala Phe Gly Glu Val Tyr Glu
 65 70 75 80

20 Gly Thr Ala Val Asp Ile Leu Gly Val Gly Ser Gly Glu Ile Lys Val
 85 90 95

25 Ala Val Lys Thr Leu Lys Lys Gly Ser Thr Asp Gln Glu Lys Ile Glu
 100 105 110

30 Phe Leu Lys Glu Ala His Leu Met Ser Lys Phe Asn His Pro Asn Ile
 115 120 125

Leu Lys Gln Leu Gly Val Cys Leu Leu Asn Glu Pro Gln Tyr Ile Ile
 130 135 140

35 Leu Glu Leu Met Glu Gly Gly Asp Leu Leu Thr Tyr Leu Arg Lys Ala
 145 150 155 160

40

45

50

55

Arg Met Ala Thr Phe Tyr Gly Pro Leu Leu Thr Leu Val Asp Leu Val
 165 170 175

5 Asp Leu Cys Val Asp Ile Ser Lys Gly Cys Val Tyr Leu Glu Arg Met
 180 185 190

10 His Phe Ile His Arg Asp Leu Ala Ala Arg Asn Cys Leu Val Ser Val
 195 200 205

Lys Asp Tyr Thr Ser Pro Arg Ile Val Lys Ile Gly Asp Phe Gly Leu
 210 215 220

15 Ala Arg Asp Ile Tyr Lys Asn Asp Tyr Tyr Arg Lys Arg Gly Glu Gly
 225 230 235 240

20 Leu Leu Pro Val Arg Trp Met Ala Pro Glu Ser Leu Met Asp Gly Ile
 245 250 255

Phe Thr Thr Gln Ser Asp Val Trp Ser Phe Gly Ile Leu Ile Trp Glu
 260 265 270

25 Ile Leu Thr Leu Gly His Gln Pro Tyr Pro Ala His Ser Asn Leu Asp
 275 280 285

30 Val Leu Asn Tyr Val Gln Thr Gly Gly Arg Leu Glu Pro Pro Arg Asn
 290 295 300

35 Cys Pro Asp Asp Leu Trp Asn Leu Met Thr Gln Cys Trp Ala Gln Glu
 305 310 315 320

Pro Asp Gln Arg Pro Thr Phe His Arg Ile Gln Asn Gln Leu Gln Leu
 325 330 335

40 Phe Arg Asn Phe Phe Leu Asn Ser Ile Tyr Gln Cys Arg Asp Glu Ala
 340 345 350

45 Asn Asn Ser Gly Val Ile Asn Glu Ser Phe Glu Gly Glu Asp Gly Asp
 355 360 365

50 Val Ile Cys Leu Asn Ser Asp Asp Ile Met Pro Val Val Leu Met Glu
 370 375 380

Thr Lys Asn Arg Glu Gly Leu Asn Tyr Met Val Leu Ala Thr Glu Cys
 385 390 395 400

55 Gly Gln Gly Glu Glu Lys Ser Glu Gly Pro Leu Gly Ser Gln Glu Ser
 405 410 415

Glu Ser Cys Gly Leu Arg Lys Glu Glu Lys Glu Pro His Ala Asp Lys
 420 425 430

5 Asp Phe Cys Gln Glu Lys Gln Val Ala Tyr Cys Pro Ser Gly Lys Pro
 435 440 445

10 Glu Gly Leu Asn Tyr Ala Cys Leu Thr His Ser Gly Tyr Gly Asp Gly
 450 455 460

Ser Asp
 465

15 <210> 13
 <211> 421
 <212> PRT
 <213> Artificial Sequence

20 <220>
 <223> Synthetic Peptide

25 <400> 13

Thr Leu Pro Thr Gln Glu Glu Ile Glu Asn Leu Pro Ala Phe Pro Arg
 1 5 10 15

30 Glu Lys Leu Thr Leu Arg Leu Leu Leu Gly Ser Gly Ala Phe Gly Glu
 20 25 30

35 Val Tyr Glu Gly Thr Ala Val Asp Ile Leu Gly Val Gly Ser Gly Glu
 35 40 45

40 Ile Lys Val Ala Val Lys Thr Leu Lys Lys Gly Ser Thr Asp Gln Glu
 50 55 60

45 Lys Ile Glu Phe Leu Lys Glu Ala His Leu Met Ser Lys Phe Asn His
 65 70 75 80

50 Pro Asn Ile Leu Lys Gln Leu Gly Val Cys Leu Leu Asn Glu Pro Gln
 85 90 95

55 Tyr Ile Ile Leu Glu Leu Met Glu Gly Gly Asp Leu Leu Thr Tyr Leu
 100 105 110

Arg Lys Ala Arg Met Ala Thr Phe Tyr Gly Pro Leu Leu Thr Leu Val
 115 120 125

55 Asp Leu Val Asp Leu Cys Val Asp Ile Ser Lys Gly Cys Val Tyr Leu
 130 135 140

145	Glu Arg Met His Phe Ile His Arg Asp Leu Ala Ala Arg Asn Cys Leu	150	155	160	
5	Val Ser Val Lys Asp Tyr Thr Ser Pro Arg Ile Val Lys Ile Gly Asp	165	170	175	
10	Phe Gly Leu Ala Arg Asp Ile Tyr Lys Asn Asp Tyr Tyr Arg Lys Arg	180	185	190	
15	Gly Glu Gly Leu Leu Pro Val Arg Trp Met Ala Pro Glu Ser Leu Met	195	200	205	
20	Asp Gly Ile Phe Thr Thr Gln Ser Asp Val Trp Ser Phe Gly Ile Leu	210	215	220	
25	Ile Trp Glu Ile Leu Thr Leu Gly His Gln Pro Tyr Pro Ala His Ser	225	230	235	240
30	Asn Leu Asp Val Leu Asn Tyr Val Gln Thr Gly Gly Arg Leu Glu Pro	245	250	255	
35	Pro Arg Asn Cys Pro Asp Asp Leu Trp Asn Leu Met Thr Gln Cys Trp	260	265	270	
40	Ala Gln Glu Pro Asp Gln Arg Pro Thr Phe His Arg Ile Gln Asp Gln	275	280	285	
45	Leu Gln Leu Phe Arg Asn Phe Phe Leu Asn Ser Ile Tyr Lys Ser Arg	290	295	300	
50	Asp Glu Ala Asn Asn Ser Gly Val Ile Asn Glu Ser Phe Glu Gly Glu	305	310	315	320
55	Asp Gly Asp Val Ile Cys Leu Asn Ser Asp Asp Ile Met Pro Val Ala	325	330	335	
60	Leu Met Glu Thr Lys Asn Arg Glu Gly Leu Asn Tyr Met Val Leu Ala	340	345	350	
65	Thr Glu Cys Gly Gln Gly Glu Glu Lys Ser Glu Gly Pro Leu Gly Ser	355	360	365	
70	Gln Glu Ser Glu Ser Cys Gly Leu Arg Lys Glu Glu Lys Glu Pro His	370	375	380	
75	Ala Asp Lys Asp Phe Cys Gln Glu Lys Gln Val Ala Tyr Cys Pro Ser	385	390	395	400

Gly Lys Pro Glu Gly Leu Asn Tyr Ala Cys Leu Thr His Ser Gly Tyr
 405 410 415

5 Gly Asp Gly Ser Asp
 420

<210> 14

<211> 7725

10 <212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic Nucleotide

15 <400> 14

20	gtgagttacta acataactcaa tactcagaaa actctgtgtt tcagttttt tcttatcact	60
25	tatttcacta atccttagaga tatatgaaat tgttctttaa aagcagtaca ttattatttc	120
30	tagaacttga atgaagaaat tcagaaaata taggagacct tgcaggcagt aatgaaataa	180
35	tactggctgg gtctggctgg atcctgaact gggcaaaatt acttcttctt tcagtatcct	240
40	tatttcatgt ctagctatga caattttatg gtgataacta tatgaaaata gtgttactga	300
45	atgttcaaaa aatattttt ggctactata tttgagatac taggatgaaa aatataagaa	360
50	gttcattaaa aattaactag tgttctgaaa gatataccctt aactctgaga tgagctctat	420
55	aagaatggaa ggaacaaaga tctagaacca aaaataccat ttgacctaga aattacatta	480
	ctagttacat acccaaagga atataaatca ttcttattaca aagatacatg cacacgtatg	540
	ttcactgttag cactattcac aataatgaat catttggaaat caacccaaat gcccgtcaac	600
	attagactgg ttgaagcaaa tgggttacat atacaccatg gcatactatg cagccataaa	660
	aaggaatgag ataatgttt tttgcaggaa tatggatgaa gctggaagct attaacctca	720
	gcaaactaat tcaggaacacg aaaacccaaac actgcgtgtt ctcacttaca agtgggagct	780
	gaacaatgag aacgcacatgca cacaaggagg ggaacaacac acactggggc ctgtcagggg	840
	gaggggtggg gggatagaga gtatttagaa aaatagctaa tgcattgtgg gcttaatacc	900
	taggtgatgg tttgcttaggt gtagtaaacc accatgggac atgtttaccc atgtaacaaa	960
	ccttcacgtc ctgcacatgt accccagaac taaaaataaa aaaatttggaa aaaaagaatg	1020
	gagggaaaat gctccaaaac ttatgatagt tttctttatt ttcatttac acttattttg	1080
	tttcaagttg agatataattt ttaatcttat caccaattca tcaaattccat cactaataaa	1140
	aacttcaaatt gctcattttaa aaatatgtaa tcatataaga atatttctga atatttcttt	1200
	ttttaaaatt tcttcttaaa aaataagata catgtgcaga acgtgcaggg ttgttacata	1260
	ggtatacatg tgccatggtg gtttgctgca cctattgacc tgcctctaa gttccctccc	1320

	ctcagctcct atccctcaac aggcctgggt gtgtgtgtt cccctctctg tatccatgtg	1380
5	ttctcaatgt tcaactccca cttatgagtg agaacacgtg ctgtttgtt ctctgttcct	1440
	gtgttaggtt gctgaggatg atgacttcca gcttcatcca tgtccctgca aaggacatga	1500
	tctcattcct tcttatggct gcatagtatt ccatggtgta tatgtaccac attttctta	1560
10	tctggttgt cattgatgga ttggcttgggt tccatgtctt tgttattgt aacagtgtg	1620
	cagtaaacat acatgtgcat gtgtctttat agtagagtga tttatactcc tttgggtatg	1680
	tactcaataa tgagattact gggtcaaatg ttatttctgg ttctagatcc ttgaggaatt	1740
15	gccatactgt cttccacaat ggttgaataa atttacttta ccaccaacag tgtaaaagta	1800
	ttccatttc tccacaccct catcagcatc tattgttcc tgactttta atagttgcc	1860
	ttctgactcg cgtgagatgg tatctcattt tagtttgat ttgtactcct ctgtatgtca	1920
20	gtgatgttga gctttttca tacgttatt ggctgcataa atccctttt gagaagtgtc	1980
	tgttcatatac ttttgcacac ttttgatgg ggttgtctgt cttttcttg taaatatgtt	2040
	taagttcattt gtacattctg gatattagcc ctttgcaga tggatagatt gcaaaatttt	2100
25	tctccatttc tgttaggttgt ctgttcactc tgatgatagt ttctttgtt gtacagaagc	2160
	tcttagttt agttagatcc cattgtcta ttttggctt tgttgccatt gctttggtg	2220
	tttagtcat gaagtctttg cccatgccta tgtcctgaat ggtattgcct aggtttctt	2280
30	ctagggtttt tatggtttg gttttacat ttaagtgttt aatccatctt gagttaaatt	2340
	ttgtataagg ttaaggaatg ggcccagttt cagtttctg catatggcta gccagtttc	2400
	ccagcaccat ttactaaata ggagatcatt tcctcattgc ttgttttgc taggtttgtc	2460
35	aaagatcaaa tggttgtaga tgtgtgggt aatttctgag gtctctgttc tgctccattg	2520
	gtctatatat ttgttttgc accagtagca tgctgtgtt ctgtagttt gtaatatagt	2580
	ttgaagtcag gtagcatgat gcctccaagt ttgttcttt tgcttaggat tgtcttggct	2640
40	acatggggtc ttcttgatt ctatgtaaa ttaaaataa cttttctaa ttctatgaag	2700
	aatgtcaacg gtagtttagat gagaatagca ttgaatctat aaattactct gggcagaatg	2760
	gccattttca tgatactcat tattcctgtc catggggatg gaatgtttt ccatttattt	2820
45	gtgtcccttc ttatttcattt gagcaatgggt ttgttagttt ctttgaagag gtccttcaca	2880
	tcccttgcata gctgtattcg taggttattt attctctttt tagctattgt gaatgggagt	2940
	tcattcatga ttggctctc tgcttccttgc ttgttgggtt aaaggaatgc ttgtgatttt	3000
50	tgcacattga tttttatct tgagacttttgc ctgaagttgc ttatcagttc aagaagttt	3060
	tgggctgaga tggatgggtt ttctaaatac aaaatcatgt catctgcaaa cagagacaac	3120
55	ttgacttcct ctcttcctat ttgaatacccttttatttctt cctcttgcct gattgccctg	3180
	accagaactt ccaatactat gttgaatagg agtgggtgaga gtggacaccc ttgtcttgcata	3240

	ctggtttca aagggaattc ttccaggtt tgctcattca atatgatatt ggctgttagt	3300
5	ttgtcataaa tagttcttat tatttagaga tatgttccat aaaaacctag tttattgaga	3360
	gttttaaca taaagggatg ttgatgtga attttatcaa aggctttc tgcatttatt	3420
	cagataatcg tgtgatttt gtcttggtt ctgttatgt gatggattac atttattgtat	3480
10	ttgcatatgt tgaatcagcc ttgcatccca gggatgaagc cgacttggtc gtggggata	3540
	tgtttttga tgtgctgctg gattcagttt gccagtattt tattgaggat ttttacatca	3600
	atgttcatca ggtatattgg cccaaagttt gttttgtgt ctctcccaag ttttggatc	3660
15	aggatgatgc tggcttcata aaatgagttt ggaaggaatt cctcctttc cattgttgg	3720
	aacagtttca gaaggaatgg taccagctcc tctttgtatt tctggtagaa ttcaagctgt	3780
	aatccatctg gtcctgggct tttttgggtt ggtgtctat taattactgc ctccattcca	3840
20	gagcttgcta ctggtctagt cagggattca acttcttcct ggttagtct tgggtatgc	3900
	atccaggaat gtatccattt cttctagatt ttctagtttta tttgcataga agagtttata	3960
	gtattatctg gtggattttt gtatttctgt ggggtcagtg gtgatatccc ctttatcatt	4020
25	ttttttgtgt ctatggattt cttctctgtc tccttcttta tttctctagc tagtggtata	4080
	ttttgttatt tattttattt tttaaaaaaa acggcttcgt gatgtgttga ttttttttgg	4140
	agggcctttt gtgtcttgtt ctccttcagt tcttctctga tcttagttt ttcttgcatt	4200
30	ctgccagctt ttggatttagt ttgctctgtc ctctctagct cttttaattt tggatgttgg	4260
	gtgacgattt gagatcttc tggcttcata atgtggcat tttagtctat gaattttcct	4320
	cttaacactg cttagttgt gtccagaga ttctggtaca ttgtctctgt tctcatttgc	4380
35	ttcaaaagaac ttatttattt ctgccttaat ttcatttattt acccaggagc cattcaggag	4440
	caagttgttc aatttccagg aaattgtgt gtttgagtg agtttcttaa tcctgggttc	4500
40	taatttgatt gctctgttgtt ctgagagact gtttggtatg atttcagctc ttttgcattt	4560
	gctgaggagt gttttacttc caattatgtg gtagatttttta gaataagtac catgtggcac	4620
	tcagaagaat gtatattctg ttgatttggg cttagaaagtt ctgttagacat ctactaggtc	4680
45	cacttgatcc agagctaagt tcaagtcctg aatatccttg ttaattttct gtcttggat	4740
	tctgtctaat actggcagtg ggggttggaa gtttcccact actattgcgt ggcagtcata	4800
	gtctctttgtt aggtctctaa gaacttactt tgtgagtctg ggtgctcttgc tattgggtgc	4860
50	atatatatttca agaatagtta actcttcttg ttgaattttt cccttacca ttatataatg	4920
	cccttcttttgc tctatggat tctttgttgg tttaaagtct gttttgtcag agactaggat	4980
	tgcaaccctc tttttttttt tttttgtttt ccatacgat ggtttttttt cctcaatccc	5040
55	tttattttga gcctgtgtgt gtctttgcattt gtaagataga tctcctgaat acaacacacc	5100

	aatgggtctt gactccttat ccaattgcc agtctgtatc ttttaattgg ggcatttagc	5160
	ccctttacat ttaaggttagg tattgttatg tgagttgat cctgtcacca tgatgctatt	5220
5	tggttatttt gcatgctagt tgatgcagtt tcttcatagt gtcattgatc tttatagttt	5280
	ggtgtgtttt tgcaatggct ggtaccagtt tttccttcc atatttagtg cttatccag	5340
	gagctgttgc agggcaggcc tggggtaac aaaatccctc agcattgct tgtctggaaa	5400
10	ggattttatt tctccttcac ttatgaagct tagttggct ggatatgaaa ttctgggttg	5460
	aaaattcttt tctttaagaa tggtgatgtt ggccccaaat ctctctggt ttgtagggtt	5520
	tatgttggaga ggtccactgt tagtctgatg ggcgtccctt tgttaggtaac ctggccttcc	5580
15	tctctggctg cccttaacag ttttacttg atttcaacct tggagaatct gatgattatg	5640
	tgtcttgggg ttgatcttct cgtggagttt cttaatggtg ttctctgtgt ttgccgaatt	5700
	tgcatgttgg cctgtcttgc taggttgggg aagttctcct ggataatatc ccgaagggtg	5760
20	ttttccacg tggggcattt ttccccatct cctcctggta ctccaaagcta tcatagggtc	5820
	agtctttta tgaagtctca tatttcttgg aggctttatt cattcctttt cattctttt	5880
	tctctttct tgcaggcatg tcttatttca ataaggtagt cttcaaactc tgatatcttc	5940
25	tcttccactt ggtcgattca gctgttgaca cttgtgtatg cttcacgaag ttcttggtct	6000
	gtgttttca gccccatcag gccatttggtt ttccatctcta aactgattat tctagttac	6060
	aattccctcca acttttatac aagggttctta gcttcttcgc attgggttag aacataactcc	6120
30	tttagctcat catagttttt tctaccatc ttgtgaagcc tacttctgtc agttcatcca	6180
	tctgatccctc cgcccgatcc tgcaccctta atggagacat tgtgatcatt tagaggagaa	6240
	gaggcactct ggccttttgg gtttcagca ttttttcat tggttcttca tcacccctgt	6300
35	gagtttgtct agttgtggtc tttgaggctg ctgacccttg tatgggtttt ttgtggggcc	6360
	ccttgggtttt gttgttgatg atgatgtgt tggtgtcaact ttctgtttat ttgtttttct	6420
40	ttcaatagtc actttccctct tctgttagggc tgctgcagtt tgctgggtt cactttaggc	6480
	cttattcatc tgatttgctc ccacgcctgg atatgtactt caaggaggct ggagagcagc	6540
	aaaaatgggt gtctgctct tcttctggga cctctgactt caaggggcac caacctgatg	6600
45	ccagtaggat cgctcctgta taggggtgtcc tgacaatccc tggtggaggg tctcacccag	6660
	ttgggtggca ccaggaggag gaccatata acgaagcact ttgtccctg gtggagaggg	6720
	tgtgtttgc tggggaaag cccacttgatc tgggcttccc agattctca gaactaccag	6780
50	gaggagaggc taagtctgtt ggtccgcaga gactgcagcc accccctcccc cttaggggtc	6840
	aggcccaggc agatctgaat tctgtccctg agcctctggc tgcaacttactt gaagattctg	6900
	cagggaaagcc ccacccactg aggaaggatg ggtgagggtt agacactgaag aggcactctg	6960
55	gccgctgact accacagctg gtgtgttggg ttgtggcgac aagtcttggg accaagctgt	7020

ccagcctcgc	tggctccgc	agggaaaaag	cacagcctgg	agctatagaa	atggatgctg	7080	
catttctccc	cgccgcccag	ggagattagc	gtgttaggca	gttgggagtc	ccagtgctgg	7140	
5	ctgctgcccc	tccctcaagg	agctcaaagg	gcttagacag	caggcagcag	aagcctgtgc	7200
tggtcaccgg	tcccccaggg	agttcagtaa	gcttaggcag	attccagctg	agaggccata	7260	
10	agaatctgta	cattctaggg	ttgggatgct	aggcctcggt	ggcatggat	cgagagtggg	7320
atcttccaat	ccatgagttg	cacagttctt	tggaaaagca	atttccccgg	ctgggtagcc	7380	
15	tgctcgatcg	cagctcccat	tggctggagg	ggaggggggtt	ccctttcccc	gtgtggttct	7440
caggtgggct	cactgctctt	ccttctctct	gtgggtcacg	ccagcctct	agtcaatttt	7500	
gatgagcgaa	tctagataacc	ttgcccgtga	aggactcaca	cacttattat	gtttttttc	7560	
aataggaacc	tctgaacgga	gttgcttcta	gtcggccatc	ttggcccccgc	ctctgaatat	7620	
20	ttcttaatg	ttgtctttcc	tcttaatata	ttctgtagaa	agatttcagt	gcagaagatt	7680
aatacttcaa	acatatcaac	caatatttc	ttttttccc	taaag		7725	

<210> 15

<211> 2914

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic Nucleotide

<400> 15

35

40

45

50

55

gtatgtgtgt ttgcaaagta cttgtaaatg acaaagaact aagaagataa ttataaaagta	60
atcaaaaagta acactattt tgcaaatgta tttatataca aacacaaaaga tcttttagtt	120
5 aaggactcac atgcattcatt acgttcttg ctcaattcct agacgttggg cttggcatgc	180
taattataaa cagatcacgt cattctcaga aatctctaac tgctcattga cactttatgg	240
aaattgtttg atcataggct catgcaacca gtattaactt aatatcagtt ttgtttaaaaa	300
10 agcttagctg atgtttaatg ttaaataatg atggcatgta aattcctgat gataatttgc	360
ttagcaagg tgaataactct ctagtgagaa atggtgatga agtagatatt tctcatactg	420
15 taaaattagg tcaggttctg aaatggtctg aagtgttagag gtcacacagg attctgtatt	480
cattggaaag attacagttt gcaatgtgtt cccagggact gaaaacacac cgtcgatgaa	540
aaccagccac tcatgaacag cctcagacct ggccagtacg gggagcacgt gaaccataac	600
20 tggcttagaa ggactgattt catgccaact tgaggggaga attccaaatt ccaaagacac	660
tcctctcaca ggactatgaa accatctttt aagaagttcc aaggacaaaa gtcacttcca	720
25 taattatagt cctggcaact tgatcttag atctatttt gcttcatctg gctctggcat	780
tcccataacc ttaaaaaatg ttccctgttca tactagagaa ttcccttggc ccttatttct	840

30

35

40

45

50

55

EP 2 881 402 B1

	aattgaaacc tccttgaagt ttctgttgct gctttcatg cagagtgaaa tacattctaa	900
5	cctgcagaac tgtcttggtg gtttgtact gtaatgatgt tcatcaatca ggtcacacat	960
	caggaaaa cttaggaccc tcattgtgt taccctgagt aacacctaa gtgctactaa	1020
10	aatgactcca tctaaatact ttgcataactc cttgctccag gtctccactg tcaggacata	1080
	gactatagga tgactgaatg attgttgtaa cttcagtgtc taaaataag tccttcagtc	1140
15	aggacactct agttagactc tgtgtactca ctgatgggt agtggaaatg caaagtgcata	1200
	gaacttggga gttgaacaag ccttattatgt ttccaagggt tgccacaata aaggaccacc	1260
20	aactgggtgg cttgaaacag tagacattta ttcttacagc tctagaggtt agaagtctga	1320
	aaccaacgta tcagcgggac tgcttgcct gatggttcta gggcagaatc catcttgcc	1380
25	tcttagcttc tggcggttac tggcagtcct tggattcct tggctcgtag gtgcataact	1440
	gtcatcatca cctcctgcat cacaagggtt tctctgtgtc caaattccc tcttcttatg	1500
30	caagtgcag tcattggatt agggccacc ctaaactact atgacctcat cttaacttga	1560
	ttacatttgt caagatctta tttctaaaca aggtcacatt aaaatattct gagtgggtat	1620
35	gaattttggg aggacatgac tcaatccagt acacaaacca tggtaaatg ctgttctt	1680
	tcctttttt aacttaagtt tcctcatctg taaaatggag atgataatat ctatcttac	1740
40	tcttaagct gttgtggact cagtgaatta aaacaacgtt atgtaaagcc ccagtagt	1800
	atgttgtaaa tagaagggtgc tcaaccaaca tcagaattct tcttcttt ctcaatggcc	1860
45	attgtgtaga gccacttcac aaattctcaa gggcctctt ctgttggatc agagttgtt	1920
	ggtaaacag tgaaatggcc aatgctaaag gtgagacgtc aaaaaatgtg taaaacact	1980
50	ctgtcctaatt gctttgtca ggatggtaat taaaggacc ctcagctccg gggAACAGCT	2040
	gtgaccaact ctgctgcct gctgctcccg atgttcttac ctttccctg cctcttatga	2100
55	ggcccgccct tcactctctg ttggcttca gaaggatgag tcaattagca ggaatagaac	2160
	cagattctcc cacatatccc taagcttacc gtggattggc accaagtccct aaaactattg	2220
	cggctctgaaa agtttcagac ctgaaatatt cttcattgtt agagaagaca taatggaa	2280
	ccttgagctt gccttgcattt attctgtaaa aagtcattcc agttatgtct tttgaaccca	2340
	gcccttgcgc tccttccatg tttcaaatga aaaacaattt gattgacttt gaggtggat	2400
	gtaggtcaat aaaaaaggaa gcaacgagcc tcagaatctc agatataatg ataactttgg	2460
	tagctgaact gtcacactt ccttatcaat tttgtattct gtatttatt gaaatatggc	2520
	ataagtaaac tacaataat gtaaaagact gaaaattgag aaaatggaaa ctcccagtt	2580
	aaaaatcatg gaataattgt cttataggtt tggaattctg gagaaagttt acccatgctg	2640
	ttagtatagg aaaaaggatc tcagctctt cttcaccact gattactcac agtttcttg	2700
	gtgggctgag ttaattggct ccatgcctca cttaggatcac tataaaacca tgctgttagc	2760

EP 2 881 402 B1

atctgtgttg ccagattatg ggagaggaat gaggtcaagg gtaaattgtg ccaaaggaca 2820
ctctctggcg ttcagtcact aagaagatct atgaacaact agaaataaca ggtatattgt 2880
5 catgtatatt ttctgtattt attattttt gcag 2914

10 <210> 16

<211> 3030

<212> DNA

10 <213> Artificial Sequence

15 <220>

<223> Synthetic Nucleotide

20 <400> 16

25

30

35

40

45

50

55

5	atgtcgccgg gcggtccatg cccagcagca gccggagggg gcccaggggg cgccctcctgc	60
	tccgtgggg cccctggcgg ggtatccatg ttccggtggc tggaggtgct ggagaaggag	120
10	ttcgacaaag cttttgtgga tgtggatctg ctcctggag agatcgatcc agaccaagcg	180
	gacatcactt atgagggcgc acagaagatg accagcctga gctcctgctt tgcacagctt	240
	tgccacaaag cccagtctgt gtctcaaattc aaccacaagc tggaggcaca gttggtggat	300
15	ctgaaatctg aactgacaga aacccaagca gagaaagttg tttggagaa agaagtacat	360
	gatcagctt tacagctgca ctctattcag ctgcagcttc atgctaaaac tggtaaagt	420
	gctgactctg gtaccattaa ggcaaaattt gaaagagagc ttgaggcaaa caaaaaagaa	480
20	aaaatgaaag aagcacaact tgaagctgaa gtgaaattgt tgagaaaaga gaatgaagcc	540
	cttcgttagac atatacgctgt tctccaggct gaagtatatg gggcgagact agctgccaag	600
	tacttggata aggaactggc aggaagggtc caacagatac aattgctagg acgagatatg	660
	aagggacctg ctcatgataa gcttttggaaac caattagaag ctgaaataca tttgcattgt	720
25	cacaaaactg tgatccgagc ctgcagagga cgtaatgact tgaaacgacc aatgcaagca	780
	ccaccaggcc atgatcaaga ttccctaaag aaaagccaag gtgttggtcc aattagaaaa	840
	gttctcctcc ttaaggaaga tcatgaaggc cttggcattt caattacagg tggaaagaa	900
30	catgggttcc caatcctcat ctctgagatc catccggggc aacctgctga tagatgcgg	960
	gggctgcacg ttggggatgc tattttggca gtcaacggag ttaacctaag ggacacaaag	1020
	cataaagaag ctgttaactat tctttctcag cagagaggag agattgaatt tgaagtagtt	1080
35	tatgtggctc ctgaagtggc ttctgtatgat gaaaacgtag agtatgaaga tgagagtgaa	1140
	catcggttacc gtttgtacct tgatgagttt gaaggagggtg gtaaccctgg tgctagttgc	1200
40	aaagacacaa gtggggaaat caaagtatta caagctggag tcccaaataa accaggcatt	1260
	cccaaattac tagaagggag taaaaattca atacagtggg agaaagctga agataatgg	1320
	tgtagaatta catactatac ctttgagata agaaagagca cttcaaataa tttacagaac	1380

45

50

55

	cagaatttaa ggtggaagat gacatttaat ggatcctgca gtagtgttt cacatggaag	1440
5	tccaaaaacc tgaaaggaat attcagttc agagtagtag ctgcaaataa tctagggtt	1500
	ggtgaatata gtggaatcag tgagaatatt atattagtt gagatgattt ttggatacca	1560
10	gaaacaagtt tcatacttac tattatagtt ggaatatttc tggttgttac aatcccactg	1620
	acctttgtct ggcatalogaag attaaagaat caaaaaagtg ccaaggaagg ggtgacagtg	1680
15	cttataaacg aagacaaaga gttggctgag ctgcgaggc tggcagccgg agtaggcctg	1740
	gctaatgcct gctatgcaat acatactctt ccaacccaag aggagattga aaatcttcct	1800
20	gccttcctc gggaaaaact gactctgcgt ctcttgctgg gaagtggagc ctttggagaa	1860
	gtgtatgaag gaacagcagt ggacatctt ggagttggaa gtggagaaat caaagtagca	1920
25	gtgaagactt tgaagaaggg ttccacagac caggagaaga ttgaattcct gaaggaggca	1980
	catctgatga gcaaatttaa tcatcccaac attctgaagc agcttggagt ttgtctgctg	2040
	aatgaacccc aatacattat cctggaactg atggagggag gagaccttct tacttattt	2100
30	cgtaaagccc ggatggcaac gtttatggt ccttactca ccttgggtga ccttgttagac	2160
	ctgtgtgtat atatttcaaa aggctgtgtc tacttggAAC ggatgcattt cattcacagg	2220
	gatctggcag ctagaaattt cttgtttcc gtgaaagact ataccagtcc acggatagtg	2280
35	aagattggag actttggact cgccagagac atctataaaa atgattacta tagaaagaga	2340
	ggggaaggcc tgctcccagt tcggtgatg gctccagaaa gtttgcgttga tggaatctt	2400
	actactcaat ctgatgtatg gtctttggaa attctgattt gggagatttt aactcttggt	2460
40	catcagcctt atccagctca ttccaacctt gatgtgttAA actatgtgca aacaggagg	2520
	agactggagc caccaagaaa ttgtcctgtat gatctgtggAA atttaatgac ccagtgtgg	2580
	gctcaagaac ccgaccaaag acctactttt catagaatttC aggaccaact tcagttattt	2640
45	agaaattttt tcttaaatag catttataag tccagagatg aagcaaacaa cagtggatgc	2700
	ataaatgaaa gctttgaagg tgaagatggc gatgtgattt gtttgcatttC agatgacatt	2760
	atgccagttt cttaatggaa aacgaagaac cgagaagggt taaactatat ggtacttgct	2820
	acagaatgtg gccaaaggta agaaaaagtct gagggtcctc taggctccca ggaatctgaa	2880
50	tcttggatgc tgagggaaaga agagaaggaa ccacatgcag acaaagattt ctgccaagaa	2940
	aaacaagtgg cttaactgccc ttctggcaag cctgaaggcc tgaactatgc ctgtctcact	3000
	cacagtggat atggagatgg gtctgattaa	3030
55	<210> 17	
	<211> 1009	
	<212> PRT	
	<213> Artificial Sequence	

<220>
<223> Synthetic Peptide

<400> 17

5

10

15

20

25

30

35

40

45

50

55

Met	Ser	Ala	Gly	Gly	Pro	Cys	Pro	Ala	Ala	Ala	Gly	Gly	Gly	Pro	Gly
1				5				10						15	
5															
Gly	Ala	Ser	Cys	Ser	Val	Gly	Ala	Pro	Gly	Gly	Val	Ser	Met	Phe	Arg
				20				25					30		
10															
Trp	Leu	Glu	Val	Leu	Glu	Lys	Glu	Phe	Asp	Lys	Ala	Phe	Val	Asp	Val
				35			40				45				
15															
Asp	Leu	Leu	Leu	Gly	Glu	Ile	Asp	Pro	Asp	Gln	Ala	Asp	Ile	Thr	Tyr
				50			55				60				
20															
Glu	Gly	Arg	Gln	Lys	Met	Thr	Ser	Leu	Ser	Ser	Cys	Phe	Ala	Gln	Leu
	65				70				75				80		
25															
Cys	His	Lys	Ala	Gln	Ser	Val	Ser	Gln	Ile	Asn	His	Lys	Leu	Glu	Ala
				85				90				95			
30															
Gln	Leu	Val	Asp	Leu	Lys	Ser	Glu	Leu	Thr	Glu	Thr	Gln	Ala	Glu	Lys
				100			105			110					
35															
Val	Val	Leu	Glu	Lys	Glu	Val	His	Asp	Gln	Leu	Leu	Gln	Leu	His	Ser
	115				120					125					
40															
Ile	Gln	Leu	Gln	Leu	His	Ala	Lys	Thr	Gly	Gln	Ser	Ala	Asp	Ser	Gly
	130				135				140						
45															
Thr	Ile	Lys	Ala	Lys	Leu	Glu	Arg	Glu	Leu	Glu	Ala	Asn	Lys	Lys	Glu
	145				150			155			160				
50															
Lys	Met	Lys	Glu	Ala	Gln	Leu	Glu	Ala	Glu	Val	Lys	Leu	Leu	Arg	Lys
				165			170			175					
55															
Glu	Asn	Glu	Ala	Leu	Arg	Arg	His	Ile	Ala	Val	Leu	Gln	Ala	Glu	Val
	180				185				190						
Tyr	Gly	Ala	Arg	Leu	Ala	Ala	Lys	Tyr	Leu	Asp	Lys	Glu	Leu	Ala	Gly
	195				200				205						
60															
Arg	Val	Gln	Gln	Ile	Gln	Leu	Leu	Gly	Arg	Asp	Met	Lys	Gly	Pro	Ala
				210			215				220				
65															
His	Asp	Lys	Leu	Trp	Asn	Gln	Leu	Glu	Ala	Glu	Ile	His	Leu	His	Arg
	225				230			235			240				

His Lys Thr Val Ile Arg Ala Cys Arg Gly Arg Asn Asp Leu Lys Arg
245 250 255

5 Pro Met Gln Ala Pro Pro Gly His Asp Gln Asp Ser Leu Lys Lys Ser
260 265 270

10 Gln Gly Val Gly Pro Ile Arg Lys Val Leu Leu Lys Glu Asp His
275 280 285

Glu Gly Leu Gly Ile Ser Ile Thr Gly Gly Lys Glu His Gly Val Pro
290 295 300

15 Ile Leu Ile Ser Glu Ile His Pro Gly Gln Pro Ala Asp Arg Cys Gly
305 310 315 320

20 Gly Leu His Val Gly Asp Ala Ile Leu Ala Val Asn Gly Val Asn Leu
325 330 335

25 Arg Asp Thr Lys His Lys Glu Ala Val Thr Ile Leu Ser Gln Gln Arg
340 345 350

Gly Glu Ile Glu Phe Glu Val Val Tyr Val Ala Pro Glu Val Asp Ser
355 360 365

30 Asp Asp Glu Asn Val Glu Tyr Glu Asp Glu Ser Gly His Arg Tyr Arg
370 375 380

35 Leu Tyr Leu Asp Glu Leu Glu Gly Gly Asn Pro Gly Ala Ser Cys
385 390 395 400

40 Lys Asp Thr Ser Gly Glu Ile Lys Val Leu Gln Ala Gly Val Pro Asn
405 410 415

45 Lys Pro Gly Ile Pro Lys Leu Leu Glu Gly Ser Lys Asn Ser Ile Gln
420 425 430

50 Trp Glu Lys Ala Glu Asp Asn Gly Cys Arg Ile Thr Tyr Tyr Ile Leu
435 440 445

Glu Ile Arg Lys Ser Thr Ser Asn Asn Leu Gln Asn Gln Asn Leu Arg
450 455 460

55 Trp Lys Met Thr Phe Asn Gly Ser Cys Ser Ser Val Cys Thr Trp Lys
465 470 475 480

Ser Lys Asn Leu Lys Gly Ile Phe Gln Phe Arg Val Val Ala Ala Asn
485 490 495

	Asn Leu Gly Phe Gly Glu Tyr Ser Gly Ile Ser Glu Asn Ile Ile Leu			
	500	505	510	
5	Val Gly Asp Asp Phe Trp Ile Pro Glu Thr Ser Phe Ile Leu Thr Ile			
	515	520	525	
10	Ile Val Gly Ile Phe Leu Val Val Thr Ile Pro Leu Thr Phe Val Trp			
	530	535	540	
	His Arg Arg Leu Lys Asn Gln Lys Ser Ala Lys Glu Gly Val Thr Val			
	545	550	555	560
15	Leu Ile Asn Glu Asp Lys Glu Leu Ala Glu Leu Arg Gly Leu Ala Ala			
	565	570	575	
20	Gly Val Gly Leu Ala Asn Ala Cys Tyr Ala Ile His Thr Leu Pro Thr			
	580	585	590	
25	Gln Glu Glu Ile Glu Asn Leu Pro Ala Phe Pro Arg Glu Lys Leu Thr			
	595	600	605	
	Leu Arg Leu Leu Leu Gly Ser Gly Ala Phe Gly Glu Val Tyr Glu Gly			
	610	615	620	
30	Thr Ala Val Asp Ile Leu Gly Val Gly Ser Gly Glu Ile Lys Val Ala			
	625	630	635	640
35	Val Lys Thr Leu Lys Lys Gly Ser Thr Asp Gln Glu Lys Ile Glu Phe			
	645	650	655	
	Leu Lys Glu Ala His Leu Met Ser Lys Phe Asn His Pro Asn Ile Leu			
	660	665	670	
40	Lys Gln Leu Gly Val Cys Leu Leu Asn Glu Pro Gln Tyr Ile Ile Leu			
	675	680	685	
45	Glu Leu Met Glu Gly Gly Asp Leu Leu Thr Tyr Leu Arg Lys Ala Arg			
	690	695	700	
50	Met Ala Thr Phe Tyr Gly Pro Leu Leu Thr Leu Val Asp Leu Val Asp			
	705	710	715	720
	Leu Cys Val Asp Ile Ser Lys Gly Cys Val Tyr Leu Glu Arg Met His			
	725	730	735	
55	Phe Ile His Arg Asp Leu Ala Ala Arg Asn Cys Leu Val Ser Val Lys			

EP 2 881 402 B1

740

745

750

5 Asp Tyr Thr Ser Pro Arg Ile Val Lys Ile Gly Asp Phe Gly Leu Ala
 755 760 765

10 Arg Asp Ile Tyr Lys Asn Asp Tyr Tyr Arg Lys Arg Gly Glu Gly Leu
 770 775 780

15 Leu Pro Val Arg Trp Met Ala Pro Glu Ser Leu Met Asp Gly Ile Phe
 785 790 795 800

20 Thr Thr Gln Ser Asp Val Trp Ser Phe Gly Ile Leu Ile Trp Glu Ile
 805 810 815

25 Leu Thr Leu Gly His Gln Pro Tyr Pro Ala His Ser Asn Leu Asp Val
 820 825 830

30 Leu Asn Tyr Val Gln Thr Gly Gly Arg Leu Glu Pro Pro Arg Asn Cys
 835 840 845

35 Pro Asp Asp Leu Trp Asn Leu Met Thr Gln Cys Trp Ala Gln Glu Pro
 850 855 860

40 Asp Gln Arg Pro Thr Phe His Arg Ile Gln Asp Gln Leu Gln Leu Phe
 865 870 875 880

45 Arg Asn Phe Phe Leu Asn Ser Ile Tyr Lys Ser Arg Asp Glu Ala Asn
 885 890 895

50 Asn Ser Gly Val Ile Asn Glu Ser Phe Glu Gly Glu Asp Gly Asp Val
 900 905 910

55 Ile Cys Leu Asn Ser Asp Asp Ile Met Pro Val Ala Leu Met Glu Thr
 915 920 925

60 Lys Asn Arg Glu Gly Leu Asn Tyr Met Val Leu Ala Thr Glu Cys Gly
 930 935 940

65 Gln Gly Glu Glu Lys Ser Glu Gly Pro Leu Gly Ser Gln Glu Ser Glu
 945 950 955 960

70 Ser Cys Gly Leu Arg Lys Glu Glu Lys Glu Pro His Ala Asp Lys Asp
 965 970 975

75 Phe Cys Gln Glu Lys Gln Val Ala Tyr Cys Pro Ser Gly Lys Pro Glu
 980 985 990

EP 2 881 402 B1

Gly Leu Asn Tyr Ala Cys Leu Thr His Ser Gly Tyr Gly Asp Gly Ser
995 1000 1005

5 Asp

<210> 18

<211> 2175

<212> DNA

10 <213> Artificial Sequence

<220>

<223> Synthetic Nucleotide

15 <400> 18

20

25

30

35

40

45

50

55

EP 2 881 402 B1

	atggctccct	ggcctgaatt	gggagatgcc	cagcccaacc	ccgataagta	cctcgaaggg	60
	gccgcaggc	agcagcccac	tgcccctgat	aaaagcaaag	agaccaacaa	aacagataac	120
5	actgaggcac	ctgtaaccaa	gattgaactt	ctgcccgtcct	actccacggc	tacactgata	180
	gatgagccca	ctgaggtgga	tgaccctgg	aacctaccca	ctcttcagga	ctcggggatc	240
10	aagtggtcag	agagagacac	caaagggaaag	attctctgtt	tattccaagg	gattgggaga	300
	ttgattttac	ttctcggatt	tctctacttt	ttcgtgtgct	ccctggatat	tcttagtgc	360
15	gccttccagc	tgggtggagc	tggagtccca	aataaaccag	gcattccaa	attactagaa	420
	gggagtaaaa	attcaataca	gtgggagaaa	gctgaagata	atggatgtag	aattacatac	480
20	tatatccttgc	agataagaaa	gagcacttca	aataatttac	agaaccagaa	tttaaggtgg	540
	aagatgacat	ttaatggatc	ctgcagtagt	gtttgcacat	ggaagtccaa	aaacctgaaa	600
25	ggaatatttc	agttcagagt	agtagctgca	aataatctag	gttttgtga	atatagtgga	660
	atcagtgaga	atattatatt	agttggagat	gatttttgg	taccagaaac	aagtttcata	720
30	cttactatta	tagttggaaat	atttctggtt	gttacaatcc	cactgacctt	tgtctggcat	780
	agaagattaa	agaatcaaaa	aagtgc当地	gaagggggtga	cagtgc当地	aaacgaagac	840
35	aaagagttgg	ctgagctgcg	aggtctggca	gccggagtag	gcctggctaa	tgcctgctat	900
	gcaatacata	ctcttccaac	ccaagaggag	attgaaaatc	ttcctgc当地	ccctcggaa	960
40	aaactgactc	tgcgtctctt	gctgggaagt	ggagccttgc	gagaagtgt	tgaaggaaca	1020
	gcagtggaca	tcttaggagt	tggaagtgg	gaaatcaaag	tagcagtgaa	gactttgaag	1080
45	aagggttcca	cagaccagga	gaagattgaa	ttcctgaagg	aggcacatct	gatgagcaaa	1140
	tttaatcatc	ccaacattct	gaagcagctt	ggagtttgc	tgctgaatga	accccaatac	1200
50	attatcctgg	aactgatgg	gggaggagac	cttcttactt	atttgc当地	agcccgatg	1260
	gcaacgtttt	atggtc当地	actcaccttgc	gttgc当地	tagacctgt	tgttagatatt	1320
55	tcaaaaggct	gtgtctactt	ggaacggatg	catttcattc	acagggatct	ggcagctaga	1380

50

55

	aattgccttg tttccgtgaa agactatacc agtccacgga tagtgaagat tggagacttt	1440
	ggactcgcca gagacatcta taaaaatgat tactatagaa agagagggga aggcctgctc	1500
5	ccagttcggt ggatggctcc agaaagttt atggatggaa tcttcactac tcaatctgat	1560
	gtatggtctt ttggaattct gatggggag attttaactc ttggtcatca gccttatcca	1620
10	gctcattcca accttgcgt gttaaactat gtgcaaacag gagggagact ggagccacca	1680
	agaaattgtc ctgatgatct gtggaattta atgacccagt gctgggctca agaaccggac	1740
	caaagaccta ctttcatac aattcaggac caacttcagt tattcagaaa tttttctta	1800
15	aatagcattt ataagtccag agatgaagca aacaacagtg gagtcataaa tgaaagctt	1860
	gaaggtgaag atggcgatgt gatgggtttt aattcagatg acattatgcc agttgctta	1920
	atggaaacga agaaccgaga agggtaaac tatatggtac ttgctacaga atgtggccaa	1980
20	ggtgaagaaa agtctgagg tcctctaggc tcccaggaat ctgaatctt tggtctgagg	2040
	aaagaagaga aggaaccaca tgcagacaaa gatttctgcc aagaaaaaca agtggcttac	2100
	tgcccttctg gcaaggctga aggcctgaac tatgcctgtc tcactcacag tggatatgga	2160
25	gatgggtctg attaa	2175

<210> 19

<211> 724

30 <212> PRT

<213> Artificial Sequence

35 <220>

<223> Synthetic Peptide

35 <400> 19

Met	Ala	Pro	Trp	Pro	Glu	Leu	Gly	Asp	Ala	Gln	Pro	Asn	Pro	Asp	Lys
1				5					10				15		

40

Tyr	Leu	Glu	Gly	Ala	Ala	Gly	Gln	Gln	Pro	Thr	Ala	Pro	Asp	Lys	Ser
					20			25					30		

45

Lys	Glu	Thr	Asn	Lys	Thr	Asp	Asn	Thr	Glu	Ala	Pro	Val	Thr	Lys	Ile
				35				40					45		

50

Glu	Leu	Leu	Pro	Ser	Tyr	Ser	Thr	Ala	Thr	Leu	Ile	Asp	Glu	Pro	Thr
						55				60					

55

Glu	Val	Asp	Asp	Pro	Trp	Asn	Leu	Pro	Thr	Leu	Gln	Asp	Ser	Gly	Ile
					65			70		75				80	

Lys	Trp	Ser	Glu	Arg	Asp	Thr	Lys	Gly	Lys	Ile	Leu	Cys	Phe	Phe	Gln
						85			90				95		

Gly Ile Gly Arg Leu Ile Leu Leu Gly Phe Leu Tyr Phe Phe Val
 100 105 110

5 Cys Ser Leu Asp Ile Leu Ser Ser Ala Phe Gln Leu Val Gly Ala Gly
 115 120 125

10 Val Pro Asn Lys Pro Gly Ile Pro Lys Leu Leu Glu Gly Ser Lys Asn
 130 135 140

Ser Ile Gln Trp Glu Lys Ala Glu Asp Asn Gly Cys Arg Ile Thr Tyr
 145 150 155 160

15 Tyr Ile Leu Glu Ile Arg Lys Ser Thr Ser Asn Asn Leu Gln Asn Gln
 165 170 175

20 Asn Leu Arg Trp Lys Met Thr Phe Asn Gly Ser Cys Ser Ser Val Cys
 180 185 190

Thr Trp Lys Ser Lys Asn Leu Lys Gly Ile Phe Gln Phe Arg Val Val
 195 200 205

25 Ala Ala Asn Asn Leu Gly Phe Gly Glu Tyr Ser Gly Ile Ser Glu Asn
 210 215 220

30 Ile Ile Leu Val Gly Asp Asp Phe Trp Ile Pro Glu Thr Ser Phe Ile
 225 230 235 240

35 Leu Thr Ile Ile Val Gly Ile Phe Leu Val Val Thr Ile Pro Leu Thr
 245 250 255

Phe Val Trp His Arg Arg Leu Lys Asn Gln Lys Ser Ala Lys Glu Gly
 260 265 270

40 Val Thr Val Leu Ile Asn Glu Asp Lys Glu Leu Ala Glu Leu Arg Gly
 275 280 285

45 Leu Ala Ala Gly Val Gly Leu Ala Asn Ala Cys Tyr Ala Ile His Thr
 290 295 300

50 Leu Pro Thr Gln Glu Glu Ile Glu Asn Leu Pro Ala Phe Pro Arg Glu
 305 310 315 320

Lys Leu Thr Leu Arg Leu Leu Leu Gly Ser Gly Ala Phe Gly Glu Val
 325 330 335

55 Tyr Glu Gly Thr Ala Val Asp Ile Leu Gly Val Gly Ser Gly Glu Ile
 340 345 350

EP 2 881 402 B1

Lys Val Ala Val Lys Thr Leu Lys Lys Gly Ser Thr Asp Gln Glu Lys
 355 360 365

5 Ile Glu Phe Leu Lys Glu Ala His Leu Met Ser Lys Phe Asn His Pro
 370 375 380

10 Asn Ile Leu Lys Gln Leu Gly Val Cys Leu Leu Asn Glu Pro Gln Tyr
 385 390 395 400

15 Ile Ile Leu Glu Leu Met Glu Gly Asp Leu Leu Thr Tyr Leu Arg
 405 410 415

20 Lys Ala Arg Met Ala Thr Phe Tyr Gly Pro Leu Leu Thr Leu Val Asp
 420 425 430

25 Leu Val Asp Leu Cys Val Asp Ile Ser Lys Gly Cys Val Tyr Leu Glu
 435 440 445

30 Arg Met His Phe Ile His Arg Asp Leu Ala Ala Arg Asn Cys Leu Val
 450 455 460

35 Ser Val Lys Asp Tyr Thr Ser Pro Arg Ile Val Lys Ile Gly Asp Phe
 465 470 475 480

40 Gly Leu Ala Arg Asp Ile Tyr Lys Asn Asp Tyr Tyr Arg Lys Arg Gly
 485 490 495

45 Glu Gly Leu Leu Pro Val Arg Trp Met Ala Pro Glu Ser Leu Met Asp
 500 505 510

50 Gly Ile Phe Thr Thr Gln Ser Asp Val Trp Ser Phe Gly Ile Leu Ile
 515 520 525

55 Trp Glu Ile Leu Thr Leu Gly His Gln Pro Tyr Pro Ala His Ser Asn
 530 535 540

60 Leu Asp Val Leu Asn Tyr Val Gln Thr Gly Gly Arg Leu Glu Pro Pro
 545 550 555 560

65 Arg Asn Cys Pro Asp Asp Leu Trp Asn Leu Met Thr Gln Cys Trp Ala
 565 570 575

70 Gln Glu Pro Asp Gln Arg Pro Thr Phe His Arg Ile Gln Asp Gln Leu
 580 585 590

75 Gln Leu Phe Arg Asn Phe Phe Leu Asn Ser Ile Tyr Lys Ser Arg Asp
 595 600 605

Glu Ala Asn Asn Ser Gly Val Ile Asn Glu Ser Phe Glu Gly Glu Asp
 610 615 620

5 Gly Asp Val Ile Cys Leu Asn Ser Asp Asp Ile Met Pro Val Ala Leu
 625 630 635 640

10 Met Glu Thr Lys Asn Arg Glu Gly Leu Asn Tyr Met Val Leu Ala Thr
 645 650 655

15 Glu Cys Gly Gln Gly Glu Glu Lys Ser Glu Gly Pro Leu Gly Ser Gln
 660 665 670

20 Glu Ser Glu Ser Cys Gly Leu Arg Lys Glu Glu Lys Glu Pro His Ala
 675 680 685

25 Asp Lys Asp Phe Cys Gln Glu Lys Gln Val Ala Tyr Cys Pro Ser Gly
 690 695 700

Lys Pro Glu Gly Leu Asn Tyr Ala Cys Leu Thr His Ser Gly Tyr Gly
 705 710 715 720

Asp Gly Ser Asp

30 <210> 20

<211> 1866

<212> DNA

<213> Artificial Sequence

35 <220>

<223> Synthetic Nucleotide

<400> 20

40 atggctccct ggcctgaatt gggagatgcc cagcccaacc ccgataagta cctcgaaggg 60

gccgcaggtc agcagccac tgcccctgat aaaagcaaag agaccaacaa aacagataac 120

actgagggcac ctgtAACCAA gattgaactt ctgcgcgtcct actccacggc tacactgata 180

45 gatgagccca ctgaggtgga tgaccctgg aacctaccca ctcttcagga ctcggggatc 240

aagtggtcag agagagacac caaagggaag attctctgtt tcttccaagg gattgggaga 300

50 ttgattttac ttctcggatt tctctacttt ttcgtgtgct ccctggatat tcttagtagc 360

gccttccagc tgggtggaga tgattttgg ataccagaaa caagttcat acttactatt 420

atagttggaa tatttctggc tgttacaatc ccactgacct ttgtctggca tagaagatta 480

55 aagaatcaaa aaagtgccaa ggaagggtg acagtgccta taaacgaaga caaagagttg 540

gctgagctgc gaggtctggc agccggagta ggcctggcta atgcctgcta tgcaatacat 600

	actcttccaa cccaaaggaa gattgaaaat cttcctgcct tccctcgaaa aaaactgact	660
5	ctgcgtctct tgctggaaag tggagcctt ggagaagtgt atgaaggaac agcagtggac	720
	atcttaggag ttggaaagtgg agaaatcaa gtacagtga agactttgaa gaagggttcc	780
10	acagaccagg agaagattga attcctgaag gaggcacatc tgatgagcaa atttaatcat	840
	cccaacattc tgaaggcagct tggagttgt ctgctgaatg aaccccaata cattatcctg	900
15	gaactgatgg agggaggaga cttcttact tatttgcgt aagccggat ggcaacgttt	960
	tatggcctt tactcacctt gttgacctt gtagacctgt gtgtagatat ttcaaaaaggc	1020
20	tgtgtctact tggaaacggat gcatttcatt cacagggatc tggcagctag aaattgcctt	1080
	gttccgtga aagactatac cagtcacgg atagtgaaga ttggagactt tggactcgcc	1140
25	agagacatct ataaaaatga ttactataga aagagagggg aaggcctgct cccagttcgg	1200
	tggatggctc cagaaagttt gatggatgga atcttcacta ctcaatctga tgtatggct	1260
	tttggaaattc tgatttggga gattttaact cttggtcatc agccttatcc agtcattcc	1320
30	aaccttgcgt tgtaaacta tgtcaaaca ggagggagac tggagccacc aagaaattgt	1380
	cctgatgatc tgtggaaattt aatgacccag tgctgggctc aagaacccga ccaaagacct	1440
	acttttcata gaattcagga ccaacttcag ttattcagaa atttttctt aaatagcatt	1500
35	tataagtcca gagatgaagc aaacaacagt ggagtcataa atgaaagctt tgaaggtgaa	1560
	gatggcgatg tgatttggaaat gaattcagat gacattatgc cagttgcttt aatggaaacg	1620
	aagaaccgag aagggttaaa ctatatggta cttgctacag aatgtggcca aggtgaagaa	1680
40	aagtctgagg gtcctctagg ctcccaggaa tctgaatctt gtggctgag gaaagaagag	1740
	aaggaaccac atgcagacaa agatttctgc caagaaaaac aagtggctta ctgcccctct	1800
	ggcaaggctg aaggcctgaa ctatgcctgt ctcactcaca gtggatatgg agatggct	1860
45	gattaa	1866

<210> 21

<211> 621

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic Peptide

50

<400> 21

Met	Ala	Pro	Trp	Pro	Glu	Leu	Gly	Asp	Ala	Gln	Pro	Asn	Pro	Asp	Lys
1				5					10				15		

55

Tyr	Leu	Glu	Gly	Ala	Ala	Gly	Gln	Gln	Pro	Thr	Ala	Pro	Asp	Lys	Ser
				20				25					30		

Lys Glu Thr Asn Lys Thr Asp Asn Thr Glu Ala Pro Val Thr Lys Ile
 35 40 45

5 Glu Leu Leu Pro Ser Tyr Ser Thr Ala Thr Leu Ile Asp Glu Pro Thr
 50 55 60

10 Glu Val Asp Asp Pro Trp Asn Leu Pro Thr Leu Gln Asp Ser Gly Ile
 65 70 75 80

15 Lys Trp Ser Glu Arg Asp Thr Lys Gly Lys Ile Leu Cys Phe Phe Gln
 85 90 95

20 Gly Ile Gly Arg Leu Ile Leu Leu Gly Phe Leu Tyr Phe Phe Val
 100 105 110

25 Cys Ser Leu Asp Ile Leu Ser Ser Ala Phe Gln Leu Val Gly Asp Asp
 115 120 125

30 Phe Trp Ile Pro Glu Thr Ser Phe Ile Leu Thr Ile Ile Val Gly Ile
 130 135 140

35 Phe Leu Val Val Thr Ile Pro Leu Thr Phe Val Trp His Arg Arg Leu
 145 150 155 160

40 Lys Asn Gln Lys Ser Ala Lys Glu Gly Val Thr Val Leu Ile Asn Glu
 165 170 175

45 Asp Lys Glu Leu Ala Glu Leu Arg Gly Leu Ala Ala Gly Val Gly Leu
 180 185 190

50 Ala Asn Ala Cys Tyr Ala Ile His Thr Leu Pro Thr Gln Glu Glu Ile
 195 200 205

55 Glu Asn Leu Pro Ala Phe Pro Arg Glu Lys Leu Thr Leu Arg Leu Leu
 210 215 220

60 Leu Gly Ser Gly Ala Phe Gly Glu Val Tyr Glu Gly Thr Ala Val Asp
 225 230 235 240

65 Ile Leu Gly Val Gly Ser Gly Glu Ile Lys Val Ala Val Lys Thr Leu
 245 250 255

70 Lys Lys Gly Ser Thr Asp Gln Glu Lys Ile Glu Phe Leu Lys Glu Ala
 260 265 270

75 His Leu Met Ser Lys Phe Asn His Pro Asn Ile Leu Lys Gln Leu Gly
 275 280 285

Val Cys Leu Leu Asn Glu Pro Gln Tyr Ile Ile Leu Glu Leu Met Glu
 290 295 300

5 Gly Gly Asp Leu Leu Thr Tyr Leu Arg Lys Ala Arg Met Ala Thr Phe
 305 310 315 320

10 Tyr Gly Pro Leu Leu Thr Leu Val Asp Leu Val Asp Leu Cys Val Asp
 325 330 335

15 Ile Ser Lys Gly Cys Val Tyr Leu Glu Arg Met His Phe Ile His Arg
 340 345 350

20 Asp Leu Ala Ala Arg Asn Cys Leu Val Ser Val Lys Asp Tyr Thr Ser
 355 360 365

25 Pro Arg Ile Val Lys Ile Gly Asp Phe Gly Leu Ala Arg Asp Ile Tyr
 370 375 380

30 Lys Asn Asp Tyr Tyr Arg Lys Arg Gly Glu Gly Leu Leu Pro Val Arg
 385 390 395 400

35 Trp Met Ala Pro Glu Ser Leu Met Asp Gly Ile Phe Thr Thr Gln Ser
 405 410 415

40 Asp Val Trp Ser Phe Gly Ile Leu Ile Trp Glu Ile Leu Thr Leu Gly
 420 425 430

45 His Gln Pro Tyr Pro Ala His Ser Asn Leu Asp Val Leu Asn Tyr Val
 435 440 445

50 Gln Thr Gly Gly Arg Leu Glu Pro Pro Arg Asn Cys Pro Asp Asp Leu
 450 455 460

55 Trp Asn Leu Met Thr Gln Cys Trp Ala Gln Glu Pro Asp Gln Arg Pro
 465 470 475 480

60 Thr Phe His Arg Ile Gln Asp Gln Leu Gln Leu Phe Arg Asn Phe Phe
 485 490 495

65 Leu Asn Ser Ile Tyr Lys Ser Arg Asp Glu Ala Asn Asn Ser Gly Val
 500 505 510

70 Ile Asn Glu Ser Phe Glu Gly Glu Asp Gly Asp Val Ile Cys Leu Asn
 515 520 525

75 Ser Asp Asp Ile Met Pro Val Ala Leu Met Glu Thr Lys Asn Arg Glu
 530 535 540

Gly Leu Asn Tyr Met Val Leu Ala Thr Glu Cys Gly Gln Gly Glu Glu
 545 550 555 560

5 Lys Ser Glu Gly Pro Leu Gly Ser Gln Glu Ser Glu Ser Cys Gly Leu
 565 570 575

10 Arg Lys Glu Glu Lys Glu Pro His Ala Asp Lys Asp Phe Cys Gln Glu
 580 585 590

15 Lys Gln Val Ala Tyr Cys Pro Ser Gly Lys Pro Glu Gly Leu Asn Tyr
 595 600 605

15 Ala Cys Leu Thr His Ser Gly Tyr Gly Asp Gly Ser Asp
 610 615 620

20 <210> 22

20 <211> 1782

20 <212> DNA

20 <213> Artificial Sequence

25 <220>

25 <223> Synthetic Nucleotide

30 <400> 22

30 atggctccct ggcctgaatt gggagatgcc cagcccaacc ccgataagta cctcgaaggg 60
 gccgcaggtc agcagcccac tgcccctgat aaaagcaaaag agaccaacaa aacagataac 120
 actgagggcac ctgtAACCAA gattgaactt ctgccgtcct actccacggc tacactgata 180
 35 gatgagccca ctgaggtgga tgacccctgg aacctaccca ctcttcagga ctcggggatc 240
 aagtggtcag agagagacac caaagggaaag attctctgtt tcttccaagg gattgggaga 300
 ttgattttac ttctcggatt tctctacttt ttcgtgtgct ccctggatat tcttagtagc 360
 40 gccttccagc tgggtggagt ctggcataga agattaaaga atcaaaaaag tgccaaggaa 420
 ggggtgacag tgcttataaa cgaagacaaa gagttggctg agctgcgagg tctggcagcc 480
 45 ggagttaggcc tggctaatgc ctgctatgca atacataactc ttccaaccca agaggagatt 540
 gaaaatcttc ctgccttccc tcggaaaaaa ctgactctgc gtctcttgct gggaaagtgga 600
 gcctttggag aagtgtatga aggaacagca gtggacatct taggagttgg aagtggagaa 660
 50 atcaaagtag cagtgaagac tttgaagaag ggttccacag accaggagaa gattgaattc 720
 ctgaaggagg cacatctgat gagcaaattt aatcatccca acattctgaa gcagcttgaa 780
 gtttgtctgc tgaatgaacc ccaatacatt atcctggAAC tgatggaggg aggagacctt 840
 55 cttacttatt tgcgtaaagc ccggatggca acgttttatg gtccttact caccttggtt 900
 gaccttggtag acctgtgtgt agatattca aaaggctgtg tctacttgaa acggatgcat 960

ttcattcaca	gggatctggc	agctagaaaat	tgccttgtt	ccgtgaaaga	ctataccagt	1020	
ccacggatag	tgaagattgg	agactttgga	ctcgccagag	acatctataa	aatgattac	1080	
5	tatagaaaaga	gaggggaagg	cctgctccca	gttcggtgga	tggctccaga	aagtttgatg	1140
gatggaatct	tcactactca	atctgatgta	tggtctttt	gaattctgat	ttgggagatt	1200	
10	ttaactctt	gtcatcagcc	ttatccagct	cattccaacc	ttgatgtgtt	aaactatgtg	1260
caaacaggag	ggagactgga	gccaccaaga	aattgtcctg	atgatctgtg	gaatttaatg	1320	
15	acccagtgct	gggctcaaga	acccgaccaa	agacctactt	ttcatagaat	tcaggaccaa	1380
cttcagttat	tcagaaattt	tttcttaaat	agcattata	agtccagaga	tgaagcaaac	1440	
aacagtggag	tcataaatga	aagcttgaa	ggtgaagatg	gcgatgtgat	ttgtttgaat	1500	
20	tcagatgaca	ttatgccagt	tgctttaatg	gaaacgaaga	accgagaagg	gttaaactat	1560
atggtacttg	ctacagaatg	tggccaaggt	gaagaaaagt	ctgagggtcc	tctaggctcc	1620	
caggaatctg	aatcttgtgg	tctgaggaaa	gaagagaagg	aaccacatgc	agacaaagat	1680	
25	ttctgccaag	aaaaacaagt	ggcttactgc	ccttctggca	agcctgaagg	cctgaactat	1740
gcctgtctca	ctcacagtgg	atatggagat	gggtctgatt	aa		1782	

<210> 23

<211> 593

30 <212> PRT

<213> Artificial Sequence

<220>

35 <223> Synthetic Peptide

<400> 23

Met	Ala	Pro	Trp	Pro	Glu	Leu	Gly	Asp	Ala	Gln	Pro	Asn	Pro	Asp	Lys
1				5					10				15		

40

Tyr	Leu	Glu	Gly	Ala	Ala	Gly	Gln	Gln	Pro	Thr	Ala	Pro	Asp	Lys	Ser
				20				25					30		

45

Lys	Glu	Thr	Asn	Lys	Thr	Asp	Asn	Thr	Glu	Ala	Pro	Val	Thr	Lys	Ile
				35				40					45		

50

Glu	Leu	Leu	Pro	Ser	Tyr	Ser	Thr	Ala	Thr	Leu	Ile	Asp	Glu	Pro	Thr
				50				55			60				

55

Glu	Val	Asp	Asp	Pro	Trp	Asn	Leu	Pro	Thr	Leu	Gln	Asp	Ser	Gly	Ile
				65				70			75			80	

Lys	Trp	Ser	Glu	Arg	Asp	Thr	Lys	Gly	Lys	Ile	Leu	Cys	Phe	Phe	Gln
							85			90			95		

Gly Ile Gly Arg Leu Ile Leu Leu Gly Phe Leu Tyr Phe Phe Val
 100 105 110

5 Cys Ser Leu Asp Ile Leu Ser Ser Ala Phe Gln Leu Val Gly Val Trp
 115 120 125

10 His Arg Arg Leu Lys Asn Gln Lys Ser Ala Lys Glu Gly Val Thr Val
 130 135 140

Leu Ile Asn Glu Asp Lys Glu Leu Ala Glu Leu Arg Gly Leu Ala Ala
 145 150 155 160

15 Gly Val Gly Leu Ala Asn Ala Cys Tyr Ala Ile His Thr Leu Pro Thr
 165 170 175

20 Gln Glu Glu Ile Glu Asn Leu Pro Ala Phe Pro Arg Glu Lys Leu Thr
 180 185 190

25 Leu Arg Leu Leu Gly Ser Gly Ala Phe Gly Glu Val Tyr Glu Gly
 195 200 205

Thr Ala Val Asp Ile Leu Gly Val Gly Ser Gly Glu Ile Lys Val Ala
 210 215 220

30 Val Lys Thr Leu Lys Lys Gly Ser Thr Asp Gln Glu Lys Ile Glu Phe
 225 230 235 240

35 Leu Lys Glu Ala His Leu Met Ser Lys Phe Asn His Pro Asn Ile Leu
 245 250 255

Lys Gln Leu Gly Val Cys Leu Leu Asn Glu Pro Gln Tyr Ile Ile Leu
 260 265 270

40 Glu Leu Met Glu Gly Gly Asp Leu Leu Thr Tyr Leu Arg Lys Ala Arg
 275 280 285

45 Met Ala Thr Phe Tyr Gly Pro Leu Leu Thr Leu Val Asp Leu Val Asp
 290 295 300

50 Leu Cys Val Asp Ile Ser Lys Gly Cys Val Tyr Leu Glu Arg Met His
 305 310 315 320

Phe Ile His Arg Asp Leu Ala Ala Arg Asn Cys Leu Val Ser Val Lys
 325 330 335

55 Asp Tyr Thr Ser Pro Arg Ile Val Lys Ile Gly Asp Phe Gly Leu Ala
 340 345 350

Arg Asp Ile Tyr Lys Asn Asp Tyr Tyr Arg Lys Arg Gly Glu Gly Leu
 355 360 365

5 Leu Pro Val Arg Trp Met Ala Pro Glu Ser Leu Met Asp Gly Ile Phe
 370 375 380

10 Thr Thr Gln Ser Asp Val Trp Ser Phe Gly Ile Leu Ile Trp Glu Ile
 385 390 395 400

Leu Thr Leu Gly His Gln Pro Tyr Pro Ala His Ser Asn Leu Asp Val
 405 410 415

15 Leu Asn Tyr Val Gln Thr Gly Gly Arg Leu Glu Pro Pro Arg Asn Cys
 420 425 430

20 Pro Asp Asp Leu Trp Asn Leu Met Thr Gln Cys Trp Ala Gln Glu Pro
 435 440 445

25 Asp Gln Arg Pro Thr Phe His Arg Ile Gln Asp Gln Leu Gln Leu Phe
 450 455 460

Arg Asn Phe Phe Leu Asn Ser Ile Tyr Lys Ser Arg Asp Glu Ala Asn
 465 470 475 480

30 Asn Ser Gly Val Ile Asn Glu Ser Phe Glu Gly Glu Asp Gly Asp Val
 485 490 495

35 Ile Cys Leu Asn Ser Asp Asp Ile Met Pro Val Ala Leu Met Glu Thr
 500 505 510

40 Lys Asn Arg Glu Gly Leu Asn Tyr Met Val Leu Ala Thr Glu Cys Gly
 515 520 525

Gln Gly Glu Glu Lys Ser Glu Gly Pro Leu Gly Ser Gln Glu Ser Glu
 530 535 540

45 Ser Cys Gly Leu Arg Lys Glu Glu Lys Glu Pro His Ala Asp Lys Asp
 545 550 555 560

50 Phe Cys Gln Glu Lys Gln Val Ala Tyr Cys Pro Ser Gly Lys Pro Glu
 565 570 575

Gly Leu Asn Tyr Ala Cys Leu Thr His Ser Gly Tyr Gly Asp Gly Ser
 580 585 590

55 Asp

<210> 24
 <211> 2112
 <212> DNA
 <213> Artificial Sequence

5 <220>
 <223> Synthetic Nucleotide

10 <400> 24
 atgcacagga ggagaagcag gagctgtcgg gaagatcaga agccagtcat ggatgaccag 60
 cgcgaccta tctccaacaa tgagcaactg cccatgctgg gccggcgccc tggggccccg 120
 15 gagagcaagt gcagccgcgg agccctgtac acaggcttt ccattctggt gactctgctc 180
 ctcgctggcc aggccaccac cgcctacttc ctgtaccagc agcagggccg gctggacaaa 240
 20 ctgacagtca cctcccagaa cctgcagctg gagaacctgc gcatgaagct tcccaagcct 300
 cccaaggctg tgagcaagat gcgcatggcc accccgctgc ttagtgcaggc gctgcccattg 360
 ggagccctgc cccaggggcc catgcagaat gccaccaagt atggcaacat gacagaggac 420
 25 catgtgatgc acctgctcca gaatgctgac cccctgaagg tgtacccgccc actgaagggg 480
 agcttcccg agaacctgag acaccttaag aacaccatgg agaccataga ctggaaggtc 540
 tttgagagct ggatgcacca ttggctcctg tttgaaatga gcaggcactc cttggagcaa 600
 30 aagcccactg acgctccacc gaaagatgat tttggatac cagaaacaag tttcatactt 660
 actattatacg ttggaatatt tctggttgtt acaatcccac tgacctttgt ctggcataga 720
 agattaaaga atcaaaaaaag tgccaaaggaa ggggtgacag tgcttataaa cgaagacaaa 780
 35 gagttggctg agctgcgagg tctggcagcc ggagtaggccc tggctaatgc ctgctatgca 840
 atacataactc ttccaaccca agaggagatt gaaaatcttc ctgccttccc tcgggaaaaaa 900
 40 ctgactctgc gtctcttgct gggaaagtggc gccttggag aagtgtatga aggaacacgca 960
 gtggacatct taggagttgg aagtggagaa atcaaagttag cagtgaagac tttgaagaag 1020
 ggttccacag accaggagaa gattgaattc ctgaaggagg cacatctgat gagcaaattt 1080
 45 aatcatccca acattctgaa gcagcttggc gtttgcctgc tgaatgaacc ccaatacatt 1140
 atcctggAAC tgatggaggg aggagacctt cttacttatt tgcgtaaagc ccggatggca 1200
 acgtttatg gtccttact caccttgggtt gaccttggtag acctgtgtgt agatatttca 1260
 50 aaaggctgtg tctacttggc acggatgcat ttcattcaca gggatctggc agctagaat 1320
 tgccttggtt ccgtgaaaga ctataccgt ccacggatag tgaagattgg agactttggc 1380
 ctcgcacagac acatctataa aaatgattac tatagaaaga gaggggaagg cctgctccca 1440
 gttcggtggc tggctccaga aagttgtatc gatggaatct tcactactca atctgtatgtc 1500
 55 tggcttttgc gaattctgat ttggagatt ttaactcttg gtcacatcagcc ttatccagct 1560

5	cattccaacc ttgatgtgtt aaactatgtg caaacaggag ggagactgga gccaccaaga	1620
	aattgtcctg atgatctgtg gaatttaatg acccagtgtc gggctcaaga acccgaccaa	1680
	agacctactt ttcataagaat tcaggaccaa cttcagttat tcagaaattt tttcttaaat	1740
10	agcatttata agtccagaga tgaagcaaac aacagtggag tcataaatga aagctttgaa	1800
	ggtgaagatg gcgatgtgat ttgttgaat tcagatgaca ttatgccagt tgcttaatg	1860
	gaaacgaaga accgagaagg gttaaactat atggtaacttg ctacagaatg tggccaaggt	1920
15	gaagaaaagt ctgagggtcc tctaggctcc caggaatctg aatcttggg tctgaggaaa	1980
	gaagagaagg aaccacatgc agacaaagat ttctgccaag aaaaacaagt ggcttactgc	2040
	ccttctggca agcctgaagg cctgaactat gcctgtctca ctcacagtgg atatggagat	2100
	gggtctgatt aa	2112
20	<210> 25	
	<211> 700	
	<212> PRT	
	<213> Artificial Sequence	
25	<220>	
	<223> Synthetic Peptide	
	<400> 25	
30	Met His Arg Arg Arg Ser Arg Ser Cys Arg Glu Asp Gln Lys Pro Val	
	1 5 10 15	
35	Met Asp Asp Gln Arg Asp Leu Ile Ser Asp Asp Glu Gln Leu Pro Met	
	20 25 30	
40	Leu Gly Arg Arg Pro Gly Ala Pro Glu Ser Arg Gly Ala Leu Tyr Thr	
	35 40 45	
45	Gly Phe Ser Ile Leu Val Thr Leu Leu Leu Ala Gly Gln Ala Thr Thr	
	50 55 60	
50	Ala Tyr Phe Leu Tyr Gln Gln Gly Arg Leu Asp Lys Leu Thr Val	
	65 70 75 80	
55	Thr Ser Gln Asn Leu Gln Leu Glu Asn Leu Arg Met Lys Leu Pro Lys	
	85 90 95	
55	Pro Pro Lys Pro Val Ser Lys Met Arg Met Ala Thr Pro Leu Leu Met	
	100 105 110	
	Gln Ala Leu Pro Met Gly Ala Leu Pro Gln Gly Pro Met Gln Asn Ala	
	115 120 125	

EP 2 881 402 B1

Thr Lys Tyr Gly Asn Met Thr Glu Asp His Val Met His Leu Leu Gln
 130 135 140

5 Asn Ala Asp Pro Leu Lys Val Tyr Pro Pro Leu Lys Gly Ser Phe Pro
 145 150 155 160

10 Glu Asn Leu Arg His Leu Lys Asn Thr Met Glu Thr Ile Asp Trp Lys
 165 170 175

Val Phe Glu Ser Trp Met His His Trp Leu Leu Phe Glu Met Ser Arg
 180 185 190

15 His Ser Leu Glu Gln Lys Pro Thr Asp Ala Pro Pro Lys Asp Asp Phe
 195 200 205

20 Trp Ile Pro Glu Thr Ser Phe Ile Leu Thr Ile Ile Val Gly Ile Phe
 210 215 220

25 Leu Val Val Thr Ile Pro Leu Thr Phe Val Trp His Arg Arg Leu Lys
 225 230 235 240

Asn Gln Lys Ser Ala Lys Glu Gly Val Thr Val Leu Ile Asn Glu Asp
 245 250 255

30 Lys Glu Leu Ala Glu Leu Arg Gly Leu Ala Ala Gly Val Gly Leu Ala
 260 265 270

35 Asn Ala Cys Tyr Ala Ile His Thr Leu Pro Thr Gln Glu Glu Ile Glu
 275 280 285

Asn Leu Pro Ala Phe Pro Arg Glu Lys Leu Thr Leu Arg Leu Leu Leu
 290 295 300

40 Gly Ser Gly Ala Phe Gly Glu Val Tyr Glu Gly Thr Ala Val Asp Ile
 305 310 315 320

45 Leu Gly Val Gly Ser Gly Glu Ile Lys Val Ala Val Lys Thr Leu Lys
 325 330 335

Lys Gly Ser Thr Asp Gln Glu Lys Ile Glu Phe Leu Lys Glu Ala His
 340 345 350

50 Leu Met Ser Lys Phe Asn His Pro Asn Ile Leu Lys Gln Leu Gly Val
 355 360 365

55 Cys Leu Leu Asn Glu Pro Gln Tyr Ile Ile Leu Glu Leu Met Glu Gly
 370 375 380

EP 2 881 402 B1

Gly Asp Leu Leu Thr Tyr Leu Arg Lys Ala Arg Met Ala Thr Phe Tyr
 385 390 395 400

5 Gly Pro Leu Leu Thr Leu Val Asp Leu Val Asp Leu Cys Val Asp Ile
 405 410 415

10 Ser Lys Gly Cys Val Tyr Leu Glu Arg Met His Phe Ile His Arg Asp
 420 425 430

15 Leu Ala Ala Arg Asn Cys Leu Val Ser Val Lys Asp Tyr Thr Ser Pro
 435 440 445

20 Arg Ile Val Lys Ile Gly Asp Phe Gly Leu Ala Arg Asp Ile Tyr Lys
 450 455 460

25 Asn Asp Tyr Tyr Arg Lys Arg Gly Glu Gly Leu Leu Pro Val Arg Trp
 465 470 475 480

30 Met Ala Pro Glu Ser Leu Met Asp Gly Ile Phe Thr Thr Gln Ser Asp
 485 490 495

35 Val Trp Ser Phe Gly Ile Leu Ile Trp Glu Ile Leu Thr Leu Gly His
 500 505 510

40 Gln Pro Tyr Pro Ala His Ser Asn Leu Asp Val Leu Asn Tyr Val Gln
 515 520 525

45 Thr Gly Gly Arg Leu Glu Pro Pro Arg Asn Cys Pro Asp Asp Leu Trp
 530 535 540

50 Asn Leu Met Thr Asn Cys Trp Ala Gln Glu Pro Asp Gln Arg Pro Thr
 545 550 555 560

55 Phe His Arg Ile Gln Asp Gln Leu Gln Leu Phe Arg Asn Phe Phe Leu
 565 570 575

60 Asn Ser Ile Tyr Lys Ser Arg Asp Glu Ala Asn Asn Ser Gly Val Ile
 580 585 590

65 Asn Glu Ser Phe Glu Gly Glu Asp Gly Asp Val Ile Cys Leu Asn Ser
 595 600 605

70 Asp Asp Ile Met Pro Val Ala Leu Met Glu Thr Lys Asn Arg Glu Gly
 610 615 620

75 Leu Asn Tyr Met Val Leu Ala Thr Glu Cys Gly Gln Gly Glu Glu Lys
 625 630 635 640

Ser Glu Gly Pro Leu Gly Ser Gln Glu Ser Glu Ser Cys Gly Leu Arg
 645 650 655

5 Lys Glu Glu Lys Glu Pro His Ala Asp Lys Lys Phe Cys Gln Glu Lys
 660 665 670

10 Glu Val Ala Tyr Cys Pro Ser Gly Lys Pro Glu Gly Leu Asn Tyr Ala
 675 680 685

Cys Leu Thr His Ser Gly Tyr Gly Asp Gly Ser Asp
 690 695 700

15 <210> 26

<211> 1228

<212> DNA

<213> Artificial Sequence

20 <220>
 <223> Synthetic Nucleotide

25 <400> 26

gtatgttagct ttggccatca ttatggagca cctaggcaaa gggtggcaa cagtaaggag	60
agtgcctatg aattccgcattgccccaaagac agtcatggtt tataccagtt tttctggcat	120
aattattaat aacttcctct tccactctca aatgtgaccc gggatggatg gaaaattatg	180
tggtttaag aaaaatacag aaaaatccat tagttccag tattttgtca tgtagctaa	240
aaacaaatga aagaaggaga aaaatattac attgaagaga atagatggta acatggttgg	300
ttgaccttggaa ggcagtgttt gagaggagag gagtttgag agccttgtgt tacgtggta	360
gccttaagtc aatcttactc catttcagaa gttgtgtat gattgcccac aaaaccttct	420
taagatagat gagtttgaa cttttgtgc cgtcataatt aaggaaaata ttcaagtgtc	480
ttatgcaaag gttcattata ttaggatcta tgcaaaaagg aattaaatga tcataggcct	540
tgctttcaga aatttataat gcaagggtgtaa aaaacaaagg atttgaagta gacacaaagg	600
tgtatctaaat cagctgttta gaggtgactt tcctttgagc aaatactcag catatctgt	660
actcaagatt ctctttaaaa aattgaaagc atttttaaca tagcagcatt ttccccccctt	720
gtagtattcc aagtgagaaa cttggctttt taaagttaac cttatggta tgggggttgat	780
ttttttggtc atagtaaatt ttgttttacg taagatgtca catgtgtgaa atagctaaga	840
gaaaagctta taaaccaga tgcattttt actaatttgc agtagtttt tatacaaatt	900
ggcaatctga agaagttaat acctactaac tttgactcaa caagctacaa taaaagtgtt	960
gaggcaatgc atacacatat atatttttat caaaattaag gtgcctagaa gtggaccatc	1020
atgctctgtc tgggtaaaag gttgtagaat agtaaagtaa agtaattagg aacccaaagt	1080

	tccacatcac cgtgtcacat aaaacacaca atactgcaaa gccatgagat atttcttct	1140
	ctctcaaaca caaataccaa taccaacaca aacttgtaca ccctatatat gtggagggtg	1200
5	gggagacaaa aatgttgcta ttttacag	1228
	<210> 27	
	<211> 24	
	<212> DNA	
10	<213> Artificial Sequence	
	<220>	
	<223> Synthetic Nucleotide Peptide	
15	<400> 27	
	acccttctcg gttctcggtt tcca	24
	<210> 28	
	<211> 24	
20	<212> DNA	
	<213> Artificial Sequence	
	<220>	
	<223> Synthetic Nucleotide	
25	<400> 28	
	tctggcgagt ccaaagtctc caat	24
	<210> 29	
30	<211> 24	
	<212> DNA	
	<213> Artificial Sequence	
	<220>	
35	<223> Synthetic Nucleotide Peptide	
	<400> 29	
	cagcaagaga cgcagagtca gttt	24
40	<210> 30	
	<211> 24	
	<212> DNA	
	<213> Artificial Sequence	
45	<220>	
	<223> Synthetic Nucleotide	
	<400> 30	
50	actggtaaaa gtgctgactc tggt	24
	<210> 31	
	<211> 24	
	<212> DNA	
	<213> Artificial Sequence	
55	<220>	
	<223> Synthetic Nucleotide	

1 <400> 31
 cagaagaga cgcagagtca gttt 24
 5 <210> 32
 <211> 24
 <212> DNA
 <213> Artificial Sequence
 10 <220>
 <223> Synthetic Nucleotide
 <400> 32
 ttggataagg aactggcagg aagg 24
 15 <210> 33
 <211> 24
 <212> DNA
 <213> Artificial Sequence
 20 <220>
 <223> Synthetic Nucleotide
 <400> 33
 accgtcatct agcggagttt cact 24
 25 <210> 34
 <211> 24
 <212> DNA
 <213> Artificial Sequence
 30 <220>
 <223> Synthetic Nucleotide
 <400> 34
 35 agccaaggc tcgttatgt ctgt 24
 <210> 35
 <211> 24
 <212> DNA
 <213> Artificial Sequence
 40 <220>
 <223> Synthetic Nucleotide
 <400> 35
 tctggcgagt ccaaagtctc caat 24
 45 <210> 36
 <211> 20
 <212> DNA
 <213> Artificial Sequence
 50 <220>
 <223> Synthetic Nucleotide
 <400> 36
 tggaaatccc atcaccatct 20
 55

5	<210> 37 <211> 20 <212> DNA <213> Artificial Sequence
10	<220> <223> Synthetic Nucleotide <400> 37 gtcttctggg tggcagtgtat 20
15	<210> 38 <211> 24 <212> DNA <213> Artificial Sequence
20	<220> <223> Synthetic Nucleotide <400> 38 ttggataagg aactggcagg aagg 21
25	<210> 39 <211> 24 <212> DNA <213> Artificial Sequence
30	<220> <223> Synthetic Nucleotide <400> 39 cagcaagaga cgccagagtca gttt 22
35	<210> 40 <211> 24 <212> DNA <213> Artificial Sequence
40	<220> <223> Synthetic Nucleotide <400> 40 tgtggctcct gaagtggatt ctga 24
45	<210> 41 <211> 24 <212> DNA <213> Artificial Sequence
50	<220> <223> Synthetic Nucleotide <400> 41 gcagctcagc caactcttgc tctt 24
55	<210> 42 <211> 20 <212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic Nucleotide

5

<400> 42

atgtcgccgg gcgggtccatg 20

<210> 43

10

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

15

<223> Synthetic Nucleotide

<400> 43

ttaatcagac ccatctccat 20

20

<210> 44

<211> 10

<212> PRT

<213> Artificial Sequence

25

<220>

<223> Synthetic Peptide

<400> 44

30

Glu	Gln	Lys	Leu	Ile	Ser	Glu	Glu	Asp	Leu
1				5				10	

<210> 45

<211> 14

35

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic Peptide

40

<400> 45

45

Ala	Gly	Ala	Gly	Cys	Gly	Gln	Gly	Glu	Glu	Lys	Ser	Glu	Gly
1				5				10					

<210> 46

<211> 14

<212> PRT

50

<213> Artificial Sequence

<220>

<223> Synthetic Peptide

55

<400> 46

Ala	Gly	Ala	Gly	Ser	Gly	Lys	Pro	Glu	Gly	Leu	Asn	Tyr	Ala
1				5				10					

<210> 47
 <211> 14
 <212> PRT
 <213> Artificial Sequence

5

<220>
 <223> Synthetic Peptide

<400> 47

10

Ala Gly Ala Gly Gly Leu Asn Tyr Ala Cys Leu Thr His Ser
 1 5 10

<210> 48
 <211> 14
 <212> PRT
 <213> Artificial Sequence

15

<220>
 <223> Synthetic Peptide

<400> 48

25

Ala Gly Ala Gly Cys Leu Thr His Ser Gly Tyr Gly Asp Gly
 1 5 10

<210> 49
 <211> 14
 <212> PRT
 <213> Artificial Sequence

30

<220>
 <223> Synthetic Peptide

35

<400> 49

Ala Gly Ala Gly Thr His Ser Gly Tyr Gly Asp Gly Ser Asp
 1 5 10

40

<210> 50
 <211> 14
 <212> PRT
 <213> Artificial Sequence

45

<220>
 <223> Synthetic Peptide

<400> 50

50

Ala Gly Ala Gly Glu Lys Ser Glu Gly Pro Leu Gly Ser Gln
 1 5 10

<210> 51
 <211> 14
 <212> PRT
 <213> Artificial Sequence

55

<220>

<223> Synthetic Peptide

<400> 51

5 Ala Gly Ala Gly Pro Leu Gly Ser Gln Glu Ser Glu Ser Cys
 1 5 10

<210> 52

<211> 14

10 <212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic Peptide

15 <400> 52

20 Ala Gly Ala Gly Glu Ser Glu Ser Cys Gly Leu Arg Lys Glu
 1 5 10

<210> 53

<211> 14

25 <212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic Peptide

30 <400> 53

35 Ala Gly Ala Gly Gly Leu Arg Lys Glu Glu Lys Glu Pro His
 1 5 10

<210> 54

<211> 14

40 <212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic Peptide

45 <400> 54

50 Ala Gly Ala Gly Glu Lys Glu Pro His Ala Asp Lys Asp Phe
 1 5 10

<210> 55

<211> 14

55 <212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic Peptide

55 <400> 55

55 Ala Gly Ala Gly Ala Asp Lys Asp Phe Cys Gln Glu Lys Gln
 1 5 10

<210> 56
 <211> 14
 <212> PRT
 <213> Artificial Sequence

5
 <220>
 <223> Synthetic Peptide

<400> 56

10
 Ala Gly Ala Gly Cys Gln Glu Lys Gln Val Ala Tyr Cys Pro
 1 5 10

<210> 57
 <211> 14
 <212> PRT
 <213> Artificial Sequence

15
 <220>
 <223> Synthetic Peptide

<400> 57

20
 Ala Gly Ala Gly Val Ala Tyr Cys Pro Ser Gly Lys Pro Glu
 1 5 10

<210> 58
 <211> 14
 <212> PRT
 <213> Artificial Sequence

25
 <220>
 <223> Synthetic Peptide

30
 <400> 58

Ala Gly Ala Gly Val Ala Tyr Cys Pro Ser Gly Lys Pro Glu
 1 5 10

35
 <210> 59
 <211> 6
 <212> PRT
 <213> Artificial Sequence

40
 <220>
 <223> Synthetic Peptide

<400> 59

45
 Ala Gly Ser Thr Leu Pro
 1 5

<210> 60
 <211> 6
 <212> PRT
 <213> Artificial Sequence

<220>

<223> Synthetic Peptide

<400> 60

5 Leu Gln Val Trp His Arg
1 5

<210> 61

<211> 6

10 <212> PRT
<213> Artificial Sequence

<220>

<223> Synthetic Peptide

15

5400 61

Leu Gln Ala Gly Val Pro
1 5

Claims

25 1. A ROS inhibitor for use in treating cancer in a patient, wherein the cancer is **characterized by** a translocation of the ROS gene or expresses a FIG-ROS polypeptide and the ROS inhibitor is selected from NVP-TAE684 and PF-02341066.

30 2. The ROS inhibitor according to claim 1 for use according to claim 1, wherein the patient has been identified as having a cancer that is **characterized by** a translocation of the ROS gene or that expresses a FIG-ROS polypeptide.

35 3. The ROS inhibitor according to claim 1 or claim 2 for use according to claim 1 or claim 2, wherein the cancer is liver cancer.

40 4. A ROS inhibitor for use in inhibiting proliferation of a cancer cell in a subject, wherein the cell exhibits a translocation of the ROS gene or expresses a FIG-ROS polypeptide and the ROS inhibitor is selected from NVP-TAE684 and PF-02341066.

45 5. The ROS inhibitor according to claim 4 for use according to claim 4, wherein the cancer is liver cancer.

6. A ROS inhibitor for use in inhibiting kinase activity of a polypeptide in a subject comprising a ROS kinase domain, wherein the ROS inhibitor is selected from NVP-TAE684 and PF-02341066.

7. The ROS inhibitor according to claim 3 or claim 5 for use according to claim 3 or claim 5, wherein the liver cancer is hepatocellular carcinoma or cholangiocarcinoma.

8. The ROS inhibitor according to any of the preceding claims for use according to any of the preceding claims, wherein the ROS inhibitor is PF-02341066.

50 Patentansprüche

55

1. ROS-Inhibitor zur Verwendung bei der Behandlung von Krebs bei einem Patienten, wobei der Krebs durch eine Translokation des ROS-Gens gekennzeichnet ist oder ein FIG-ROS-Polypeptid exprimiert und der ROS-Inhibitor aus NVP-TAE684 und PF-02341066 ausgewählt ist.
2. ROS-Inhibitor nach Anspruch 1, zur Verwendung nach Anspruch 1, wobei der Patient identifiziert wurde einen Krebs aufzuweisen, der durch eine Translokation des ROS-Gens gekennzeichnet ist oder ein FIG-ROS-Polypeptid exprimiert.

- 3. ROS-Inhibitor nach Anspruch 1 oder Anspruch 2, zur Verwendung nach Anspruch 1 oder Anspruch 2, wobei der Krebs Leberkrebs ist.
- 5. 4. ROS-Inhibitor zur Verwendung bei der Inhibierung der Proliferation einer Krebszelle in einem Patienten, wobei die Zelle eine Translokation des ROS-Gens aufweist oder ein FIG-ROS-Polypeptid exprimiert und der ROS-Inhibitor aus NVP-TAE684 und PF-02341066 ausgewählt ist.
- 10. 5. ROS-Inhibitor nach Anspruch 4, zur Verwendung nach Anspruch 4, wobei der Krebs Leberkrebs ist.
- 15. 6. ROS-Inhibitor zur Verwendung bei der Inhibierung der Kinase-Aktivität eines Polypeptids in einem Patienten, das eine ROS-Kinase-Domäne umfasst, wobei der ROS-Inhibitor aus NVP-TAE684 und PF-02341066 ausgewählt ist.
- 20. 7. ROS-Inhibitor nach Anspruch 3 oder Anspruch 5, zur Verwendung nach Anspruch 3 oder Anspruch 5, wobei der Leberkrebs ein hepatzelluläres Karzinom oder Cholangiokarzinom ist.
- 25. 8. ROS-Inhibitor nach einem der vorhergehenden Ansprüche zur Verwendung nach einem der vorhergehenden Ansprüche, wobei der ROS-Inhibitor PF-02341066 ist.

20 Revendications

- 1. Inhibiteur de ROS pour une utilisation dans le traitement du cancer chez un patient, dans lequel le cancer est **caractérisé par** une translocation du gène de ROS ou exprime un polypeptide de FIG-ROS et l'inhibiteur de ROS est choisi parmi NVP-TAE684 et PF-02341066.
- 25. 2. Inhibiteur de ROS selon la revendication 1, pour une utilisation selon la revendication 1, dans lequel le patient a été identifié comme ayant un cancer qui est **caractérisé par** une translocation du gène de ROS ou qui exprime un polypeptide de FIG-ROS.
- 30. 3. Inhibiteur de ROS selon la revendication 1 ou la revendication 2, pour une utilisation selon la revendication 1 ou la revendication 2, dans lequel le cancer est le cancer du foie.
- 35. 4. Inhibiteur de ROS, pour une utilisation dans l'inhibition de la prolifération d'une cellule cancéreuse chez un sujet, dans lequel la cellule présente une translocation du gène de ROS ou exprime un polypeptide de FIG-ROS et l'inhibiteur de ROS est choisi parmi NVP-TAE684 et PF-02341066.
- 40. 5. Inhibiteur de ROS selon la revendication 4, pour une utilisation selon la revendication 4, dans lequel le cancer est le cancer du foie.
- 45. 6. Inhibiteur de ROS, pour une utilisation dans l'inhibition de l'activité de kinase d'un polypeptide chez un sujet comprenant un domaine de kinase de ROS, dans lequel l'inhibiteur de ROS est choisi parmi NVP-TAE684 et PF-02341066.
- 7. Inhibiteur de ROS selon la revendication 3 ou la revendication 5, pour une utilisation selon la revendication 3 ou la revendication 5, dans lequel le cancer du foie est un carcinome hépatocellulaire ou un cholangiocarcinome.
- 45. 8. Inhibiteur de ROS selon l'une quelconque des revendications précédentes, pour une utilisation selon l'une quelconque des revendications précédentes, dans lequel l'inhibiteur de ROS est PF-02341066.

50

55

Figure 1: Genomic information of FIG-ROS






Figure 2: FIG-ROS in liver cancer



- FIG-ROS (L): exon 7 of FIG fused to exon 34 of ROS
- FIG-ROS (S): exon 3 of FIG fused to exon 35 of ROS

Figure 3:
Expression of FIG-ROS in liver cancer



$2/23=8.7\%$

Figure 4: Expression of FIG-ROS in MS positive samples




Figure 5: Genomic PCR of FIG-ROS




Figure 6: Stable expression of FIG-ROS fusions




Figure 7: Soft Agar Assay (3T3 cells)





Figure 8: Transforming activity of FIG-ROS






Figure 9A: Subcellular localization of FIG-ROS fusions




Figure 9B: Subcellular localization of FIG-ROS fusions

Figure 10: Stable expression of FIG-ROS fusions





Figure 11: IL3 independent growth (BaF3 cells)

Day -7: Transfect BaF3 cells with retrovirus for gene of interest

Day -5: Select transfected BaF3 cells with Neomycin in the presence of IL3

Day 0: withdrawal IL3 to test transforming ability

Figure 12: In vitro kinase assay




Figure 13:
FIG-ROS is sensitive to TAE-684




Figure 14: TAE-684 induces apoptosis in FIG-ROS expression BaF3 cells





Figure 15: Phosphorylation of FIG-ROS is inhibited by TAE-684

Figure 16




Figure 17




Figure 18




Figure 19A





Figure 19B



REFERENCES CITED IN THE DESCRIPTION

This list of references cited by the applicant is for the reader's convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.

Patent documents cited in the description

- WO 2007084631 A [0007]
- WO 2007084631 PCT [0039]
- WO 2009051846 PCT [0039]
- EP 0464533 A [0111]
- CA 2045869 [0111]
- EP 0232262 A [0111]
- WO 9312227 A, Lonberg [0120]
- US 5545806 A [0120]
- WO 9110741 A, Kucherlapati [0120]
- US 6150584 A [0120]
- US 4474893 A [0120]
- US 4816567 A, Cabilly [0120]
- US 4676980 A, Segel [0120]
- WO 9520401 A [0121]
- US 5789208 A [0121]
- US 6335163 B [0121]
- WO 04009618 PCT [0121]
- WO 9117271 A, Dower [0122]
- WO 9201047 A, McCafferty [0122]
- US 5969108 A [0122]
- US 6355245 B [0122]
- US 6180370 B [0122]
- US 5693762 A [0122]
- US 6407213 B [0122]
- US 6548640 B [0122]
- US 5565332 A [0122]
- US 5225539 A [0122]
- US 6103889 A [0122]
- US 5260203 A [0122]
- US 5675063 A [0127]
- US 5194392 A, Geysen [0129]
- US 5480971 A, Houghten [0129]
- US 20050214301 A [0130]
- EP 394827 A [0137]
- WO 03016861 A [0138]
- US 4727022 A [0164]
- US 4659678 A [0164]
- US 4376110 A [0164]
- US 5756696 A [0184]
- US 5447841 A [0184]
- US 5776688 A [0184]
- US 5663319 A [0184]
- US 7468252 B [0186]
- WO 2002020825 PCT [0192]
- US 20040202655 A [0218]
- US 20040086503 A [0218]
- US 20040033543 A [0218]
- EP 1423428 A [0218] [0220]
- US 6319690 B [0219]
- US 6300064 B [0219] [0220]
- US 5840479 A [0219]
- US 20030219839 A [0219] [0223]
- US 6734017 B [0224]
- US 6710174 B [0224]
- US 6617162 B [0224]
- US 6340674 B [0224]
- US 5783683 A [0224]
- US 5610288 A [0224]
- US 20040047847 A [0225]
- US 20040038921 A [0226] [0229]
- US 20020086356 A [0226]
- US 20040229266 A [0226] [0229]
- US 20030170891 A [0232] [0236]
- US 20040236517 A [0232]
- US 20040023390 A [0233]
- US 20040209832 A [0236]
- US 20040175703 A [0236]
- US 4522811 A [0240]
- WO 9106309 A [0240]
- EP 43075 A [0240]
- US 6395713 B [0241]
- WO 9402595 A [0241]
- WO 0053722 A [0242]
- WO 9931262 A [0242]
- WO 9610391 A [0246]
- WO 9610390 A [0246]
- WO 9610392 A [0246]
- WO 8403564 A [0254]
- US 20030044848 A [0258]
- US 2010024109 W [0344]
- US 61207484 B [0344]

Non-patent literature cited in the description

- **KURZOCK et al.** *N. Engl. J. Med.*, 1988, vol. 319, 990-998 [0003]
- **FALINI et al.** *Blood*, 2002, vol. 99 (2), 409-426 [0004]
- **SAMBROOK et al.** *Molecular Cloning: A Laboratory Manual*. Cold Spring Harbor Laboratory Press, 1989 [0029]

- Handbook of Molecular and Cellular Methods in Biology in Medicine. CRC Press, 1995 [0029]
- Directed Mutagenesis: A Practical Approach. IRL Press, 1991 [0029]
- **GOODMAN ; GILMAN'S.** The Pharmacological Basis of Therapeutics. McGraw Hill Companies Inc, 2006 [0029]
- **J. ACQUAVIVA et al.** *Biochim. Biophys. Acta*, 2009, vol. 1795 (1), 37-52 [0031]
- **RIKOVA, K et al.** *Cell*, 2007, vol. 131, 1190-1203 [0039]
- **BOWIE et al.** *Science*, vol. 247 [0052]
- **SMITH ; JOHNSON.** *Gene*, 1988, vol. 67, 31-40 [0054]
- **SMITH ; WATERMAN.** *Advances in Applied Mathematics*, 1981, vol. 2, 482-489 [0056] [0089]
- **FIELDS ; SONG.** *Nature*, 1989, vol. 340, 245-246 [0060]
- **GEYSEN et al.** *Proc. Natl. Acad. Sci. USA*, 1983, vol. 81, 3998-4002 [0061]
- **WILSON et al.** *Cell*, 1984, vol. 37, 767-778 [0062]
- MOLECULAR CLONING, A LABORATORY MANUAL. Cold Spring Harbor Laboratory Press, 1989 [0082] [0181]
- **GENTZ et al.** *Proc. Natl. Acad. Sci. USA*, 1989, vol. 86, 821-824 [0084]
- **WILSON et al.** *Cell*, 1984, vol. 37, 767 [0084]
- GENES II. John Wiley & Sons, 1985 [0085]
- **VERMA et al.** HUMAN CHROMOSOMES: A MANUAL OF BASIC TECHNIQUES. Pergamon Press, 1988 [0090] [0184]
- **BOWIE et al.** Deciphering the Message in Protein Sequences: Tolerance to Amino Acid Substitutions. *Science*, 1990, vol. 247, 1306-1310 [0092]
- **SARKAR, G.** *PCR Methods Applic.*, 1993, vol. 2, 318-322 [0094]
- **TRIGLIA et al.** *Nucleic Acids Res.*, 1988, vol. 16, 8186 [0095]
- **LAGERSTROM et al.** *PCR Methods Applic.*, 1991, vol. 1, 111-119 [0096]
- **PARKER et al.** *Nucleic Acids Res.*, 1991, vol. 19, 3055-3060 [0096]
- **AUSUBEL et al.** CURRENT PROTOCOLS IN MOLECULAR BIOLOGY. John Wiley & Sons, 1989 [0106]
- **GRANT et al.** *Methods Enzymol.*, 1997, vol. 153, 516-544 [0106]
- **DAVIS et al.** BASIC METHODS IN MOLECULAR BIOLOGY, 1986 [0107]
- **BENNETT et al.** *Journal of Molecular Recognition*, 1995, vol. 8, 52-58 [0111]
- **JOHANSON et al.** *The Journal of Biological Chemistry*, 1995, vol. 270 (16), 9459-9471 [0111]
- CURRENT PROTOCOLS IN MOLECULAR BIOLOGY. Wiley Interscience, vol. 2 [0113]
- **M. WALKER et al.** *Molec. Immunol.*, 1989, vol. 26, 403-11 [0120]
- **MORRISON et al.** *Proc. Natl. Acad. Sci.*, 1984, vol. 81, 6851 [0120]
- **NEUBERGER et al.** *Nature*, 1984, vol. 312, 604 [0120] [0125]
- ANTIBODIES: A LABORATORY MANUAL. Cold Spring Harbor Laboratory, 1988, 75-76 [0126]
- **CZERNIK.** *Methods In Enzymology*, 1991, vol. 201, 264-283 [0126]
- **MERRIFIELD.** *J. Am. Chem. Soc.*, 1962, vol. 85, 21-49 [0126]
- **KOHLER ; MILSTEIN.** *Nature*, 1975, vol. 265, 495-97 [0127]
- **KOHLER ; MILSTEIN.** *Eur. J. Immunol.*, 1976, vol. 6, 511 [0127]
- CURRENT PROTOCOLS IN MOLECULAR BIOLOGY. 1989 [0127]
- **W. HUSE.** *Science*, 1989, vol. 246, 1275-81 [0128]
- **MULLINAX et al.** *Proc. Natl. Acad. Sci.*, 1990, vol. 87, 8095 [0128]
- **STEPLEWSKI et al.** *Proc. Natl. Acad. Sci.*, 1985, vol. 82, 8653 [0128]
- **SPIRA et al.** *J. Immunol. Methods*, 1984, vol. 74, 307 [0128]
- ANTIBODY ENGINEERING PROTOCOLS. Humana Press, 1995 [0128]
- **CZERNIK et al.** *Methods in Enzymology*, 1991, vol. 201, 264-283 [0130]
- **TRAUNECKER et al.** *Nature*, 1988, vol. 331, 84-86 [0137]
- **FOUNTOULAKIS et al.** *J Biochem*, 1995, vol. 270, 3958-3964 [0137]
- **GERBER et al.** *Proc. Natl. Acad. Sci. U.S.A.*, 2003, vol. 100, 6940-5 [0138]
- **K. BAROVSKY.** *Nanotech. Law & Bus.*, 2004, vol. 1 (2) [0162]
- **E. MAGGIO.** Enzyme-Immunoassay. CRC Press, Inc, 1980 [0164]
- **CHOW et al.** *Cytometry (Communications in Clinical Cytometry)*, 2001, vol. 46, 72-78 [0167]
- ANTIBODIES: A LABORATORY MANUAL. Cold Spring Harbor Laboratory, 1988 [0168]
- **J.M. POLAK ; S. VAN NOORDEN.** INTRODUCTION TO IMMUNOCYTOCHEMISTRY. 1997 [0169]
- ROYAL MICROSCOPY SOCIETY MICROSCOPY HANDBOOK. BioScientific. Springer-Verlag, vol. 37 [0169]
- **MELBY et al.** *J. Immunol. Methods*, 1993, vol. 159, 235-244 [0182]
- **DUPLAA et al.** *Anal. Biochem.*, 1993, 229-236 [0182]
- **PRICE, C. M.** *Blood Rev.*, 1993, vol. 7, 127-134 [0183]
- **TRASK, B. J.** *Trends Genet.*, 1991, vol. 7, 149-154 [0183]
- *Genome Issue of Science*, 1994, vol. 265, 1981f [0184]
- **GATTI et al.** *Nature*, 1988, vol. 336, 577-580 [0185]

- **ELLIOT et al.** *Br J Biomed Sci* 2008, 2008, vol. 65 (4), 167-171 [0187]
- **CRISTALLINI et al.** *Acta Cytol.*, 1992, vol. 36 (3), 416-22 [0191]
- **CRISTOFANILLI et al.** *New Engl. J. of Med.*, 2004, vol. 351 (8), 781-791 [0192]
- **ADAMS et al.** *J. Amer. Chem. Soc.*, July 2008, vol. 130 (27), 8633-8631 [0192]
- **KAL.** *Cancer Treat Res.*, 1995, vol. 72, 155-69 [0196]
- **WINOGRAD et al.** *In Vivo.*, 1987, vol. 1 (1), 1-13 [0196]
- **SCHWALLER et al.** *EMBO J.*, 1998, vol. 17, 5321-333 [0196]
- **KELLY et al.** *Blood*, 2002, vol. 99, 310-318 [0196]
- **DEWAR et al.** *Blood*, 2005, vol. 105 (8), 3127-32 [0214]
- **MERLUZZI et al.** *Adv Clin Path.*, 2000, vol. 4 (2), 77-85 [0217]
- CURRENT PROTOCOLS IN IMMUNOLOGY. John Wiley & Sons, Inc, 1992 [0219]
- **COHEN, J.** *Trends in Pharmacol. Sci.*, 1989, vol. 10 (11), 435-437 [0225]
- **MARCUS-SEKURA.** *Anal. Biochem.*, 1988, vol. 172, 289-295 [0225]
- **WEINTRAUB, H.** *Sci. AM.*, 1990, 40-46 [0225]
- **VAN DER KROL et al.** *BioTechniques*, 1988, vol. 6 (10), 958-976 [0225]
- **SKORSKI et al.** *Proc. Natl. Acad. Sci. USA*, 1994, vol. 91, 4504-4508 [0225]
- **HAMMOND et al.** *Nature*, 2000, vol. 404, 293-296 [0227]
- **GRAHAM et al.** *Virol.*, 1973, vol. 52, 456 [0233]
- **MCCUTCHAN et al.** *J. Natl. Cancer Inst.*, 1968, vol. 41, 351 [0233]
- **CHU et al.** *Nucl. Acids Res.*, 1987, vol. 15, 1311 [0233]
- **FRALEY et al.** *J. Biol. Chem.*, 1980, vol. 255, 10431 [0233]
- **CAPECCHI.** *Cell*, 1980, vol. 22, 479 [0233]
- **FEIGNER et al.** *Proc. Natl. Acad. Sci USA*, 1987, vol. 84, 7413 [0233]
- **GOU et al.** *FEBS.*, 2003, vol. 548, 113-118 [0234]
- **SUI, G. et al.** A DNA vector-based RNAi technology to suppress gene expression in mammalian cells. *Proc. Natl. Acad. Sci.*, 2002, vol. 99, 5515-5520 [0234]
- **YU et al.** *Proc. Natl. Acad. Sci.*, 2002, vol. 99, 6047-6052 [0234]
- **PAUL, C. et al.** *Nature Biotechnology*, 2002, vol. 19, 505-508 [0234]
- **MCMANUS et al.** *RNA*, 2002, vol. 8, 842-850 [0234]
- **AKHTAR et al.** DELIVERY STRATEGIES FOR AN-TISENSE OLIGONUCLEOTIDE THERAPEUTICS. *Trends Cell Bio.*, 1992, vol. 2, 139 [0241]
- **MAURER et al.** *Mol. Membr. Biol.*, 1999, vol. 16, 129-140 [0241]
- **HOFLAND ; HUANG.** *Handb. Exp. Pharmacol.*, 1999, vol. 137, 165-192 [0241]
- **LEE et al.** *ACS Symp. Ser.*, 2000, vol. 752, 184-192 [0241]
- **CONRY et al.** *Clin. Cancer Res.*, 1999, vol. 5, 2330-2337 [0242]
- **JOLLIET-RIANT ; TILLEMENT.** *Fundam. Clin. Pharmacol.*, 1999, vol. 13, 16-26 [0245]
- **EMERICH et al.** *Cell Transplant*, 1999, vol. 8, 47-58 [0245]
- *Prog Neuro-psychopharmacol Biol Psychiatry*, 1999, vol. 23, 941-949 [0245]
- **BOADO et al.** *J. Pharm. Sci.*, 1998, vol. 87, 1308-1315 [0245]
- **TYLER et al.** *FEBS Lett.*, 1999, vol. 421, 280-284 [0245]
- **PARDRIDGE et al.** *PNAS USA.*, 1995, vol. 92, 5592-5596 [0245]
- **BOADO.** *Adv. Drug Delivery Rev.*, 1995, vol. 15, 73-107 [0245]
- **ALDRIAN-HERRADA et al.** *Nucleic Acids Res.*, 1998, vol. 26, 4910-4916 [0245]
- **TYLER et al.** *PNAS USA.*, 1999, vol. 96, 7053-7058 [0245]
- **LASIC et al.** *Chem. Rev.*, 1995, vol. 95, 2601-2627 [0246]
- **ISHIWATA et al.** *Chem. Pharm. Bull.*, 1995, vol. 43, 1005-1011 [0246]
- **LASIC et al.** *Science*, 1995, vol. 267, 1275-1276 [0246]
- **OKU.** *Biochim. Biophys. Acta*, 1995, vol. 1238, 86-90 [0246]
- **LIU et al.** *J. Biol. Chem.*, 1995, vol. 42, 24864-24870 [0246]
- REMINGTON'S PHARMACEUTICAL SCIENCES. Mack Publishing Co, 1985 [0247]
- **RUSH et al.** *Nat. Biotechnol.*, 2005, vol. 23 (1), 94-101 [0260]
- **RAPP SILBER et al.** *Anal. Chem.*, 2003, vol. 75 (3), 663-70 [0263]
- **RIKOVA et al.** *Cell*, 2007, vol. 131, 1190-1203 [0264]
- **CARR et al.** *Mol. Cell Proteomics*, 2004, vol. 3, 531-533 [0267]
- **COOLS et al.** *N. Engl. J. Med.*, 2003, vol. 348, 1201-1214 [0275]
- **GALKIN et al.** *Proc. National Acad. Sci*, 2007, vol. 104 (1), 270-275 [0310]
- **VERMA et al.** Human Chromosomes: A Manual of Basic Techniques. Pergamon Press, 1988 [0319]
- **BLECHACZ et al.** *Hepatology*, 2008, vol. 48, 308-321 [0327]
- **GROEN, P.C.** *N Engl J Med*, 1999, vol. 341, 1368-1378 [0327]

Mutáns ROS expresszió humán májrákban

Szabadalmi igénypontok

1. ROS inhibitor páciensben rák kezelésében történő alkalmazásra, ahol a rák az ROS gén transzlokációjával jellemzett vagy egy FIG-ROS polipeptidet fejez ki, és az ROS inhibitor NVP-TAE684 és PF-02341066 közül választott.
2. Az 1. igénypont szerinti ROS inhibitor az 1. igénypont szerinti alkalmazásra, ahol a páciens rákosként azonosított, mely az ROS gén transzlokációjával jellemzett vagy egy FIG-ROS polipeptidet fejez ki.
3. Az 1. vagy 2. igénypont szerinti ROS inhibitor az 1. vagy 2. igénypont szerinti alkalmazásra, ahol a rák májrák.
4. Egy ROS inhibitor alanyban ráksejt proliferációjának gátlásában történő alkalmazásra, ahol a sejt az ROS gén transzlokációját okozza vagy egy FIG-ROS polipeptidet fejez ki, és az ROS inhibitor NVP-TAE684 és PF-02341066 közül választott.
5. A 4. igénypont szerinti ROS inhibitor a 4. igénypont szerinti alkalmazásra, ahol a rák májrák.
6. Egy ROS inhibitor alanyban egy polipeptid kínázaktivitásának gátlásában történő alkalmazásra, ahol az ROS inhibitor NVP-TAE684 és PF-02341066 közül választott.
7. A 3. igénypont vagy 5. igénypont szerinti ROS inhibitor a 3. igénypont szerinti vagy 5. igénypont szerinti alkalmazásra, ahol a májrák májsejt karcinóma vagy cholangiocarcinoma.
8. Az előző igénypontok bármelyike szerinti ROS inhibitor az előző igénypontok bármelyike szerinti alkalmazásra, ahol az ROS inhibitor PF-02341066.



SZTNH-100076316